<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002947.pub2" GROUP_ID="MUSKEL" ID="606700060813451846" MERGED_FROM="" MODIFIED="2016-04-04 09:30:47 +0100" MODIFIED_BY="Renea Johnston" REVIEW_NO="A008R" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-04-04 17:27:52 +1000" MODIFIED_BY="Renea Johnston">
<TITLE MODIFIED="2012-04-16 16:50:23 +1000" MODIFIED_BY="Renea Johnston">Oral herbal therapies for treating osteoarthritis</TITLE>
<CONTACT>
<PERSON ID="16854" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Melainie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cameron</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>mcameron@usc.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Health and Sport Sciences, Cluster for Health Improvement</DEPARTMENT>
<ORGANISATION>University of the Sunshine Coast</ORGANISATION>
<ADDRESS_1>Sippy Downs campus</ADDRESS_1>
<ADDRESS_2>Locked Bag 4</ADDRESS_2>
<CITY>Maroochydore DC</CITY>
<ZIP>4558</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61 7 5459 4545</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-04-04 17:27:52 +1000" MODIFIED_BY="Renea Johnston">
<PERSON ID="16854" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Melainie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cameron</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>mcameron@usc.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Health and Sport Sciences, Cluster for Health Improvement</DEPARTMENT>
<ORGANISATION>University of the Sunshine Coast</ORGANISATION>
<ADDRESS_1>Sippy Downs campus</ADDRESS_1>
<ADDRESS_2>Locked Bag 4</ADDRESS_2>
<CITY>Maroochydore DC</CITY>
<ZIP>4558</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61 7 5459 4545</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="ED4869A482E26AA2015BF05F692A87CB" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Sigrun</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chrubasik</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>sigrun.chrubasik@klinikum.uni-freiburg.de</EMAIL_1>
<EMAIL_2/>
<URL>http://www.uniklinik-freiburg.de/rechtsmedizin/live/forschung/phytomedicine.html</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Freiburg</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Freiburg</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-04-16 15:10:34 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="8" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="8" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2016-03-07 14:07:59 +1100" MODIFIED_BY="Renea V Johnston">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2016-03-07 14:07:59 +1100" MODIFIED_BY="Renea V Johnston">
<DATE DAY="7" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>Responded to feedback</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-03-07 14:07:27 +1100" MODIFIED_BY="Renea V Johnston">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-03-07 14:07:27 +1100" MODIFIED_BY="Renea V Johnston">
<DATE DAY="25" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Substantive update including changed conclusions; new authors added.</P>
<P>Change in conclusions on update: small, statistically significant benefits in terms of pain and function now reported for two herbal preparations, <I>Boswellia serrata</I> extracts and avocado-soyabean unsaponifiables. Many other herbal preparations included.</P>
<P>Methods were updated in accordance with current Cochrane Collaboration recommendations: risk of bias assessment and summary of findings tables were added, and substantial re-writing was performed in the reporting of the methods and results to align with the standards recommended by the Cochrane Collaboration's Methodological Expectations of Cochrane Intervention Reviews (MECIR) project.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-07 14:07:26 +1100" MODIFIED_BY="Renea V Johnston">
<DATE DAY="29" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>An additional 45 studies were added to this review update, plus four studies were included from the original review.</P>
<P>The updated review is now divided into two parts: oral and topical herbal therapies for treating osteoarthritis. This review covers oral herbal therapies only. Inclusion criteria have been narrowed to strictly apply the World Health Organization (WHO) definition of herbal medicines, thereby excluding studies of interventions that include non-herbal components (for example zinc, magnesium), or extracted or synthetic single compounds.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-04-16 15:11:45 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID A008R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-04-16 15:21:00 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-04-09 12:31:20 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-04-09 12:31:10 +1000" MODIFIED_BY="[Empty name]">
<NAME>Victoria University</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>Victoria University provided one author with time release from normal duties (2004-2009) for review training and to undertake this review.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-04-09 12:26:22 +1000" MODIFIED_BY="[Empty name]">
<NAME>University of Freiburg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>University of Freiburg provided one author with time release from normal duties to complete the review. A staff member of the Cochrane Centre Germany, based at the University of Frieburg, assisted with data extraction from German lanugage manucripts.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-04-09 12:30:59 +1000" MODIFIED_BY="[Empty name]">
<NAME>Australian Catholic University</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>The Australian Catholic University provided one author with time release from normal duties (2010-2011) to undertake this review. Librarians from the Australian Catholic University assisted with the acquisition of full manuscripts of studies included in this review.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-04-09 12:31:20 +1000" MODIFIED_BY="[Empty name]">
<NAME>University of the Sunshine Coast</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>The University of the Sunshine Coast provided one author with time release from normal duties (2012) to complete this review.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-04-16 15:21:00 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-04-16 15:21:00 +1000" MODIFIED_BY="[Empty name]">
<NAME>National Center for Complementary and Alternative Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>This work was partially funded by Grant Number R24 AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM). The contents of this systematic review are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM or the National Institutes of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-04 18:28:07 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-03-07 13:59:14 +1100" MODIFIED_BY="Renea V Johnston">
<TITLE MODIFIED="2012-05-24 21:09:21 +1000" MODIFIED_BY="[Empty name]">Oral herbal therapies for treating osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2016-03-07 13:59:14 +1100" MODIFIED_BY="Renea V Johnston">
<P>
<B>Background: what is osteoarthritis and what is herbal therapy?</B>
</P>
<P>Osteoarthritis (OA) is a disease of the joints (commonly knees, hips, hands). When joints lose cartilage, bone grows to try to repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and limit movement. OA can affect your physical function, particularly your ability to use your joints.</P>
<P>Herbal medicines are defined as being finished, labelled medicinal products that contain as active ingredients aerial or underground parts of plants or other plant material, or combinations thereof, whether in the crude state or as plant preparations (for example extracts, oils, tinctures).</P>
<P>
<B>Study characteristics</B>
</P>
<P>This summary of an update of a Cochrane review presents what we know from research about the effects of herbal therapies consumed orally by people with osteoarthritis. After searching for all relevant studies to August 2013, we included 45 new studies since the last review, giving a total of 49 studies (on 33 herbal interventions) that included 5980 participants, most with mild to moderate symptomatic osteoarthritis of the knee or hip. Thirty-three different medicinal plant products were compared with placebo or active intervention controls and many comparisons had single studies only; thus, we have restricted reporting of results here to multiple studies of <I>Boswellia serrata</I> (monoherbal) and avocado-soyabean unsaponifiables (ASU) (two herb combination) products<I>.</I>
</P>
<P>
<B>Key results</B>
</P>
<P>
<B>
<I>Boswellia serrata</I> </B>
</P>
<P>Pain on a scale of 0 to 100 points (lower scores mean reduced pain):</P>
<P>- people who used 100 mg of enriched <I>Boswellia serrata</I> extract rated their pain 17 points lower (range 8 to 26 points lower) (17% absolute improvement) at 90 days compared with placebo;</P>
<P>- people who used enriched <I>Boswellia serrata</I> extract 100 mg rated their pain as 23 points;</P>
<P>- people who used a placebo preparation rated their pain as 40 points.</P>
<P>Physical function on a scale of 0 to 100 points (lower scores means better physical function):</P>
<P>- people who used 100 mg of enriched <I>Boswellia serrata</I> extract rated their physical function 8 points better (2 to 14 points better) on a 100 point scale (8% absolute improvement) at 90 days compared with placebo;</P>
<P>- people who used 100 mg of enriched <I>Boswellia serrata</I> extract rated their physical function as 25 points;</P>
<P>- people who used placebo rated their physical function as 33 points.</P>
<P>
<B>Avocado-soyabean unsaponifiables (ASU) product Piascledine®</B>
</P>
<P>Pain on a scale of 0 to 100 points (lower scores mean less pain):</P>
<P>- people who used ASU 300 mg rated their pain 8 points lower (1 to 16 points lower) on a 100 point scale (8% absolute improvement) at 3 to 12 months compared with placebo;</P>
<P>- people who used ASU 300 mg rated their pain as 33 points;</P>
<P>- people who used placebo rated their pain as 41 points.<BR/>
</P>
<P>Physical function on a scale of 0 to 100 mm scale (lower scores means better physical function):</P>
<P>- people who used ASU 300 mg rated their physical function 7 mm better (2 to 12 mm better) on a 100 mm scale (7% absolute improvement) at 3 to 12 months compared with placebo;</P>
<P>- people who used ASU 300 mg rated their physical function as 40 mm;</P>
<P>- people who used placebo rated their physical function as 47 mm.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>There is moderate-quality evidence that in people with osteoarthritis <I>Boswellia serrata </I>slightly improved pain and function. Further research may change the estimates.</P>
<P>There is moderate-quality evidence that avocado-soybean unsaponifiables (ASU) probably improved pain and function slightly, but may not preserve joint space. Further research may change the estimates.</P>
<P>We are uncertain whether other oral herbal products improve osteoarthritis pain or function, or slow progression of joint structure damage because the available evidence is limited to single studies or studies that cannot be pooled, and some of these studies are of low to very low quality. Quality of life was not measured.</P>
<P>Herbal therapies may cause side effects, however we are uncertain if there is an increased risk of these.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-04-04 18:13:59 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-05-14 14:09:50 +1000" MODIFIED_BY="[Empty name]">
<P>Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in full detail, interactions with common inflammatory mediators provide a rationale for using them to treat osteoarthritic complaints.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-16 13:41:58 +1000" MODIFIED_BY="[Empty name]">
<P>To update a previous Cochrane review to assess the benefits and harms of oral medicinal plant products in treating osteoarthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-05-09 17:42:53 +1000" MODIFIED_BY="[Empty name]">
<P>We searched electronic databases (CENTRAL, MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to 29 August 2013, unrestricted by language, and the reference lists from retrieved trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-04-16 13:58:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of orally consumed herbal interventions compared with placebo or active controls in people with osteoarthritis were included. Herbal interventions included any plant preparation but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-05-09 17:45:27 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors used standard methods for trial selection and data extraction, and assessed the quality of the body of evidence using the GRADE approach for major outcomes (pain, function, radiographic joint changes, quality of life, withdrawals due to adverse events, total adverse events, and serious adverse events).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-04-04 17:29:04 +1000" MODIFIED_BY="[Empty name]">
<P>Forty-nine randomised controlled studies (33 interventions, 5980 participants) were included. Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias. The remaining 32 studies of exploratory design were at higher risk of bias. Due to differing interventions, meta-analyses were restricted to <I>Boswellia serrata</I> (monoherbal) and avocado-soyabean unsaponifiables (ASU) (two herb combination) products.</P>
<P>Five studies of three different extracts from <I>Boswellia serrata</I> were included. Moderate-quality evidence from two studies (85 participants) indicated that 90 days treatment with 100 mg of enriched <I>Boswellia serrata</I> extract improved symptoms compared to placebo. Mean pain was 40 points on a 0 to 100 point VAS scale (0 is no pain) with placebo, enriched <I>Boswellia serrata</I> reduced pain by a mean of 17 points (95% confidence interval (CI) 8 to 26); number needed to treat for an additional beneficial outcome (NNTB) 2; the 95% CIs did not exclude a clinically significant reduction of 15 points in pain. Physical function was 33 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched <I>Boswellia serrata</I> improved function by 8 points (95% CI 2 to 14); NNTB 4. Assuming a minimal clinically important difference of 10 points, we cannot exclude a clinically important benefit in some people. Moderate-quality evidence (one study, 96 participants) indicated that adverse events were probably reduced with enriched <I>Boswellia serrata</I> (18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92). Possible benefits of other <I>Boswellia serrata </I>extracts over placebo were confirmed in moderate-quality evidence from two studies (97 participants) of <I>Boswellia serrata </I>(enriched) 100 mg plus non-volatile oil, and low-quality evidence from small single studies of a 999 mg daily dose of <I>Boswellia serrata</I> extract and 250 mg daily dose of enriched<I> Boswellia serrata</I>. It was uncertain if a 99 mg daily dose of <I>Boswellia serrata</I> offered benefits over valdecoxib due to the very low-quality evidence from a small single study. It was uncertain if there was an increased risk of adverse events or withdrawals with <I>Boswellia serrata</I> extract due to variable reporting of results across studies. The studies reported no serious adverse events. Quality of life and radiographic joint changes were not measured.</P>
<P>Six studies examined the ASU product Piasclidine®. Moderate-quality evidence from four studies (651 participants) indicated that ASU 300 mg produced a small and clinically questionable improvement in symptoms, and probably no increased adverse events compared to placebo after three to 12 months treatment. Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8. ASU 300 mg improved function (standardised mean difference (SMD) -0.42, 95% CI -0.73 to -0.11). Function was estimated as 47 mm (0 to 100 mm scale, where 0 is no loss of function) with placebo, ASU 300 mg improved function by a mean of 7 mm (95% CI 2 to 12 mm); NNTB 5 (3 to 19). There were no differences in adverse events (5 studies, 1050 participants) between ASU (53%) and placebo (51%) (RR 1.04, 95% CI 0.97 to 1.12); withdrawals due to adverse events (1 study, 398 participants) between ASU (17%) and placebo (15%) (RR 1.14, 95% CI 0.73 to 1.80); or serious adverse events (1 study, 398 participants) between ASU (40%) and placebo (33%) (RR 1.22, 95% CI 0.94 to 1.59). Radiographic joint changes, measured as change in joint space width (JSW) in two studies (453 participants) did not differ between ASU 300 mg treatment (-0.53 mm) and placebo (-0.65 mm); mean difference of -0.12 (95% CI -0.43 to 0.19). Moderate-quality evidence from a single study (156 participants) confirmed possible benefits of ASU 600 mg over placebo, with no increased adverse events. Low-quality evidence (1 study, 357 participants) indicated there may be no differences in symptoms or adverse events between ASU 300 mg and chondroitin sulphate. Quality of life was not measured.</P>
<P>All other herbal interventions were investigated in single studies, limiting conclusions. No serious side effects related to any plant product were reported.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-04-04 18:13:59 +1000" MODIFIED_BY="[Empty name]">
<P>Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate for short term use, but studies over a longer term and against an apparently active control are less convincing. Several other medicinal plant products, including extracts of <I>Boswellia serrata</I>, have moderate-quality evidence for trends of benefits that warrant further investigation in light of the fact that the risk of adverse events appear low.</P>
<P>There is no evidence that Piasclidine® significantly improves joint structure, and limited evidence that it prevents joint space narrowing. Structural changes were not tested for with any other herbal intervention.</P>
<P>Further investigations are required to determine optimum daily doses producing clinical benefits without adverse events.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-04 18:28:07 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-05-14 14:01:21 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Oral herbal therapies for treating osteoarthritis</HEADING>
<P>Herbal medicines have a long tradition in the treatment of osteoarthritis. Although the mechanism of action of oral medicinal plant products has not been fully elucidated, experimental studies indicate interactions with mediators of inflammation and cartilage destruction, providing a rational basis for the putative effectiveness of oral medicinal plant products in alleviating osteoarthritis. This review is an update of an earlier review from 2000. Four of the studies in the original review and 45 new studies are included in this review, evaluating the effects of 33 different oral medicinal plants or combinations of plants from Europe, Africa, Asia, and the Americas. The review shows that oral medicinal plant products may improve osteoarthritic complaints, but multiple studies providing moderate to high evidence of effectiveness are only available for proprietary products from avocado-soyabean unsaponifiables (ASU) and <I>Boswellia serrata</I>. For the other medicinal plant products the quality and quantity of the studies are insufficient to draw definitive conclusions on effectiveness. Although the included studies did not report serious adverse events related to the products, safety data are limited.</P>
<P>Herbal medicinal products are used in a variety of forms for the treatment of osteoarthritis (OA) worldwide. Although their mechanisms of action have not yet been elucidated in full detail, interactions with mediators of inflammation and cartilage destruction provide a rationale for using them to treat OA complaints (<LINK REF="REF-Cameron-2009" TYPE="REFERENCE">Cameron 2009</LINK>). The knowledge on herbal medicine gleaned over centuries of medicinal use is collated in textbooks and monographs (for example the German Commission E monographs (<LINK REF="REF-Blumenthal-1998" TYPE="REFERENCE">Blumenthal 1998</LINK>)). All include empirical knowledge. The more recent Western monographs also include information on animal studies and clinical trials, for example the monographs of the European Scientific Cooperative on Phytotherapy (<LINK REF="REF-ESCOP-2003" TYPE="REFERENCE">ESCOP 2003</LINK>; <LINK REF="REF-ESCOP-2009" TYPE="REFERENCE">ESCOP 2009</LINK>), the monographs of the American Herbal Pharmacopeia (www.herbal-ahp.org), and the World Health Organization (WHO) monographs on selected medicinal plants (http://apps.who.int/medicinedocs/en/d/Js2200e/). Whereas the ESCOP and American and WHO monographs are not official, they provide scientific information on the safety, efficacy, and quality of medicinal plants and provide recommendations for their use in clinical practice (for example the doses, types of preparation). In contrast, the European Medicines Agency (EMA) monographs (www.ema.europa.eu/ema/index.jsp?curl=search.jsp&amp;q=Herbal+monographs&amp;btnG=Search&amp;mid=WC0b01ac05800240cf) serve as guidance for application dossiers to obtain marketing authorizations by the regulatory authorities of the individual countries in the European Union. These monographs, however, have not used an evidence-based approach.  <BR/>
</P>
</SUBSECTION>
<CONDITION MODIFIED="2014-05-09 20:45:17 +1000" MODIFIED_BY="[Empty name]">
<P>Lawrence and Felson (<LINK REF="REF-Lawrence-2008" TYPE="REFERENCE">Lawrence 2008</LINK>) estimated that among US adults, nearly 27 million had clinical OA in 2005 (up from the estimate of 21 million for 1995). OA is characterized by degeneration of the joints. Any joint of the body can be affected, but the most prominent joints include the hips, knees, and hands. Women are affected with OA more often than men and the prevalence increases with increasing age. Overweight and heavy physical work may explain OA in some cases, but non-mechanical factors and genetic disposition are involved as well (<LINK REF="REF-van-den-Berg-2011" TYPE="REFERENCE">van den Berg 2011</LINK>; <LINK REF="REF-Zhang-2010a" TYPE="REFERENCE">Zhang 2010a</LINK>). Primary OA has to be distinguished from secondary OA that is induced, for example, by traumatic events and endocrine or metabolic disorders. Both primary and secondary forms result in impaired quality of life due to pain and physical disability (<LINK REF="REF-Schmitz-2010" TYPE="REFERENCE">Schmitz 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-05-09 20:48:53 +1000" MODIFIED_BY="[Empty name]">
<P>For the purpose of this review we have adopted the WHO guidelines (<A HREF="http://www.who.int/medicines/areas/traditional/definitions/en/">www.who.int/medicines/areas/traditional/definitions/en/</A>) for the definition of medicinal plant products, that is, "Herbal medicines include herbs, herbal materials, herbal preparations and finished herbal products, that contain as active ingredients parts of plants, or other plant materials, or combinations.</P>
<UL>
<LI>Herbs: crude plant material such as leaves, flowers, fruit, seed, stems, wood, bark, roots, rhizomes or other plant parts, which may be entire, fragmented or powdered.</LI>
<LI>Herbal materials: in addition to herbs, fresh juices, gums, fixed oils, essential oils, resins and dry powders of herbs. In some countries, these materials may be processed by various local procedures, such as steaming, roasting, or stir-baking with honey, alcoholic beverages or other materials.</LI>
<LI>Herbal preparations: the basis for finished herbal products and may include comminuted or powdered herbal materials, or extracts, tinctures and fatty oils of herbal materials. They are produced by extraction, fractionation, purification, concentration, or other physical or biological processes. They also include preparations made by steeping or heating herbal materials in alcoholic beverages and/or honey, or in other materials.</LI>
<LI>Finished herbal products: herbal preparations made from one or more herbs. If more than one herb is used, the term mixture herbal product can also be used. Finished herbal products and mixture herbal products may contain excipients in addition to the active ingredients. However, finished products or mixture products to which chemically defined active substances have been added, including synthetic compounds and/or isolated constituents from herbal materials, are not considered to be herbal."</LI>
</UL>
<P>The WHO also notes that "in some traditions, materials of inorganic or animal origin may also be present", however, in this review we have applied the strict definition and excluded herbal products combined with non-herbal materials (http://apps.who.int/medicinedocs/en/d/Jh2945e/4.html).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-05-09 21:00:37 +1000" MODIFIED_BY="[Empty name]">
<P>There is evidence that pro-inflammatory cytokines play a significant role in the pathogenesis of OA, in which articular cartilage, subchondral bone, and synovial membrane are involved. Cytokines including interleukin-1 (IL-1), tumour necrosis factor &#945; (TNF&#945;), IL-6, and members of the IL-6 protein superfamily including adiponectin, oncostatin M, and pre-B cell colony enhancing factor (also known as visfatin), IL-7, IL-17, and IL-18 can promote articular cartilage extracellular matrix protein degradation or synergize with other cytokines to amplify and accelerate cartilage destruction. Attempts to modify the progression of human OA in well designed, controlled clinical trials with an IL-1 receptor antagonist protein (IRAP) have not been successful (<LINK REF="REF-Malemud-2010" TYPE="REFERENCE">Malemud 2010</LINK>). Anabolic cytokines (also termed growth factors), including transforming growth factor-beta (TGF-&#946;), insulin-like growth factor-1 (IGF-1), and fibroblast growth factor-2 (FGF-2), have been characterized as potential chondroprotective agents (<LINK REF="REF-Malemud-2010" TYPE="REFERENCE">Malemud 2010</LINK>). Both aging and the OA process itself induce deranged TGF-&#946; receptor expression, causing a shift to dominant usage of activin receptor-like kinase-1 (ALK-1) instead of ALK-5, and resulting in a TGF-&#946; mediated catabolic pathway (<LINK REF="REF-van-den-Berg-2011" TYPE="REFERENCE">van den Berg 2011</LINK>).</P>
<P>Recently, other cytokines were also identified as being involved in the progressive breakdown of articular cartilage. Transcription factor hypoxia-inducible factor-2&#945; (HIF-2&#945;), which is highly enhanced in OA cartilage, has been shown to activate catabolic metalloproteinases (MMP) including MMP-13. In addition, HIF-2&#945; suppresses chondrocyte autophagy, promoting chondrocyte apoptosis. MMP-13 production is also activated via the chondrocyte discoidin domain receptor (DDR-2) through interaction with denatured collagen type II. The latter might occur in a proteoglycan depleted pericellular matrix where DDR-2 expression is enhanced, such as in OA cartilage. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-5) was identified to stimulate proteoglycan loss by interacting with transmembrane proteoglycan syndecan-4. Furthermore, the alarmins (also know as myeloid-related proteins), calcium binding proteins S100A8 and S100A9, were identified as catabolic mediators (<LINK REF="REF-van-den-Berg-2011" TYPE="REFERENCE">van den Berg 2011</LINK>). An improved understanding of the balance between pro-inflammatory, anabolic, and catabolic cytokines may eventually result in the commercial development of disease-modifying OA drugs (<LINK REF="REF-Malemud-2010" TYPE="REFERENCE">Malemud 2010</LINK>).  </P>
<P>Inflammation and imbalance in complex cytokine interactions cause morphological OA changes at the molecular level. Medicinal plant products may inhibit inflammatory mediators and interact with various cytokines, at least under experimental conditions (<LINK REF="REF-Cameron-2009" TYPE="REFERENCE">Cameron 2009</LINK>). The mechanism of action of the oral herbal medicines is likely to be broader than that of non-steroidal anti-inflammatory drugs. Some studies in animals indicate a promising cartilage-protective effect for some of the oral medicinal plant products, including Piascledine® containing ASU (<LINK REF="REF-Mazieres-1993" TYPE="REFERENCE">Mazieres 1993</LINK>), the <I>Harpagophytum</I> extract FB9195 (<LINK REF="REF-Chrubasik-2006" TYPE="REFERENCE">Chrubasik 2006</LINK>; <LINK REF="REF-Hadhyiski-2006" TYPE="REFERENCE">Hadhyiski 2006</LINK>), and a Chinese herbal mixture SKI306X® (<LINK REF="REF-Choi-2002" TYPE="REFERENCE">Choi 2002</LINK>). In a later, long term confirmatory study in humans, Piascledine® showed no effect on joint space loss (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>). It remains to be demonstrated whether the experimental observations of promising effects on surrogate markers of cartilage destruction by medicinal plant products are of clinical relevance.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-05-14 14:01:21 +1000" MODIFIED_BY="[Empty name]">
<P>Medicinal plant preparations are part of the armamentarium of traditional treatments for people with OA. This review is important to summarise the evidence of effectiveness of medicinal plant products used orally for OA, and to update the information on these products. We have undertaken this research to investigate the effectiveness and adverse side effects of these products so that people with OA and their healthcare providers may make more informed decisions about the usefulness of these interventions.</P>
<P>In the previous Cochrane review on herbal medicines for OA, oral and topical herbal medicines were considered together. When the update of this review became particularly large, a separation of topical and oral medicinal plant products seemed advisable because: (a) only oral products are purported to have any effect on joint structure, (b) topical herbal medicines may act as counter-irritants via the skin (for example nettle, peppermint, <I>Capsicum</I>), and (c) some products cannot be administered orally due to systemic toxicity (<I>Arnica</I>, comfrey).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-05-21 15:17:06 +1000" MODIFIED_BY="[Empty name]">
<P>To update an existing Cochrane systematic review to assess the benefits and harms of oral medicinal plant products in treating OA. Data were added from relevant randomised controlled trials published in the period from January 2000 to August 2013.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-03-07 14:14:03 +1100" MODIFIED_BY="Renea V Johnston">
<SELECTION_CRITERIA MODIFIED="2014-05-21 14:48:02 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-05-09 21:15:47 +1000" MODIFIED_BY="[Empty name]">
<P>All randomised controlled (placebo or active control) parallel and crossover trials examining the effects of oral herbal interventions for treating OA.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-05-21 14:48:02 +1000" MODIFIED_BY="[Empty name]">
<P>All persons diagnosed with OA according to the American College of Rheumatology (ACR) criteria (<LINK REF="REF-Altman-1986" TYPE="REFERENCE">Altman 1986</LINK>; <LINK REF="REF-Altman-1990" TYPE="REFERENCE">Altman 1990</LINK>; <LINK REF="REF-Altman-1991" TYPE="REFERENCE">Altman 1991</LINK>) or the equivalent European League Against Rheumatism (EULAR) criteria (<LINK REF="REF-Zhang-2009" TYPE="REFERENCE">Zhang 2009</LINK>; <LINK REF="REF-Zhang-2010a" TYPE="REFERENCE">Zhang 2010a</LINK>; <LINK REF="REF-Zhang-2010b" TYPE="REFERENCE">Zhang 2010b</LINK>). Studies with samples defined according to vague descriptions (for example 'joint pain') were not considered. Studies with participant samples defined according to incomplete or partial ACR and EULAR criteria were included, and notes were provided to identify possible weaknesses in sample selection in these studies.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-05-14 14:03:22 +1000" MODIFIED_BY="[Empty name]">
<P>Any orally consumed herbal intervention compared with an inert (placebo) or active control was included. Herbal interventions included any plant preparation (whole, powder, extract, standardised mixture) but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin.</P>
<P>In the methods published for the original review, herbal therapies used in conjunction with other treatments or combined with a non-herbal substance were also to be included if the effect of the non-herbal intervention was consistent among all groups and quantifiable such that the effect of the herbal intervention could be determined. In this review, however, we have confined interventions to those that comply with the WHO definition of 'herbal' (<A HREF="http://www.who.int/medicines/areas/traditional/definitions/en/">www.who.int/medicines/areas/traditional/definitions/en/</A>). Accordingly, extracted single compounds, synthetic reproductions of naturally occurring compounds, and herbal therapies combined with non-herbal substances are no longer herbal treatments. This definition is important because non-herbal substances may interact with herbs and change their effects, potency, and safety profile. Even if the non-herbal substance occurs in the same concentration in the placebo control (as is the case in one excluded study, <LINK REF="STD-Park-2009" TYPE="STUDY">Park 2009</LINK>), the intervention-control comparison is not valid because the non-herbal substance may interact uniquely with the herbs (for example enhanced absorption of ingredients) and not with the placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-05-09 21:30:36 +1000" MODIFIED_BY="[Empty name]">
<P>The main outcome measures considered were consistent with those used across Cochrane Musculoskeletal Group systematic reviews of interventions for OA: pain, function, adverse events, joint structure changes, and quality of life (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0024">Altman 1996</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0047">Pham 2004</A>).</P>
<P>To assess the benefits of treatment:</P>
<UL>
<LI>pain, measured on a visual analogue scale (VAS) (0 to 100), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (0 to 4, or VAS 0 to 100), numerical rating scale (0 to 3), or other pain scales;</LI>
<LI>physical function, measured by a VAS (0 to 100), WOMAC function subscale (0 to 4, or VAS 0 to 100), algofunctional index (0 to 3), time to perform functional tasks, or other validated functional scales.</LI>
</UL>
<P>To assess the safety of treatment:</P>
<UL>
<LI>number of participants reporting any adverse event.</LI>
</UL>
<P>Minor outcomes included:</P>
<UL>
<LI>withdrawals due to adverse events;</LI>
<LI>serious adverse events;</LI>
<LI>radiographic joint changes measured as minimum joint space width;</LI>
<LI>quality of life measured by the Short Form-36 (SF-36) or other validated scales.</LI>
</UL>
<P>We extracted data from the last time point in each trial. Because most interventions were not purported to be structure modifying, we also extracted data from earlier time points in some studies to allow data pooling with trials of shorter duration.</P>
<P>We included the following outcomes in the summary of findings tables, derived from the list of outcomes recommended by the Cochrane Musculoskeletal Group (CMSG) for inclusion in reviews of interventions for osteoarthritis: pain; function; number of participants experiencing any adverse event; withdrawals due to adverse events; serious adverse events; radiographic joint structure; and quality of life.</P>
<P>We did not extract data for re-analysis on any other outcome measures, such as swelling, use of rescue medications, or blood markers although these data were included in many of the included studies.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-05-09 21:37:12 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-05-09 21:35:44 +1000" MODIFIED_BY="[Empty name]">
<P>For this review update we searched the following electronic databases from the date of the last search in the previously published version of the review (to November 2008) and updated the search again on 21 May 2009, 14 December 2010, 16 May 2011, 12 December 2011, 15 June 2012, 25 and 27 February 2013, 15 March 2013, 7 May 2013, and finally on 29 August 2013:</P>
<OL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), part of <I>The Cochrane Library</I> (accessed 29 August 2013);</LI>
<LI>DARE, part of <I>The Cochrane Library</I> (accessed 29 August 2013);</LI>
<LI>MEDLINE (via Ovid) (2000 to 29 August 2013);</LI>
<LI>MEDLINE  (Ovid MEDLINE® In-Process &amp; Other Non-Indexed Citations) (to 29 August 2013);</LI>
<LI>EMBASE (via Ovid) (2000 to 29 August 2013);</LI>
<LI>CINAHL (via Ovid) (2000 to Week 5 2008); via EBSCOhost (2008 to 29 August 2013);</LI>
<LI>AMED (via Ovid) (1985 to 29 August 2013);</LI>
<LI>ISI Web of Knowledge (2000 to 29 August 2013);</LI>
<LI>Dissertation Abstracts, ProQuest (2000 to 29 August 2013);</LI>
<LI>WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch) (accessed 29 August 2013).</LI>
</OL>
<P>Thesaurus and free text searches appropriate to each database, which combined terms describing osteoarthritis and terms describing herbal medicine, were performed. No methodological filter was applied and the search was not limited by language.</P>
<P>The full search strategies for each database are outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-05-09 21:37:12 +1000" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of included trials for any other potential studies. Unpublished research reports and theses (grey literature) were sought directly from pharmaceutical companies (Steigerwald Pharmaceuticals) (<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>) and university libraries (<LINK REF="STD-Guyader-1984" TYPE="STUDY">Guyader 1984</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-03-07 14:14:03 +1100" MODIFIED_BY="Renea V Johnston">
<STUDY_SELECTION MODIFIED="2014-05-09 21:40:08 +1000" MODIFIED_BY="[Empty name]">
<P>This review was an update of a previous review. Two authors of the original review (CL, TP) and two other colleagues (JG, AB) made some contributions to this review and are acknowledged here as investigators. Because these investigators did not contribute to the totality of the review, they are identified in the <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK> rather than listed as authors of this review.</P>
<P>All titles and abstracts identified from electronic databases and other searches were independently examined by three investigators (MC, SC, CL). The full manuscript was retrieved for each record that had the possibility of meeting the review criteria.</P>
<P>Three review authors (MC, SC, CL) independently assessed the eligibility of retrieved studies for the review according to the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-03-07 14:14:03 +1100" MODIFIED_BY="Renea V Johnston">
<P>Data were extracted from each eligible study by two review authors acting independently. Because of the length of time taken to complete this review and the associated review of topical medicinal plant products for OA, the large number of studies included in this update, and the inclusion of studies in languages other than English, five investigators (MC, SC, AB, JG, TP) contributed to the data extraction.</P>
<P>Two review authors (MC, SC) independently extracted the following data from the included trials and entered the data in RevMan 5:</P>
<P>1) trial characteristics including size and location of the trial, and source of funding;</P>
<P>2) characteristics of the study population including age; and characteristics of the disease including diagnostic criteria and disease duration;</P>
<P>3) characteristics of the therapy in all trial arms including type and dose of therapy;</P>
<P>4) risk of bias domains as outlined in 'Assessment of risk of bias in included studies', below;</P>
<P>5) outcome measures, as the mean and standard deviation for continuous outcomes, and number of events for dichotomous outcomes (as outlined in <A HREF="http://archie.cochrane.org/sections/documents/#CRIT_OUTCOMES">Types of outcome measures</A>).</P>
<P>If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0039">Juni 2006</A>; <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0049">Reichenbach 2007</A>) and extracted data on the pain scale that was highest on the following list:</P>
<OL>
<LI>global pain; </LI>
<LI>pain on walking; </LI>
<LI>WOMAC pain subscore; </LI>
<LI>composite pain scores other than WOMAC;</LI>
<LI>pain with activities other than walking;</LI>
<LI>rest pain or pain during the night;</LI>
<LI>WOMAC global algofunctional score; </LI>
<LI>Lequesne osteoarthritis index global score; </LI>
<LI>other algofunctional scale;</LI>
<LI>patient's global assessment; </LI>
<LI>physician's global assessment.</LI>
</OL>
<P>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy:</P>
<OL>
<LI>global disability score; </LI>
<LI>walking disability; </LI>
<LI>WOMAC disability subscore; </LI>
<LI>composite disability scores other than WOMAC; </LI>
<LI>disability other than walking; </LI>
<LI>WOMAC global scale; </LI>
<LI>Lequesne osteoarthritis index global score; </LI>
<LI>other algofunctional scale; </LI>
<LI>patient&#8217;s global assessment; </LI>
<LI>physician&#8217;s global assessment.</LI>
</OL>
<P>If data on more than one quality of life scale were provided for a trial, we extracted data according to the hierarchy:</P>
<OL>
<LI>SF-36;</LI>
<LI>EuroQoL;</LI>
<LI>Sickness Impact Profile (SIP);</LI>
<LI>Nottingham Health Profile (NHP).</LI>
</OL>
<P>To avoid multiple outcome reporting in the review, we adopted the following rules to extract data.</P>
<UL>
<LI>Where outcomes were reported at several time points, we extracted the measure at the end of the intervention as the main outcome. Studies of similar duration were analysed using end of intervention data only. We also extracted data at interim time points and reported these data for completeness but did not include them in meta-analyses.</LI>
<LI>Where trial authors reported both final values and change from baseline values for the same outcome, we extracted the final values.</LI>
<LI>Where trial authors reported data analysed based on the intention-to-treat (ITT) sample and another sample (e.g. per protocol, as-treated), we extracted ITT-analysed data.</LI>
<LI>For crossover trials, data were extracted only up to the point of crossover given the potential for carry-over effects of these particular interventions and to bias the treatment effect following crossover.</LI>
</UL>
<P>Adverse events were measured as the number of patients experiencing any adverse event, patients who were withdrawn or dropped out because of adverse events, and patients experiencing any serious adverse events. Serious adverse events were defined as events resulting in in-patient hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life-threatening events, or death.</P>
<P>If additional data were required, we contacted the trial authors to obtain these data. Some data were converted to normalised scales prior to extraction and reporting. Where data were imputed or calculated (for example standard deviations calculated from standard errors, P values, or confidence intervals; imputed from graphs; or from the standard deviations in other trials) we reported these adjustments (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Any disagreements were resolved by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-05-10 12:29:03 +1000" MODIFIED_BY="[Empty name]">
<P>Two review investigators (MC, SC) independently assessed the risk of bias of each included trial against the key criteria: random sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias in accordance with methods recommended by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Each of these criteria were explicitly judged as: (a) low, (b) unclear (either lack of information or uncertainty over the potential for bias), or (c) high risk of bias. Potential disagreements were discussed and resolved by referring to the original protocol and, if necessary, arbitration by member(s) of the editorial group.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-05-10 12:31:24 +1000" MODIFIED_BY="[Empty name]">
<P>When possible, the analyses were based on ITT data (outcomes provided for every randomised participant) from the individual trials. For each trial, we presented outcome data as point estimates with the mean and standard deviation for continuous outcomes and risk ratio (RR) with corresponding 95% confidence interval for dichotomous outcomes. Where possible, for continuous outcomes we extracted the end of treatment scores rather than change from baseline scores. For continuous data, results were presented as mean differences (MD) and 95% confidence intervals (CI). We had planned that when different scales were used to measure the same outcome or concept, standardised mean difference (SMD) would be used. This was applicable to one analysis (ASU 300 mg versus placebo) for function. Outcomes pooled using SMD were re-expressed as a mean difference by multiplying the SMD by a representative control group baseline standard deviation from one trial using a familiar instrument.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-06 12:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Where a study was defined as a crossover trial, data were extracted only up to the point of crossover, given the potential for carry-over effects of these particular interventions to bias the treatment effect following crossover.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-05-10 12:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes we used the number randomised as the denominator, making the assumption that any participants missing at the end of treatment did not have a positive outcome. For continuous outcomes with no standard deviation reported, we calculated standard deviations (SD), if possible, from standard errors (SEM), P values, or CIs. For four studies we converted the VAS data from a 10 cm scale to a 100 mm scale (<LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>), and for three studies we converted SEM to SD (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>).</P>
<P>If no measures of variance were reported and the SD could not be calculated, we had planned to impute SDs from other studies in the same meta-analysis, using the average of the other SDs that were available, provided only a small proportion of studies comprising the meta-analysis had missing data. This imputation of missing data was not required for any of the meta-analyses.</P>
<P>We contacted trial authors to obtain details of methods that were missing from the trial reports. Details of author responses, as well as data conversion and imputation, are explained in characteristics of included studies and the associated table (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-05-10 12:34:31 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed included trials for clinical homogeneity in terms of participants, interventions, and comparators. For studies judged as clinically homogenous, we quantified the possible magnitude of inconsistency (that is heterogeneity) across studies using the I<SUP>2 </SUP>statistic with a rough guide to interpretation as follows: 0% to 40% might not be important; 30% to 60% might represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; 75% to 100% considerable heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-05-21 12:35:36 +1000" MODIFIED_BY="[Empty name]">
<P>To examine the possibility of publication bias, we planned to construct funnel plots if at least 10 studies were available for the meta analysis of a primary outcome, however we identified too few trials for this analysis.</P>
<P>We planned to assess the presence of small study bias in the overall meta-analysis by checking if the random-effects model estimate of the intervention effect was more beneficial than the fixed-effect model estimate, but again there were too few trials for this analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-05-21 14:49:28 +1000" MODIFIED_BY="[Empty name]">
<P>As far as data extraction was possible, descriptive results were reported for all included studies. We pooled data from clinically homogenous trials; that is with the same interventions, doses, comparators, and outcomes. Where we could not combine data, we have summarised the effect estimates and 95% CIs of each trial narratively. Meta-analyses are reported for multiple studies of ASU and <I>Boswellia serrata </I>only, using the random-effects model, based on the assumption that clinical and methodological heterogeneity was likely.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>See: 'Summary of findings' tables.</P>
<P>The main results (pain, function, joint structure, adverse events, withdrawals due to adverse events, serious adverse events, quality of life) of the review are presented in summary of findings tables (<LINK REF="REF-Schunemann-2011a" TYPE="REFERENCE">Schunemann 2011a</LINK>; <LINK REF="REF-Schunemann-2011b" TYPE="REFERENCE">Schunemann 2011b</LINK>). The overall grading of the evidence using the GRADE approach, classifying the evidence for each herbal intervention as: (a) high, (b) moderate, (c) low, or (d) very low, is included as an indication of our confidence in the results of the studies.</P>
<P>Continuous outcomes pooled using SMDs were re-expressed as MD by multiplying the SMD by a representative control group baseline SD from a trial using a familiar instrument (<LINK REF="REF-Schunemann-2011b" TYPE="REFERENCE">Schunemann 2011b</LINK>).</P>
<P>In the comments column of the summary of findings table we reported the absolute per cent difference, the relative per cent change from baseline, and the number needed to treat (NNT); NNT was reported only when the outcome showed a statistically significant difference).</P>
<P>For dichotomous outcomes, such as adverse events, the NNT was calculated from the control group event rate and the relative risk (RR) using the Visual Rx NNT calculator (<LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK>). The NNT for continuous measures was calculated using the Wells calculator (available at the CMSG Editorial office, <A HREF="http://musculoskeletal.cochrane.org/">http://musculoskeletal.cochrane.org/</A>).</P>
<P>For dichotomous outcomes, the absolute risk difference was calculated from the risk difference statistic in RevMan and the result expressed as a percentage. For continuous outcomes, the absolute benefit or change was calculated as the improvement in the intervention group minus the improvement in the control group, in the original units.</P>
<P>The relative per cent change for dichotomous data was calculated as the RR - 1 and expressed as a percentage. For continuous outcomes, the relative difference in the change from baseline was calculated as the absolute benefit divided by the baseline mean of the control group.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-05-10 12:39:30 +1000" MODIFIED_BY="[Empty name]">
<P>In order to explain the heterogeneity between the results of the included studies, we have included some subgroup analyses by type and length of intervention.</P>
<P>Data from studies of ASU compared with placebo have been subgrouped according to dose (300 mg or 600 mg) and length of intervention (three, six, or 36 months) (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>), or in the case of one study planned over two years but not reported the data available after 12 months of intervention (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>).</P>
<P>Data from studies of <I>Boswellia serrata</I> extracts have been subgrouped by proprietary product because although these products all contain <I>Boswellia serrata</I> extract we cannot be certain that the active principles are identical (<LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>).</P>
<P>There were insufficient data available on most oral herbal products to justify subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-05-14 14:04:19 +1000" MODIFIED_BY="[Empty name]">
<P>We planned a sensitivity analysis to investigate the robustness of the treatment effect on pain and function relative to allocation concealment and participant blinding, by removing the trials that reported inadequate or unclear allocation concealment and lack of participant blinding from the meta-analysis to see if this changed the overall treatment effect. There were insufficient data to perform these analyses.<BR/>
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-05-14 14:06:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-05-10 13:04:45 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Note: proprietary names underlined; botanical names are set in italics.</P>
<P>Forty-nine randomised controlled studies involving 5980 patients with OA met the inclusion criteria for this review (45 studies were identified for this review update and four studies were included in the original review).</P>
<P>Most of the studies were of parallel design, with two groups comparing a herbal intervention to a placebo (inert) control only (n = 28). A further seven studies compared herbal interventions to both active and placebo controls in three (or more) arm designs (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>; <LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>). One study included a non-intervention control in a third arm comparison against a herbal intervention and placebo (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>). Thirteen studies were head-to-head comparisons between herbal products and active controls (<LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>).</P>
<P>All studies including active controls used a non-inferiority design, however in five of these studies we queried the activity of the comparator agent (<LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>).</P>
<P>Only seven studies used true crossover designs (<LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>), versus placebo, and one of these studies included a third arm against an active control (<LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>). One study was described as a crossover trial but the methodology and reported results indicated that this study was conducted as a parallel trial (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>), and in this review this study was classified as a parallel design.</P>
<P>Eighteen studies were of confirmatory design (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>), that is effect size was estimated a priori, statistical power and alpha level were set, and sample size recruitment undertaken according to these calculations. The remaining 32 studies were of exploratory design and were generally of poorer methodological quality.</P>
<SEARCH_RESULTS MODIFIED="2014-05-10 12:54:02 +1000" MODIFIED_BY="[Empty name]">
<P>This review was formed from the division of a broader review of herbal therapies for the treatment of OA. In the original review both topical and oral medicinal plant products were considered. The search strategy for this updated review was structured from the protocol used in the original review. The searches for this review update have been repeated several times since 2005. It is not possible, therefore, to give a precise account of the search results as the number of records identified from all searches.</P>
<P>A full search was completed before the current review was divided into two parts (December 2011). In that full search of all databases we identified, after the removal of duplicates, 288 abstracts on topical or oral herbal medicines in the treatment of OA.</P>
<P>In recent repeat searches (June 2012, February 2013, May 2013, August 2013) we identified approximately 2500 citations, reduced to 309 citations after removal of duplicates from previous searches, and from these titles and abstracts we sought 99 items in full. Three studies published as abstracts only were excluded because they were identified as duplicate publications of full text manuscripts already included in this review. A further seven studies currently obtained only in abstract form are awaiting classification should full text reports become available. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for our best estimate of results from the searches.</P>
<P>A total of 45 new studies, including four studies published between 1988 and 1997 that had been overlooked in the previous review (<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>), were identified for inclusion in the updated review (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>; <LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>; <LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). These new studies were added to the four studies of oral herbal products included in the original review (<LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-05-10 13:03:22 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Thirty-three different medicinal plant products were tested in the included studies. Products were compared with placebo, active, and non-intervention controls. Due to differing study protocols and different herbal interventions, meta-analyses were restricted to data from multiple studies of proprietary products from avocado-soyabean unsaponifiables (ASU) and <I>Boswellia serrata</I>.</P>
<P>Monoherbal products studied were medicinal plant products derived from <I>Boswellia serrata </I>(gum resin extracts), <I>Curcuma domestica </I>(ethanolic root extract), the Malay jewel vine (<I>Derris scandens</I>) (ethanolic stem extract), <I>Garcinia kola </I>(crude seed), devil's claw (<I>Harpagophytum procumbens</I>) (aqueous or etholic extractions or crude powdered plant material), <I>Petiveria alliacea </I>(tipi tea) (aqueous extract), <I>Pinus pinaster</I> (polyphenol concentrate from pine bark), <I>Rosa canina lito </I>(crude plant material from fruit and seed), <I>Salix pupurea </I>+<I> daphnoides </I>(ethanolic bark extract), <I>Uncaria guianensis</I> (aqueous bark extract), <I>Vitellaria paradoxa</I> (patented seed extract), and <I>Zingiber officinale </I>(acetone or carbon dioxide extracts).</P>
<P>Mixtures of two herbal preparations included medicinal products from <I>Boswellia carteri</I> (gum resin extract) and <I>Curcuma longa</I> (root extract), <I>Persea gratissma</I> (unsaponifiables) and <I>Glycine max</I> (unsaponifiables), <I>Phellondenron amurense</I> (bark extract) and <I>Citrus sinensis </I>(peel extract), <I>Uncaria guianensis</I> and<I> Lepidium meyenii </I>(aqueous bark extracts), and a combination of root extracts of two ginger species (<I>Zingiber officinalis</I> and <I>Alpinia galanga </I>(also known as Thai ginger)).</P>
<P>Polyherbal preparations included two European mixtures, Phytodolor N® and Reumalex®; a Korean mixture SKI306X®; 10 Ayurvedic formulae: RA-11®, Antarth, shunthi-guduchi (SGC), shunthi-guduchi with guggal (SGCG), and five formulae known only as A, B, C, D, or E; two Chinese herbal mixtures: Duhuo Jisheng Wan and blood-nourishing, hard-softening (BNHS); and a Japanese herbal mixture called Boiogito.</P>
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for preparation details of all products.</P>
<P>A wide range of outcome measures were used and the reporting of measures differed among studies, limiting the utility of some studies for meta-analysis. All VAS were 100 mm lines with anchor points identified as 0 (nil symptom) and 100 (worst possible symptom), but in four studies the VAS scores were reported on a centimetre scale in the range 0 to 10 cm (<LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>). For ease of comparison between trials we converted all VAS data to the 0 to 100 mm scale.</P>
<P>Several studies used the WOMAC, but this index may be used with two possible scoring methods: a battery of 0 to 4 Likert scales, or a battery of 100 mm VAS. Typically the Likert scale scores are presented as aggregate scores (sums) for each of the three subscales (pain subscore range 0 to 20, stiffness subscore range 0 to 8, physical function subscore range 0 to 68), whereas the VAS may be aggregated (pain subscore range 0 to 500, stiffness subscore range 0 to 200, physical function subscore range 0 to 1700) or converted to normalised units (means) for each subscale (all subscales scored 0 to 100). Although both scoring systems are acceptable for clinical and research use, there is no agreed conversion ratio between them so studies using the differing systems are not comparable. Also, in a few studies although standardised measures such as the WOMAC were used the data were reported in atypical forms that required some conversion or estimation before they could be included in these analyses. Specific details of all data conversions are included in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-05-10 13:04:45 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Reasons for excluding studies were: (a) not a randomised controlled trial (<LINK REF="STD-Grahame-1981" TYPE="STUDY">Grahame 1981</LINK>; <LINK REF="STD-Guyader-1984" TYPE="STUDY">Guyader 1984</LINK>; <LINK REF="STD-Kagore-2011" TYPE="STUDY">Kagore 2011</LINK>; <LINK REF="STD-Linsheng-1997" TYPE="STUDY">Linsheng 1997</LINK>; <LINK REF="STD-Loew-1996" TYPE="STUDY">Loew 1996</LINK>; <LINK REF="STD-Mishra-and-Singh-2003" TYPE="STUDY">Mishra and Singh 2003</LINK>; <LINK REF="STD-Myers-2010" TYPE="STUDY">Myers 2010</LINK>; <LINK REF="STD-Saley-1987" TYPE="STUDY">Saley 1987</LINK>; <LINK REF="STD-Srivastava-1989" TYPE="STUDY">Srivastava 1989</LINK>; <LINK REF="STD-Wang-1985" TYPE="STUDY">Wang 1985</LINK>; <LINK REF="STD-Wegener-2003" TYPE="STUDY">Wegener 2003</LINK>; <LINK REF="STD-Xu-2005" TYPE="STUDY">Xu 2005</LINK>; <LINK REF="STD-Yuelong-2011" TYPE="STUDY">Yuelong 2011</LINK>; <LINK REF="STD-Zell-1993" TYPE="STUDY">Zell 1993</LINK>), (b) review or discussion paper (<LINK REF="STD-Anonymous-1993" TYPE="STUDY">Anonymous 1993</LINK>; <LINK REF="STD-Brien-2006" TYPE="STUDY">Brien 2006</LINK>; <LINK REF="STD-Chrubasik-1998" TYPE="STUDY">Chrubasik 1998</LINK>; <LINK REF="STD-Dharmananda-1985" TYPE="STUDY">Dharmananda 1985</LINK>; <LINK REF="STD-Falch-1997" TYPE="STUDY">Falch 1997</LINK>; <LINK REF="STD-Gendo-1997" TYPE="STUDY">Gendo 1997</LINK>; <LINK REF="STD-Kielczynski-1997" TYPE="STUDY">Kielczynski 1997</LINK>; <LINK REF="STD-Long-2001" TYPE="STUDY">Long 2001</LINK>; <LINK REF="STD-Reuss-1981" TYPE="STUDY">Reuss 1981</LINK>), (c) not a herbal intervention (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Levy-2009" TYPE="STUDY">Levy 2009</LINK>; <LINK REF="STD-Park-2009" TYPE="STUDY">Park 2009</LINK>), (d) unable to identify the herbal components of the intervention (<LINK REF="STD-Jacquet-2009" TYPE="STUDY">Jacquet 2009</LINK>; <LINK REF="STD-Kulkarni-1991" TYPE="STUDY">Kulkarni 1991</LINK>), (e) individualised treatments thus not a standardised herbal intervention (<LINK REF="STD-Fang-2008" TYPE="STUDY">Fang 2008</LINK>; <LINK REF="STD-Hamblin-2008" TYPE="STUDY">Hamblin 2008</LINK>), (f) mixed sample and unable to extract data for participants with OA only (<LINK REF="STD-Biswas-1998" TYPE="STUDY">Biswas 1998</LINK>; <LINK REF="STD-Du-2006" TYPE="STUDY">Du 2006</LINK>; <LINK REF="STD-Lechner-2011" TYPE="STUDY">Lechner 2011</LINK>; <LINK REF="STD-Schaffner-1997" TYPE="STUDY">Schaffner 1997</LINK>), (g) duplicate publication or part thereof (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Lung-2004" TYPE="STUDY">Lung 2004</LINK>; <LINK REF="STD-Rein-2004b" TYPE="STUDY">Rein 2004b</LINK>; <LINK REF="STD-Schmid-2001" TYPE="STUDY">Schmid 2001</LINK>; <LINK REF="STD-Winther-2004" TYPE="STUDY">Winther 2004</LINK>), (h) abstract publication only (<LINK REF="STD-Biswas-1997" TYPE="STUDY">Biswas 1997</LINK>; <LINK REF="STD-Schmid-1998a" TYPE="STUDY">Schmid 1998a</LINK>), or (i) did not include functional or clinical outcomes (<LINK REF="STD-Zeng-2008" TYPE="STUDY">Zeng 2008</LINK>). Subanalyses of two studies (<LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>) were identified in other publications (<LINK REF="STD-Lung-2004" TYPE="STUDY">Lung 2004</LINK>; <LINK REF="STD-Rein-2004b" TYPE="STUDY">Rein 2004b</LINK>; <LINK REF="STD-Winther-2004" TYPE="STUDY">Winther 2004</LINK>) and were excluded from this review to avoid repetition of data. In the original review, one study was classified as pending assessment subject to full translation of the texts (<LINK REF="STD-Loew-1996" TYPE="STUDY">Loew 1996</LINK>), but in this update language was no barrier to inclusion and this study was excluded on other grounds.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-05-14 14:06:14 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, 'Risk of bias' tables.</P>
<P>The risk of bias of each study was assessed independently by two review authors according to the criteria described in the methods (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Schunemann-2011a" TYPE="REFERENCE">Schunemann 2011a</LINK>). Quality of the included studies was variable and should be taken into account when interpreting results. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the risk of bias assessment. Only three studies adequately met all six validity criteria and thus were at minimal risk of bias (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>).</P>
<P>Although not directly measures of bias, we considered if authors reported that they had obtained ethics committee approval, clinical trials registration, or complied with the Declaration of Helsinki and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals in Human Use Good Clinical Practice (ICH GCP) guidelines. Further, we considered that risk of bias could be assumed to be low if these oversights implied that a risk of bias was reduced. For example, the ICH GCP guidelines were recommended in Germany, France, Great Britain, and Scandanavia from 1986 onwards, therefore we have assumed that Human Research Ethics committee approvals granted for studies after this time, in these countries, necessitated compliance with the guidelines regarding randomisation, allocation concealment, and blinding of participants and assessors. In 1989, these guidelines were recommended across the European Community (EC) as it was then constituted. Again, we have assumed that from this date studies with ethics committee approval, conducted in EC countries, have complied with these guidelines. In 1996, compliance with the ICH CGP guidelines was required under German law governing clinical trials.</P>
<P>The ICH GCP guidelines are now adopted by the WHO and most countries, including many developing countries, are listed as following these guidelines. Formally constituted human research ethics committees are charged with ensuring that clinical trials are conducted in compliance with these guidelines and associated regional legislation. Six studies reported some form of board approval or review but did not specify that the board was a formally constituted human research ethics committee nor reported compliance with relevant guidelines or legislation (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>). Nine studies did not report any form of ethical oversight or compliance with research design guidelines (ICH GCP guidelines or Declaration of Helsinki) (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>).</P>
<ALLOCATION MODIFIED="2014-05-14 14:06:08 +1000" MODIFIED_BY="[Empty name]">
<P>We attributed low risk of bias to 28 studies that fully described an appropriate process of generating a randomisation schedule (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). We also attributed low risk of bias to two studies that reported compliance with the ICH GCP guidelines but did not fully describe the randomisation processes because in these studies adequate randomisation processes could be inferred (see <LINK TAG="OTHER_BIAS_SOURCES" TYPE="SECTION">Other potential sources of bias</LINK>) (<LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>).</P>
<P>A further 13 studies were described as randomised but the method of randomisation was not reported (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>; <LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>; <LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>). In another two studies randomisation was reported in insufficient detail to allow replication of the method (<LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>), and in a further two studies the methods could be more accurately described as quasi-randomisation (<LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>). We classified each of these studies as having unclear risk of bias due to randomisation procedures. One study was not randomised (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>) and has been classified as having high risk of bias.</P>
<P>Allocation concealment was poorly described in most studies. Allocation concealment was assessed according to the Cochrane format, as described in the methods (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We attributed low risk of bias to three studies (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>) in which allocation concealment was explicitly reported, and the 20 studies in which it could reasonably be inferred from the description of methods (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). One study reported that allocation was not concealed, neither from participants nor the research assistant (<LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>). This study has been classified as having a high risk of bias.</P>
<P>Allocation concealment could not be determined in any other study; neither could failure to conceal allocation be determined. These studies have been classified as having unclear risk of bias for this domain.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-05-10 19:45:21 +1000" MODIFIED_BY="[Empty name]">
<P>Low risk of bias has been attributed to 33 studies in which the herbal products and placebo or active controls could not be distinguished by colour, size, smell, shape, packaging, or treatment regimen (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>).</P>
<P>In a small number of studies (n = 9), the method of blinding was inadequately described and no reference to governing guidelines made (see <LINK TAG="OTHER_BIAS_SOURCES" TYPE="SECTION">Other potential sources of bias</LINK>). Although we considered it highly likely that these studies were sufficiently blinded, we downgraded the risk of blinding to unclear (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>). Risk of bias has been downgraded to high in studies that were open label, single blinded, or where interventions could be clearly distinguished (<LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>).</P>
<P>In some studies where allocation concealment was inadequately described (see <LINK TAG="ALLOCATION" TYPE="SECTION">Allocation (selection bias)</LINK>) it was unclear whether clinical examiners were blinded to treatment (detection bias). We have classified these studies as having unclear risk of bias in the blinding domain.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-05-14 14:06:14 +1000" MODIFIED_BY="[Empty name]">
<P>Low risk of bias has been assigned to 28 studies in which participant withdrawals were fully reported and analyses conducted according to an ITT model. in these studies methods for replacing missing data were fully reported (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>; <LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>; <LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>; <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>; <LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>; <LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). Unclear risk of attrition bias has been attributed to 17 studies in which withdrawals were reported but not considered in the analyses (per protocol analysis only) (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>; <LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>). Studies that neither reported participant withdrawals nor applied any method for replacement of missing data were ascribed a high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-05-10 21:10:39 +1000" MODIFIED_BY="[Empty name]">
<P>Some studies adopted validated measures but outcome data were reported as non-standardised scores (VAS 0 to 10 instead of 0 to 100, paracetamol in tablets rather than milligrams). We converted these data to standardised forms prior to re-analysis and have noted these data conversions in this section of the risk of bias tables but not attributed any increased risk.</P>
<P>In three studies we identified errors in data during conversion and have downgraded these studies to unclear risk (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>).</P>
<P>We have downgraded to unclear risk of bias 12 studies in which data were insufficiently reported to allow extraction for re-analysis (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>; <LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>; <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>; <LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>).</P>
<P>Examples of selective reporting included providing mean scores only (omission of SDs) at some or all time points, or reporting data spread as standard errors of measure (SEM) rather than SDs. Similarly, data reported only as group change scores, percentages, or raw scores without measures of data spread, and data presented in graphical form only, were inadequate for re-analysis. In some cases we were able to calculate the unreported data (for example convert SEM to SD), however we considered that the classification of unclear risk of bias should still be applied to this selective reporting (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>; <LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>).</P>
<P>A few studies were particularly poorly reported and have been classified as having high risk of bias for this criterion. Examples of very poor reporting included omission of key demographic data (for example age, gender, concomitant disease) and failure to report reasons for withdrawals or adverse events (that is a safety concern). In one study that was described as a crossover design with three arms (intervention, placebo control, and non-intervention control) data were reported from the intervention and placebo control groups only, and no data were reported after the apparent crossover (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>). We cannot be certain whether the reporting bias in this study occurred in the description of the research design or reporting of the results. We have treated this study as a two group parallel design and classified it as having a high risk of reporting bias.</P>
<P>In some studies reporting bias was difficult to identify. Omission of details may not be apparent if consistent throughout the report. For example, in one study of pine bark extract the outcome data were reported at 90 days only (<LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>) whereas in the other two studies of this product the outcome data were reported at more frequent intervals (<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>; <LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>). We considered it unlikely that the former study was planned as a simple pre-post analysis over such a wide treatment period and questioned whether mid-point data may have been omitted from the report.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-05-10 21:18:01 +1000" MODIFIED_BY="[Empty name]">
<P>Selection bias due to diagnostic criteria (see <LINK TAG="ALLOCATION" TYPE="SECTION">Allocation (selection bias)</LINK>) is reported under the heading of 'other bias' in the risk of bias tables.</P>
<P>We attributed low risk of bias to studies that recruited and assessed participants consistently with the ACR and EULAR criteria, obtained ethics committee approval, had clinical trials registration, used validated outcome measures, and reported compliance with the Declaration of Helsinki and ICH GCP guidelines. Further, we considered that risk of bias could be assumed to be low if satisfying one of these conditions implied the satisfaction of another. For example, the ICH GCP guidelines were recommended in Germany, France, Great Britain, and Scandanavia from 1986 onwards, therefore we have assumed that Human Research Ethics committee approvals granted after this time for studies in these countries necessitated compliance with the guidelines. In 1989, these guidelines were recommended across the European Community (EC) as it was then constituted. Again, we have assumed that from this date studies with ethics committee approval and conducted in EC countries have complied with these guidelines regarding randomisation, allocation concealment, and blinding of participants and assessors.</P>
<P>In 1996, compliance with the ICH CGP guidelines was required under German law governing clinical trials. The ICH GCP guidelines are now adopted by the WHO and most countries, including many developing countries, are listed as following these guidelines. Formally constituted human research ethics committees are charged with ensuring that clinical trials are conducted in compliance with these guidelines and associated regional legislation. We have classified as low risk all studies that reported either compliance with ICH GCP guidelines or ethics committee approval, or both.</P>
<P>Unclear risk of bias has been attributed to six studies that reported some form of board approval or review but did not specify that the board was a formally constituted human research ethics committee nor reported compliance with relevant guidelines or legislation (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>; <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>; <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>). High risk of bias has been attributed to the nine studies that did not report any form of ethical oversight or compliance with research design guidelines (ICH GCP guidelines or Declaration of Helsinki) (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-05-14 14:06:38 +1000" MODIFIED_BY="[Empty name]">
<P>See: 'Additional tables', <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: Herbal medicinal products used for the treatment of OA.</P>
<P>Results are listed below, grouped by the intervention in alphabetical order. Medicinal products from single plants are listed first, by botanical name, followed by products formed from two plants, followed by herbal mixtures from three or more plants. For consistency and ease of reading this same order of presentation was used in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: Herbal medicinal products used for the treatment of OA.</P>
<SUBSECTION>
<HEADING LEVEL="3">Medicinal products from single plants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Boswellia serrata </I>versus placebo</HEADING>
<P>
<I>Boswellia serrata </I>extracts have been subgrouped by proprietary products because we cannot be certain that the active principle in each product is identical.</P>
<P>One study investigated the proprietary Boswellia product CapWokvel®. The extract of <I>Boswellia serrata</I> was compared with placebo in 30 participants with OA in a crossover trial of two periods of eight weeks intervention separated by a three week washout period (<LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>). In this review, data have been extracted for the first arm of the trial only and may be considered as from an eight week parallel group trial. Pain and function (loss of movement) were rated using a 0 to 3 scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe), and statistically significant improvements in favour of the <I>Boswellia serrata </I>group were reported over the eight weeks of intervention (pain: MD -2.45, 95% CI -2.85 to -2.23, P &lt; 0.01; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; function: MD -2.16, 95% CI -2.56 to -1.76, P &lt; 0.01; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Two studies investigated the proprietary <I>Boswellia serrata</I> product 5-Loxin®. Both studies were undertaken by the same author team and were of similar design, suitable for pooling. Both studies involved three parallel groups, two intervention groups and one placebo control, over 12 weeks. The earlier study by <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK> was a dose-finding study comparing high (250 mg/day) and low (100 mg/day) doses. Participants who took 250 mg of 5-Loxin reported less pain (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) and better function (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) than participants who took the placebo. The risk of adverse events did not meaningfully differ between groups (5-Loxin 27/57 events, placebo 30/57 events; RR 0.90, 95% CI 0.62 to 1.30). The higher dose of 5-Loxin did not produce significantly greater clinical outcomes than the 100 mg dose.</P>
<P>In the subsequent study (<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>), 100 mg of 5-Loxin® was compared with 100 mg/day of an alternative <I>Boswellia serrata</I> product. Meta-analysis of the data from the two 100 mg 5-Loxin® groups in both studies showed that 90 days treatment with this product produced improvements over placebo in pain (MD -16.94, 95% CI -22.39 to -11.50; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and function (MD -9.62, 95% CI -11.35 to -7.89; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). Also, the risk of adverse events appeared lower in the 5-Loxin group than in the placebo group (5-Loxin 18/48 events, placebo 30/48 events; RR 0.60, 95% CI 0.39 to 0.92; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>Two studies investigated the proprietary <I>Boswellia serrata</I> product Aflapin® (<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>; <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>). In the three way comparison of Aflapin® and 5-Loxin® against placebo in 60 patients over 90 days, both treatment groups reported significantly greater improvements in pain (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and function (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) than did the placebo group, and Aflapin® consistently outperformed 5-Loxin® (<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>). This study was conducted using an ANOVA model and results of the three groups were presented as a series of student's t-tests; multivariate analysis would be required to confidently account for any chance effect from multiple two group comparisons. Data were extracted from the Aflapin® group in this study and subgrouped but not meta-analysed with data from an additional study (<LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>), a two parallel group test against placebo in patients with OA over 30 days, because of the substantial difference in length of intervention between these studies (30 days, <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>; 90 days, <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>). Viewing these studies together, trends of effectiveness of Aflapin® to reduce pain (30 days: MD -14.80, 95% CI -20.29 to -9.31; 90 days: MD -18.10, CI -24.95 to -11.25; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and increase function (30 days: MD -14.30, 95% CI -20.70 to -8.53; 90 days: MD -15.80, 95% CI -21.92 to -9.68; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). The risk of participants reporting adverse events did not differ between Aflapin® and the placebo groups after 30 or 90 days of intervention (30 days: Aflapin® 1/30, placebo 1/29; RR 0.97, 95% CI 0.06 to 14.74; 90 days: Aflapin® 1/19, placebo 1/19; RR 1.00, 95% CI 0.07 to 14.85; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Boswellia serrata</I> versus cyclo-oxygenase-II (COX-II) inhibitor anti-inflammatory drugs</HEADING>
<P>A single study compared the<I> Boswellia serrata </I>extract Cap Wovkel against the COX-II inhibitor anti-inflammatory drug valdecoxib in 66 participants over six months. Although follow-up was continued for an additional month, we extracted all data at the end of the intervention period. Although the authors reported that results favoured the intervention, re-analysis of the data indicated that results slightly favoured the intervention for WOMAC pain subscale scores only (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Results favoured control on all other outcomes, including function (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). Fewer participants in the valdecoxib group reported adverse events, thus the risk of adverse events appeared greater in the <I>Boswellia serrata </I>group (Cap Wovkel 4/33, valdecoxib 2/33; RR 2.00, 95% CI 0.39 to 10.18; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Curcuma domestica</I> versus NSAIDs</HEADING>
<P>A single study (107 participants recruited) compared six weeks intervention with an ethanolic root extract from <I>Curcuma domestica </I>against ibuprofen in a randomised, active control, parallel trial. Particpants within both groups showed statistically significant mean improvements in all outcomes over time at all time points (two, four, and six weeks). Between-group differences were not significant (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>) suggesting that <I>Curcuma domestica </I>has comparable efficacy to ibuprofen in the treatment of osteoarthritic pain and pain-related functional impairments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Derris scandens </I>versus NSAIDs</HEADING>
<P>An ethanolic extract from the stem of <I>Derris scandens</I> was tested in a head-to-head comparison with naproxen in a two group parallel trial over four weeks in people with OA of the knee (<LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>). Outcomes were reported using the WOMAC-VAS, but on a 10 cm scale. We extracted these data and converted them to normalised scores (range 0 to 100), and in so doing identified an error in one of the CIs. We contacted the authors who confirmed our correction. Our re-analysis supported the authors' conclusions that the effectiveness of <I>Derris scandens</I> was not significantly different from naproxen in improving OA pain (MD 5.00, 95% CI -1.84 to 11.84; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>) and physical function (MD 5.11, 95% CI -0.13 to 10.33; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>), but that the mean differences and CIs may be larger than originally reported. Also, of particular importance in comparisons against non-steroidal anti-inflammatory drugs (NSAIDs) <I>Derris scandens </I>showed a favourable adverse events profile: fewer participants in the <I>Derris scandens</I> group reported adverse events (<I>Derris scandens</I> 22/63, naproxen 29/62) and the risk of an adverse event occurring in that group was markedly lower than in the naproxen group (RR 0.75, 95% CI 0.49 to 1.15; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Garcinia kola</I>
</HEADING>
<P>The crude seed of <I>Garcinia kola </I>was compared over six weeks to two NSAIDs, naproxen and celecoxib, as well as a placebo control in a four group parallel trial of 143 patients with OA of the knee (<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>). Results favoured all active interventions over placebo for reductions in pain and function. These outcomes appeared to have been measured using two independent WOMAC subscales with differing reporting and scoring formats: pain was measured using the WOMAC-VAS, and function using the WOMAC 0 to 4. Data were reported as change scores, percentages, CIs, and P values, insufficient for extraction in this review. Comparing efficacy of the active agents, pain relief appeared to have been most rapid and persistent in the celecoxib group, and most delayed and least persistent in the <I>Garcinia kola</I> group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Harpagophytum procumbens</I> (Devil's claw)</HEADING>
<P>Four studies investigated three different products from the roots of <I>Harpagophytum procumbens. </I>Three studies compared two different extracts to placebo in trials completed by 174 participants (<LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>). One study (92 participants) compared cryoground root powder to the weak NSAID diacerhein (<LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>).</P>
<P>In the studies using the ethanolic <I>Harpagophytum </I>extract Flexiloges®, no improvement in WOMAC pain scores was found (<LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>; <LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>). These authors provided post hoc definitions of improvement that favoured the intervention. 'Responders' to treatment were defined as participants whose WOMAC pain scores did not increase by more than 20%, either with (<LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>) or without (<LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>) additional rescue medication (up to 4000 mg ibuprofen) in weeks 17 to 20 of the study. These definitions of response were inconsistent with the American College of Rheumatology (ACR) criteria for response, and data derived from these measures have not been reproduced in this review.</P>
<P>In contrast, the aqueous <I>Harpagophytum </I>extract Arthrotabs® showed favourable effects on OA pain measured using a 0 to 4 categorical rating scale, but these data were also insufficiently reported (<LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>).</P>
<P>The <I>Harpagophytum </I>powder Harpadol® was not inferior to diacerhein in reducing pain, as measured using a 100 mm VAS (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>). This study constituted moderate evidence that four months daily use of 2610 mg of <I>Harpagophytum procumbens </I>powder was not significantly different from 100 mg diacerhein, producing comparable improvements in pain. In this same study participants in the <I>Harpagophytum</I> group used fewer NSAIDS (diclofenac) and analgesics (acetominophen supplemented by caffeine) at all time points (30, 60, and 120 days) than did participants in the diacerhein group. Due to differences in the protocols and outcome measures these studies were not suitable for data pooling.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Petiveria alliacea </I>(tipi tea)</HEADING>
<P>Overall, the study of tipi tea (<LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>) was inadequately reported, although it should be noted that the study was published only in the form of a letter. Attempts to obtain a report of the study in greater detail were not successful. Data reported in this study were not adequate for re-analysis but were reported descriptively for the sake of completeness. Participants receiving tipi tea and participants receiving placebo tea both showed some improvement although no significant differences were found between the two groups. The study was small (n = 20, crossover design) and provided little detail with regard to inclusion criteria. Pain scales against which the outcomes were quantified were not disclosed. Five participants, three during use of the placebo tea and two during use of the tipi tea, reported mild adverse effects. Two participants failed to complete the trial but the reasons for their withdrawal were not explained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Pinus pinaster </I>(synonym<I> Pinus maritima</I>)</HEADING>
<P>Although the pine bark extract Pycnogenol® was investigated in three studies (293 participants) the data could not be pooled despite all studies returning results that favoured the intervention over placebo. The two smaller, earlier studies used identical doses of Pycnogenol® (150 mg daily) over the same intervention period (three months) but the content of the marker substance in the daily dose differed considerably. Moreover, the reported pain and physical function data used two different forms of outcome measure, the VAS 0 to 100 mm items of the WOMAC (<LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>) and the 0 to 4 grading (<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>). Unlike another Cochrane review exclusively on this product, in which results of these two studies were pooled (<LINK REF="REF-Schoonees-2012" TYPE="REFERENCE">Schoonees 2012</LINK>), we have reported data from these studies independently. Data in one study were reported graphically (<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>), which was insufficient to allow extraction for re-analysis without a considerable margin for error. Results from the other study demonstrated improvements in pain (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>) and physical function (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>) for the Pycnogenol® group over the placebo, but the small sample size (n = 37) of this study was noted as caution against generalisation of these results.</P>
<P>The more recent, larger study used a confirmatory design and reported outcome data using the WOMAC 0 to 4 (<LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>). Despite positive outcomes from this study the data could not be pooled with the earlier studies because a smaller dose of pine bark extract (100 mg daily) with an undeclared content of marker substance in the daily dose was used in the confirmatory study. Results from this study also favoured pine bark extract over placebo for improvements in pain (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>) and physical function (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>). Observed together, these three studies provided modest evidence that pine bark extract was effective in reducing pain and improving physical function in people with OA even at daily doses as low as 100 mg.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Ricinus officinalis </I>(castor oil)</HEADING>
<P>Castor seed oil was compared to diclofenac (NSAID) in 110 patients with probable OA of the knee in a parallel trial over four weeks (<LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>). Pain was reported on a 100 mm VAS. Results of this exploratory study were insufficiently reported to allow extraction and re-analysis. Results favoured diclofenac over <I>Rinicus officinalis</I> for improvement in pain, although pain decreased in both the intervention and active control groups over time. The adverse event profile markedly favoured castor oil over placebo (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>), however it was unclear whether pain (possibly due to untreated OA) was included among the adverse events reported in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Rosa canina lito </I>(rose hip)</HEADING>
<P>Three studies (306 participants) compared daily doses of 5 g of a rose hip and seed powder (<I>Rosae caninae </I>pseudofructus cum fructibus powder) to placebo. Two studies reported reductions in OA pain on a standardised five point scale (0 to 4: 0 = no relief, 4 = almost total relief) (<LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>) and the third used the WOMAC-VAS (<LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). Although the WOMAC-VAS included a pain subscale, these pain data were not pooled. The data in one study were insufficiently reported to allow extraction for re-analysis (<LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>) and the remaining two studies used differing outcome measures to report pain (<LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>). Also, the periods of intervention differed between studies: three months (<LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>), and four months (<LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>).</P>
<P>Previously it has been suggested that it was likely that some participants may have been in common between the <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK> and <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK> reports such that pooling data from these studies would double count some individuals (<LINK REF="REF-Vlachojannis-2009" TYPE="REFERENCE">Vlachojannis 2009</LINK>), but correspondence with the study authors confirmed that the data were not transferred between these studies (Winther, personal communication, 21 September 2011). In this review we have treated these reports as independent studies.</P>
<P>These studies constituted modest and somewhat conflicting evidence that daily consumption of 5 g of <I>Rosa canina lito</I> powder produced improvements in OA pain superior to placebo (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Salix daphnoides</I> or <I>Salix pupurea x daphnoides </I>(willow)</HEADING>
<P>Two studies (205 participants recruited) of willow bark preparations returned differing results (<LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>; <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>). One study compared an ethanolic bark extract of <I>Salix daphnoides</I>, equivalent to 240 mg salicin, to placebo and active (100 mg diclofenac) controls in parallel groups over six weeks to determine that although slightly more effective than placebo, willow bark was less effective than diclofenac in reducing OA pain measured using the WOMAC pain scale (<LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>). In this study similar numbers and severities of adverse events were reported for both the willow bark and ibuprofen interventions.</P>
<P>Another study compared the same daily dose of <I>Salix purpurea </I>x <I>daphnoides</I> ethanolic bark extract to placebo and reported improvements in WOMAC pain scores after two weeks of intervention (<LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>).</P>
<P>Although these products have different names, both are drawn from the subspecies daphnoides (subspecies of <I>Salix purpurea</I>) and may be considered together, however data from these studies were not suitable for meta-analysis because the authors did not report measures of variance (SD) for mean scores at the 14 day time point. In this review mean WOMAC pain and function scores were reported for a descriptive comparison (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>; <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>; <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>; <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>).</P>
<P>The risk of participants reporting adverse events was not significantly different between <I>Salix</I> extract and placebo (<I>Salix</I> 19/43, placebo 20/41; RR 0.91, 95% CI 0.57 to 1.43; <LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>), but when compared against diclofenac the adverse events profile of <I>Salix daphnoides </I>was favourable (<I>Salix </I>19/43, diclofenac 30/43; RR 0.63, 95% CI 0.43 to 0.93; <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Uncaria guianensis </I>(cat's claw)</HEADING>
<P>In a 4 week, parallel group trial comparing aqueous bark extract of <I>Uncaria guianensis</I> with placebo (<LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>) participants using cat's claw reported a statistically significant reduction in pain with activity within the first week of treatment (P &lt; 0.01). The same pattern of improvements were seen in physicians' and patients' global assessments of disease activity. These improvements were maintained throughout the four week trial, but data from these measures were not reported in sufficient detail to allow re-analysis in this review. In contrast, reduction in night pain (MD -11.10, 95% CI -26.4 to 4.24, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>) was not statistically significant although changes on this measure somewhat favoured cat's claw over placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Vitellaria paradoxa </I>(shea)</HEADING>
<P>A patented seed extract of <I>Vitellaria paradoxa</I>, the African shea tree, was tested against placebo in a single centre, two group parallel trial for 89 patients with OA of the hip or knee (<LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>). Clinical outcomes were measured using the WOMAC and the Comprehensive Osteoarthritis Test (COAT). Results were equivocal on all clinical outcomes, and none of these data were reported in sufficient detail to allow extraction. The authors focused their report on improvements in biomarkers, which were not of importance in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Zingiber officinale </I>(ginger)</HEADING>
<P>Data from three studies of ginger could not be pooled because the ginger preparations were dissimilar, including acetone extract (<LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>), carbon dioxide extract (<LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>), and a mixture of two ginger species (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>).</P>
<P>A crossover trial of Zintona EC, a standardised carbon dioxide extract containing <I>Zingiber officinale </I>(also known as Chinese ginger), with placebo reported results in favour of the intervention on measures of pain on movement and function (handicap), using the 100 mm VAS for these domains from the Hebrew version of the WOMAC (<LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>) (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>; <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). The first arm of the crossover included 24 participants; one participant in the ginger group reported an adverse effect with the intervention (heartburn) (ginger 1/12, placebo 0/12; RR 3.05, 95% CI 0.16 to 78.19; <LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>).</P>
<P>Another study compared a 510 mg daily dose of standardised acetone extract of <I>Zingiber officinale</I> (EV.EXT 33) with 1200 mg ibuprofen and both tablet and capsule placebos in a crossover trial in 67 participants (56 completed) and reported results in favour of ibuprofen for measures of pain (100 mm VAS), Lequesne algofunctional index, and use of NSAIDS (<LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>). Data reporting in this study was insufficient to allow extraction for re-analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Medicinal products from two plants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Boswellia carteri</I> and<I> Curcuma longa </I>
</HEADING>
<P>Although the authors described this study as a crossover trial, their reporting of the research method was consistent with a two group parallel trial of a <I>Boswellia-curcuma</I> mixture compared with placebo over three months of intervention among people with OA (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>). Minutes of pain free walking time, considered in this review as a measure of function, were recorded in each group after one, two, and three months of intervention. At each time point the placebo group reported a shorter mean pain free walking time, and at two and three months the differences between the placebo and intervention groups on this measure were statistically significant (one month: MD 2.5, 95% CI -0.07 to 5.07, P = 0.06; two months: MD 4.00, 95% CI 1.31 to 6.69, P = 0.004; 3 months: MD 3.5, 95% CI 0.65 to 6.35, P = 0.02; <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>), but none of these measures were adjusted for baseline scores.</P>
<P>For measures of pain on passive movement and pain on active movement, group means and mean changes from baseline were calculated from frequency tables reported in the paper (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>). No measures of data spread were reported and SDs could not be calculated from the data provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Persea gratissma</I> and <I>Glycine max </I>(avocado-soyabean unsaponifiables (ASUs)) versus placebo</HEADING>
<P>The avocado-soyabean unsaponifiable (ASU) product Piascledine® was investigated in six studies; in five studies ASU was compared with placebo (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>) and in a sixth study ASU was tested head-to-head against a 1200 mg daily dose of chondroitin sulphate (<LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>). When compared against chondroitin sulphate, ASU was not inferior on any outcome (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>; <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>; <LINK REF="CMP-021.03" TYPE="ANALYSIS">Analysis 21.3</LINK>).</P>
<P>On the basis of two studies (<LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>) the original review concluded that the evidence for ASU in the treatment of OA was convincing (Little 2000). A further study supported this conclusion (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>). Another study of Piascledine® over two years did not reveal any differences between groups, neither in the primary outcome measure of joint space width nor in clinical parameters including pain, function, and NSAID consumption (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>). A further study over three years (36 months) showed no differences between the ASU and placebo groups on any clinical or functional outcomes, but radiological assessment of joint space width revealed that 20% fewer participants in the ASU group showed progressive narrowing of joint space width (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>).</P>
<P>Each of the five placebo-controlled studies used a daily dose of 300 mg Piascledine®, and one study included an additional group that received 600 mg daily (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>). A total of 1008 participants with OA completed these trials. In one study a subgroup of patients with OA of the hip and of the knee were identified and analysed independently (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>). Pooling of results for NSAID consumption measured as diclofenac equivalents, pain measured using a 100 mm VAS, and Lequesne functional index indicated that these studies were highly hetergeneous, returning an I<SUP>2</SUP> of approximately 80% for the meta-analysis of each of these outcome measures. Although the longer trials returned results that conflicted with the shorter trials, they were designed to investigate structural joint changes as the primary outcome and clinical outcomes were of secondary importance (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>). Lequesne and colleagues reported that they were surprised by the lack of symptomatic improvements among participants in the Piascledine® group and were unable to explain why this trial was markedly different to those of other well designed trials of Piascledine® in patients with OA (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>). Rather than present a single meta-analysis, we subgrouped these studies according to the dose of Piascledine® and the length of the intervention period.</P>
<SUBSECTION>
<HEADING LEVEL="5">Pain</HEADING>
<P>In two studies (326 participants) pain was measured on a 100 mm VAS after three months of 300 mg Piascledine® daily (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>). Using a random-effects model the pooled results were a MD of -11.90 (95% CI -23.95 to 0.15; <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>). Results after six months of treatment with 300 mg daily also favoured Piascledine® (MD -10.40, 95% CI -17.20 to -3.60) (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>) but after 12 months the results indicated no superior performance compared with placebo (MD 1.00, 95% CI -6.58 to 8.58) (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>).</P>
<P>Results from the one study (156 participants) that included a 600 mg daily dose were consistent in favour of Piascledine® (MD -14.20, 95% CI -20.82 to -7.58; <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>) (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>).</P>
<P>Results after 36 months of treatment were reported as changes from baseline rather than absolute scores (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>). Because of the considerable difference in length of intervention, these results have not been meta-analysed with the results from shorter duration studies. In this study of 399 participants there was no significant difference in pain reduction between the ASU and placebo groups (MD -0.66, 95% CI -7.39 to 6.07; <LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>).</P>
<P>Results also differed somewhat according to pain location. <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK> reported greater improvement amongst participants with OA of the hip (MD -13.80, 95% CI -25.22 to -2.38) compared with those with OA of the knee (MD -7.10, 95% CI -14.45 to 0.25; <LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>), but in both subgroup analyses the CIs overlapped the midline indicating inconclusive results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Physical function</HEADING>
<P>The Lequesne algofunctional index was used as a measure of overall physical function in all studies, but these data were extracted from three studies only (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>) because the other studies also reported function using outcome measures prioritised over Lequesne by the Cochrane Musculoskeletal Review Group. Again, results differed according to the length of intervention. Results after three months of treatment with either 300 mg or 600 mg Piascledine® daily favoured use of this intervention for improvements in function (300 mg: MD -1.80, 95% CI -2.68 to -0.92; <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>; 600 mg: MD -1.30, 95% CI -2.38 to -0.22; <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>). After 12 months of treatment with the 300 mg dose the MD for function was 0.10 (95% CI -0.78 to 0.98; <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>). In one study functional disability was also measured with a 100 mm VAS; participants taking 300 mg Piascledine® daily reported improvement compared with participants taking placebo after six months of treatment (MD -13.20, 95% CI -20.00 to -6.40; <LINK REF="CMP-019.04" TYPE="ANALYSIS">Analysis 19.4</LINK>) (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>). In another study the WOMAC functional scale was used as a key outcome after 36 months of treatment (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>). Results in this study showed a MD of -1.00 (95% CI -7.14 to 5.14; <LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>).</P>
<P>For the four studies that measured function at the end of treatment ASU 300 mg improved function (SMD -0.42, 95% CI -0.73 to -0.11; I<SUP>2</SUP> = 74%; <LINK REF="CMP-019.07" TYPE="ANALYSIS">Analysis 19.7</LINK>). Re-expressed, this translates to a mean reduction in functional disability of 7 mm (-5 mm to -12 mm) on a 0 to 100 mm VAS disability scale (0 is best score). The high heterogeneity was accounted for by the result from <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>, the 12 month study which showed no effect of ASU 300 mg compared with placebo.</P>
<P>Overall there was moderate evidence that three or six months of daily use of 300 mg of Piascledine® afforded statistically significant improvements in pain (100 mm VAS) and physical function (Lequesne algofunctional index) but these improvements did not persist in longer studies. Despite multiple studies with adequate sample sizes, the evidence was graded as moderate because allocation concealment was unreported (unclear) in each of the studies showing these improvements. In all other ways, these studies were well designed, and the consistent results across three studies were convincing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Joint space width</HEADING>
<P>Joint space width was reported in only two of the six studies of ASU (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>). In a study of 108 participants over 24 months between group differences were identified only when the participants were subgrouped into those with below median and above median joint space width (JSW) scores at baseline (<LINK REF="CMP-019.11" TYPE="ANALYSIS">Analysis 19.11</LINK>). The below median JSW subgroup who consumed ASU showed significantly less reduction in joint space width (that is preservation of joint space) compared with participants who consumed placebo (MD -0.43, 95% CI -0.73 to -0.13), but changes in JSW from baseline were not significantly different between the placebo and intervention groups in the above median JSW subgroup (MD 0.16, 95% CI -0.31 to 0.63) (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>). After 36 months there was no significant difference in changes in JSW from baseline between the ASU and placebo groups (MD -0.03, 95% CI -0.22 to 0.16).</P>
<P>In the longest term study participants were identified as 'progressors' if they showed a JSW reduction of greater than or equal to 0.5 mm over three years (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>). In the ASU group 40.4% of participants were identified as progressors compared with 50.3% of participants in the placebo group. These data were insufficiently reported for extraction and re-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The number of participants who reported adverse events was reported per group in each study. In two studies more participants in the placebo groups reported adverse events (<LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>), and in the other two studies more participants in the 300 mg ASU groups reported adverse events (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>). When these data were meta-analysed for the 300 mg dose of ASU there was a negligible difference in the odds of a participant in either the placebo or intervention group reporting an adverse event (ASU 267/521, placebo 270/529; RR 1.04, 95% CI 0.97 to 1.12; <LINK REF="CMP-019.08" TYPE="ANALYSIS">Analysis 19.8</LINK>). These studies together constituted high level evidence that participants taking 300 mg of ASU daily experienced no greater odds of adverse events than did participants taking a placebo preparation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Phellondendron amurense</I> and <I>Citrus sinensis </I>(NP 06-1)</HEADING>
<P>The medicinal plant product NP 06-1 is a mixture of <I>Phellondenron amurense</I> bark extract and <I>Citrus sinensis </I>peel extract. <LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK> and colleagues tested this product against placebo in a four group parallel study of 80 patients with OA of the knee over eight weeks. Two groups (one intervention and one control) included participants of normal body weight; the other two groups included overweight participants. Results in both the normal weight and overweight participants favoured NP 06-1 over placebo for improvement of knee function as measured using the Lequesne algofunctional index (MD -3.82, 95% CI -7.05 to -0.59; <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>). NP 06-1 contains berberine, which may have contributed to weight loss in the overweight participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Uncaria guianensis</I> and <I>Lepidium meyenii</I> (Reparagen®)</HEADING>
<P>Reparagen® is a mixture of aqueous bark extracts of <I>Uncaria guianensis</I> and <I>Lepidium meyenii. </I>It was tested against glucosamine sulphate in a two group parallel trial in 95 patients with OA of the knee (<LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>). Results from this trial suggested that Reparagen® was not significantly different from glucosamine sulphate for the remediation of OA pain. These results were insufficiently reported to allow data extraction for re-analysis. The adverse event profile of Reparagen® appeared favourable (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Zingiber officinale</I> and <I>Alpinia galanga</I>
</HEADING>
<P>A standardised extract (EV.EXT 77) of ginger (<I>Zingiber officinale) </I>and galangal (<I>Alpina officinale</I>, also known as Thai ginger) was compared with placebo in 261 people with OA of the knee (<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>). Significant improvements in favour of ginger were reported for pain (100 mm VAS) after walking 50 feet (MD -9.60, 95% CI -16.81 to -2.39, P = 0.009; <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>). Also, improvements in all components of the WOMAC score were reported in favour of the ginger group over placebo. These improvements were statistically significant for the WOMAC stiffness score and the WOMAC total score but not for the pain and function domains of the WOMAC that were considered in this review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Medicinal products from three or more plants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Korean herbal mixture: SKI306X®</HEADING>
<P>Two studies compared the Korean herbal preparation SKI306X® to placebo (<LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>) or diclofenac controls (<LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>). The earlier study (139 participants) was undertaken to determine the dose and safety profile of the intervention. The latter study (249 participants) was conducted to determine clinical efficacy. In the earlier study, daily doses of 200 mg, 400 mg, and 600 mg were compared with placebo and outcomes measured using a pain VAS and Lesquesne index. Meta-analyses of these results (pooling doses) demonstrated consistent effects in favour of SKI306X® for reducing pain (MD -17.36, 95% CI -22.57 to -12.15; <LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>) and improving physical function (MD -2.73, 95% CI -3.71 to -1.74; <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>). Effect sizes for these outcomes did not show a consistent linear relationship to dose. There was moderate evidence that, regardless of dose (600 mg, 1200 mg, 1800 mg), four weeks daily use of SKI306X® produced statistically significant improvements in the pain VAS and Lequesne algofunctional index compared to placebo.</P>
<P>The number of participants who reported adverse events was reported per group, and more participants receiving 400 mg SKI306X® reported adverse events than did participants in any other group. When each of the intervention subgroups was compared with the placebo group the risk ratios (RR) differed between comparisons, but for each subgroup the risk of participants reporting adverse events was not clearly greater in the placebo or intervention groups. When these data were meta-analysed, there was negligible difference in the risk of a participant in either the placebo or SKI306X group reporting an adverse event (overall SKI306X 14/70, placebo 15/69; RR 0.93, 95% CI 0.49 to 1.79; <LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>).</P>
<P>In a follow-up study, a daily dose of 600 mg SKI306X® was compared with 100 mg diclofenac. Results favoured diclofenac for the same outcome measures of 100 mm VAS for pain (MD 1.31, 95% CI -2.78 to 5.40; <LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>) and Lequesne's algofunctional index (MD 0.77, 95% CI 0.10 to 1.44; <LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>). Statistically significant changes in these measures were seen within both groups over time. Between-group differences in physical function were statistically significant (P = 0.02) but differences in self-reported pain were not (P = 0.53). This study constituted moderate evidence that daily use of 600 mg of SKI306X over four weeks produced improvements in pain (100 mm VAS) that were not statistically significantly different from 100 mg diclofenac. When compared against diclofenac, 600 mg SKI306X appeared to have a favourable adverse event risk profile (SKI306X 22/125, diclofenac 36/124; RR 0.61, 95% CI 0.38 to 0.97; <LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Phytodolor®N</HEADING>
<P>Three studies compared Phytodolor®N (prepared from ash bark, aspen leaf, aspen bark, golden rod herb; for details see table) to placebo or active control (piroxicam) in 176 participants and reported results in favour of Phytodolor®N for reduced use of NSAIDs (diclofenac) and improvement in range of motion as measured by finger to ground distance in lumbar flexion (<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>). Finger to ground distance is one of the methods used to quantify the Schober test (lumbar spine flexion in standing) and is a measure of physical function that is more commonly used in the assessment of people with low back pain than with OA. It is probably a meaningful measure of physical function in participants with OA of the lumbar spine but none of these studies were limited to participants with spinal OA.</P>
<P>These studies could be viewed with some skepticism because they were undertaken by the manufacturer (Steigerwald Pharmaceuticals). One of these studies was a crossover design with intervention periods of seven days duration and used a dose of Phytodolor®N 33% greater than that used in the two other studies (<LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>). The other two studies were of parallel design, one of three weeks intervention with measures at weekly intervals (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>) and the other of four weeks intervention with measures at baseline and weeks one, two, and four (<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>). Because doses of Phytodolor®N and some of the measures differed among trials, and because most of the data from these studies were reported as composite statistics (Chi<SUP>2</SUP>, P values), data could not be pooled for meta-analyses. In this review all available mean data were reported for descriptive comparison (<LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>; <LINK REF="CMP-027.02" TYPE="ANALYSIS">Analysis 27.2</LINK>; <LINK REF="CMP-027.03" TYPE="ANALYSIS">Analysis 27.3</LINK>). For one study, group means and mean changes from baseline were calculated from frequency tables reported in the paper (<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>). SDs could not be calculated from the data provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reumalex®</HEADING>
<P>A self-prescribed dose ("2 tablets at a time") of the herbal mixture Reumalex® was compared with placebo over two months of treatment. Both patients with rheumatoid arthritis and OA were recruited for this study. Separate data for the OA subgroup were provided for the primary outcomes of the AIMS 2 pain score and modified Ritchie index (<LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>). At the end of the treatment period the mean reduction in AIMS 2 pain score was greater in the Reumalex® group (MD -0.89, 95% CI -1.73 to -0.05; <LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>).</P>
<P>Four participants withdrew from each of the placebo and intervention groups due to side effects, and a further five (Reumalex® n = 2, placebo n = 3) complained of exacerbation of symptoms, but it was unclear how many of these participants were people with OA (RR 1.08, 95% CI 0.40 to 2.91; <LINK REF="CMP-028.02" TYPE="ANALYSIS">Analysis 28.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chinese herbal mixture: Duhuo Jisheng Wan</HEADING>
<P>The Chinese herbal mixture Duhuo Jisheng Wan (DJW) was tested in a head-to-head comparison against diclofenac sodium over four weeks intervention (following one week run-in) in patients with unilateral or bilateral OA of the knee (<LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>). Pain and stiffness across a range of conditions were measured using a battery of VAS. The Lequesne algofunctional index was used to capture joint function data. DJW appeared to be as effective as diclofenac in reducing joint pain (<LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>) and improving function (<LINK REF="CMP-029.02" TYPE="ANALYSIS">Analysis 29.2</LINK>). Unfortunately, the risk of adverse events associated with DJW were also comparable to diclofenac (DJW 28/100, diclofenac 27/100; RR 1.04, 95% CI 0.66 to 1.63; <LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>). This toxicity profile, combined with the fact that DJW was administered as an 18 capsule per day dose, meant that it was unlikely to gain credence as a viable alternative to NSAIDs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chinese herbal mixture: blood-nourishing, hard-softening</HEADING>
<P>The Chinese mixture for blood-nourishing and hard-softening (BNHS) is an extract from the root of <I>Paeoniae alba, Gentiana macrophylla, </I>and <I>Glycyrrhiza</I> (species not stated, possibly <I>uralensis</I>). This product was tested against two active controls (western medicine control: glucosamine sulphate, Chinese medicine control: counter osteophyte herbal mixture) although the activity of the controls was not demonstrated in the paper and may be questionable. Although Cao and colleagues reported this investigation as one study it was really two distinct clinical trials run simultaneously over four weeks in different hospitals (<LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>). Sixty participants (30 at each site) were randomised to receive BNHS capsules and 30 participants were randomised to receive one of the two active control drugs. Data from the two trials were presented independently.</P>
<P>When compared with glucosamine sulphate, BNHS capsules produced slightly superior improvements in VAS measures of pain on walking (MD -2.00, 95% CI -6.81 to 2.81; <LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>) but no mean improvements in WOMAC function (MD 0.00, 95% CI -2.53 to 2.53; <LINK REF="CMP-031.02" TYPE="ANALYSIS">Analysis 31.2</LINK>). No adverse events were reported in this trial.</P>
<P>In comparison with the alternate Chinese herbal mixture counter osteophytes, BNHS capsules produced a slight mean increase in pain on walking (MD 2.00, 95% CI -7.12 to 11.12; <LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>) and slight improvement in physical function (MD -2.00, 95% CI -7.57 to 3.57; <LINK REF="CMP-030.02" TYPE="ANALYSIS">Analysis 30.2</LINK>). Four participants in this trial reported adverse events with use of BNHS. No participants reported adverse events associated with use of the alternative Chinese mixture. Because the sample size was small, and all adverse events occurred in one group, the risk of adverse events associated with BNHS appeared considerable in this trial (RNHS 4/30, Chinese control 0/30; RR 9.00, 95% CI 0.51 to 160.17; <LINK REF="CMP-030.03" TYPE="ANALYSIS">Analysis 30.3</LINK>) but this result may be viewed with some skepticism considering that no participants in the other trial reported any adverse events with BNHS capsule use.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ayurvedic formulae</HEADING>
<P>Three studies investigated seven Ayurvedic formulae. Two studies investigated formulae available as proprietary products: Antarth® (<LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>) and RA-II® (<LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>). The third study compared five Ayurvedic formulae formed from combinations of five plant extracts (<LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>) (for details see table). Because none of the Ayurvedic formulae were the same these studies were not suitable for pooling and are described independently.</P>
<SUBSECTION>
<HEADING LEVEL="5">Ayurvedic formulae: A, B, C, D and E</HEADING>
<P>Five Ayurvedic formulae formed from five herbal ingredients in varying combinations were tested against each other and against placebo in a six group trial over 16 weeks in 245 patients with OA of the knee (<LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>). Pain was measured on a 0 to 10 VAS and physical function was measured using the Indian version of the WOMAC 0 to 4. Results of this exploratory study were not reported in full detail to allow extraction and re-analysis. Generally results were equivocal on most outcomes. This study may have been underpowered to detect changes in a six group comparison (35 participants per group). The adverse event profile was noteworthy: participants who received formula D showed markedly greater odds of reporting adverse events (<LINK REF="CMP-032.01" TYPE="ANALYSIS">Analysis 32.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ayurvedic formula: Antarth</HEADING>
<P>Antarth was compared against placebo in a two group parallel trial over 12 weeks in 90 patients with OA of the knee (<LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>). Pain was measured on a 0 to 10 cm VAS, which we converted to a 0 to 100 mm scale during data extraction. Results slightly favoured Antarth over placebo for the reduction of pain in OA (<LINK REF="CMP-033.01" TYPE="ANALYSIS">Analysis 33.1</LINK>) but should be interpreted with caution because this exploratory study may have been underpowdered to detect clinical effects of Antarth.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ayurvedic formula: RA-11</HEADING>
<P>RA-11 was tested against placebo in a two group parallel trial over 32 weeks in 90 people with OA of the knee (<LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>). Pain, stiffness, and physical function were measured using the Indian modification of the WOMAC 0 to 4. Because the study was fully powered, with 45 participants in each group, and rescue medication was not permitted this study was well designed to capture data on the pain reducing effects of RA-11. An ITT model was applied to the analyses and missing data were replaced by the last observation carried forward method. Three participants were removed from the trial by the investigators due to "efficacy failure". Forcibly withdrawing participants with worsening pain and carrying forward data from the last observation of these participants may have somewhat exaggerated the effects of of RA-11 on pain. Results favoured RA-11 over placebo for improvements in pain (<LINK REF="CMP-034.01" TYPE="ANALYSIS">Analysis 34.1</LINK>) and function (<LINK REF="CMP-034.02" TYPE="ANALYSIS">Analysis 34.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ayurvedic formulae: SGC and SGCG</HEADING>
<P>Ayurvedic formulae SGC and SGCG were tested against glucosamine sulphate and celecoxib in a four parallel group trial over 24 weeks (<LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>). On measures of pain (VAS 0 to 100), function (WOMAC function), and with regard to participants reporting adverse events, both Auryvedic formulae were comparable to both glucosamine sulphate and celecoxib.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Japanese herbal mixture: Boiogito</HEADING>
<P>The Japanese herbal mixture Boiogito was compared head-to-head with loxoprofen for the management of knee pain and effusion in a small (n = 50) exploratory study over 12 weeks. Participants who took Boiogito reported slightly better Knee Society Rating System knee scores, including less joint effusion, than participants who took loxoprofen, but the results did not differ significantly between groups (MD -1.30, 95% CI -8.90 to 6.30; <LINK REF="CMP-039.01" TYPE="ANALYSIS">Analysis 39.1</LINK>). On the other hand participants who took loxoprofen reported slightly greater functional capacity on the stair climbing component of the Knee Society Rating System (MD 3.60, 95% CI 0.51 to 6.69; <LINK REF="CMP-039.02" TYPE="ANALYSIS">Analysis 39.2</LINK>) and no adverse events. One participant using Boiogito reported an adverse event (Boiogito 1/24, loxoprofen 0/23; RR 2.88, 95% CI 0.12 to 67.29; <LINK REF="CMP-039.03" TYPE="ANALYSIS">Analysis 39.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-04 18:28:07 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-05-10 23:14:27 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty-one medicinal plant products from single plant parts (<I>Boswellia serrata</I>, <I>Curcuma domestica Derris scandens</I>, <I>Garcinia kola</I>, <I>Harpagophytum procumbens</I>, <I>Petiveria alliacea</I>, <I>Pinus pinaster</I>, <I>Rosa canina lito</I>, <I>Salix pupurea+daphnoides, Uncaria guianensis</I>, <I>Vitellaria paradoxa</I> and <I>Zingiber officinale</I>); five mixtures of two herbal preparations (<I>Boswellia carteri</I> and <I>Curcuma longa</I>, <I>Persea gratissma</I> and <I>Glycine max</I>, <I>Phellondenron amurense</I> and <I>Citrus sinensis</I>, <I>Uncaria guianensis</I> and<I> Lepidium meyenii</I>, and <I>Zingiber officinalis</I> and <I>Alpinia galanga</I>) and the polyherbal preparations Phytodolor®N, Reumalex®, SKI306X®, Chinese herbal mixtures Duhuo Jisheng Wan and blood-nourishing, hard-softening, Ayurvedic formulae RA-11, A, B, C, D, E, and Antarth, and Japanese herbal mixture Boiogito were compared in 47 studies against placebo (n = 38), active control (n = 19), and no intervention (n = 1). Due to the differing study protocols (different outcome measures and times of outcome assessments) and medicinal plant products employed, pooling of data was only possible for the proprietary products avocado-soybean unsaponifiables (ASU) and <I>Boswellia serrata</I>.</P>
<P>Despite the great number of clinical trials carried out, reliable data could only be achieved for the ASU product Piascledine®. The pooled data of three studies with a confirmatory study design showed OA improvements, but another definitive study over two years failed to demonstrate effectiveness except in a subgroup of people with less severe complaints. The most recent comparison of Piascledine® and chondroitin sulphate showed that the ASU product was not inferior to the slow-acting anti-arthritic substance for which effectiveness within six months is controversial (<LINK REF="REF-Lee-2010" TYPE="REFERENCE">Lee 2010</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>; <LINK REF="REF-Wandel-2010" TYPE="REFERENCE">Wandel 2010</LINK>). Also, the most recent placebo-controlled study lasting three years failed to show any benefit for ASU in clinical outcome measures including the WOMAC index. The study was planned to confirm slower radiographic progression in symptomatic hip OA (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>) but only 20% fewer progressors were identified in the post hoc analysis, with progressors defined as patients with joint width space loss &gt; -0.5 mm.</P>
<P>Of the five studies that investigated three different extracts from <I>Boswellia serrata </I>gum resin, pooled data from two studies indicated OA improvement for the <I>Boswellia</I> product 5-Loxin®. The remaining 38 studies showed unproven benefit in the alleviation of OA for the herbal medicinal products investigated, which originated from Africa, Asia, Europe, India, and the Americas. Serious adverse events were not reported for any of the medicinal plant products.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-05-10 23:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>Evidence from studies that recruited patients with diagnoses of OA confirmed according to ACR or EULAR criteria may be directly applied to clinical practice. In some studies diagnostic criteria applied at recruitment were not labelled as ACR or EULAR criteria but were described in sufficient detail to be confident that they were fully consistent with the recommendations of these authorities. In six studies, however, ACR and EULAR criteria were not fully considered and these studies have been downgraded to unclear risk of selection bias (<LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>; <LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>; <LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>; <LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>; <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>; <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>). The applicability of evidence from these studies to clinical practice is also unclear. In another five studies selection was so broad as to almost certainly have included recruitment of participants with conditions other than OA (<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>; <LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>; <LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>; <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>; <LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>). These studies are classified as having high risk of bias and evidence from these studies may be of questionable use in clinical practice.</P>
<P>The WHO recommends that the manufacturing procedure of medicinal plant products should be described in detail (for example if other substances are added during manufacture in order to adjust the plant preparation to a certain level of active or characteristic constituents or for any other purpose). A method for identification and, where possible, assay of the plant preparation should be added. If identification of the active principle is not possible it should be sufficient to identify a characteristic ingredient or mixture of ingredients (for example the 'chromatographic fingerprint') to ensure consistent quality of the preparation in order to be able to re-do the study with an essentially similar product (having a comparable active principle, see below).</P>
<P>The active principle of a medicinal plant product is the sum of all ingredients that produce the medicinal action. The active principle has not been fully been identified for any of the anti-inflammatory acting herbal medicinal products. Co-active ingredients include flavonoids (<I>Acacia catechu, Citrus sinensis</I>, <I>Curcuma</I> species,<I> Derris scandens, Garcinia kola</I>,<I> Harpagophytum procumbens</I>, <I>Petiveria alliacea</I>, Phytodolor®N<I>, Rosa canina</I>, <I>Salix</I> species, <I>Scutellaria baicalensis</I>,<I> Zingiber </I>species), unsaturated fatty acids (Piascledine®, <I>Ricinus officinalis</I>, <I>Rosa canina</I>, SKI306X®, <I>Vitellaria paradoxa</I>), alkaloids (<I>Acacia catechu </I>(tryptamine derivatives), <I>Garcinia kola</I>,<I> Lepidium meyenii </I>(lepidiline), <I>Phellondenron amurense </I>(berberine), <I>Symphytum officinale, Uncaria</I> species) and in particular polyphenols (<I>Acacia catechu</I>, <I>Citrus sinensis</I>,<I> Pines pinaster</I>,<I> Rosa canina</I>), iridoid glycosides calculated as harpagoside (<I>Harpagophytum procumbens</I>), gingerols (<I>Zingiber </I>species), boswellic acids (<I>Boswellia</I> species), curcurminoids (<I>Curcuma</I> longa), or mustard glycosides (<I>Lepidium meyenii</I>). Mixtures of two or more herbal preparations form a new entity with their characteristic active principle being different from that of the single medicinal plant products, as are the actions and adverse events. If herbal extracts are combined the superiority of the mixture over the individual herbal preparation has to be established in vitro, in animal experiments, and in human pharmacological studies in order to demonstrate the superior effect and the safety.</P>
<P>The minimum information given for a medicinal plant product in an article should include the plant part, the brand name (if the preparation has not been solely prepared for the study), the excipient added in the case of extracts and the drug extract ratio if no crude plant material is used. The daily dosage of the 'native' plant preparation should be stated otherwise the extract dose may also contain additives (<LINK REF="REF-Chrubasik-1996" TYPE="REFERENCE">Chrubasik 1996</LINK>). Although not requested by regulatory authorities, it is desirable to know the content of at least one characteristic marker substance (if possibly a co-active ingredient). Only few studies provided all this information (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The results of studies with insufficient declared characteristics are only attributable to the particular product used in the study and cannot be transferred to other medicinal products from this plant material unless bioequivalence of the products has been demonstrated (<LINK REF="REF-Chrubasik-2003" TYPE="REFERENCE">Chrubasik 2003</LINK>).</P>
<P>Salicin, the characteristic ingredient of <I>Salix </I>species, is an ineffective pro-drug. However, during absorption salicin is metabolized into co-active salicylic acid derivatives. Surprisingly, the amount of salicylic acid produced from a daily dose of <I>Salix</I> bark extract containing 240 mg of salicin corresponds to an aspirin dose of only 100 mg, a cardioprotective rather than an anti-inflammatory dose (<LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>). This <I>Salix</I> extract dose, however, cannot be used to replace aspirin as a blood thinner because it has been shown not to have a major impact on blood clotting (<LINK REF="REF-Krivoy-2001" TYPE="REFERENCE">Krivoy 2001</LINK>). It is implausible that the regulatory authority EMA has restricted the use of willow bark preparations to four weeks (<LINK REF="REF-Vlachojannis-2013" TYPE="REFERENCE">Vlachojannis 2013</LINK>) in light of the fact that NSAIDs in current use, with a higher risk benefit ratio than willow extract, are used for longer treatment durations, for example up to 138 weeks (<LINK REF="REF-Reginister-2007" TYPE="REFERENCE">Reginister 2007</LINK>). Acute toxicity studies in rats could not determine a lethal dose of willow bark extract even in doses 200 times the experimental level (<LINK REF="REF-Glinko-1998" TYPE="REFERENCE">Glinko 1998</LINK>). Data on chronic toxicity are still lacking (<LINK REF="REF-EMA-2009" TYPE="REFERENCE">EMA 2009</LINK>; <LINK REF="REF-ESCOP-2003" TYPE="REFERENCE">ESCOP 2003</LINK>;). Possible interactions with natural or synthetic blood thinners need to be elucidated, especially if higher doses of willow bark extract (with 360 mg or 480 mg salicin per day) are employed. A life-threatening anaphylactic reaction was observed in a patient with a history of allergy to salicylates (<LINK REF="REF-Boullata-2003" TYPE="REFERENCE">Boullata 2003</LINK>). Known salicylate allergy is therefore a contra-indication for the use of willow bark preparations.</P>
<P>The clinical studies investigating medicinal products from <I>Harpagophytum procumbens </I>included a cryoground powder, an aqueous and an ethanolic extract. The extracts contained only half the amount of harpagoside in the daily dosage than what would be expected after complete extraction and if no additives were added. The ethanolic extracts were incompletely extracted (<LINK REF="REF-Sporer-1999" TYPE="REFERENCE">Sporer 1999</LINK>) and the aqueous extract contained additives (<LINK REF="REF-Chrubasik-1996" TYPE="REFERENCE">Chrubasik 1996</LINK>). According to the European Pharmacopoeia it is required that the starting material for <I>Harpagophytum</I> products contains a minimum of 1.2% of harpagoside. Since the daily dose of extracts should be prepared from 4.5 to 9 g of crude plant material, the daily dosage would provide 50 to 100 mg of harpagoside or more (European Medicines Agency (EMA) monographs). Thus, of the four studies investigating <I>Harpagophytum </I>products only one has used an appropriate dose.</P>
<P>In general, the daily dosages of medicinal products are based on information from monographs or textbooks and are not the result of dose-finding studies. It seems likely that an increase in dose might improve the clinical effect. This was shown for aqueous <I>Harpagophytum </I>and ethanolic <I>Salix </I>extracts in a patient population suffering from acute exacerbations of chronic low back pain (<LINK REF="REF-Chrubasik-1999" TYPE="REFERENCE">Chrubasik 1999</LINK>; <LINK REF="REF-Chrubasik-2000" TYPE="REFERENCE">Chrubasik 2000</LINK>). However, for some medicinal products a ceiling effect was demonstrated. For example, a 600 mg dose of Piascledine® per day was not more effective than a half dose (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>), and 600 mg or 400 mg of the herbal mixture SKI306X® was not more effective than 200 mg per day (<LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>), or 250 mg of the proprietary <I>Boswellia serrata</I> extract 5-Loxin® was not more effective than 100 mg per day (<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>). The first medical report on the use of dried and powdered willow bark dates back to 1763 (<LINK REF="REF-Stone-1763" TYPE="REFERENCE">Stone 1763</LINK>). The empirically chosen daily dose (up to 24 g) might have contained up to 1000 mg of salicin as the crude plant material generally contains about 4% salicin. Higher doses than that used in the study by <LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK> may reliably improve OA complaints. Future studies are required to identify the optimum daily doses of medicinal products.</P>
<P>Unsaturated fatty acids contribute to the anti-inflammatory effect of some medicinal plant products (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>; <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>; <LINK REF="REF-Cameron-2011" TYPE="REFERENCE">Cameron 2011</LINK>; <LINK REF="REF-J_x00e4_ger-2007" TYPE="REFERENCE">Jäger 2007</LINK>; <LINK REF="REF-J_x00e4_ger-2008" TYPE="REFERENCE">Jäger 2008</LINK>; <LINK REF="REF-Wenzig-2008" TYPE="REFERENCE">Wenzig 2008</LINK>). It seems likely that castor seed oil may improve OA complaints. Because a dose-finding study has not been undertaken, and high doses of castor oil produce unpleasant laxative effects, we question whether higher doses of castor oil are likely to be tolerated by people with OA.</P>
<P>The net benefit of an intervention may be defined as the magnitude of benefit minus the magnitude of harm (<LINK REF="REF-ICH-2004" TYPE="REFERENCE">ICH 2004</LINK>). Benefit and harm are not always measurable in standardised effect size units, complicating the calculation of net effect. However, the point remains that for each of the herbal medicines where clinical benefit is reported, clinical harm (adverse events, toxicity) must be considered in making an overall judgement of the usefulness of the intervention. Among the non-herbal medications commonly used to treat OA, NSAIDs in particular are associated with frequent and sometimes severe side effects (<LINK REF="REF-Gabriel-1991" TYPE="REFERENCE">Gabriel 1991</LINK>), particularly gastrointestinal complications including dyspepsia, perforations, ulcers, and bleeds (<LINK REF="REF-Ofman-2002" TYPE="REFERENCE">Ofman 2002</LINK>; <LINK REF="REF-Ofman-2003" TYPE="REFERENCE">Ofman 2003</LINK>), which add considerable cost to the usual care of people with OA (<LINK REF="REF-Smalley-1996" TYPE="REFERENCE">Smalley 1996</LINK>). In theory, ginger and <I>Curcuma</I> products might go along with an increased risk of stomach bleeding, however this has not been sufficiently evaluated (www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2011/09/WC500112680.pdf'; www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2010/02/WC500070703.pdf). In fact, no serious adverse events were reported with any herbal intervention in the included studies. It appears that the benefit risk ratio of medicinal plant products is superior to that of NSAIDs. A recent pharmacovigilance analysis revealed 117 reported adverse events, mostly cutaneous, hepatic and gastrointestinal disorders, associated with the intake of Piascledine®. Although the incidence of adverse events seems to be 'very rare', in light of the fact that the product is widely prescribed in France there is concern regarding possible under-reporting of adverse events (<LINK REF="REF-Olivier-2010" TYPE="REFERENCE">Olivier 2010</LINK>) (www.drugcite.com/?q=PIASCLEDINE&amp;s=&amp;a=).</P>
<P>A systematic review of adverse events is available for <I>Harpagophytum procumbens</I> that includes 28 clinical studies (mostly observational) reporting on 6892 patients who consumed <I>Harpagophytum</I> extract for up to one year. In none of the double blind studies was the incidence of adverse events higher during treatment with <I>Harpagophytum </I>than during placebo treatment. Minor adverse events (AE) were described across 20 studies in 138 of 4274 <I>Harpagophytum </I>consumers. This corresponds to an overall adverse event rate of around 3% for <I>Harpagophytum</I> preparations with a maximum of 100 mg harpagoside as the daily dosage (<LINK REF="REF-Vlachojannis-2008" TYPE="REFERENCE">Vlachojannis 2008</LINK>). Some of the adverse events, particularly minor gastrointestinal complaints and allergies, were probably related to <I>Harpagophytum</I>. Three studies on preclinical toxicity indicated very low acute toxicity (<LINK REF="REF-ESCOP-2003" TYPE="REFERENCE">ESCOP 2003</LINK>). Data on chronic toxicity, including mutagenicity, carcinogenicity, teratogenicity, and embryogenicity, were not found (<LINK REF="REF-ESCOP-2003" TYPE="REFERENCE">ESCOP 2003</LINK>). For most medicinal plant products preclinical data are not available, and only some of them report on their AE profiles (<LINK REF="REF-Basch-2004" TYPE="REFERENCE">Basch 2004</LINK>; <LINK REF="REF-Chrubasik-2005" TYPE="REFERENCE">Chrubasik 2005</LINK>; <LINK REF="REF-ESCOP-2003" TYPE="REFERENCE">ESCOP 2003</LINK>; <LINK REF="REF-ESCOP-2009" TYPE="REFERENCE">ESCOP 2009</LINK>; <LINK REF="REF-Krishnaraju-2010" TYPE="REFERENCE">Krishnaraju 2010</LINK>; <LINK REF="REF-Schoonees-2012" TYPE="REFERENCE">Schoonees 2012</LINK>; <LINK REF="REF-Stohs-2011" TYPE="REFERENCE">Stohs 2011</LINK>; <LINK REF="REF-Valerio-2005" TYPE="REFERENCE">Valerio 2005</LINK>; www.herbal-ahp.org, http://apps.who.int/medicinedocs/en/d/Js2200e/). It is thus recommended to do safety pharmacological studies according to published guidelines (www.fda.gov/cder/guidance/index.htm, www.emea.europa.eu/pdfs/human/ich/030095en.pdf) for the individual medicinal plant products. If a carcinogenic effect is assumed, carcinogenicity studies are also mandatory (www.ich.org/LOB/media/MEDIA489.pdf). If the guidelines of good manufacturing practice including those for the starting material (www.api-conference.org/pa4.cgi?src=eca_news_data.htm&amp;nr=488&amp;show=daten/news/GMP_News_488.htm&amp;id=S11510781142) are considered, contamination of medicinal products with other herbal medicines, pesticides, heavy metals, or drugs can be ruled out.</P>
<P>The adverse effect quota and profile for Phytodolor®N appear to be better than for NSAIDs. Gastrointestinal complaints were most frequently reported (2.6%), and occasionally allergic skin reactions have occurred. Some adverse effects are partly due to the alcohol content of Phytodolor®N (45.6% vol, 0.7 g per 40 drops), which poses a health risk to children and to adults with liver disease, alcoholism, epilepsy, or brain damage. Caution is advised during pregnancy or lactation and for drivers and individuals who operate machines, even though no impairment of consciousness or reactivity is expected to occur with 0.7 g of alcohol per dose. Studies on mutagenicity, teratogenicity, and toxicity in the parent animals and their progeny gave no evidence for any toxic effects arising from the intake of the combination during pregnancy and the lactation period (<LINK REF="REF-Gundermann-2001" TYPE="REFERENCE">Gundermann 2001</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-04 18:28:07 +1000" MODIFIED_BY="[Empty name]">
<P>Generally the studies included in this review are of lower quality than desired, but we stress that these studies represent the current best quality evidence for the effectiveness of oral medicinal plant interventions in the treatment of OA. Poorer quality studies with non-randomised, uncontrolled designs were excluded (for example <LINK REF="STD-Guyader-1984" TYPE="STUDY">Guyader 1984</LINK>; <LINK REF="STD-Myers-2010" TYPE="STUDY">Myers 2010</LINK>; <LINK REF="STD-Rosen-2013" TYPE="STUDY">Rosen 2013</LINK>). We excluded clinical trials of products that are not strictly herbal so as to avoid misinterpretation of the results of these studies in herbal medicine practice (for example <LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Jacquet-2009" TYPE="STUDY">Jacquet 2009</LINK>; <LINK REF="STD-Kulkarni-1991" TYPE="STUDY">Kulkarni 1991</LINK>; <LINK REF="STD-Levy-2009" TYPE="STUDY">Levy 2009</LINK>). We note that more recent studies typically have higher quality reporting than older studies, and commend researchers in this field for the improvement of research design and reporting.</P>
<P>There is moderate-quality evidence that in people with OA, <I>Boswellia serrata </I>slightly improved pain and function. The evidence was downgraded to moderate as there is a potential for imprecision due to the small number of participants contributing to these outcomes. There is moderate-quality evidence that avocado-soybean unsaponifiables (ASU) probably improved pain and function slightly but may not preserve joint space. Evidence was downgraded due to inconsistency across results, or imprecision. Further research may change our estimates of the size of effects, and the precision around estimates.</P>
<P>We are uncertain whether other oral herbal products improve OA pain or function, or slow progression of joint structure damage because the evidence available is limited to single studies only, or studies providing data that cannot be pooled. Some of these studies are of low to very low quality, and some important outcome measures (eg: quality of life, joint space width) were omitted.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-05-10 23:44:35 +1000" MODIFIED_BY="[Empty name]">
<P>Incomplete reporting in some studies may have led us to undervalue the evidence of effectiveness, because we made strict judgements of methodological quality on the basis of reporting. On the other hand, incomplete reporting may be indicative of bias in studies such that incompletely reported trials may overestimate the treatment effects, thus we stand by our strict, conservative judgements (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For example, in countries in which the ICH guidelines are implemented in law, Human Research Ethics Committees would approve a clinical trial protocol only if it accords with the ICH good clinical practice consolidated guidelines (<LINK REF="REF-ICH-2004" TYPE="REFERENCE">ICH 2004</LINK>). Randomisation, blinding, masking of outcome assessment, and allocation concealment will probably have been adequately conducted even if the study was simply reported as "randomised and double-blind". To allow full and accurate assessment of future studies, we recommend that authors conform to the Consolidated Standards of Reporting Trials (CONSORT) (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).        </P>
<P>Studies fail for a variety of reasons and, although venturing into conjecture, we consider that groups may have differed at baseline according to some parameters that were not measured, but may have influenced the primary outcome measures. For example, baseline data in the <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK> study did not include details of the quantity of NSAIDs consumed or use of opioids for pain. Neither was anything reported about the mood state of the participants, which may also have influenced pain measures. Joint space loss was significantly reduced in patients with mild OA possibly indicating that early use of ASU may act preventively, but this suggestion needs to be confirmed in a follow-up study. Concerns regarding baseline differences between groups are amplified for studies with inadequate or unclear methods of randomisation and allocation concealment.</P>
<P>Many studies, although well designed, were probably underpowered and the lack of evidence of effect may be due to Type II error. Trends to effectiveness may be suggested from underpowered studies if improvements can be calculated and reported as effect sizes.</P>
<P>Glucosamine sulphate and chondroitin sulphate were used as active controls in some studies (<LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>) but we question this assumption. Several recent systematic reviews suggest that chondroitin sulphate has negligible effect on OA pain (<LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>; <LINK REF="REF-Wandel-2010" TYPE="REFERENCE">Wandel 2010</LINK>) and a small but significant protective effect against joint space narrowing (<LINK REF="REF-Lee-2010" TYPE="REFERENCE">Lee 2010</LINK>). Glucosamine sulphate does not act on pain pathways or mediators. Glucosamine is an amino acid that may enhance cartilage repair and, due to this reparative process, pain may reduce in people with OA but typically these changes take six to 12 weeks to occur and effect sizes are not large (<LINK REF="REF-Lee-2010" TYPE="REFERENCE">Lee 2010</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>). In a meta-analysis of 10 large randomised controlled trials of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in OA of the hip or knee Wandel and colleagues determined that glucosamine use produced a mean reduction in pain of 4 mm on a 100 mm VAS, an effect that did not exceed a minimum clinically important difference (<LINK REF="REF-Wandel-2010" TYPE="REFERENCE">Wandel 2010</LINK>).</P>
<P>We attempted to minimise bias in this review through transparent and thorough methods. We adopted a broad search strategy without language restrictions. We attempted to include grey literature by seeking manufacturers' reports, theses and unpublished reports as well as searching electronic databases. We removed duplicate publications from our analysis and reported fully our reasons for excluding or not assessing any trials. We conducted independent data extraction, in duplicate, of all included studies. Despite these strategies the review may be subject to some bias, particularly our personal biases due to our clinical practice experiences in arthritis care (MC) and herbal medicine (SC).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-05-14 14:02:36 +1000" MODIFIED_BY="[Empty name]">
<P>This review is the update of a Cochrane review (Little 2000), which we divided into two parts. For completeness, the updated review of topical herbal medicines for the treatment of OA (<LINK REF="REF-Cameron-2013" TYPE="REFERENCE">Cameron 2013</LINK>) should be read in conjunction with this updated review.</P>
<P>The results of this review are largely consistent with the findings of earlier reviews that included meta-analyses of trials of ASU (<LINK REF="REF-Cameron--2007" TYPE="REFERENCE">Cameron 2007</LINK>; <LINK REF="REF-Cameron-2009" TYPE="REFERENCE">Cameron 2009</LINK>; <LINK REF="REF-Christensen-2008a" TYPE="REFERENCE">Christensen 2008a</LINK>; Little 2000), which showed that this combination of two herbs shows benefits for OA pain and function in the short term. The addition of larger and longer term studies to these meta-analyses suggests that the effects of ASU on pain and function are not sustained over longer periods of two to three years, and that the effects of ASU on joint structure are small at best (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>; <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>).</P>
<P>In people with low back pain the ethanolic <I>Salix</I> bark extract in two doses demonstrated a dose-dependent effect superior to placebo (<LINK REF="REF-Chrubasik-2000" TYPE="REFERENCE">Chrubasik 2000</LINK>), and was not inferior to the synthetic rofecoxib (<LINK REF="REF-Chrubasik-2001" TYPE="REFERENCE">Chrubasik 2001</LINK>). In one of the two studies included in this review, a comparable dose of <I>Salix</I> extract failed to produce a significant effect in patients with OA, while the control group responded favourably to treatment with diclofenac (<LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>). It may well be that a higher <I>Salix</I> extract dose might have relieved OA patients' pain; empirically, higher willow bark extract doses have been used for the treatment of pain since the middle ages (<LINK REF="REF-Vlachojannis-2009" TYPE="REFERENCE">Vlachojannis 2009</LINK>).</P>
<P>This review is also largely consistent with a previous systematic review and meta-analysis of randomised controlled trials of <I>Rosa canina</I> for OA (<LINK REF="REF-Christensen-2008b" TYPE="REFERENCE">Christensen 2008b</LINK>). The same three studies are included in both reviews. Unlike Christensen and colleagues we did not pool pain scores for meta-analysis because different outcome measures were used across two of the three trials (<LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>; <LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>), and in the third study pain data were reported insufficiently for data extraction and re-analysis (<LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>). We concur with Christensen and colleagues that <I>Rosa canina</I> probably reduces pain in OA but we recommend that this purported effect be thoroughly tested in a sufficiently powered randomised controlled trial using standardised outcome measures.</P>
<P>This review differs somewhat from an earlier Cochrane review exclusively on pine bark extract (<LINK REF="REF-Schoonees-2012" TYPE="REFERENCE">Schoonees 2012</LINK>). We identified and included the studies from the Schoonees and colleagues' review but we have reported data from these studies independently rather than pooling them for meta-analysis because different outcome measures (WOMAC-VAS (<LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>) and WOMAC 0 to 4 (<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>)) were used across the studies, and data in one study were reported graphically (<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>), insufficient to allow extraction for re-analysis.</P>
<P>This review is compromised by many poorly designed clinical trials that were underpowered and inadequately blinded. Herbal medicine is not a field known for the widespread adoption of evidence-based practice, however, in light of the low quality body of evidence in oral herbal treatment for OA, practitioners might continue to ignore the research and do what they 'have always done'. Even small effect sizes may represent clinically meaningful improvements, particularly if these small effects represent improvements in a common condition with a substantial population burden of disease (for example OA). In light of the fact that serious adverse events related to any of the medicinal plant products were not observed, physicians and patients should not be discouraged in using herbal medicines at all. In this section, therefore, we have chosen to address some of the common biases in herbal medicine as well as in this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-05-11 00:01:03 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-05-10 23:51:38 +1000" MODIFIED_BY="[Empty name]">
<P>See: 'Summary of findings' tables.</P>
<P>We have provided a tabulated summary of key clinical messages to assist practitioners in transferring the findings of this updated review into their clinical work. The current available evidence for herbal treatment of osteoarthritis (OA) is generally sparse. For most medicinal plant products there is insufficient evidence to support or discourage use.</P>
<P>The original review concluded that there was consistent evidence that a proprietary product from avocado-soybean unsaponifiables (ASU) can provide long term symptomatic relief, particularly for patients with chronic but stable OA of the hip, and that ASU may also help patients to reduce their consumption of non-steroidal anti-inflammatory drugs (NSAIDs). These results need to be reconsidered in the light of three new studies: one study over six months that supports the previous findings (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>), another longer term study that reported no improvements over placebo among people using 300 mg ASU daily for 12 to 24 months (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>), and the most recent showing ASU as not inferior to chondroitin sulphate (<LINK REF="STD-Pavelka-2010" TYPE="STUDY">Pavelka 2010</LINK>). Despite symptomatic improvements, ASU does not appear to have a major impact on joint structure in patients with OA. Similarly, non-inferiority to chondroitin sulphate may mean little because chondroitin sulphate is not significantly effective in reducing osteoarthritic pain, and has only a small effect on joint space narrowing that occurs only with long term (two plus years) treatment (<LINK REF="REF-Wandel-2010" TYPE="REFERENCE">Wandel 2010</LINK>). We suggest that the length of intervention may be an important factor that differs among these studies, and recommend that clinicians consider monitoring pain and physical function as part of routine care for patients using ASU, particularly with prolonged use of this intervention.</P>
<P>High tolerance of the medicinal plant products was demonstrated in all studies. Caution is warranted in interpreting safety. Although no serious drug-related adverse events occurred in the studies so far, comprehensive safety data are still required for all medicinal plant products except for the mixture Phytodolor®.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-05-11 00:01:03 +1000" MODIFIED_BY="[Empty name]">
<P>Several studies were excluded from this review on the grounds of flawed research design, including unclear recruitment criteria and inadequate definition of the herbal interventions. Other studies were included but are of limited usefulness because the selection criteria were incomplete or data were manipulated post hoc to support the authors' preferred conclusions. High quality, adequately powered clinical studies investigating herbal interventions are required. We recommend that future researchers give attention to the detail of study design, ensuring that participant samples are well defined according to ACR criteria and recruited without bias; that herbal preparations are reported in detail, including dose, extraction method, and active principle; and that study results are recorded using reliable, valid outcome measures, in particular for the consensus criteria of the Outcomes Measures in Rheumatology-Osteoarthritis Research Sicuety International (OMERACT-OARSI) that combine pain and functional impairments in the identification of treatment response (<LINK REF="REF-Pham-2003" TYPE="REFERENCE">Pham 2003</LINK>; <LINK REF="REF-Pham-2004" TYPE="REFERENCE">Pham 2004</LINK>) be used in these studies to be able to compare the efficacy of different medicinal plant products.</P>
<P>So far, longer term studies over one and two years have been carried out only for aqueous <I>Harpagophytum </I>extract with 50 mg harpagoside in a daily dosage (<LINK REF="REF-Chrubasik-2007" TYPE="REFERENCE">Chrubasik 2007</LINK>) and the ASU product Piascledine® (<LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>). Since OA is a chronic condition, future long term studies over several years are needed to prove the effective and safe use of medicinal plant products.</P>
<P>OA of the knee, hip, and spine is a degenerative disease affecting the joint cartilage and the underlying subchondral cartilage. Progressive loss of articular cartilage, appositional new bone formation in the subchondral trabeculae, and formation of new cartilage and bone at the joint margins result in pain, stiffness, limitation of function, and diminished quality of life (<LINK REF="REF-Sangha-2000" TYPE="REFERENCE">Sangha 2000</LINK>). Although there is no clear explanation for differences in effect among body regions, some investigators have reported that pain from hip OA responds better to treatment with a herbal medicinal product than does OA pain in other regions (<LINK REF="REF-Chrubasik-2002" TYPE="REFERENCE">Chrubasik 2002</LINK>; <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>), suggesting that the site of joint disease may influence pain outcomes. We suggest that future researchers consider recruiting participants with particular joint involvement or stratify results according to site of disease.</P>
<P>There is also a tendency to duplicate publications in this field, by publishing abstracts of conference presentations as well as complete papers, or publishing the same paper in multiple languages. Duplication of publications may be legitimate but tends to create the appearance of a larger body of evidence than actually exists. We advise caution in the duplication of publications and recommend that, where possible, authors indicate that a manuscript or part thereof has been previously published elsewhere.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-13 05:25:25 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank the Cochrane Musculoskeletal editorial team for their editorial suggestions.</P>
<P>Christine Little (CL) and Tessa Parsons (TP) authored the original review that formed the template for this updated version. CL contributed to paper selection for this review, and TP extracted data from some studies. We gratefully acknowledge their contributions to the foundational work for this review.</P>
<P>Charles Malemud edited portions of the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> and <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> relevant to cytokine activity in osteoarthritis. Anette Blümle (AB) of the German Cochrane Centre, and Mason Leung, advised on the inclusion or exclusion of manuscripts in German and Chinese respectively. AB and Joel Gagnier (JG) contributed to data extraction from some studies. Rudolf Bauer gave advice on the inclusion of study medications and Ulf Müller-Ladner on the interpretation of the study results with the proprietary ASU product. Renea Johnston, of the Cochrane Musculoskeletal Group, provided extensive feedback on the manuscript and assisted in calculation of numbers needed to treat (NNT). We thank these colleagues for their support and assistance in finalising this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-05-21 16:36:27 +1000" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-21 16:36:11 +1000" MODIFIED_BY="[Empty name]">
<P>SC and MC contributed to the paper selection and data extraction. MC and SG completed the data analysis and interpretation, and wrote, checked, proof-read, and approved the updated review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-05-11 00:02:49 +1000" MODIFIED_BY="[Empty name]">
<P>For this review update, we expanded the inclusion criteria so studies that included an active control as well as placebo controls, unpublished reports of randomised controlled trials, and trials in any language were eligible for inclusion. Changes to the methods of quality assessment (replaced by assessment of 'risk of bias') and analysis and presentation of results are consistent with updated Cochrane Collaboration and Cochrane Musculoskeletal Group methods introduced since the original review. We restricted included studies to those investigations of interventions that strictly satisfied the WHO guidelines for herbal medicines. This updated review is limited to oral medicinal plant products. In the original review, studies of the same herbal therapy that used the same outcome measure were pooled regardless of the length of the intervention period. In this update, these data and comparisons are subgrouped according to intervention time, rather than pooled. The table of herbal interventions has been extensively revised so that it offers detailed information about the herbal medicines, including full botanical names, part/s of the plant used, details of extraction methods, drug:extract ratios, and active principles</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-05-21 14:51:21 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-05-11 00:51:47 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-05-11 00:45:48 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adegbehingbe-2008" MODIFIED="2011-09-15 23:27:45 +1000" MODIFIED_BY="[Empty name]" NAME="Adegbehingbe 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-09-15 23:27:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adegbehingbe OO, Adesanya SA, Idowu TO, Okimi OC, Oyelami OA, Iwalewa EO, et al</AU>
<TI>Clinical effects of <I>Garcinia kola </I>in knee osteoarthritis</TI>
<SO>Journal of Orthopedic Surgery</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altman-2001" MODIFIED="2013-05-21 17:41:30 +1000" MODIFIED_BY="[Empty name]" NAME="Altman 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 17:41:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD, Marcussen KC</AU>
<TI>Effects of a ginger extract on knee pain in patients with osteoarthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>11</NO>
<PG>2531-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appelboom-2001" MODIFIED="2013-05-21 17:41:45 +1000" MODIFIED_BY="[Empty name]" NAME="Appelboom 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 17:41:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY</AU>
<TI>Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double-blind, prospective, placebo-controlled study</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>4</NO>
<PG>242-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badria-2002" MODIFIED="2013-05-21 17:42:00 +1000" MODIFIED_BY="[Empty name]" NAME="Badria 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-05-21 17:42:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batoty MF</AU>
<TI>Boswellia-curcumin preparation for treating knee osteoarthritis: A clinical evaluation</TI>
<SO>Alternative &amp; Complementary Therapies</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>6</NO>
<PG>341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2008" MODIFIED="2013-09-08 15:37:04 +1000" MODIFIED_BY="[Empty name]" NAME="Belcaro 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-08 15:37:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al</AU>
<TI>Treatment of osteoarthritis with Pycnogenol<SUP>®</SUP>. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>518-23</PG>
<IDENTIFIERS MODIFIED="2011-06-20 12:06:40 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-20 12:06:40 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.2376"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Bernhardt-1991" MODIFIED="2011-09-15 23:26:18 +1000" MODIFIED_BY="[Empty name]" NAME="Bernhardt 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-09-15 23:26:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Bernhardt M, Keimel A, Belucci G, et al</AU>
<TI>Double-blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations</TI>
<SO>Unpublished Pharma Report</SO>
<YR>1991</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Steigrwald Pharmaceuticals, Germany"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biegert-2004" MODIFIED="2013-05-21 17:42:38 +1000" MODIFIED_BY="[Empty name]" NAME="Biegert 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 17:42:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, et al</AU>
<TI>Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double-blind controlled trials</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>11</NO>
<PG>2121-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biller-2002" MODIFIED="2008-06-04 12:01:30 +1000" MODIFIED_BY="[Empty name]" NAME="Biller 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-04 12:01:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Biller A</AU>
<TI>Results of two randomized controlled studies and of a post-marketing surveillance study investigating a Devil's claw extract</TI>
<TO>Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt</TO>
<SO>In: Phylopharmaka VII</SO>
<YR>2002</YR>
<PG>81-92</PG>
<ED>Schulz V, Rietbrock N, Roots I, Loew D</ED>
<PB>Steinkopf-Verlag</PB>
<CY>Darmstadt</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bliddal-2000" NAME="Bliddal 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, et al</AU>
<TI>A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blotman-1997" MODIFIED="2013-05-21 17:43:06 +1000" MODIFIED_BY="[Empty name]" NAME="Blotman 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-21 17:43:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A</AU>
<TI>Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip</TI>
<TO>Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques</TO>
<SO>Revue du Rhumatisme [Éd Fr Joint Bone Spine]</SO>
<YR>1997</YR>
<VL>64</VL>
<NO>12</NO>
<PG>825-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2005" MODIFIED="2013-05-21 17:43:28 +1000" MODIFIED_BY="[Empty name]" NAME="Cao 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-21 17:43:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao Y, Shi Y, Zheng Y, Shi M, Lo SK</AU>
<TI>Blood-nourishing and hard-softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial</TI>
<SO>eCAM</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>3</NO>
<PG>363-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheras-2010" MODIFIED="2013-05-21 17:44:54 +1000" MODIFIED_BY="[Empty name]" NAME="Cheras 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-21 17:44:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheras PA, Myers SP, Paul-Brent P, Outerbridge KH, Nielsen GVL</AU>
<TI>Randomised double-blind placebo-controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<PG>1126-31</PG>
<IDENTIFIERS MODIFIED="2012-04-08 15:45:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-08 15:45:47 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.3075"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-08 15:45:25 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chopra-2004" MODIFIED="2013-05-21 17:45:20 +1000" MODIFIED_BY="[Empty name]" NAME="Chopra 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 17:45:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chopra A, Lavin P, Patwardhan B, Chitre D</AU>
<TI>A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees</TI>
<SO>Journal of Clinical Rheumatology</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>5</NO>
<PG>236-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chopra-2011" MODIFIED="2012-06-23 21:39:51 +1000" MODIFIED_BY="[Empty name]" NAME="Chopra 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-06-23 21:39:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chopra A, Saluja M, Tillu G, Venugopalan A, Sarmukaddam S, Raut AK, et al</AU>
<TI>A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project</TI>
<SO>Evidence-based Complementary and Alternative Medicine</SO>
<YR>2011</YR>
<VL>8</VL>
<PG>1-12</PG>
<PB>Hindawi Publishing Corporation</PB>
<IDENTIFIERS MODIFIED="2011-06-20 11:59:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-20 11:59:39 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1155/2011/724291"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chopra-2013" MODIFIED="2014-05-11 00:45:48 +1000" MODIFIED_BY="[Empty name]" NAME="Chopra 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-11 00:45:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, et al</AU>
<TI>Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence trial</TI>
<SO>Rheumatology</SO>
<YR>2013</YR>
<VL>52</VL>
<NO>8</NO>
<PG>1408-17</PG>
<IDENTIFIERS MODIFIED="2013-08-31 16:42:35 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-31 16:42:35 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/rheumatology/kes414"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cisar-2008" MODIFIED="2013-05-21 17:45:41 +1000" MODIFIED_BY="[Empty name]" NAME="Cisar 2008" YEAR="">
<REFERENCE MODIFIED="2013-05-21 17:45:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cisár P, Jány R, Waczulíková I, Sumegová K, Muchová J, VojtaSSák J, et al</AU>
<TI>Effect of pine bark extract (Pycnogenol<SUP>®</SUP>) on symptoms of knee osteoarthritis</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>1087-92</PG>
<IDENTIFIERS MODIFIED="2011-03-01 20:48:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-01 20:48:03 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.2461"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farid-2007" MODIFIED="2013-05-21 17:46:02 +1000" MODIFIED_BY="[Empty name]" NAME="Farid 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-21 17:46:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farid R, Mirfeizi Z, Mirheidari M, Rezaieyazdi Z, Mansouri H, Esmaelli H, et al</AU>
<TI>Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis</TI>
<SO>Nutrition Research</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>692-7</PG>
<IDENTIFIERS MODIFIED="2011-06-20 11:55:17 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-20 11:55:17 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.nutres.2007.09.007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferraz-1991" MODIFIED="2013-05-21 17:46:15 +1000" MODIFIED_BY="[Empty name]" NAME="Ferraz 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-21 17:46:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz MB, Pereira RB, Iwata NM, Atra E</AU>
<TI>Tipi. A popular analgesic tea: A double-blind cross-over trial in osteoarthritis (letter)</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>205-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frerick-2001" MODIFIED="2011-09-15 22:20:54 +1000" MODIFIED_BY="[Empty name]" NAME="Frerick 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-09-15 22:20:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frerick H, Biller A, Schmidt U</AU>
<TI>A treatment schedule for coxarthrosis: A double-blind study with Devil's claw</TI>
<TO>Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle</TO>
<SO>Der Kassenarzt</SO>
<YR>2001</YR>
<VL>5</VL>
<PG>34-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2011" MODIFIED="2011-09-15 22:39:53 +1000" MODIFIED_BY="[Empty name]" NAME="Gupta 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-09-15 22:39:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Acharya K, Sancheti PS, Joshi RS</AU>
<TI>A double-blind, randomized, multicentric, placebo-controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis</TI>
<SO>Indian Journal of Pharmacology</SO>
<YR>2011</YR>
<VL>43</VL>
<PG>69-72</PG>
<IDENTIFIERS MODIFIED="2011-06-20 10:54:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-20 10:54:44 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.4103/0253-7613.75674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Huber-1991" MODIFIED="2013-09-08 16:00:32 +1000" MODIFIED_BY="[Empty name]" NAME="Huber 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-21 17:46:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber B</AU>
<TI>Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N</TI>
<TO>Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1991</YR>
<VL>109</VL>
<PG>248-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2001" MODIFIED="2013-05-21 17:46:57 +1000" MODIFIED_BY="[Empty name]" NAME="Jung 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 17:46:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung YB, Roh KJ, Jung JA, Jung K, Yoo H, Cho YB, et al</AU>
<TI>Effect of SKI306X, a new herbal anti-arthritic agent, in patients with osteoarthritis if the knee: A double-blind placebo controlled study</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>3-4</NO>
<PG>485-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2004" MODIFIED="2012-04-09 14:59:15 +1000" MODIFIED_BY="[Empty name]" NAME="Jung 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-04-09 14:59:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung YB, Seong SC, Lee MC, Shin YU, Kim DH, Kim JM, et al</AU>
<TI>A four-week randomized, double-blind trial of the efficacy and safety of SKI306X: A herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>2</NO>
<PG>291-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimmatkar-2003" MODIFIED="2012-05-17 18:20:03 +1000" MODIFIED_BY="[Empty name]" NAME="Kimmatkar 2003" YEAR="">
<REFERENCE MODIFIED="2012-05-17 18:20:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimmatkar N, Thawani V, Hingorani L, Khiyani R</AU>
<TI>Efficacy and tolerability of <I>Boswellia serrata</I> extract in treatment of osteoarthritis of knee - A randomized double blind placebo controlled trial</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuptniratsaikul-2009" MODIFIED="2013-05-21 17:47:17 +1000" MODIFIED_BY="[Empty name]" NAME="Kuptniratsaikul 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-21 17:47:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuptniratsaikul V, Thanakhumtorn S, et al</AU>
<TI>Efficacy and safety of <I>Curcumica domestica </I>extracts in patients with knee osteoarthritis</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>891-7</PG>
<IDENTIFIERS MODIFIED="2012-04-09 15:28:02 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-09 15:28:02 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1089/acm.2008.0186"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuptniratsaikul-2011" MODIFIED="2013-05-21 17:47:36 +1000" MODIFIED_BY="[Empty name]" NAME="Kuptniratsaikul 2011" YEAR="2008">
<REFERENCE MODIFIED="2013-05-21 17:47:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuptniratsaikul V, Pinthong T, Bunjob M, Thanakhumtorn S, Chinswangwatanakul P, Thamlikitkul V</AU>
<TI>Efficacy and safety of <I>Derris scandens</I> benth extracts in patients with knee osteoarthritis</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2011</YR>
<VL>17</VL>
<PG>147-53</PG>
<IDENTIFIERS MODIFIED="2011-06-20 10:51:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-20 10:51:39 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1089/acm.2010.0213"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-06-20 10:51:24 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leblan-2000" MODIFIED="2013-05-21 17:47:51 +1000" MODIFIED_BY="[Empty name]" NAME="Leblan 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-05-21 17:47:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leblan D, Chantre P, Fournié B</AU>
<TI>
<I>Harpogophytum procumbens</I> in the treatment of knee and hip osteoarthritis: Four-month results of a prospective, multicenter, double-blind trial versus diacerhein</TI>
<TO>L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine</TO>
<SO>Revue du Rhumatisme [Éd Fr Joint Bone Spine]</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>5</NO>
<PG>462-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lequesne-2002" MODIFIED="2013-05-21 17:48:30 +1000" MODIFIED_BY="[Empty name]" NAME="Lequesne 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-05-21 17:48:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lequesne M, Maheu E, Cadet C, Dreiser RL</AU>
<TI>Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip</TI>
<SO>Arthritis Care &amp; Research</SO>
<YR>2002</YR>
<VL>47</VL>
<PG>50-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maheu-1998" NAME="Maheu 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E, Mazieres B, Valat J-P, Loyau G, Le Loet X, Bourgeois P, et al</AU>
<TI>Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>1</NO>
<PG>81-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maheu-2013" MODIFIED="2013-05-07 12:16:05 +1000" MODIFIED_BY="[Empty name]" NAME="Maheu 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-05-07 12:16:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, Dougados M, Mazières B, Spector TD, Halhol H, Grouin JM, Lequesne M</AU>
<TI>Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>Jan 23</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS MODIFIED="2013-05-07 10:16:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-07 10:16:55 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/annrheumdis-2012-202485"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majima-2012" MODIFIED="2012-06-23 22:26:17 +1000" MODIFIED_BY="[Empty name]" NAME="Majima 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-06-23 22:26:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majima T, Inoue M, Kasahara Y, Onodera T, Takahashi D, Minami A</AU>
<TI>Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion</TI>
<SO>Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>3</PG>
<IDENTIFIERS MODIFIED="2012-06-19 12:58:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-19 12:58:31 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1758-2555-4-3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Medhi-2009" MODIFIED="2013-05-21 17:49:01 +1000" MODIFIED_BY="[Empty name]" NAME="Medhi 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-21 17:49:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medhi B, Kishore K, Singh U, Seth SD</AU>
<TI>Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis</TI>
<SO>Phytotherapy Research</SO>
<YR>2009</YR>
<VL>23</VL>
<PG>1469-73</PG>
<IDENTIFIERS MODIFIED="2012-04-09 14:53:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-09 14:53:21 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.2804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehta-2007" MODIFIED="2013-09-08 15:44:24 +1000" MODIFIED_BY="[Empty name]" NAME="Mehta 2007" YEAR="">
<REFERENCE MODIFIED="2013-09-08 15:44:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehta K, Gala J, Bhasale S, Naik S, Modak M, Thakur H, et al</AU>
<TI>Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>34</PG>
<IDENTIFIERS MODIFIED="2011-03-01 20:58:23 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-01 20:58:23 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1472-6882-7-34"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mills-1996" MODIFIED="2013-05-21 17:49:21 +1000" MODIFIED_BY="[Empty name]" NAME="Mills 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-05-21 17:49:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mills SY, Jacoby RK, Chacksfield M, Willoughby M</AU>
<TI>Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double-blind study</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>35</VL>
<PG>874-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oben-2009" MODIFIED="2011-09-15 22:44:53 +1000" MODIFIED_BY="[Empty name]" NAME="Oben 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-09-15 22:44:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oben J, Enonchong E, Kothari S, Chambliss W, Garrison R, Dolnick D</AU>
<TI>Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study</TI>
<SO>Nutrition Journal</SO>
<YR>2009</YR>
<VL>8</VL>
<PG>38</PG>
<IDENTIFIERS MODIFIED="2011-02-27 11:59:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-27 11:59:33 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1475-2891-8-38"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2010" MODIFIED="2013-09-08 15:45:01 +1000" MODIFIED_BY="[Empty name]" NAME="Pavelka 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-08 15:45:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Coste P, Géher P, Krejci G</AU>
<TI>Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee</TI>
<SO>Clinical Rheumatology</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>659-70</PG>
<IDENTIFIERS MODIFIED="2012-06-09 12:05:19 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-09 12:05:19 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10067-010-1384-8"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piscoya-2001" MODIFIED="2013-05-21 17:49:58 +1000" MODIFIED_BY="[Empty name]" NAME="Piscoya 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 17:49:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piscoya J, Rodriguez Z, Bustamante SA, Okuhama NN, Miller MJS, Sandoval M</AU>
<TI>Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species <I>Uncaria guianensis</I>
</TI>
<SO>Inflammation Research</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>442-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rein-2004a" MODIFIED="2013-05-21 17:50:12 +1000" MODIFIED_BY="[Empty name]" NAME="Rein 2004a" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 17:50:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rein E, Kharazami A, Winther K</AU>
<TI>A herbal remedy, Hyben Vital (stand. powder of a subspecies of <I>Rosa canina</I> fruits), reduces pain and improves general wellbeing in patients with osteoarthritis - a double-blind, placebo-controlled, randomised trial</TI>
<SO>Phytomedicine</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>383-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Schadler-1988" MODIFIED="2013-09-08 15:41:44 +1000" MODIFIED_BY="[Empty name]" NAME="Schadler 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-05-21 17:50:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schadler W</AU>
<TI>Phytodolor for the treatment of activated arthrosis</TI>
<SO>Rheuma</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>288-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmelz-1997" MODIFIED="2013-05-21 17:50:43 +1000" MODIFIED_BY="[Empty name]" NAME="Schmelz 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-21 17:50:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Schmelz H, Hammerle HD, Springorum HW</AU>
<TI>Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases</TI>
<TO>Analgetische Wirkung eines Teufelskrallenwurzel-Extraktes bei verschiedenen chronisch-degenerativen Gelenkerkrankungen</TO>
<SO>Rheumatherapie mit Phytopharmaka</SO>
<YR>1997</YR>
<PG>86-9</PG>
<ED>Chrubasik S, Wink M</ED>
<PB>Hippokrates Verlag</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmid-2000" MODIFIED="2008-06-04 12:52:31 +1000" MODIFIED_BY="[Empty name]" NAME="Schmid 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-06-04 12:52:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmid B, Ludtke R, Selbmann HK, Kotter I, Tschirdewahn B, Schaffner W, et al</AU>
<TI>Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo-controlled double blind clinical trial</TI>
<TO>Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose-patienten: Randomisierte, placebo-kontrollierte doppelblindstudie</TO>
<SO>Zeitschrift für Rheumatologie</SO>
<YR>2000</YR>
<VL>59</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sengupta-2008" MODIFIED="2011-04-17 21:00:39 +1000" MODIFIED_BY="[Empty name]" NAME="Sengupta 2008" YEAR="">
<REFERENCE MODIFIED="2011-04-17 21:00:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KVS, et al</AU>
<TI>A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee</TI>
<SO>Arthritis Research &amp; Therapy</SO>
<YR>2008</YR>
<VL>10</VL>
<PG>R85</PG>
<IDENTIFIERS MODIFIED="2011-03-01 21:24:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-01 21:24:53 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/ar2461"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sengupta-2010" MODIFIED="2013-09-08 15:45:55 +1000" MODIFIED_BY="[Empty name]" NAME="Sengupta 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-08 15:45:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Trimurtulu G, Sarma KVS, et al</AU>
<TI>Comparative efficacy and tolerability of 5-Loxin<SUP>®</SUP> and Aflapin<SUP>®</SUP> against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study</TI>
<SO>International Journal of Medical Sciences</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>6</NO>
<PG>366-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sontakke-2007" MODIFIED="2013-05-21 17:51:32 +1000" MODIFIED_BY="[Empty name]" NAME="Sontakke 2007" YEAR="">
<REFERENCE MODIFIED="2013-05-21 17:51:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sontakke S, Thawani V, Pimpalkhute S, Kambra P, Babhulkar S, Hingorani L</AU>
<TI>Open, randomized, controlled trial of <I>Boswellia serrata</I> extract as compared to valdecoxib in osteoarthritis of knee</TI>
<SO>Indian Journal of Pharmacology</SO>
<YR>2007</YR>
<VL>39</VL>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teekachunhatean-2004" MODIFIED="2012-06-23 22:29:38 +1000" MODIFIED_BY="[Empty name]" NAME="Teekachunhatean 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-23 22:29:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teekachunhatean S, Kunanusom P, Rojanasthien N, Sananpanich K, Pojchamarnwitputh S, Lheiochaiphunt S, Pruksakorn S</AU>
<TI>Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial</TI>
<SO>BMC Comlementary and Alternative Medicine</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>19</PG>
<IDENTIFIERS MODIFIED="2012-04-09 15:39:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-09 15:39:26 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1186/1472-6882-4-19"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vishal-2011" MODIFIED="2013-05-21 17:51:57 +1000" MODIFIED_BY="[Empty name]" NAME="Vishal 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-21 17:51:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vishal AA, Mishra A, Raychaudhuri SP</AU>
<TI>A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin<SUP>®</SUP> in subjects with osteoarthritis of the knee</TI>
<SO>International Journal of Medical Sciences</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>7</NO>
<PG>615-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warholm-2003" MODIFIED="2008-06-03 21:35:13 +1000" MODIFIED_BY="[Empty name]" NAME="Warholm 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-06-03 21:35:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warholm O, Skaar S, Hedman E, Molmen HM, Eik L</AU>
<TI>The effects of a standardized herbal remedy made from a subtype of <I>Rosa canina</I> in patients with osteoarthritis: A double-blind, randomized, placebo-controlled clinical trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>1</NO>
<PG>21-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wigler-2003" MODIFIED="2013-05-21 17:52:12 +1000" MODIFIED_BY="[Empty name]" NAME="Wigler 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-21 17:52:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wigler I, Grotto I, Caspi D, Yaron M</AU>
<TI>The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>783-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winther-2005" MODIFIED="2013-05-21 17:52:28 +1000" MODIFIED_BY="[Empty name]" NAME="Winther 2005" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 17:52:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winther K, Apel K, Thamsborg G</AU>
<TI>A powder made from seeds and shells of a rose-hip subspecies (<I>Rosa canina</I>) reduces symptoms of knee and hip osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>34</VL>
<PG>302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-09-15 22:34:20 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-05-11 00:49:28 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1993" MODIFIED="2013-05-21 17:52:48 +1000" MODIFIED_BY="[Empty name]" NAME="Anonymous 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-05-21 17:52:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>The garlic treatment: detoxifying with garlic.</TI>
<TO>Die knoblauchkur: entschlackung durch knoblauch</TO>
<SO>Natur &amp; Heilen</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>10</NO>
<PG>520-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2010" MODIFIED="2013-05-21 17:53:12 +1000" MODIFIED_BY="[Empty name]" NAME="Belcaro 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-21 17:53:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al</AU>
<TI>Efficacy and safety of Meriva<SUP>®</SUP>, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients</TI>
<SO>Alternative Medicine Review</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>4</NO>
<PG>337-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswas-1997" MODIFIED="2013-05-21 17:53:27 +1000" MODIFIED_BY="[Empty name]" NAME="Biswas 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-21 17:53:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Biswas NR, Biswas A, Pandey RM</AU>
<TI>EASE - a herbal preparation for rheumatoid arthritis, non specific arthritis and osteoarthritis</TI>
<SO>FACT: Focus on Alternative and Complementary Therapies. Proceedings of 4th Annual Symposium on Complementary Health Care</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>4</NO>
<PG>186-7</PG>
<CY>Exeter (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswas-1998" MODIFIED="2013-05-21 17:53:50 +1000" MODIFIED_BY="[Empty name]" NAME="Biswas 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-05-21 17:53:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biswas NR, Biswas K, Pandey M, Pandy RM</AU>
<TI>Treatment of osteoarthritis, rheumatoid arthritis and non-specific arthritis with a herbal drug: a double-blind, active drug controlled parallel study</TI>
<SO>JK Practitioner</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>2</NO>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brien-2006" MODIFIED="2013-05-21 17:54:04 +1000" MODIFIED_BY="[Empty name]" NAME="Brien 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-21 17:54:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brien S, Lewith GT, McGregor G</AU>
<TI>Devil's Claw (<I>Harpagophytum procumbens</I>) as a treatment for osteoarthritis: A review of safety and efficacy</TI>
<SO>The Journal of Alternative and Complementary Medicine</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>981-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chantre-2000" MODIFIED="2013-05-21 17:54:16 +1000" MODIFIED_BY="[Empty name]" NAME="Chantre 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-05-21 17:54:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B</AU>
<TI>Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis</TI>
<SO>Phytomedicine</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-1998" MODIFIED="2008-06-04 12:53:18 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-04 12:53:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Wink M</AU>
<TI>Traditional herbal therapy for the treatment of rheumatic pain: Preparations from Devil's claw and stinging nettle</TI>
<SO>Pain Digest</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>94-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dharmananda-1985" NAME="Dharmananda 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dharmananda S</AU>
<TI>Chinese herbal therapies for chronic joint pain</TI>
<SO>The American Chiropractor</SO>
<YR>1985</YR>
<VL>January</VL>
<PG>38-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2006" MODIFIED="2013-05-21 17:54:36 +1000" MODIFIED_BY="[Empty name]" NAME="Du 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-21 17:54:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du T-X, Han X-F, Gao S-T</AU>
<TI>Effect of hanshibi granule on rheumatism due to blockage of cold and damp</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>148-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falch-1997" MODIFIED="2008-06-04 12:28:58 +1000" MODIFIED_BY="[Empty name]" NAME="Falch 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-04 12:28:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Falch VB</AU>
<TI>Ginger - not only a spice. Review of its effect and efficacy profile</TI>
<TO>Ingwer - nicht nur ein Gewurz. Untersuchungen zu Wirkungen und Wirksamkeit</TO>
<SO>Deutsche Apotheker Zeitung</SO>
<YR>1997</YR>
<VL>137</VL>
<PG>47-52, 55-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-2008" MODIFIED="2013-05-21 17:55:03 +1000" MODIFIED_BY="[Empty name]" NAME="Fang 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-21 17:55:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang R, Meng Q-C, Deng Y-J, Song G, Bai Y-P</AU>
<TI>Effects of Bu Shen Tong Luo decoction on matrix metalloproteinase-1, matrix metalloproteinase-3, tissue inhibitor of matrix metalloprotease-1 and interleukin-1beta content in the synovial fluid and serum of patients with knee osteoarthritis</TI>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2008</YR>
<VL>12</VL>
<PG>5581-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gendo-1997" MODIFIED="2008-06-04 12:32:12 +1000" MODIFIED_BY="[Empty name]" NAME="Gendo 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-04 12:32:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gendo U</AU>
<TI>Chronische Polyarthritis in view of traditional Chinese medicine (TCM)</TI>
<TO>Die chronische Polyarthritis aus der Sicht der traditionellen Chinesischen Medizin (TCM)</TO>
<SO>Naturamed</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>10</NO>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grahame-1981" MODIFIED="2008-06-03 21:37:21 +1000" MODIFIED_BY="[Empty name]" NAME="Grahame 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-06-03 21:37:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grahame R, Robinson BV</AU>
<TI>Devil's claw (<I>Harpagophytum procumbens</I>): Pharmacological and clinical studies</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1981</YR>
<VL>40</VL>
<PG>632</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyader-1984" MODIFIED="2014-05-11 00:48:28 +1000" MODIFIED_BY="[Empty name]" NAME="Guyader 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-05-11 00:48:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Guyader M</AU>
<TI>Herbal anti-rheumatic therapies: A longitudinal, pharmacological and clinical study of the treatment of 50 osteoarthritic patients with <I>Harpagophytum procumbens</I> (Devil's Claw) following hospital intervention</TI>
<TO>Les plantes anti-rhumatismales. Etude historique et pharmacologique, et etude clinique du nebulisat d'harpagophytum procumbens D.C. chez 50 patients arthrosiques suivis en service hospitalier</TO>
<SO>Thesis for the award of the degree Doctor of Medicine.</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamblin-2008" MODIFIED="2013-05-21 17:55:46 +1000" MODIFIED_BY="[Empty name]" NAME="Hamblin 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-21 17:55:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamblin L, Laird A, Parkes E, Walker AF</AU>
<TI>Improved arthritic knee health in a pilot RCT of phytotherapy</TI>
<SO>The Journal of the Royal Society for the Promotion of Health</SO>
<YR>2008</YR>
<VL>128</VL>
<NO>5</NO>
<PG>255-62</PG>
<IDENTIFIERS MODIFIED="2012-06-19 12:41:25 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-19 12:41:25 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="00651201"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacquet-2009" MODIFIED="2013-09-08 15:47:00 +1000" MODIFIED_BY="[Empty name]" NAME="Jacquet 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-08 15:47:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacquet A, Girodet P, Pariente A, Forest K, Mallet, Moore N</AU>
<TI>Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial</TI>
<SO>Arthritis Research &amp; Therapy</SO>
<YR>2009</YR>
<VL>11</VL>
<PG>R192</PG>
<IDENTIFIERS MODIFIED="2012-04-08 16:20:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-08 16:20:47 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/ar2891"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kagore-2011" MODIFIED="2013-05-21 17:57:05 +1000" MODIFIED_BY="[Empty name]" NAME="Kagore 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-21 17:57:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kogure T, Tatsumi T, Shigeta T, Fujinaga H, Sato T, Niizawa A</AU>
<TI>Effect of Kampo medicine on pain and range of motion of osteoarthritis of the hip accompanied by acetabular dysplasia: Case report and literature review</TI>
<SO>Integrative Medicine Highlights</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>13-7</PG>
<IDENTIFIERS MODIFIED="2012-06-19 12:40:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-19 12:40:24 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.4137/IMI.S7884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kielczynski-1997" MODIFIED="2008-06-03 20:43:18 +1000" MODIFIED_BY="[Empty name]" NAME="Kielczynski 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-03 20:43:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kielczynski W</AU>
<TI>Osteoarthritis - clinical outcomes after uniform, long-term herbal treatment</TI>
<SO>The European Journal of Herbal Medicine</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>2</NO>
<PG>29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulkarni-1991" MODIFIED="2013-05-21 17:57:29 +1000" MODIFIED_BY="[Empty name]" NAME="Kulkarni 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-05-21 17:57:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B</AU>
<TI>Treatment of osteoarthritis with a herbomineral formulation: A double-blind, placebo-controlled, cross-over study</TI>
<SO>Journal of Ethnopharmacology</SO>
<YR>1991</YR>
<VL>33</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lechner-2011" MODIFIED="2013-09-08 15:47:30 +1000" MODIFIED_BY="[Empty name]" NAME="Lechner 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-08 15:47:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lechner M, Steirer I, Brinkhaus B, Chen Y, Krist-Dungl C, Koschier A, et al</AU>
<TI>Efficacy of individualized Chinese herbal medication in osteoarthrosis of hip and knee: a double-blind, randomized-controlled clinical study</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>6</NO>
<PG>539-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-2009" MODIFIED="2012-05-21 22:48:44 +1000" MODIFIED_BY="[Empty name]" NAME="Levy 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-21 22:48:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy RM, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP</AU>
<TI>Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study</TI>
<SO>Nutrition Research</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>298-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linsheng-1997" MODIFIED="2013-05-21 17:58:24 +1000" MODIFIED_BY="[Empty name]" NAME="Linsheng 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-21 17:58:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linsheng W</AU>
<TI>Treatment of bony arthritis with herbal medicine and by massotherapy - analysis of 121 cases</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loew-1996" MODIFIED="2008-06-04 12:31:46 +1000" MODIFIED_BY="[Empty name]" NAME="Loew 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-04 12:31:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Loew D, Schuster O, Mollerfeld J</AU>
<TI>Stability and biopharmaceutical quality. A postulate for bioavailability and effectiveness of <I>Harpagophytum procumbens</I>
</TI>
<TO>Stabilitat und biopharmazeutische Qualitat. Voraussetzung fur Bioverfugbarkeit und Wirksamkeit von <I>Harpagophytum procumbens</I>
</TO>
<SO>Phytopharmaka II. Forschung und klinische Anwendung</SO>
<YR>1996</YR>
<PG>83-93</PG>
<ED>Loew D, Rietcrock N</ED>
<PB>Steinkopf-Verlag</PB>
<CY>Darmstadt</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Long-2001" MODIFIED="2013-05-21 17:58:44 +1000" MODIFIED_BY="[Empty name]" NAME="Long 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 17:58:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Long L, Soeken K, Ernst E</AU>
<TI>Herbal medicines for the treatment of osteoarthritis: A systematic review</TI>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<PG>779-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lung-2004" MODIFIED="2013-05-21 17:59:04 +1000" MODIFIED_BY="[Empty name]" NAME="Lung 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 17:59:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lung YB, Seong SC, Lee MC, Shin YU, Kim DH, Kim JM, et al</AU>
<TI>A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee</TI>
<SO>The American Journal of Chinese Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>291-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishra-and-Singh-2003" MODIFIED="2013-05-21 17:59:26 +1000" MODIFIED_BY="[Empty name]" NAME="Mishra and Singh 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-21 17:59:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishra LC, Singh BB, Vinjamury SP</AU>
<TI>The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study</TI>
<SO>Althernative Therapies in Health and Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-2010" MODIFIED="2013-05-21 17:59:44 +1000" MODIFIED_BY="[Empty name]" NAME="Myers 2010" YEAR="">
<REFERENCE MODIFIED="2013-05-21 17:59:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers S, O'Connor J, Fitton JH, Brooks L, Rolfe M, Connellan P, et al</AU>
<TI>A combined phase I and phase II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis</TI>
<SO>Biologics: Targets &amp; Therapy</SO>
<YR>2010</YR>
<VL>4</VL>
<PG>33-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2009" MODIFIED="2013-05-21 18:00:03 +1000" MODIFIED_BY="[Empty name]" NAME="Park 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-21 18:00:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park SH, Kim SK, et al</AU>
<TI>Effects of AIF on knee osteoarthritis patients: Double-blind, randomized, placebo-controlled study</TI>
<SO>Korean Journal of Physiology and Pharmacology</SO>
<YR>2009</YR>
<VL>13</VL>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rein-2004b" MODIFIED="2013-09-08 15:48:53 +1000" MODIFIED_BY="[Empty name]" NAME="Rein 2004b" YEAR="">
<REFERENCE MODIFIED="2013-09-08 15:48:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rein E, Kharazmi A, Thamsborg G, Winther K</AU>
<TI>A herbal remedy, made from a subspecies of rose-hip <I>Rosa canina</I>, reduces symptoms of knee and hip osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl 2</VL>
<PG>S80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuss-1981" MODIFIED="2008-06-04 12:33:07 +1000" MODIFIED_BY="[Empty name]" NAME="Reuss 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-06-04 12:33:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ruess D</AU>
<TI>Echinacin in the treatment of primary chronic polyarthritis</TI>
<TO>Echinacin in der Therapie der primar-chronischen Polyarthritis</TO>
<SO>ZFA - Stuttgart</SO>
<YR>1981</YR>
<VL>57</VL>
<NO>11</NO>
<PG>865</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosen-2013" MODIFIED="2014-05-11 00:49:28 +1000" MODIFIED_BY="[Empty name]" NAME="Rosen 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-11 00:49:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosen PD, Liakeas GP, Sadigim E, Bied AM</AU>
<TI>A pilot study assessing the short term use of <I>Tanacetum parthenium</I> for treatment of osteoarthritis</TI>
<SO>Integrative Medicine</SO>
<YR>2013</YR>
<VL>12</VL>
<NO>3</NO>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sagar-1988" NAME="Sagar 1988" YEAR="1988-">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sagar VMV</AU>
<TI>A clinical study of Amavata with special reference to some indigenous drugs</TI>
<SO>Rheumatism</SO>
<YR>1988-89</YR>
<VL>24</VL>
<NO>3</NO>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saley-1987" NAME="Saley 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saley SR, Tilak MN, Deshmukh SS</AU>
<TI>Amavata - a clinical study of 41 cases</TI>
<SO>Rheumatism</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>2</NO>
<PG>46-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaffner-1997" MODIFIED="2013-05-21 18:00:54 +1000" MODIFIED_BY="[Empty name]" NAME="Schaffner 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-21 18:00:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Schaffner W</AU>
<TI>Willow bark - an antirheumatic in modern phytotherapy?</TI>
<TO>Weidenrinde - Ein Antirheumatikum der modernen Phytotherapie?</TO>
<SO>Rheumatherapie mit Phytopharmaka</SO>
<YR>1997</YR>
<PG>125-7</PG>
<ED>Chrubasik S, Wink M</ED>
<PB>Hippokrates Verglag</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmid-1998a" MODIFIED="2013-05-21 18:01:11 +1000" MODIFIED_BY="[Empty name]" NAME="Schmid 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-05-21 18:01:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmid B, Tschirdewahn B, Kotter I, Gunaydin I, Ludtke R, Selbmann HK, et al</AU>
<TI>Analgesic effects of willow bark extract in osteoarthritis: results of a clinical double-blind trial</TI>
<SO>FACT:Focus on Alternative and Complementary Therapies</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>4</NO>
<PG>186</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmid-2001" MODIFIED="2013-05-21 18:01:26 +1000" MODIFIED_BY="[Empty name]" NAME="Schmid 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-21 18:01:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmid B, Lüdtke R, Selbmann H-K, Kötter I, Tschirdewahn B, Schaffner W, Heide L</AU>
<TI>Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo-controlled double blind clinical trial</TI>
<SO>Phytotherapy Research</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>344-50</PG>
<IDENTIFIERS MODIFIED="2012-04-10 18:22:36 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-10 18:22:36 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srivastava-1989" MODIFIED="2013-09-08 15:49:47 +1000" MODIFIED_BY="[Empty name]" NAME="Srivastava 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-09-08 15:49:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava KC, Mustafa T</AU>
<TI>Ginger (<I>Zingiber officinale</I>) and rheumatic disorders</TI>
<SO>Medical Hypotheses</SO>
<YR>1989</YR>
<VL>29</VL>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1985" MODIFIED="2013-02-27 15:59:53 +1100" MODIFIED_BY="[Empty name]" NAME="Wang 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-02-27 15:59:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZM, Chang JY, et al</AU>
<TI>A report on 310 cases of articular rheumatism treated with Feng Shi Han Tong tablet</TI>
<SO>Chung Hsi I Chieh Ho Tsa Chih</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>5</NO>
<PG>284-5, 260</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegener-2003" MODIFIED="2013-05-21 18:02:07 +1000" MODIFIED_BY="[Empty name]" NAME="Wegener 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-21 18:02:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegener T, Lupke NP</AU>
<TI>Treatment of patients with arthrosis of hip or knee with an aqueous extract of Devil's claw (<I>Harpagophytum procumbens</I> DC)</TI>
<SO>Phytotherapy Research</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winther-2004" MODIFIED="2013-05-21 18:02:29 +1000" MODIFIED_BY="[Empty name]" NAME="Winther 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-21 18:02:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winther K, Kharazmi A, Rein E</AU>
<TI>A powder made from a subspecies of rosehip (<I>Rosa canina</I>) reduces WOMAC symptoms scores as well as cholesterol levels in patients suffering from osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>13 Suppl A</VL>
<PG>S93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2005" MODIFIED="2013-05-21 18:03:59 +1000" MODIFIED_BY="[Empty name]" NAME="Xu 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-21 18:03:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu J-W, Ding J-X</AU>
<TI>An analysis on the clinical therapeutic effect of the manipulation matched with Chinese medical herb washing for treatment of osteoarthritis of the knee</TI>
<SO>Journal of Beijing Teachers College of Physical Education</SO>
<YR>2005</YR>
<VL>1</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuelong-2011" MODIFIED="2013-05-21 18:04:17 +1000" MODIFIED_BY="[Empty name]" NAME="Yuelong 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-21 18:04:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuelong C, Hongsheng Z, Jian P, Feiyue L, Shaojian X, Jinghua G, et al</AU>
<TI>Individually integrated traditional Chinese medicine approach in the management of knee osteoarthritis: study protocol for a randomized controlled trial</TI>
<SO>Trials</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>160</PG>
<IDENTIFIERS MODIFIED="2012-04-09 09:13:06 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-09 09:13:06 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1745-6215-12-160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zell-1993" MODIFIED="2013-05-21 18:04:37 +1000" MODIFIED_BY="[Empty name]" NAME="Zell 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-05-21 18:04:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zell J, Ecker R, Batz H, Vestweber AM</AU>
<TI>Mistletoe for hip and knee arthrosis: Segment - or immunotherapy?</TI>
<TO>Misteltherapie bei Gon- und Coxarthrose: Segment - oder Immuntherapie? Eine Pilotstudie</TO>
<SO>Heilkunst</SO>
<YR>1993</YR>
<VL>106</VL>
<NO>9</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2008" MODIFIED="2013-05-21 18:04:58 +1000" MODIFIED_BY="[Empty name]" NAME="Zeng 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-21 18:04:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng Y-R, Fan Y-G, Wu F, Li X-P, Fan H-J</AU>
<TI>Effects of compound herb of invigorating kidney and promoting blood flow on serum matrix metalloproteinases-3, tumor necrosis factor alpha, interleukin-1, hyaluronic acid, lipid peroxidation levels and superoxide dismutase activity in patients with knee osteoarthritis</TI>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2008</YR>
<VL>12</VL>
<PG>5436-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-05-11 00:51:47 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2012" MODIFIED="2014-05-11 00:50:04 +1000" MODIFIED_BY="[Empty name]" NAME="Gao 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-11 00:50:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao G, Wu H, Tian J, Du J, Xie X, Gao J</AU>
<TI>Clinical efficacy of bushen huoxue qubi decoction on treatment of knee-osteoarthritis and its effect on hemarheology, anti-inflammation and antioxidation</TI>
<SO>Zhongguo Zhong Yao Za Zhi</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>3</NO>
<PG>390-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hochberg-2012" MODIFIED="2013-09-13 03:05:32 +1000" MODIFIED_BY="[Empty name]" NAME="Hochberg 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-13 03:05:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Lao LX, Langenberg P, Fong HHS, Lee DYW, Berman B</AU>
<TI>Efficacy and Safety of the Chinese Herbal Compound Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of the Knee: Results of a Phase II International Study [Abstract]</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>10</NO>
<PG>S112</PG>
<IDENTIFIERS MODIFIED="2013-09-12 20:30:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-12 20:30:03 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/art.37993"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2011" MODIFIED="2014-05-11 00:50:39 +1000" MODIFIED_BY="[Empty name]" NAME="Kang 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-05-11 00:50:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang XZ, Wu QF, Jie HY</AU>
<TI>Clinical study on the treatment of knee osteoarthritis by wangbi tablet</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of integrated Traditional and Western Medicine]</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2013-05-21 18:05:17 +1000" MODIFIED_BY="[Empty name]" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-21 18:05:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu H-B, Zhang J-F, Zhong L-W, Yang H</AU>
<TI>Manipulation plus pyrola compound traditional Chinese medicine in treatment of senile osteoarthritis of knee</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>23</NO>
<PG>30-2</PG>
<IDENTIFIERS MODIFIED="2012-06-19 12:46:25 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-19 12:46:25 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="00613036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinsornsak-2012" MODIFIED="2014-05-11 00:51:47 +1000" MODIFIED_BY="[Empty name]" NAME="Pinsornsak 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-11 00:51:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinsornsak P, Niempoog S</AU>
<TI>The efficacy of <I>Curcuma longa L</I>. extract as an adjuvant therapy in primary knee osteoarthritis: A randomized controlled trial</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2012</YR>
<VL>95 Suppl 1</VL>
<PG>S51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tao-2009" MODIFIED="2013-05-21 18:05:31 +1000" MODIFIED_BY="[Empty name]" NAME="Tao 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-21 18:05:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tao QW, Xu Y, Jin DE, Yan XP</AU>
<TI>Clinical efficacy and safety of Gubitong Recipe () in treating osteoarthritis of knee joint</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>6</NO>
<PG>458-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006" MODIFIED="2013-05-21 18:05:55 +1000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-21 18:05:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong Q-S, Ye G-H, Wang H-Z, Lin S-H</AU>
<TI>Treatment of knee osteoarthritis by invigorating the kidney, dispelling the cold and activating the collaterals: A randomized controlled study</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-05-21 14:51:21 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-05-21 14:51:21 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1986" MODIFIED="2013-05-21 18:06:15 +1000" MODIFIED_BY="[Empty name]" NAME="Altman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al</AU>
<TI>The American College of Rheumatology crtieria for the classification and reporting of osteoarthritis of the knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1986</YR>
<VL>29</VL>
<PG>1039-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1990" MODIFIED="2013-05-21 18:06:29 +1000" MODIFIED_BY="[Empty name]" NAME="Altman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K</AU>
<TI>The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>1601-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1991" MODIFIED="2013-05-21 18:06:43 +1000" MODIFIED_BY="[Empty name]" NAME="Altman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al</AU>
<TI>The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1991</YR>
<VL>34</VL>
<PG>505-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Basch-2004" MODIFIED="2013-05-21 18:07:23 +1000" MODIFIED_BY="[Empty name]" NAME="Basch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Basch E, Boon H, Davies-Heerema T, Foppo I, Hashmi S, Hasskarl J, et al</AU>
<TI>Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration</TI>
<SO>Journal of Herbal Pharmacotherapy</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>3</NO>
<PG>63-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2013-05-21 18:08:17 +1000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horeton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT Statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenthal-1998" MODIFIED="2013-05-21 18:08:37 +1000" MODIFIED_BY="[Empty name]" NAME="Blumenthal 1998" TYPE="BOOK">
<AU>Blumenthal M</AU>
<SO>The complete German Commission E Monographs</SO>
<YR>1998</YR>
<PB>American Botanical Council</PB>
<CY>Austin, TX</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boullata-2003" MODIFIED="2014-05-21 14:42:03 +1000" MODIFIED_BY="[Empty name]" NAME="Boullata 2003" TYPE="JOURNAL_ARTICLE">
<AU>Boullata JI, McDonnell PJ, Oliva CD</AU>
<TI>Anaphylactic reaction to a dietary supplement containing willow bark</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>832-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cameron-2011" MODIFIED="2014-05-21 14:46:29 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron 2011" TYPE="COCHRANE_REVIEW">
<AU>Cameron M, Gagnier JJ, Chrubasik S</AU>
<TI>Herbal therapy for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-05-21 14:46:29 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-21 14:46:29 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cameron-2013" MODIFIED="2014-05-21 14:51:21 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron 2013" TYPE="COCHRANE_REVIEW">
<AU>Cameron M, Chrubasik S</AU>
<TI>Topical herbal therapies for treating osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-05-21 14:44:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-21 14:44:03 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010538"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2008" MODIFIED="2013-07-29 11:29:36 +1000" MODIFIED_BY="[Empty name]" NAME="Cates 2008" TYPE="OTHER">
<AU>Cates CD</AU>
<TI>Visual Rx NNT Calculator. Dr Chris Cates EBM website</TI>
<SO>Available from http://www.nntonline.net/, 2008</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Choi-2002" MODIFIED="2013-05-21 18:09:08 +1000" MODIFIED_BY="[Empty name]" NAME="Choi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, et al</AU>
<TI>Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>471-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-2008a" MODIFIED="2013-05-08 15:39:07 +1000" MODIFIED_BY="[Empty name]" NAME="Christensen 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Christensen R, Bartels EM, Astrup A, Bliddal H</AU>
<TI>Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials.</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2008</YR>
<VL>16</VL>
<PG>399-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-2008b" MODIFIED="2013-05-21 18:09:44 +1000" MODIFIED_BY="[Empty name]" NAME="Christensen 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H</AU>
<TI>Does the hip powder of <I>Rosa canina</I> (rosehip) reduce pain in osteoarthritis patients? A meta-analysis of randomized controlled trials</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2008</YR>
<VL>16</VL>
<PG>965-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-1996" MODIFIED="2013-05-21 18:14:18 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Sporer F, Wink M</AU>
<TI>Active ingredients in medicines from <I>Harpagophytum procumbens</I>
</TI>
<TO>Zum Wirkstoffgehalt in Arzneimitteln aus <I>Harpagophytum procumbens</I>
</TO>
<SO>Forschende Komplementarmedizin</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-1999" MODIFIED="2013-05-21 18:14:34 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 1999" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H</AU>
<TI>Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: A randomized, placebo-controlled, double-blind study</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>118-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2000" MODIFIED="2008-06-03 21:51:21 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C</AU>
<TI>Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>109</VL>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2001" MODIFIED="2013-05-21 18:14:56 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Künzel O, Model A, Conradt C, Black A</AU>
<TI>Treatment of low back pain with a herbal or syntheticantirheumatic: a randomized controlled study</TI>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<PG>1388-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2002" MODIFIED="2008-06-03 20:25:06 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Fiebich B, Black A, Pollak S</AU>
<TI>Treating low back pain with an extract of Harpagophytum that inhibits cytokine release</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2003" NAME="Chrubasik 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Roufogalis B.</AU>
<TI>Bioequivalence of herbal medicines</TI>
<SO>New Zealand Journal of Pharmacy</SO>
<YR>2003</YR>
<VL>53</VL>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2005" MODIFIED="2012-06-09 16:37:39 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Pittler MH, Roufogalis BD</AU>
<TI>Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles</TI>
<SO>Phytomedicine</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>9</NO>
<PG>684-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2006" MODIFIED="2008-06-03 21:51:42 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik JE, Lindhorst E, Neumann E, Gerlach U, Faller-Marquardt M, Torda T, Muller-Ladner U, Chrubasik S</AU>
<TI>Potential molecular basis of the chondroprotective effect of <I>Harpagophytum procumbens</I>
</TI>
<SO>Phytomedicine</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>598-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-2007" MODIFIED="2013-05-21 18:15:23 +1000" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik JE, Roufogalis BD, Chrubasik S</AU>
<TI>Evidence of effectiveness of herbal anti-inflammatory drugs in the treatment of painful osteoarthritis including chronic low back pain</TI>
<SO>Phytotherapy Research</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>675-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2013-05-07 13:17:42 +1000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMA-2009" MODIFIED="2014-05-21 14:31:41 +1000" MODIFIED_BY="[Empty name]" NAME="EMA 2009" TYPE="OTHER">
<AU>European Medicines Agency (EMA)</AU>
<TI>Assessment report on salicis cortex (willow bark) and herbal preparation(s) thereof with well-established use and traditional use</TI>
<SO>EMA, London, 2009</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESCOP-2003" NAME="ESCOP 2003" TYPE="BOOK">
<AU>European Scientific Cooperative on Phytotherapy (Eds)</AU>
<SO>ESCOP Monographs</SO>
<YR>2003</YR>
<PB>Thieme-Verlag Stuttgart</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESCOP-2009" MODIFIED="2012-06-09 15:02:49 +1000" MODIFIED_BY="[Empty name]" NAME="ESCOP 2009" TYPE="BOOK">
<AU>European Scientific Cooperative on Phytotherapy (Eds)</AU>
<SO>ESCOP Monographs</SO>
<YR>2009</YR>
<VL>Supplement</VL>
<PB>Thieme Press</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabriel-1991" MODIFIED="2013-05-21 18:15:49 +1000" MODIFIED_BY="[Empty name]" NAME="Gabriel 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel SE, Jaakkimainen L, Bombardier C</AU>
<TI>Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>787-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glinko-1998" MODIFIED="2014-05-21 14:40:41 +1000" MODIFIED_BY="[Empty name]" NAME="Glinko 1998" TYPE="OTHER">
<AU>Glinko A</AU>
<TI>Pharmacological properties of a standardized extract from Willow Bark (Cortex salicis) [treatise]</TI>
<SO>Chair of Pharmacology and Toxicology. Pomeranian Academy of Medicine</SO>
<YR>1998</YR>
<CY>Szczecin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gundermann-2001" NAME="Gundermann 2001" TYPE="BOOK">
<AU>Gundermann KJ</AU>
<TI>Phytodolor solution</TI>
<SO>Clinical expert report</SO>
<YR>2001</YR>
<PB>Steigerwald</PB>
<CY>Darmstadt, Germany</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadhyiski-2006" MODIFIED="2008-06-03 21:55:31 +1000" MODIFIED_BY="[Empty name]" NAME="Hadhyiski 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hadzhiyski H, Lindhorst E, Raif W, Torda T, Chrubasik S</AU>
<TI>Impact of <I>Harpagophytum procumbens</I> on the urinary pyridinoline deoxypyridinoline ratio in experimental osteoarthritis [Abstract]</TI>
<SO>FACT: Focus on Alternative and Complementary Therapies</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-03-15 21:28:48 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies.</TI>
<SO>Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH-2004" MODIFIED="2008-10-08 16:14:54 +1100" MODIFIED_BY="[Empty name]" NAME="ICH 2004" TYPE="OTHER">
<AU>ICH</AU>
<TI>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</TI>
<SO>Synopsis of ICH guidelines and topics</SO>
<YR>2004</YR>
<PB>Author</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4_ger-2007" MODIFIED="2013-05-21 18:16:13 +1000" MODIFIED_BY="[Empty name]" NAME="Jäger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jäger AK, Eldeen IM, van Staden J</AU>
<TI>COX-1 and -2 activity of rose hip</TI>
<SO>Phytotherapy Research</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>12</NO>
<PG>1251-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4_ger-2008" MODIFIED="2013-05-21 18:16:30 +1000" MODIFIED_BY="[Empty name]" NAME="Jäger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jäger AK, Petersen KN, Thomasen G, Christensen SB</AU>
<TI>Isolation of linoleic and alpha-linolenic acids as COX-1 and -2 inhibitors in rose hip</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>7</NO>
<PG>982-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krishnaraju-2010" MODIFIED="2013-05-21 18:17:57 +1000" MODIFIED_BY="[Empty name]" NAME="Krishnaraju 2010" TYPE="JOURNAL_ARTICLE">
<AU>Krishnaraju AV, Sundararaju D, Vamsikrishna U, Suryachandra R, Machiraju G, Sengupta K, Trimurtulu G</AU>
<TI>Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product</TI>
<SO>Toxicology Mechanisms and Methods</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>9</NO>
<PG>556-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krivoy-2001" MODIFIED="2013-05-21 18:18:10 +1000" MODIFIED_BY="[Empty name]" NAME="Krivoy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brooks G</AU>
<TI>Effect of <I>Salicis cortex</I> extract on human platelet aggregation</TI>
<SO>Planta Medica</SO>
<YR>2001</YR>
<VL>67</VL>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawrence-2008" MODIFIED="2011-04-25 08:10:47 +1000" MODIFIED_BY="[Empty name]" NAME="Lawrence 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. National Arthritis Data Workgroup</AU>
<TI>Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<PG>26-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2010" MODIFIED="2013-05-21 18:18:36 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lee YH, Woo JH, Choi SJ, Ji JD, Song GG</AU>
<TI>Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis</TI>
<SO>Rheumatology International</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>3</NO>
<PG>357-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malemud-2010" MODIFIED="2011-04-25 08:31:20 +1000" MODIFIED_BY="[Empty name]" NAME="Malemud 2010" TYPE="JOURNAL_ARTICLE">
<AU>Malemud CJ</AU>
<TI>Anticytokine therapy for osteoarthritis: Evidence to date</TI>
<SO>Drugs &amp; Aging</SO>
<YR>2010</YR>
<VL>27</VL>
<PG>95-115</PG>
<IDENTIFIERS MODIFIED="2011-04-25 08:31:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-25 08:31:20 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.2165/11319950-000000000-00000"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mazieres-1993" MODIFIED="2008-06-03 20:51:10 +1000" MODIFIED_BY="[Empty name]" NAME="Mazieres 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mazieres B, Tempesta C, Tiechard M, Vaguier G</AU>
<TI>Pathologic and biochemical effects of a lipidic avocado and soya extract on an experimental post-contusive model of OA [Abstract]</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2013-05-21 18:19:02 +1000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ofman-2002" MODIFIED="2013-05-21 18:19:24 +1000" MODIFIED_BY="[Empty name]" NAME="Ofman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P</AU>
<TI>A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs</TI>
<SO>Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>804-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ofman-2003" MODIFIED="2013-05-21 18:19:46 +1000" MODIFIED_BY="[Empty name]" NAME="Ofman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle PG</AU>
<TI>Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>49</VL>
<PG>508-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivier-2010" MODIFIED="2013-05-21 18:20:28 +1000" MODIFIED_BY="[Empty name]" NAME="Olivier 2010" TYPE="JOURNAL_ARTICLE">
<AU>Olivier P, Montastruc JL</AU>
<TI>Réseau français des centres régionaux de pharmacovigilance</TI>
<TO>Post-marketing safety profile of avocado-soybean unsaponifiables</TO>
<SO>Presse Medicale</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>10</NO>
<PG>e211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2003" MODIFIED="2013-05-21 18:20:42 +1000" MODIFIED_BY="[Empty name]" NAME="Pham 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al</AU>
<TI>Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria</TI>
<SO>Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<PG>1645-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2004" MODIFIED="2013-05-21 18:21:32 +1000" MODIFIED_BY="[Empty name]" NAME="Pham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al</AU>
<TI>OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reginister-2007" MODIFIED="2014-05-21 14:41:46 +1000" MODIFIED_BY="[Empty name]" NAME="Reginister 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS</AU>
<TI>Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<PG>945-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2007" MODIFIED="2013-05-21 18:21:57 +1000" MODIFIED_BY="[Empty name]" NAME="Reichenbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, et al</AU>
<TI>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>8</NO>
<PG>580-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sangha-2000" MODIFIED="2013-05-21 18:22:14 +1000" MODIFIED_BY="[Empty name]" NAME="Sangha 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sangha O</AU>
<TI>Epidemiology of rheumatic diseases</TI>
<SO>Rheumatology</SO>
<YR>2000</YR>
<VL>39 Suppl 2</VL>
<PG>3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmid-1998b" MODIFIED="2012-06-23 22:06:14 +1000" MODIFIED_BY="[Empty name]" NAME="Schmid 1998b" TYPE="UNPUBLISHED">
<AU>Schmid B</AU>
<TI>Treatment of hip and knee osteoarthritis with willow bark extract</TI>
<TO>Behandlung von Cox- und Gonarthrosen mit einem Weidenrindenextrakt</TO>
<SO>Dissertation Universität Tübingen</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitz-2010" MODIFIED="2013-05-21 18:22:35 +1000" MODIFIED_BY="[Empty name]" NAME="Schmitz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz N, Kraus VB, Aigner T</AU>
<TI>Targets to tackle--the pathophysiology of the disease</TI>
<SO>Current Drug Targets</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>521-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoonees-2012" MODIFIED="2014-05-21 14:38:29 +1000" MODIFIED_BY="[Empty name]" NAME="Schoonees 2012" TYPE="COCHRANE_REVIEW">
<AU>Schoonees A, Visser J, Musekiwa A, Volmink J</AU>
<TI>Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-05-21 14:38:29 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-21 14:38:29 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008294.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2011a" MODIFIED="2013-05-07 13:36:25 +1000" MODIFIED_BY="[Empty name]" NAME="Schunemann 2011a" TYPE="BOOK_SECTION">
<AU>Schunemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and 'Summary of findings' tables</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>updated March 2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2011b" MODIFIED="2013-05-07 13:36:56 +1000" MODIFIED_BY="[Empty name]" NAME="Schunemann 2011b" TYPE="BOOK_SECTION">
<AU>Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>updated March 2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smalley-1996" MODIFIED="2013-05-21 18:23:20 +1000" MODIFIED_BY="[Empty name]" NAME="Smalley 1996" TYPE="JOURNAL_ARTICLE">
<AU>Smalley WE, Griffin MR, Fought RL, Ray WA</AU>
<TI>Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>461-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sporer-1999" MODIFIED="2013-05-21 18:23:02 +1000" MODIFIED_BY="[Empty name]" NAME="Sporer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sporer F, Chrubasik S</AU>
<TI>Preparations from Devil's claw (<I>Harpagophytum procumbens</I>)</TI>
<TO>Präparate aus der Teufelskralle (<I>Harpagophytum procumbens</I>)</TO>
<SO>Zeitschrift für Phytotherapie</SO>
<YR>1999</YR>
<VL>20</VL>
<PG>235-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stohs-2011" MODIFIED="2013-05-21 18:23:48 +1000" MODIFIED_BY="[Empty name]" NAME="Stohs 2011" TYPE="JOURNAL_ARTICLE">
<AU>Stohs SJ, Preuss HG, Shara M</AU>
<TI>The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine</TI>
<SO>Phytotherapy Research</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1421-8</PG>
<IDENTIFIERS MODIFIED="2012-06-09 16:49:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-09 16:49:21 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.3490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stone-1763" MODIFIED="2012-06-23 22:44:18 +1000" MODIFIED_BY="[Empty name]" NAME="Stone 1763" TYPE="JOURNAL_ARTICLE">
<AU>Stone E</AU>
<TI>An account of the success of the bark of the willow in the cure of agues</TI>
<SO>Philosophy. Trans: Royal Society London</SO>
<YR>1763</YR>
<VL>53</VL>
<PG>195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valerio-2005" MODIFIED="2012-06-09 16:36:16 +1000" MODIFIED_BY="[Empty name]" NAME="Valerio 2005" TYPE="JOURNAL_ARTICLE">
<AU>Valerio LG Jr, Gonzales GF</AU>
<TI>Toxicological aspects of the South American herbs cat's claw (Uncaria tomentosa) and Maca (Lepidium meyenii) : a critical synopsis</TI>
<SO>Toxicology Review</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>1</NO>
<PG>11-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Berg-2011" MODIFIED="2013-05-21 18:24:15 +1000" MODIFIED_BY="[Empty name]" NAME="van den Berg 2011" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg WB</AU>
<TI>Osteoarthritis year 2010 in review: Pathomechanisms</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2011</YR>
<VL>19</VL>
<PG>338-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vlachojannis-2008" MODIFIED="2013-05-21 18:24:34 +1000" MODIFIED_BY="[Empty name]" NAME="Vlachojannis 2008" TYPE="JOURNAL_ARTICLE">
<AU>Vlachojannis JE, Roufogalis BD, Chrubasik S</AU>
<TI>Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2</NO>
<PG>149-52</PG>
<IDENTIFIERS MODIFIED="2013-05-08 13:21:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-08 13:21:32 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ptr.2314"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vlachojannis-2009" MODIFIED="2013-05-21 18:25:12 +1000" MODIFIED_BY="[Empty name]" NAME="Vlachojannis 2009" TYPE="BOOK_SECTION">
<AU>Vlachojannis JE, Duke RK, Tran VH, Duke CC, Chrubasik S</AU>
<TI>Anti-inflammatory herbal medicines for the control of pain</TI>
<SO>Novel Therapeutic Agents from Plants</SO>
<YR>2009</YR>
<PG>339-67</PG>
<ED>Carpinella M C, Rai M</ED>
<PB>Science Publisher</PB>
<CY>Enfield, NH, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vlachojannis-2013" MODIFIED="2014-05-14 14:09:02 +1000" MODIFIED_BY="[Empty name]" NAME="Vlachojannis 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vlachojannis C, Magora F, Chrubasik S</AU>
<TI>Pro and contra duration restriction of willow bark treatment</TI>
<SO>Phytotherapy Research</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>1</NO>
<PG>148-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wandel-2010" MODIFIED="2012-06-03 08:46:32 +1000" MODIFIED_BY="[Empty name]" NAME="Wandel 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S</AU>
<TI>Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c4675</PG>
<IDENTIFIERS MODIFIED="2012-06-03 08:45:36 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-03 08:45:36 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.c4675"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wenzig-2008" MODIFIED="2013-05-21 18:25:36 +1000" MODIFIED_BY="[Empty name]" NAME="Wenzig 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wenzig EM, Widowitz U, Kunert O, Chrubasik S, Bucar F, Knauder E, Bauer R</AU>
<TI>Phytochemical composition and in vitro pharmacological activity of two rose hip (Rosa canina L.) preparations</TI>
<SO>Phytomedicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>10</NO>
<PG>826-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2009" MODIFIED="2013-05-21 18:25:57 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al</AU>
<TI>EULAR evidence based recommendations for the diagnosis of hand osteoarthritis - report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<PG>8-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2010a" MODIFIED="2013-05-21 18:26:17 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Jordan JM</AU>
<TI>Epidemiology of osteoarthritis</TI>
<SO>Clinical Geriatric Medicine</SO>
<YR>2010</YR>
<VL>26</VL>
<PG>355-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2010b" MODIFIED="2013-05-21 18:26:44 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al</AU>
<TI>EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>3</NO>
<PG>483-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-14 14:02:36 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cameron--2007" MODIFIED="2013-05-21 18:26:59 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron  2007" TYPE="JOURNAL_ARTICLE">
<AU>Cameron M, Chrubasik S, Parsons T, Gagnier J, Blümle A, Little C</AU>
<TI>Herbal therapy for treating osteoarthritis: Update of a Cochrane review</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66 Supp II</VL>
<PG>494</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cameron-2009" MODIFIED="2013-05-21 18:27:24 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cameron M, Gagnier J, Little C, Parsons T, Blümle A, Chrubasik S</AU>
<TI>Evidence of the effectiveness of herbal medicinal products in the treatment of arthritis. Part A: Osteoathritis</TI>
<SO>Phytotherapy Research</SO>
<YR>2009</YR>
<VL>23</VL>
<PG>1497-515</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/ptr.3007"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-05-11 00:38:27 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-05-11 00:34:40 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-05-11 00:04:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adegbehingbe-2008">
<CHAR_METHODS MODIFIED="2014-05-11 00:03:38 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo and active controls, 4 parallel groups, single centre study. Duration 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:03:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=143, Completed n=84. Mean age: placebo control 53.2 yrs, active control 1 (naproxen 1000mg) 51.0 yrs, active control 2 (Celebrex 400mg) 52.5 yrs, intervention 54.1 yrs. M:F placebo control 7:14, active control A 6:15, active control B 6:15, intervention 5:16. Inclusion: primary or secondary OA knee (ACR criteria), pain at rest VAS 0-100 &gt;45mm at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:03:47 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided: <I>Garcinia kola 4</I>00mg (2 x 200mg), tablets</P>
<P>Active control A: naproxen 1000mg (2 x 500mg), tablets</P>
<P>Active control B: celecoxib (Celebrex) 400mg (2 x 200mg), tablets</P>
<P>Placebo control: ascorbic acid 200mg (2 x 100g), tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:03:49 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (Pain), WOMAC 0-4 (Function), walking distance, time to pain relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:04:00 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results favour intervention and active controls over placebo. Reductions in pain were not significantly different between <I>Garcinia kola</I> and the active controls, although onset of pain relief was most rapid and most persistent in the celebrex group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:04:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altman-2001">
<CHAR_METHODS MODIFIED="2014-05-11 00:04:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups, 10 centre study. Duration 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:04:24 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=261, Completed n=247. Mean age 65 yrs. M:F 37:63. Inclusion: OA knee stage II-IV (ACR criteria), knee pain on standing 40-90mm on VAS 100mm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:04:31 +1000" MODIFIED_BY="[Empty name]">
<P>EV.EXT 77: mixture of <I>Zingiber officinale</I> (ginger) and <I>Alpina galanga</I> (galangal) extracts, 510mg (2 x 255mg), capsules</P>
<P>Placebo control: coconut oil, capsules</P>
<P>Rescue medication permitted: acetominophen, up to 4000mg (4 x 2 x 500mg) daily PRN</P>
<P>Concurrent medication permitted: aspirin, up to 325mg daily for anticoagulation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:04:32 +1000" MODIFIED_BY="[Empty name]">
<P>Pain on standing, pain walking 50ft, WOMAC-VAS (normalised units), SF-12, patient global 1-5</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 13:22:46 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; statistical power not reported, but <I>post-hoc</I> calculation of power based on sample size and design indicates adequate power to detect medium to large effects (if d=0.5, then P=0.97). Reported compliance with ICH GCP guidelines and ethics committee approval. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:05:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appelboom-2001">
<CHAR_METHODS MODIFIED="2014-05-11 00:05:32 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 3 parallel groups, multicentre study. Duration 90 days (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:05:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=260, Completed n=206. Age range 45-80 yrs. M:F 55:205. Inclusion: OA knee (ACR criteria), VAS 0-100 pain on standing 40-90mm, baseline analgesia 90-110mg diclofenac equivalents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:05:05 +1000" MODIFIED_BY="[Empty name]">
<P>Piascledine 300*: <I>Persa gratissma</I> and <I>Glycine max</I>, avocado / soyabean unsaponifiables, 300mg / 600mg, OD, tablets</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:05:12 +1000" MODIFIED_BY="[Empty name]">
<P>NSAID use (diclofenac equivalents), days without NSAIDs, pain VAS 0-100, Lesquesne index, patient efficacy assessment, clinician efficacy assessment, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 13:23:19 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power not reported, but post-hoc calculation of power based on sample size and design indicates adequate power to detect medium to large effects (if Cohen's f=0.25, then P=0.90). Reported ethics committee approval. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:06:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Badria-2002">
<CHAR_METHODS MODIFIED="2014-05-11 00:05:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 3 parallel groups (intervention, placebo control, non-intervention control). Erroneously described as "cross-over trial". Duration 3 months (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:06:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=60; intervention n=30, placebo n=15, non-intervention control n=15. Age and gender data not reported. Inclusion: OA knee (criteria not specified)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:06:04 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. Boswellia-curcuma extract mixture, 1500mg (3 x 500mg), capsules</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:06:10 +1000" MODIFIED_BY="[Empty name]">
<P>Nocturnal pain, pain with active movement 0-3, pain with passive movement 0-3, tenderness 0-3, knee effusion 0-3, pain-free walking time minutes, antioxidant enzyme SOD, free radical damage markers NO, nitrate, nitrite, and CD, CD4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:06:16 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:06:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2008">
<CHAR_METHODS MODIFIED="2014-05-11 00:06:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel group study. Duration 3 months (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:06:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=156; intervention n=77, control n=79. Completed n=143. Mean age: control 47.8 yrs, intervention 48.6 yrs. M:F: control 39:40, intervention 39:38. Inclusion: OA knee (radiographic criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:06:48 +1000" MODIFIED_BY="[Empty name]">
<P>Pycnogenol<SUP>®</SUP>: <I>Pinus pinaster</I>, pine bark extract, 100mg (2 x 50mg), tablets</P>
<P>Placebo control: ingredients not reported, tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:06:50 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC 0-4, mobility (treadmill walking)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 13:24:33 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; statistical power 80%, alpha set at 0.05. Reported ethics committee approval and compliance with Declaration of Helsinki. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:07:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernhardt-1991">
<CHAR_METHODS MODIFIED="2014-05-11 00:07:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, active control (unblinded), 3 parallel groups. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:07:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=108; intervention n=36, placebo n=36, piroxicam n=36. Completed n=108. Mean age 52 yrs. M:F 22:50. Inclusion: OA (criteria not specified), acute or recurrent degenerative arthritic complaints</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:07:29 +1000" MODIFIED_BY="[Empty name]">
<P>Phytodolor<SUP>R</SUP>N: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 30 drops, tincture</P>
<P>Active control: piroxicam (Feldene 20), 20mg, OD</P>
<P>Placebo control: ingredients not reported</P>
<P>Concurrent treatment permitted: balneology (thermal baths), and physiotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:07:31 +1000" MODIFIED_BY="[Empty name]">
<P>Pain with movement 0-3, enduring pain 0-3, mobility impairment 0-3, finger-ground distance, grip strength, PGA 0-6, patient perception efficacy 0-3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 13:22:08 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined <I>a priori.</I> Did not report ethical oversight or compliance with guidelines. Results favour intervention. Some outcome measures (eg: finger-ground distance) are non-specific and may be of limited use in rheumatological assessment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:08:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biegert-2004">
<CHAR_METHODS MODIFIED="2014-05-11 00:07:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, active control, 3 parallel groups. Duration 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:08:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=127, Completed n=106. Mean age 62 yrs. M:F 53:74. Inclusion: OA knee or hip (ACR criteria), WOMAC &gt;30mm, aspirin 100mg/d</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:08:06 +1000" MODIFIED_BY="[Empty name]">
<P>Assalix*: <I>Salix daphnoides</I> cortex (willow bark), ethanolic extract, 1572.96mg (2 x 2 x 393.24mg, equivalent to 240mg salicin), tablets</P>
<P>Active control: diclofenac, 100mg (2 x 2 x 25mg), tablets</P>
<P>Placebo control: ingredients not reported, tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:08:08 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (normalised units), SF-36, patient efficacy assessment VAS 0-100, physician efficacy assessment VAS 0-100, HAQ-DI (German)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 13:25:47 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power 80%, alpha set at 0.05 (2 tailed). Reported compliance with ICH GCP guidelines and the Declaration of Helsinki. Results equivocal.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:08:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biller-2002">
<CHAR_METHODS MODIFIED="2014-05-11 00:08:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:08:32 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=78, Completed n=77. Age and gender data not reported. Inclusion: OA knee (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:08:34 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>LoHar 45 flexi-loges</U>
<SUP>®*</SUP>: <I>Harpagophytum procumbens</I> (devil's claw), ethanolic extract, 960mg, tablets</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:08:38 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (German version). Post hoc "responders&#8221; to treatment were defined as participants whose WOMAC pain scores increased by not more than 20% without additional rescue medication in weeks 17-20</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:08:44 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance with ICH GCP guidelines. Results equivocal: no improvement on primary outcome measure (WOMAC).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:09:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bliddal-2000">
<CHAR_METHODS MODIFIED="2014-05-11 00:09:18 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, active control, 3 group crossover. Duration 12 weeks (1 week washout followed by 3 weeks intervention)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:09:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=67, Completed n=56. Mean age 66 yrs, range 24-87 yrs. M:F 15:41. Inclusion: OA hip or knee, radiologically verified Kellgren grade I-IV, VAS 0-100 pain on mvt &gt;30mm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:09:30 +1000" MODIFIED_BY="[Empty name]">
<P>Eurovita.EXT 33: <I>Zingiber officinale</I> (Chinese ginger) extract, 510mg (3 x 170mg), capsules</P>
<P>Active control: ibuprofen, 400mg, tablets</P>
<P>Placebo control: ingredients not reported, capsules and tablets</P>
<P>Rescue medicine permitted: paracetamol (acetominophen), 3000mg daily, PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:09:32 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100, Lequesne index, range of motion (hip or knee), acetominophen use, investigator treatment preference, daily pain diary (4 point Likert scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 13:28:01 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined <I>a priori. </I>Reported ethics committee approval and compliance with ICH GCP guidelines. Results favour ibuprofen over ginger, ginger over placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:10:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blotman-1997">
<CHAR_METHODS MODIFIED="2014-05-11 00:09:50 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n not specified). Duration 90 days (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:09:54 +1000" MODIFIED_BY="[Empty name]">
<P>Completed n=163. Mean age 63 yrs. M:F 55:108. Inclusion: OA knee (n=101) or hip (n=62) (ACR criteria), Kellgren grade IB-III, pain requiring NSAIDs for 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:10:03 +1000" MODIFIED_BY="[Empty name]">
<P>Piascledine 300*: <I>Persa gratissma</I> and <I>Glycine max</I>, avocado / soyabean unsaponifiables, 300mg / 600mg, OD, tablets</P>
<P>Placebo control: ingredients not reported</P>
<P>Rescue medication permitted: one of 7 predefined NSAIDs taken by all participants for first 45 days. Resumption of same NSAID allowed during second 45 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:10:09 +1000" MODIFIED_BY="[Empty name]">
<P>Resumption of NSAIDS, time off NSAIDS, NSAID use (diclofenac equivalents), Lequesne index, pain VAS 0-100, patient global 0-4, physician global 0-4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 13:28:43 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design, power 80%, alpha 0.05. Reported compliance with Helsinki Declaration and ethics committee approval. Results favour intervention for reduced use of NSAIDs, but pain scores are similar in the two groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:10:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2005">
<CHAR_METHODS MODIFIED="2014-05-11 00:10:27 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, unblinded, active control, 2 parallel groups, two centres. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:10:28 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=120, intervention (n=60; n=30 at x centres), Chinese control n=30, Western control n=30. Completed n=116. Inclusion: OA knee (ACR criteria), at least 5 days on NSAIDs, adverse events with NSAIDs, pain with walking at least 20mm (VAS 0-100) in the previous 48h</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:10:40 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. Chinese herbal mixture (blood-nourishing, hard-softening; BNHS), 3150mg</P>
<P>Active control (Chinese): Chinese mixture to counter osteophytes, 5250mg, capsules</P>
<P>Active control (Western): Viatril-s 2250mg (crystalline glucosamine sulphate 1884mg equivalent to glucosamine sulphate 1500mg, sodium chloride 384mg)</P>
<P>Rescue medication permitted: paracetamol (acetominophen), up to 4000mg daily, PRN; and aspirin, up to 100mg daily in a stable dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:10:41 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (normalised scores), pain during walking 0-100 VAS, patient global 0-4, physician global 0-4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 14:29:50 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined <I>a priori</I>. Reported ethics committee approval and compliance with ICH GCP guidelines. Improvements occured in all groups over time. Results indicate that BNHS is not inferior to counter osteophyte Chinese mixture or Viatril-s.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:11:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheras-2010">
<CHAR_METHODS MODIFIED="2014-05-11 00:10:59 +1000" MODIFIED_BY="[Empty name]">
<P>Ramdonised, double-blind, placebo control, 2 parallel groups, single centre. Duration 18 weeks (3 weeks washout, 15 weeks trial)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:11:00 +1000" MODIFIED_BY="[Empty name]">
<P>Completed n=89, intervention n=39, control n=50. OA hip or OA knee (ACR criteria), overall WOMAC score=30 at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:11:03 +1000" MODIFIED_BY="[Empty name]">
<P>SheaFlex70: <I>Vitellaria paradoxia</I>, 100% sheabutter extract with 75% triterpene esters, 2250mg (3 x 750mg), capsules</P>
<P>Placebo control: 100% canola oil, 2250mg (3 x 750mg), capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:11:05 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC, Comprehensive Osteoarthritis Test (COAT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 13:30:00 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined <I>a priori. </I>Reported ethics committee approval and clinical trials registration (ACTRN12606000162516). Results equivocal on clinical outcomes. Changes in WOMAC scores were not significant either within or between groups. Significant decrease in COAT pain subscale score within the shea group over time was not significantly different from this outcome in the control group at the end of the trial. Significant differences in some inflammatory markers were reported, but are not of relevance to this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:11:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chopra-2004">
<CHAR_METHODS MODIFIED="2014-05-11 00:11:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 32 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:11:43 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=90, intervention n=45, control n=45. Midpoint (16 weeks) n=78. Completed n=62, intervention n=31, control n=31. Age 35+ years. OA knee (ACR criteria). Stable NSAIDs for 1 month at baseline. Not pregnant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:11:48 +1000" MODIFIED_BY="[Empty name]">
<P>RA-11: Ayurvedic medication, 2 capsules</P>
<P>Placebo control: ingredients not reported</P>
<P>Rescue medication not permitted</P>
<P>Concurrent medication permitted: stable medication for concomitant diseases</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:11:50 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC 0-4 (Asian - Indian modification), VAS 0-100, 50 feet walk time (seconds), physician global assessment 0-4, patient global assessment 0-4, early morning stiffness (minutes), knee swelling 0-3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-13 11:29:01 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design, power 80%, alpha 0.05 (2 tailed). Did not report ethical oversight or compliance with guidelines. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:12:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chopra-2011">
<CHAR_METHODS MODIFIED="2014-05-11 00:12:10 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo and active control, 7 parallel groups, multicentre (n not specified). Duration 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:12:17 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=245, all groups n=35. Completed n=202. Data available for analysis n=236. Mean age: placebo control 54 yrs, active control 54.2 yrs, intervention A 57.5 yrs, intervention B 56.6 yrs, intervention C 56.8 yrs, intervention D 56.2 yrs, intervention E 56.2 yrs. M:F not reported. Inclusion: OA knee (ACR criteria with lower age limit reduced to 40 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:12:23 +1000" MODIFIED_BY="[Empty name]">
<P>Tradenames not provided. five Ayurvedic formulations containing <I>Zingiber officinale</I> and <I>Tinospora cordifolia </I>and combinations of<I> Emblica officinale, Withania somnifera, </I>or <I>Tribulus terrestris</I>, variable doses (4 x approx 500mg), capsules</P>
<P>Active control: glucosamine sulphate, 1000mg (4 x 250mg). Capsule mass approx 500mg</P>
<P>Placebo control: charcoal and synthetic ginger essence, 2000mg (4 x 500mg), capsules</P>
<P>Rescue medication permitted: paracetamol (acetominophen), 2000mg (4 x 500mg) PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:12:24 +1000" MODIFIED_BY="[Empty name]">
<P>Pain on weightbearing VAS 0-10, WOMAC 0-4 (Indian version), paracetamol use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:12:33 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results equivocal for primary outcomes. Trend to favour intervention C for pain relief, paracetamol use, and knee function</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:13:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chopra-2013">
<CHAR_METHODS MODIFIED="2014-05-11 00:12:54 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, active control, multicentre (n=3), 4 parallel groups. Duration 24 weeks (+2 to 5 days washout for participants using NSAIDs)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:12:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=440, intervention SGC n=110, intervention SGCG n=110, active control celecoxib n=110, active control glucosamine n=110. Completed n=314, SGC n=75, SGCG n=75, celecoxib n=78, glucosamine n=86. Age range 40-70 years. Inclusion: OA knee (ACR criteria with modified age range), unilateral or bilateral knee OA, baseline VAS 0-100 (pain on weightbearing) &gt;54mm. Not pregnant or lactating, not taking medications likely to influence pain / functional outcomes, no known GIT bleeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:13:13 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. Standardised Ayurvedic formulation (shunthi-guduchi, SGCG), 2400mg (2 x 400mg, TID), capsules</P>
<P>Tradename not provided. Standardised Ayurvedic formulation (shunthi-guduchi with guggal, SGCG), 2400mg (2 x 400mg, TID), capsules</P>
<P>Active control A: celecoxib, 200mg (2 x 33.3mg, TID), capsules</P>
<P>Active control B: glucosamine sulphate, 2000mg (2 x 333mg, TID), capsules</P>
<P>Rescue medication permitted: 500mg acetominophen (paracetamol), PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:13:15 +1000" MODIFIED_BY="[Empty name]">
<P>Pain on weightbearing VAS 0-10, WOMAC 0-4 (Indian version for hip and knee; pain and function subscales only), patient global 1-5, physical global 1-5, HAQ</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-03 13:18:47 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power 80%, alpha set at 0.05 (2 tailed). Reported compliance with ICH GCP guidelines, and Declaration of Helsinki. Reported clinical trial registration (CTRI/2008/091/000063). Results for Ayurvedic interventions show equivalent outcomes in pain and function to glucosamine sulphate and celecoxib, but the more participants in the Ayurvedic group reported (unexpected) adverse events.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:14:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cisar-2008">
<CHAR_METHODS MODIFIED="2014-05-11 00:13:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 12 weeks intervention, plus 2 weeks washout/follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:14:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=100, Completed intervention n=90, Completed washout n=81. Mean age 54 yrs. M:F control 18:32, intervention 14:36. Inclusion: OA knee (ACR criteria), Kellgren grade I or II, mild-moderate pain in target knee for at least 3 months, morning stiffness, knee crepitus, age &gt; 25 years. Female participants not pregnant, nor planning pregnancy for &gt; 12 months post study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:14:06 +1000" MODIFIED_BY="[Empty name]">
<P>Pycnogenol<SUP>®</SUP>: <I>Pinus pinaster,</I> pine bark extract with 90% proanthocyanines, 150mg (3 x 50mg), in 50mg doses TID with meals, tablets</P>
<P>Placebo control: ingredients not reported, tablets</P>
<P>Concurrent medication permitted: stable NSAIDs and analgesics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:14:07 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC 0-4 (Slovak version), Pain VAS 0-100</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:14:13 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:14:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farid-2007">
<CHAR_METHODS MODIFIED="2014-05-11 00:14:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 3 months (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:14:36 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=37; intervention n=19, control n=18. Completed n=35. Mean age: control 48.9 yrs, intervention 47.5yrs. M:F: control 1:17, intervention 2:18. Inclusion: OA knee (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:14:44 +1000" MODIFIED_BY="[Empty name]">
<P>Pycnogenol<SUP>®</SUP>: <I>Pinus pinaster</I>, pine bark extract with 70% proanthocyanines, 150mg (3 x 50mg), tablets</P>
<P>Placebo control: "inactive ingredient", ingredients not report, tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:14:51 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (aggregated scores), NSAID/COX-2 inhibitor use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:14:57 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:15:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferraz-1991">
<CHAR_METHODS MODIFIED="2014-05-11 00:15:16 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 group crossover. Duration 3 weeks (2 x 1 week crossover, 1 week washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:15:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=22, Completed n=20. Mean age 62 yrs, range 47-78 yrs. Inclusion: OA hip or knee, clinical and radiographic verification (criteria not specified)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>Tipi tea: <I>Petiveria alliacea</I>, aqueous extract, 3 x 200ml tea (equivalent to 9gm tipi)</P>
<P>Placebo control: Sape, <I>Imperata exaltata </I>(dose not specified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:15:25 +1000" MODIFIED_BY="[Empty name]">
<P>Pain (scale not reported) at rest, pain with mvt, pain at night, 15 metre walking time, MACTAR patient preference questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:15:34 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results equivocal.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:16:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frerick-2001">
<CHAR_METHODS MODIFIED="2014-05-11 00:15:52 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:15:54 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=46; intervention n=24, control n=22. Completed n=41, intevention n=21, control n=20. Mean age: intervention 58 yrs, control 61 yrs. Gender data not reported. Inclusion: OA hip (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:16:02 +1000" MODIFIED_BY="[Empty name]">
<P>LoHar-45 flexi-loges<SUP>®</SUP>: <I>Harpagophytum procumbens</I> (devil's claw), 960mg, ethanolic extract, tablets</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:16:04 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (German version). Post hoc "responders&#8221; to treatment were defined as participants whose WOMAC pain scores did not increase by more than 20% in weeks 17 to 20 of the study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:16:10 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance with ICH GCP guidelines. Results equivocal: no improvement on primary outcome measure (WOMAC).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:16:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-2011">
<CHAR_METHODS MODIFIED="2013-05-21 17:01:08 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n=3). Duration 3 months (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:16:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=90. Completed n=88; intervention n=44, control n=44. Inclusion: OA knee (knee pain, swelling, stiffness, tenderness, age 45+ years, one or more radiological signs)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:16:39 +1000" MODIFIED_BY="[Empty name]">
<P>Antarth, Ayurvedic phytomedicine (mixture), dose not stated, 2 x BID, capsules</P>
<P>Placebo control: ingredients not reports, capsules</P>
<P>Rescue medication permitted: diclofenac sodium, up to 50mg BID; ranitidine up to 150mg OD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:16:47 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-10, pain walking 0-4, pain squatting 0-4, pain crossing legs 0-4, pain climbing stairs 0-4, physician global (descriptive), patient global (descriptive), rescue medication use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:16:52 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results slightly favour intervention. Participants receiving Antarth used less rescue medication and may be more satisfied than participants receiving placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:17:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-1991">
<CHAR_METHODS MODIFIED="2014-05-11 00:17:09 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo control, 2 parallel groups. Duration 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:17:11 +1000" MODIFIED_BY="[Empty name]">
<P>Recruited n=40, Completed n=38. Age range 50-80 yrs. M:F 4:24. Inclusion: OA (criteria not specified), at least one indication for treatment with antirheumatics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:17:16 +1000" MODIFIED_BY="[Empty name]">
<P>Phytodolor<SUP>R</SUP>N: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 30 drops, tincture</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:17:17 +1000" MODIFIED_BY="[Empty name]">
<P>Rescue medication use, joint size, maximum ROM, pain at rest, pain with mvt, pressure pain, finger-ground distance (spine only), Schober index, percussion pain, serum biochemistry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:17:29 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results favour intervention. Some outcome measures (eg: Schober index) are non-specific and may be of limited use in rheumatological assessment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:18:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jung-2001">
<CHAR_METHODS MODIFIED="2014-05-11 00:17:49 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 4 parallel groups, multicentre (n=2). Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:17:51 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=96, Completed n=93. Mean age 58 yrs. M:F 9:84. Inclusion: OA knee, clinical and radiographic verification (criteria not specified), pain VAS 0-100 &gt;35mm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:17:54 +1000" MODIFIED_BY="[Empty name]">
<P>SKI306X: standardised extract mixture of <I>Clematis mandshurica</I>, <I>Prunella vulgaris</I>, <I>Trichosanthes kirilowii</I>, 600mg (3 x 200mg), 1200mg (3 x 400mg), 1800mg (3 x 600mg), tablets</P>
<P>Placebo control: ingredients not reported, tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:18:01 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100, Lequesne index, patient opinion of efficacy 1-5, investigator opinion of efficacy 1-5, tolerability, serum biochemistry, heamatology, urinanalysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 14:09:51 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design, but statistical power not reported. Reported compliance with Helsinki Declaration and ethics committee approval. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:18:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jung-2004">
<CHAR_METHODS MODIFIED="2014-05-11 00:18:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, active control, 2 parallel groups. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:18:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=249, Completed n=214. Mean age 60 yrs. M:F 18:231. Inclusion: OA knee (ACR criteria), pain VAS 0-100 &gt;35mm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:18:29 +1000" MODIFIED_BY="[Empty name]">
<P>SKI306X: standardised extract mixture of <I>Clematis mandshurica</I>, <I>Prunella vulgaris</I>, <I>Trichosanthes kirilowii</I>, 600mg (3 x 200mg), tablets</P>
<P>Active control: diclofenac SR, 100mg OD, tablets</P>
<P>Placebo controls: ingredients not reported, tablets (double dummy)</P>
<P>Concurrent medication permitted: medications for conditions unrelated to OA, if known not to interact with either study medications</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:18:30 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100, Lequesne, patient global 1-5, physician global 1-5, tolerability, serum biochemistry, haematology, urinanalysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 14:30:41 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design, statistical power 80%, alpha 0.05.Reported compliance with the Declaration of Helsinki and institutional review board oversight. Results equivocal: SKI306X equally effective as diclofenac on pain, Lequesne index, patient and physician global scores. Participants using SKI306X reported fewer adverse events.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:19:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kimmatkar-2003">
<CHAR_METHODS MODIFIED="2014-05-11 00:18:50 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, crossover. Duration 19 weeks (2 x 8 weeks intervention + 3 week washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:18:51 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=30, Completed n=30. No withdrawals. Mean age 59 yrs, range 45-72 yrs. M:F 12:18. Inclusion: OA knee, clinical and radiographic verification (criteria not specified), currently using physiotherapy and NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:18:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>Cap Wokvel</U>&#8482;: <I>Boswellia serrata</I> (Gajabhakshya) extract with 40% boswellic acid, 1000mg (3 x 333mg), capsules</P>
<P>Placebo control: starch powder, capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:19:02 +1000" MODIFIED_BY="[Empty name]">
<P>Joint pain 0-3, loss of function 0-3, swelling 0-3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:19:11 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Reported that study formed part of an academic coursework requirement. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:19:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuptniratsaikul-2009">
<CHAR_METHODS MODIFIED="2014-05-11 00:19:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, single blind, active control, 2 parallel groups. Duration 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:19:31 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=107, Completed n=91. Mean age intervention 61.4 yrs, active control 60.0 yrs. Primary OA knee (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:19:34 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided.<I> Curcuma domestica</I> extract, 2000mg (4 x 500mg) with 1000mg curcuminoids, capsules</P>
<P>Active control: ibuprofen, 800mg (2 x 400mg), method of administration not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:19:35 +1000" MODIFIED_BY="[Empty name]">
<P>Pain on level walking NRS 0-10, pain on stair climbing NRS 0-10, 100m walk (seconds), stair climb and descent (seconds)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 14:46:44 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design, power 80%, alpha 0.05. Reported ethics committee approval. Efficacy of <I>Curcuma domestica</I> is not significantly different from active control (ibuprofen).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:20:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuptniratsaikul-2011">
<CHAR_METHODS MODIFIED="2014-05-11 00:19:56 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, single blind, active control, 2 parallel groups. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:19:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=125; intervention n=63, control n=62. Completed n=107; intervention n=55, control n=52. Inclusion: primary OA knee (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. <I>Derris scandens </I>extract, 800mg (400mg BID)</P>
<P>Active control: naproxen, 500mg (250mg BID)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:20:02 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (10cm normalised scores), 6 minute walk, patient global (categorical 1-6), patient satisfaction (categorical 1-6)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 14:47:28 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; power 80%, alpha 0.05. Reported ethics committee approval. Efficacy of <I>Derris scandens</I> is not significantly different from active control (naproxen). </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:20:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leblan-2000">
<CHAR_METHODS MODIFIED="2014-05-11 00:20:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, active control, 2 parallel groups, multicentre (n=30 rheumatology practices). Duration 4 months (~20 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:20:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=122, Completed n=92. Mean age 61 yrs. M:F 45:77. Inclusion: primary OA knee or hip (ACR criteria), Kellgren stage I-III</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:20:30 +1000" MODIFIED_BY="[Empty name]">
<P>Harpadol<SUP>®</SUP>: <I>Harpagophytum procumbens </I>(devil's claw), freeze-ground powder, 2610 mg (6 x 435mg), equivalent to 60mg harpagoside, capsules.</P>
<P>Active control: diacerhein, 100mg (2 x 50mg), capsules</P>
<P>Placebo controls: ingredients not reports, capsules (double dummy)</P>
<P>Rescue medication permitted: acetaminophen-caffeine OD PRN, followed by diclofenac 150mg (3 x 50mg) PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:20:36 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100, disability VAS 0-100, Lequesne index, rescue medication use, patient global, investigator treatment preference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 14:49:26 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power 90%, alpha 0.05 (1 tailed). Reported compliance with Declaration of Helsinki and ethics committee approval. Results indicate Harpagophytum equally effective as diacerhein on pain, function, and Lequesne index. Participants using Harpagophytum used less rescue medication (acetaminophen-caffeine or diclofenac) and reported significantly fewer adverse effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:21:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lequesne-2002">
<CHAR_METHODS MODIFIED="2014-05-11 00:20:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 parallel groups, multicentre (50 rheumatology practices). Duration 2 years (~104 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:21:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=163, Completed n=96, Returned 2 radiographs n=108. Mean age 63 years. M:F 102:61. Inclusion: OA hip (ACR criteria), Kellgren stage I-III, joint space narrowing &gt;1mm, Lequesne index &gt;4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:21:12 +1000" MODIFIED_BY="[Empty name]">
<P>Piascledine 300: <I>Persa gratissma </I>and <I>Glycine max</I> (avocado-soyabean unsaponifiables), 300mg, capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
<P>Rescue medication permitted: NSAIDs measured in diclofenac equivalents, and analgesics (not specified), PRN</P>
<P>Concurrent medication permitted: all concomitant medications for medical diseases</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:21:14 +1000" MODIFIED_BY="[Empty name]">
<P>Joint space width, Lequesne index, global pain VAS 0-100, NSAID use (diclofenac equivalents), patient global (verbal 7 point scale), investigator global (verbal 4 point scale), days of sick leave, n participants requiring hip replacements</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 14:50:18 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power 80%, alpha 0.05. Reported ethics committee approval. Results equivocal; results favour intervention in subgroup of participants with advanced joint space narrowing.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:21:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maheu-1998">
<CHAR_METHODS MODIFIED="2014-05-11 00:21:31 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n not specified). Duration 8.5 months (~34 weeks); 15 day washout, 6 month intervention (~24 weeks), 2 month follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:21:33 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=164, Completed n=144. Mean age 64 yrs. M:F 46:118. Inclusion: OA knee or hip (ACR criteria), Kellgren stage IB-III, active OA for 6 months, regular pain for 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:21:43 +1000" MODIFIED_BY="[Empty name]">
<P>Piascledine 300: <I>Persa gratissma</I> and <I>Glycine max</I> (avocado-soyabean unsaponifiables), 300mg, capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
<P>Rescue medication permitted: analgesics PRN, up to 1 intra-articular injection of corticosteroid "if absolutely necessary"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:21:45 +1000" MODIFIED_BY="[Empty name]">
<P>Lequesne index, pain VAS 0-100, disability VAS 0-100, number of participants using NSAIDs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-06 14:40:37 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; statistical power 90%, alpha 0.05. Reported review board approval, but unclear whether a formally constituted HREC approved the study protocol. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:22:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maheu-2013">
<CHAR_METHODS MODIFIED="2014-05-11 00:21:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n=122; 52 rheumatology clinics, 70 general practices). Duration 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:22:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=399, Completed n=345. Mean age 62 yrs. M:F 46:54. Inclusion: OA hip (ACR criteria), joint space width (JSW) 1-4mm, Lequesne index 3-10 (scale 0-24), pain for at least 1 year. Most symptomatic hip selected as target joint</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:22:19 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>Piascledine 300</U>: <I>Persa gratissma</I> and <I>Glycine max</I> (avocado/soyabean unsaponifiables), 300mg, capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
<P>Rescue medication permitted: analgesics or NSAIDs PRN recorded in self-report diary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:22:21 +1000" MODIFIED_BY="[Empty name]">
<P>Change in joint space width (JSW; narrowest point on pelvis / hip AP view), WOMAC-VAS, Lequesne index (normalised 0-100)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 14:51:50 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; planned recruitment n=380 for statistical power 90%, alpha 0.05; actual power exceeded 75%. Reported ethics committee approval. Results equivocal for clinical outcomes. Fewer participants (20%) in the intervention group showed progression of joint space narrowing. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:23:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Majima-2012">
<CHAR_METHODS MODIFIED="2014-05-11 00:22:40 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, unblinded, adjunct to active treatment, 2 parallel groups. Duration 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:22:47 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=50; intervention n=25, control n=25. Inclusion: primary knee OA (criteria not specified) with joint effusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:22:52 +1000" MODIFIED_BY="[Empty name]">
<P>Boiogito: Japanese herbal mixture containing extract of <I>Sinomenium acutum</I>, Astragalus, Atractylodes Lancea, Jujube, Glycyrrhiza, ginger, 7.5g (2.5g TID); and loxoprofen 60mg (20mg TID)</P>
<P>Control: loxoprofen 60mg (20mg TID)</P>
<P>Boiogito provided as adjunct therapy to loxoprofen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:22:53 +1000" MODIFIED_BY="[Empty name]">
<P>Knee Society Rating System, SF-36, joint effusion (joint puncture)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:23:02 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported institutional review board oversight, but unclear whether a formally consistuted Human Research Ethics Committee approved the research design. Improvement in pain and function occured in both groups over time. Interventiong roup showed reduction in joint effusion as well as other measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:23:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Medhi-2009">
<CHAR_METHODS MODIFIED="2014-05-11 00:23:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, active control, 2 parallel groups. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:23:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=110; intervention n=55, control n=55. Completed n=100; intervention n=50, control n=50. Age 40+ years. OA knee (not ACR criteria), knee pain, knee swelling</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:23:31 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. <I>Ricinus officinalis. </I>Castor oil, 2.7ml (3 x 0.9ml), capsule</P>
<P>Active control: diclofenac sodium, 150mg (3 x 50mg), capsule</P>
<P>Concurrent intervention permitted: all participants encouraged to have physiotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:23:33 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:23:38 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results favour diclofenac over castor oil for improvement in osteoarthritic knee pain. Pain improved in both intervention and active control groups, but improvement was greater in the diclofenac group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:24:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mehta-2007">
<CHAR_METHODS MODIFIED="2014-05-11 00:23:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, active control (glucosamine sulfate), 2 parallel groups. Duration 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:24:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=95; intervention n=48, control n=47. Completed n=79; intervention n=41, control n=38. Mean age: control 55.1 yrs, intevention 51.9 yrs. OA knee (ACR criteria), Kellgren II or III, function VAS 0-100 between 40mm and 80mm at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:24:07 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>Reparagen®</U>: combination of <I>Uncaria guianensis </I>(cat's claw; 300mg) and <I>Lepidium meyenii </I>(1500mg), 1800mg (2 x 2 x 450mg)</P>
<P>Active control: glucosamine sulfate, 1500mg (2 x 2 x 375mg), capsules</P>
<P>Rescue medication permitted: paracetamol (acetaminophen), up to 1500mg (3 x 500mg) per day in weeks 1-4, 1000mg (2 x 500mg) per day in weeks 5-8</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:24:09 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC 0-4, pain VAS 0-100, rescue medication use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:24:17 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance with Helsinki Declaration and ethics committee approval. Reported clinical trials registration (ISRCTN25438351). Efficacy of Reparagen® is not significantly different from glucosamine sulfate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:24:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mills-1996">
<CHAR_METHODS MODIFIED="2014-05-11 00:24:41 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo control, 2 parallel groups. Duration 2 months (~8 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:24:47 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=82 (all participants, OA and RA), Completed n=52 (plus RA n=20). Mean age (all participants, OA and RA) 62 yrs. Gender data not reported. Inclusion: Self-identified arthritis pain, subsequently assessed by rheumatologist (ACR criteria), AIMS2 pain score of at least 3, not using prescribed salicylates, NSAIDs, or analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:24:51 +1000" MODIFIED_BY="[Empty name]">
<P>Reumalex: polyherbal mixture including extracts of willow bark, guaiacum resin, black cohosh, sarsparilla, and poplar bark, 2 "at a time", tablets.</P>
<P>Placebo control: calcium phosphate, tablets</P>
<P>Concurrent medication permitted: stable self-prescribed analgesics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:24:52 +1000" MODIFIED_BY="[Empty name]">
<P>Pain AIMS 2, modified Ritchie index, analgesic use (diary)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:24:59 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori<I>.</I> Reported ethics committee approval. Results equivocal; medium effect size improvements in pain, but no reduction in analgesic use.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:25:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oben-2009">
<CHAR_METHODS MODIFIED="2014-05-11 00:25:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo control, 4 parallel groups (2 x normal weight patients, 2 x overweight patients). Duration 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:25:24 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=80, Completed n=45. Age range 25-60 yrs (mean age not reported). Gender data not reported. OA knee (ACR criteria) in adults of normal weight and overweight</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:25:28 +1000" MODIFIED_BY="[Empty name]">
<P>NP 06-1: mixture of <I>Phellodendron amurense</I> tree bark extract with 50% berberine and <I>Citrus sinensis</I> peel extract a minimum of 30% polymethoxylated flavones, 1480mg (2 x 2 x 370mg), capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:25:34 +1000" MODIFIED_BY="[Empty name]">
<P>Lequesne index, BMI, CRP, ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:25:40 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported university oversight, but unclear whether a formally consistuted human research ethics committee approved the research design. Results favour intervention. In the overweight intervention group, weight loss during the intervention period may have contributed to improvement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:26:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavelka-2010">
<CHAR_METHODS MODIFIED="2014-05-11 00:26:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, active control, 2 parallel groups, multicentre (26 centres in 5 countries). Duration 8 months (6 months intervention, 2 months follow up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:26:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=361; intervention n=183, control n=178. Completed n=263; intervention n=142, control n=121. Included in ITT analyses n=357, intervention n=181, control n=176. Age 45+ years (range not reported). M:F 62:299. OA knee (ACR criteria)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:26:11 +1000" MODIFIED_BY="[Empty name]">
<P>Piascledine 300: <I>Persa gratissma </I>and <I>Glycine max</I> (avocado-soyabean unsaponifiables), 300mg, capsules</P>
<P>Active control: chondroitin sulphate, 1200mg (3 x 400mg), capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
<P>Rescue medication permitted: paracetamol (acetominophen), dose not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:26:13 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (aggregated scores), pain with active movement VAS 0-100, pain at rest VAS 0-100, Lequesne index (0-24), use of rescue medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-13 09:39:18 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study; statistical power 80%, alpha 0.05. Reported ethics committee application (approval not specified), and compliance with ICH GCP guidelines. WOMAC aggregated scores converted to normalised scores for data extraction and re-analysis. Results show that ASU is not inferior to chondroitin sulphate on any outcome.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:27:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piscoya-2001">
<CHAR_METHODS MODIFIED="2013-05-21 17:18:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 parallel groups, multicentre study. Duration 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-21 17:18:03 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=45, Completed n=45. Reported no withdrawals. Assume that group sizes were allocated a priori; intervention n=30, control n=15. Mean age 60 yrs, range 45-75 yrs. All male. Inclusion: OA knee (ACR criteria), Kellgren stage II-III, pain most days of the month, NSAIDs for 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-21 17:18:10 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. <I>Uncaria guianensis</I> (cat's claw), aqueous extract, freeze-dried, 100mg, tablets</P>
<P>Placebo control: ingredient not reported, "same excipient but without cat's claw", tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-21 17:18:12 +1000" MODIFIED_BY="[Empty name]">
<P>Pain at rest VAS 0-10, pain at night VAS 0-10, tenderness 0-3, global tolerance 0-4, blood variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:27:00 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance with Declaration of Helsinki. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:27:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rein-2004a">
<CHAR_METHODS MODIFIED="2014-05-11 00:27:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 group crossover. Duration 6.5 months; 14 days run-in, 2 x 3 months (~12 weeks) intervention, no washout period)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:27:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=112, Completed stage 1 n=97, Completed stage 2 n=85. Mean age 67 yrs. M:F 41:71. Inclusion: primary OA hip, knee, hand, shoulder, or neck, radiographic verification (criteria not specified), mild to moderate pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:27:28 +1000" MODIFIED_BY="[Empty name]">
<P>Hyben Vital: <I>Rosa canina lito </I>(rosehip and seed), 5000mg (2 x 5 x 500mg) equivalent to 1.5mg galactolipid, capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
<P>Rescue medication permitted: self-prescribed analgesics, measured in paracetamol equivalents</P>
<P>Concurrent medication permitted: stable prescribed NSAIDs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:27:31 +1000" MODIFIED_BY="[Empty name]">
<P>Pain change 0-4, rescue medication use (paracetamol equivalents), joint stiffness change 0-4, point in time severity of pain, joint stiffness, wellbeing diary (mood, energy, sleep), patient treatment preference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:27:37 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results moderately favour intervention. Evidence of carry-over effect in the group receiving the intervention prior to the placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:28:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schadler-1988">
<CHAR_METHODS MODIFIED="2014-05-11 00:28:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo control, 2 group crossover. Duration 14 days (~2 weeks); 2 x 7 days (~1 week) intervention, no washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:28:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=30, Completed n=30. Mean age 66 yrs, range 45-81 yrs. M:F 7:23. Inclusion: OA knee, hip, thumb, shoulder (criteria not specified)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:28:06 +1000" MODIFIED_BY="[Empty name]">
<P>Phytodolor<SUP>R</SUP>N: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 40 drops, tincture</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:28:08 +1000" MODIFIED_BY="[Empty name]">
<P>Diclofenac use, pain at rest 0-3, pressure pain 0-3, pain with mvt 0-3, mobility impairment (scale not reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:28:15 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results favour intervention (reduced used of diclofenac only, results equivocal for other outcomes).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:28:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmelz-1997">
<CHAR_METHODS MODIFIED="2014-05-11 00:28:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 parallel groups. Duration 30 days (~4 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:28:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=56, Completed n=56. Age and gender data not reported. Inclusion: OA spine (criteria not specified), acute exacerbations</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:28:39 +1000" MODIFIED_BY="[Empty name]">
<P>Arthrotabs<SUP>®</SUP>: <I>Harpagophytum procumbens </I>(devil's claw), aqueous extract, 4290mg (2 x 3 x 715mg), tablets</P>
<P>Placebo control: ingredients not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:28:41 +1000" MODIFIED_BY="[Empty name]">
<P>Pain 0-4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:28:59 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:29:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmid-2000">
<CHAR_METHODS MODIFIED="2014-05-11 00:29:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 parallel, stratified groups. Duration 2 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:29:25 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=78, Completed n=68. Mean age 53 yrs. M:F 59:19. Inclusion: OA hip or knee (ACR criteria), clinical, radiographic and laboratory verification</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:29:29 +1000" MODIFIED_BY="[Empty name]">
<P>Tradename not provided. <I>Salix purpurea x daphnoides </I>cortex (willow bark) extract, 1360mg (2 x 2 x 340mg, equivalent to 240mg salicin), tablets</P>
<P>Placebo control: cellulose and lactose, tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:29:30 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC, patient global, physician global, haematology, urinanalysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval and compliance with ICH GCP guidelines. Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:30:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sengupta-2008">
<CHAR_METHODS MODIFIED="2014-05-11 00:29:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo control, 3 parallel groups (2 x intervention). Duration 90 days (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:30:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=75, Completed n=70, intervention low dose (100mg/day 5-Loxin) n=24, intervention high dose (250mg/day 5-Loxin) n=23, control n=23 Mean age: control 52.4 yrs, intervention low dose 52.3 yrs, intervention high dose 53.2 yrs. M:F intervention low dose 7:17, intervention high dose 8:15, control 5:18. OA knee (ACR criteria), must report pain with movement VAS 0-100 between 40mm and 70mm and Lequesne index &gt; 7 points at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:30:06 +1000" MODIFIED_BY="[Empty name]">
<P>5-Loxin<SUP>®</SUP>: extract of <I>Boswellia serrata </I>with 30% 3-O-acetyl-11-keto-beta-boswellic acid, low dose 100mg (2 x 50mg), high dose 250mg (5 x 50mg), capsules</P>
<P>Placebo control: rice bran, capsules</P>
<P>Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:30:08 +1000" MODIFIED_BY="[Empty name]">
<P>VAS, Lequesne index, WOMAC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 15:15:46 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design: statistical power 80%, alpha set at 0.05 ( 2 tailed). Reported institutional review board oversight, but unclear whether a formally constituted HREC approved the research design. Reported clinical trails registration (ISRCTN05212803). Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:30:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sengupta-2010">
<CHAR_METHODS MODIFIED="2014-05-11 00:30:37 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 3 parallel groups (2 active products derived from the same herb), single centre trial. Duration 90 days (~12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:30:40 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=60, Completed n=57, intervention A (100mg/day 5-Loxin) n=19, intervention B (100mg/day Aflapin) n=19, control n=19. Mean age: intervention A 51.6 yrs, intervention B 53.2 yrs, control 52.4 yrs. M:F intervention A 3:16, intervention B 7:12, control 9:10. OA knee (ACR criteria), regular NSAID or acetominophen use for pain, must report pain VAS 0-100 between 40mm and 70mm and Lequesne index &gt; 7 points at baseline after regular medication washout</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:30:51 +1000" MODIFIED_BY="[Empty name]">
<P>5-Loxin<SUP>®</SUP>: extract of <I>Boswellia serrata</I> with 30% 3-O-acetyl-11-keto-beta-boswellic acid 100mg (2 x 50mg), capsules</P>
<P>Aflapin<SUP>®</SUP>: extract of<I> Boswellia serrata</I>, enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid, and non-volatile <I>Boswellia serrata</I> oil, 100mg (2 x 50mg), capsules</P>
<P>Placebo control: ingredients not reported, "filled with a suitable excipient", capsules</P>
<P>Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:30:52 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS 0-100, Lequesne index, WOMAC-VAS (normalised units) pain, stiffness, physical function subscales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-01 15:20:56 +1000" MODIFIED_BY="[Empty name]">
<P>Confirmatory study design; statistical power 80%, alpha set at 0.05 (2 tailed). Reported institutional review board oversight, but unclear whether a formally constituted human research ethics committee approved the research design. Reported clinical trials registration (ISRCTN80793440). Results favour Aflapin over 5-Loxin, and both products over placebo. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:31:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sontakke-2007">
<CHAR_METHODS MODIFIED="2014-05-11 00:31:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, unblinded, active control (valdecoxib), 2 parallel groups. Duration 7 months; 6 months (~24 weeks) intervention, plus 1 month follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:31:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=66; intervention n=33, control n=33. Completed n=57; intervention n=31, control n=27. Age 40-70 years. OA knee (ACR criteria). Not pregnant or lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:31:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cap Wovkel&#8482;: containing <I>Boswellia serrata </I>extract with 65% organic acids, 999mg (3 x 333mg), capsules</P>
<P>Active control: valdecoxib, 10mg OD, tablets</P>
<P>Rescue medication permitted: ibuprofen, up to 1200mg (400mg TID), PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:31:28 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS (aggregated scores)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:31:40 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported university oversight, but unclear whether a formally constituted HREC approved the research design. WOMAC aggregated scores converted to normalised VAS 0-100 scale during data extraction for re-analysis. Results reported to favour intervention, but re-analysis of data indicates that results slightly favour intervention for WOMAC pain subscale scores only. Results favour control on all other outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:32:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teekachunhatean-2004">
<CHAR_METHODS MODIFIED="2014-05-11 00:31:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, active control, 2 parallel groups. Duration 5 weeks; 1 week run-in, 4 weeks intervention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:31:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=200, Completed n=188. Mean age 62 yrs. M:F 41:159. Inclusion: OA knee unilateral or bilateral (ACR criteria), Kellgren stage II-IV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:32:03 +1000" MODIFIED_BY="[Empty name]">
<P>Duhuo Jisheng Wan (DJW): herbal mixture containing angelica root and mulberry mistletoe, 9000mg (6 x 3 x 500mg), capsules</P>
<P>Active control: diclofenac sodium (Voltaren), 75mg (3 x 25mg), tablets packed in capsules</P>
<P>Placebo controls: cane sugar, tablets packed in capsules, and capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:32:05 +1000" MODIFIED_BY="[Empty name]">
<P>Battery of pain VAS 0-100 (night pain, pain with standing, pain with movement, pain with stair climbing, resting pain, total pain), battery of stiffness VAS 0-100 (morning stiffness, stiffness at rest, total stiffness), Lequesne index, time to climb 10 stairs, patient opinion of improvement VAS 0-100, investigator opinion of improvement VAS 0-100</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:32:13 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval and compliance with Declaration of Helsinki. Reported clinical trials registration (ISRCTN70292892). DJW equally effective as diclofenac on pain, stiffness, and Lequesne index. Participants using DJW reported improvements after a longer period of intervention that participants using diclofenac. Toxicity profiles of interventions are approximately equal. DJW is a large dose (9g, administered as 18 capsules per day) which may be a barrier to long-term clinical compliance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:32:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vishal-2011">
<CHAR_METHODS MODIFIED="2014-05-11 00:32:28 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo control, 2 parallel groups. Duration 30 days (~5 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:32:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=60; intervention n=30, control n=30. Completed n=59; intervention n=30, control n=29. Age 40-80 years. OA knee (ACR criteria), most painful knee VAS &gt;40mm, Lequesne index &gt;7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:32:33 +1000" MODIFIED_BY="[Empty name]">
<P>Aflapin<SUP>®</SUP>: extract of<I> Boswellia serrata</I> with 30% 3-O-acetyl-11-keto-beta-boswellic acid and non-volatile <I>Boswellia serrata</I> oil, 100mg (2 x 50mg), capsules.</P>
<P>Placebo control: ingredients not reported, "similar organoleptic properties", capsules</P>
<P>Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:32:34 +1000" MODIFIED_BY="[Empty name]">
<P>VAS, Lequesne index, WOMAC-VAS (normalised units), pain, stiffness, physical function subscales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:32:44 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported institutional review board oversight, but unclear whether a formally constituted HREC approved the research design. Reported clinical trials registration (ISRCTN69643551). Results favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:33:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warholm-2003">
<CHAR_METHODS MODIFIED="2014-05-11 00:32:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 parallel groups. Duration 4 months (~20 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:33:03 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=100; intervention n=50, control n=50. Completed n=96; intervention n= 48, control n=48. Mean age 65 yrs. M:F 35:65. Inclusion: OA hip or knee, radiographic verification (criteria not specified)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:33:07 +1000" MODIFIED_BY="[Empty name]">
<P>Hyben Vital: <I>Rosa canina lito</I> (rosehip and seed), 5000mg (2 x 5 x 500mg), equivalent to 1.5mg galactolipid, capsules</P>
<P>Placebo control: ingredients not reported, capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:33:08 +1000" MODIFIED_BY="[Empty name]">
<P>Active and passive range of motion (goniometer), activities of daily living VAS 0-10, pain relief 0-4, NSAID use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:33:13 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical oversight or compliance with guidelines. Results favour intervention for some ranges of motion and pain, but are less convincing for activities of daily living.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:33:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wigler-2003">
<CHAR_METHODS MODIFIED="2014-05-11 00:33:37 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo control, 2 group crossover. Duration 48.5 weeks; 4 days run-in, 2 x 12 weeks crossover, 24 weeks open follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:33:41 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=29, Completed stage 1 n=24, Completed stage 2 n=20, Completed stage 3 (open trial) n=17. Mean age 62 yrs, range 42-85 yrs Inclusion: OA knee (ACR criteria), Kellgren II-IV, pain VAS 0-100 &gt;35mm. Not pregnant or lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:33:44 +1000" MODIFIED_BY="[Empty name]">
<P>Zintona EC: <I>Zingiber officinale </I>(ginger) extract, 1000mg (4 x 250mg), equivalent to 40mg gingerol, capsules. Capsule contains 10mg gingerol absorbed on maltodextrin</P>
<P>Placebo control: maltodextrin only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:33:46 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC (Hebrew), knee circumference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:33:52 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results equivocal in stage 1. Results in stage 2 and stage 3 favour intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-11 00:34:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winther-2005">
<CHAR_METHODS MODIFIED="2014-05-11 00:34:12 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo control, 2 group crossover. Duration 6.5 months; 14 days run-in, 2 x 3 months (~12 weeks) intervention, no washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:34:14 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised n=94, Completed stage 1 n=94, Completed stage 2 n=80. Mean age 66 yrs. M:F 40:54. Inclusion: aged 35+ years, primary OA hip or knee, radiographic verification (ACR criteria), mild to moderate pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:34:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>LitoZin</U>: <I>Rosa canina lito </I>(rosehip and seed), 5000mg (2 x 5 x 500mg), equivalent to 1.5mg galactolipid, capsules</P>
<P>Placebo control: ingredients not reported, "inactive powder of similar taste, smell, and colour", capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:34:23 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC-VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:34:29 +1000" MODIFIED_BY="[Empty name]">
<P>Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics committee approval. Results moderately favour intervention. Evidence of carryover effect in the group receiving the intervention prior to the placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Unless otherwise stated, all oral medications are reported as total daily doses, which may have been administered in single or divided doses.</P>
<P>Unless subscales are named, outcome measures (eg: WOMAC, HAQ, COAT) were used in entirety. Unless specified, all outcome measures were administered, scored, and scaled according to Osteoarthritis Research Society International (OARSI) standards.</P>
<P>1. Reported compliance with ICH GCP guidelines (<LINK REF="REF-ICH-2004" TYPE="REFERENCE">ICH 2004</LINK>) anchored in European law, or ethics committee oversight that would require the same, so adequate randomisation, allocation concealment, and blinding can be assumed.</P>
<P>2. Indicates that the tradename was not provided in the manuscript, but has been determined through communication with the manufacturing company noted in the acknowledgements.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-05-11 00:36:53 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:34:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:34:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:34:58 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention included extracted or synthetic curcumin and another synthetic compound from soy lecithin (isolated compounds), therefore not herbal as per WHO definition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biswas-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:01 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Unable to identify individual herbal interventions. Ingredients not listed in sufficient detail to allow replication of the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biswas-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:02 +1000" MODIFIED_BY="[Empty name]">
<P>Mixed sample, including people with rheumatoid arthritis and non-specific arthritis. Unable to extract data on OA only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brien-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:07 +1000" MODIFIED_BY="[Empty name]">
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chantre-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:10 +1000" MODIFIED_BY="[Empty name]">
<P>Repeat publication of <LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:11 +1000" MODIFIED_BY="[Empty name]">
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dharmananda-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:13 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:15 +1000" MODIFIED_BY="[Empty name]">
<P>Mixed sample, including people with "rheumatism due to blockage of cold and damp". Unable to extract data on OA only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falch-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:22 +1000" MODIFIED_BY="[Empty name]">
<P>Individualised treatments, not a standardised dose, therefore, considered as a case series rather than RCT. Metabolic outcomes only. No functional or clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gendo-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:24 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grahame-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:26 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guyader-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:28 +1000" MODIFIED_BY="[Empty name]">
<P>Case series, not RCT. Used inappropriate statistical analyses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamblin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:29 +1000" MODIFIED_BY="[Empty name]">
<P>Individualised treatments, not a standardised plant product or dose, therefore, a case series rather than RCT. Abstract only available from CENTRAL. Cannot locate full manuscript</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacquet-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:40 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention not purely herbal. Unable to identify effects of herbal intervention alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kagore-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:42 +1000" MODIFIED_BY="[Empty name]">
<P>Case study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kielczynski-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:43 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kulkarni-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:46 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention not purely herbal. Unable to identify effects of herbal interventions alone. Ingredients not listed in sufficient detail to allow replication of the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lechner-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:50 +1000" MODIFIED_BY="[Empty name]">
<P>Individualised treatments, not a standardised plant product or dose, therefore, considered as a case series rather than RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levy-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:54 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention (Limbrel) included extracted biacalin and catechin (flavanoids, isolated compounds), therefore not herbal as per WHO definition. According to the manufacturer, "each capsule of Limbrel also contains 50 mg of citrated zinc bisglycinate, which provides 10 mg of elemental zinc", a potentially active substance (<A HREF="http://www.limbrel.com/limbrel.php">http://www.limbrel.com/limbrel.php</A>). Study is only repeatable using the proprietary product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linsheng-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:56 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:35:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loew-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:35:57 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT. Primary measures not consistent with the topic of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Long-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:03 +1000" MODIFIED_BY="[Empty name]">
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lung-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:04 +1000" MODIFIED_BY="[Empty name]">
<P>Repeat analysis (safety data only) of <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mishra-and-Singh-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:07 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT (single group trial). Author list in indexed citation differs from actual publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myers-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:08 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT (open label, uncontrolled study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:15 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention included magnesium (mineral), therefore not herbal as per WHO definition. Magnesium is a potentially active substance that may alter the active principle of the herbal extracts, unless it has been demonstrated that they are essentially similar</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rein-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:17 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Subgroup analysis of <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuss-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:18 +1000" MODIFIED_BY="[Empty name]">
<P>Discussion paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosen-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT. Open-label, uncontrolled, cohort (single group) study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sagar-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:21 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saley-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:26 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaffner-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:28 +1000" MODIFIED_BY="[Empty name]">
<P>Mixed sample, including people with back pain not due to osteoarthritis. Unable to extract data on OA only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmid-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:30 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Abstract to <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK> and <LINK REF="STD-Schmid-2001" TYPE="STUDY">Schmid 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmid-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:31 +1000" MODIFIED_BY="[Empty name]">
<P>Repeat publication of <LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Srivastava-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:33 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:38 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wegener-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:39 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winther-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:41 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Subgroup analysis of <LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT (case series)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuelong-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT (protocol for RCT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zell-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:52 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-11 00:36:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeng-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-11 00:36:53 +1000" MODIFIED_BY="[Empty name]">
<P>Metabolic outcomes only. No functional or clinical outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-05-11 00:38:27 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-05-11 00:37:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-2012">
<CHAR_METHODS MODIFIED="2014-05-11 00:36:55 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, 2 parallel groups. Duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:36:56 +1000" MODIFIED_BY="[Empty name]">
<P>n=96 (intervention n=48, active control n=48)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:36:58 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: Bushen Huoxue Qubi decoction (ingredients unknown), one bag/day</P>
<P>Active control: diacerein (50 mg Bid, Po) and celecoxib (0.2 Qd, Po)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:37:08 +1000" MODIFIED_BY="[Empty name]">
<P>VAS (outcome and scale unknown), WOMAC, relative viscosity, aggregation index and IL-1beta, NO, iNOS, LPO, SOD in serum, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-13 03:24:22 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>China Journal of Chinese materia medica </I>indexed, but not held in known collections. Full manuscript sought in hard copy via inter-library loan.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:37:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hochberg-2012">
<CHAR_METHODS MODIFIED="2014-05-11 00:37:12 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, multicentre (n=2; USA and Hong Kong), 2 parallel groups. Duration: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-11 00:37:14 +1000" MODIFIED_BY="[Empty name]">
<P>n=92 (USA n=53, Hong Kong n=39)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:37:16 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: Hou-Lou-Xiao-Ling Dan 5,180 mg/day (15 capsules in 3 divided doses)</P>
<P>Control: placebo (ingredients unknown), dose matched to intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:37:22 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC, patient global, patient global assessment of response to therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-12 18:54:46 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. Abstracts from the annual ACR meeting are published in Arthritis and Rheumatism. This study will be classified if a full manuscript published. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:37:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kang-2011">
<CHAR_METHODS MODIFIED="2014-05-11 00:37:25 +1000" MODIFIED_BY="[Empty name]">
<P>RCT, 3 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-29 11:57:17 +1000" MODIFIED_BY="[Empty name]">
<P>n=160 (A: intervention n=76, B: active control n=42, C: intervention plus active control n=46)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-29 12:18:45 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: wangbi (ingredients and dose unknown)</P>
<P>Active control: voltaren (dose unknown)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:37:30 +1000" MODIFIED_BY="[Empty name]">
<P>Morning stiffness, joint tenderness, swelling, pain, functional activities, adverse reactions (outcome measures unknown). Results favour combination therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-12 18:46:06 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>Chinese Journal of Intergrated Traditional and Western medicine </I>indexed, but not held in known collections. Full manuscript sought in hard copy via inter-library loan.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:37:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006">
<CHAR_METHODS MODIFIED="2013-02-25 10:41:29 +1100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-21 17:35:57 +1000" MODIFIED_BY="[Empty name]">
<P>n=86. 4 groups: manipulation plus pyrola (n=22), manipulation (n=22), pyrola compound traditional Chinese medicine (n=22), and self-exercise (n=20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-25 10:44:05 +1100" MODIFIED_BY="[Empty name]">
<P>The manipulation group: Prone position, rolling manipulation to the affected thigh for 5 minutes, mainly the Weizhong and Weiyang of the fossa poplitea and the posterolateral part of the leg; Supine position, rolling manipulation for 5 minutes to affected side of quadriceps femoris and superior part of the whirbone; Alternately manipulation of pressing-kneading, flicking-poking and digital-pressing to Dubi, xiyan, Yanglingquan, Heding, Xiyangguan and Liangqiu; Rotating of the knee joint cooperated by the passive stretch, flexion, inward and lateral rotation; At last, spreading some ointment of Chinese holly leaf on the affected knee joint and scrubbing until give the patient a warm sensation. The treatment was done three times weekly for 4 weeks. </P>
<P>Pyrola group: The patients were treated with Chinese herbs orally (modified pyrola compound traditional Chinese medicine) twice a day with water for weeks. </P>
<P>Manipulation plus pyrola group: Patients were treated by Chinese herb orally besides the manipulation with the same processes as the manipulation group for 4 weeks. </P>
<P>Self-exercise group: Patients were told to do exercise themselves such as stretching exercises, active and passive range-of-motion exercises, strengthening exercises and so on for 4 weeks. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:37:46 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC 0-100, 20m walk time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-29 11:59:40 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>Chinese Journal of Clinical Rehabilitation</I> not indexed. Full manuscript sought in hard copy via inter-library loan.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:38:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinsornsak-2012">
<CHAR_METHODS MODIFIED="2013-08-29 11:42:39 +1000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-29 11:40:04 +1000" MODIFIED_BY="[Empty name]">
<P>n=88 (intervention n=44, control n=44)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:37:58 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: diclofenac 75mg/day with 1000mg/day curcumin (<I>Curcuma longa</I> extract)</P>
<P>Active control: diclofenac 75mg/day with placebo (unknown)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:38:00 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS, KOOS. Results equivocal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-29 11:59:41 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>Journal of the Medical Association of Thailand </I>indexed, but not held in known collections. Full manuscript sought in hard copy via inter-library loan.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:38:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tao-2009">
<CHAR_METHODS MODIFIED="2013-08-29 12:25:58 +1000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-29 12:26:13 +1000" MODIFIED_BY="[Empty name]">
<P>n=90 (intervention n=45, control n=45)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-29 12:27:21 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: gubitong decoction (dose and ingredients unknown)</P>
<P>Control: glucosamine sulfate 1500mg/day (3 x 500mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:38:09 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC, symptom VAS. Results equivocal: statistically significant improvement in treatment and control groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-11 00:38:11 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>Chinese Journal of Integrative Medicine</I> not indexed. Full manuscript sought in hard copy via inter-library loan.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-11 00:38:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006">
<CHAR_METHODS MODIFIED="2013-02-25 10:29:24 +1100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-25 10:27:09 +1100" MODIFIED_BY="[Empty name]">
<P>n=88 (intervention n=44, control n=44)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-11 00:38:19 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention: Bushen Quhan Tongluo herbs by orally or externally washing</P>
<P>Bushen Quhan. Tongluo: Hutaorou (12 g), Buguzhi (12 g), Chaoduzhong (12 g), Shudi (15 g), Dahuixiang (9 g), Luoshiteng (15 g), Zhichuanwu (9 g), Sanqi (6 g), Wugong (3 g), Jixieteng (15 g). The prescription for external washing: Tuogucao (40 g), Danggui (15 g), Sumu (15 g), Shengdahuang (15 g), Shengnanxing (10 g), Ruxiang (10 g), Meyao (10 g), Bingpian (3 g). Oral administration: The medicine shall be taken with water of 37 degrees C one dose a day.</P>
<P>Patients in the control group were given sulfated glucosamine (Weiguli Capsule. Each capsule contains 314 mg of sulfated glucosamine crystal, which is equal to 250 mg of sulfated glucosamine) two capsules a time and 3 times a day as well as piroxicam (Yantong Xikang Pill) once a day and 20 mg each time. Patients in both groups were administrated for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-11 00:38:27 +1000" MODIFIED_BY="[Empty name]">
<P>WOMAC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-25 10:41:15 +1100" MODIFIED_BY="[Empty name]">
<P>Abstract only available. <I>Chinese Journal of Clinical Rehabilitation</I> not indexed. Full manuscript sought in hard copy via inter-library loan.</P>
<P>Unable to distinguish oral administration internvention group from topical administration intervention group results from abstract alone. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-05-11 00:34:40 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-05-11 00:34:32 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Randomised in blocks of four within each stratum, using computer generated random number sequences</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Randomised to one of two groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:05:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:06:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Described as randomised, method not reported. Group sizes dissimilar and likely to have been determined a priori</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:06:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Participants allocated to treatment groups using randomisation by block allocation sequences created from a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Randomised to one of three groups using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 16:46:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Randomised to one of three groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 16:48:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Described as randomised, method not reported<SUP>1</SUP>. Authors contacted: provided full details of computer generated randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Described as randomised, method of randomisation incompletely reported<SUP>1</SUP>. Reported as randomised in blocks of six to one of three groups, with further randomisation of treatment sequence within blocks. Authors contacted for confirmation, but further details not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Described as randomised, in blocks of four, stratified according to site of arthritis (hip or knee), to one of two groups, using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Described as randomised, method inadequately reported: "sealed envelope method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:11:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Randomised to one of two groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:11:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Described as randomised: "...assigned to the active or placebo groups as per a predetermined computer generated randomisation schedule..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Described as randomised, but participants allocated directly to groups on order of enrolment into the trial (quasi-randomised)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-08 16:36:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Randomised in order of enrolment in the trial. "The study biostatistician (S.S.) used a standard software program to generate a randomized schedule of permuted block randomization with block size 4 for blinded (coded) drug allotment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:14:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Described as randomised, method not reported<SUP>1</SUP>. Authors contacted: provided full details of computer generated randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:31 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Not randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Randomised in blocks of four or six to one of two groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Randomised to one of two groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Described as randomised, method of randomisation incompletely reported. Reported as "a computer randomisation code kept by a research assistant"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Randomisation according to computer generated randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Described as randomised, method of randomisation incompletely reported. Reported as randomised in blocks of four patients at each study centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Randomised in blocks of four, to one of two groups, by an independent statistical unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Randomised in blocks of four, to one of two groups, using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:22:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Described as randomised: "Randomisation...by blocks of two for each stratum defined by baseline JSW"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:24:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Used a fixed allocation randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Described as randomised, but participants allocated directly to groups on order of enrolment into the trial (quasi-randomised): "Assigned by accession to pre-set lists of allocations randomised for equalisation in every ten, and after stratification by clinical condition, to one of two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:26:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Described as randomised, method of randomisation incompletely reported<SUP>1</SUP>. "Randomisation to the two treatment groups was performed using the computer program Rancode 1.0". Author contacted: provided full details of computer generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 17:18:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Described as randomised, method not reported. Assume that group sizes were allocated a priori</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Randomised in blocks of four, to one of two groups, using a computer generated allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:28:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Described as randomised, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 17:22:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Randomised in blocks of four, using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:30:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Computer generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:30:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Computer generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Randomised using an independent computerised system: "The patients were randomly allocated by SAS for Windows..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Described as randomised, method not reported. Baseline parameters compared for significant differences</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Computer generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:33:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Randomised using an independent computerised system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Randomised to one of two groups using a computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Randomised in blocks of four, to one of two groups, using a computer generated allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-05-11 00:34:33 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Adequate allocation concealment: Medications prepared by nursing staff, administered by blinded senior orthopaedic registrar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "both the investigators and the patients were blinded to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:05:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:06:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:08:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>. Authors contacted for confirmation, but details of allocation concealment not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:08:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>. Authors contacted for confirmation, but details of allocation concealment not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>. Authors contacted for confirmation, but details of allocation concealment not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Allocation concealment can be inferred: "sealed envelope method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:11:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Allocation "held by a third party to the investigator and trial sponsor"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-01 13:33:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "A sealed copy of the randomization code was kept with the sponsor and the chief investigator but was not revealed to the subjects or the clinical staff until completion of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:13:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:14:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Adequate concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Allocation concealment not reported<SUP>1</SUP>. Authors contacted for confirmation, but details of allocation concealment not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "The clinical orthopedic investigator and the patients were blind for the interventions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Allocation not concealed from participants or research assistant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Adequate. Allocation completed by an independent statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:22:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "Randomisation list established by an independent company"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Allocation concealment not reported. Participants "selected from outpatients" may imply that allocation was unconcealed, or that participation in the study was not voluntary (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:24:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:26:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>. Author contacted: confirmed allocation concealment using single sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-21 17:18:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:28:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>. Authors contacted for confirmation, but details of allocation concealment not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:30:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "The clinical trial pharmacist and statistician ensured that treatment codes remained confidential"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:46 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Open trial. Allocation not concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "Randomization codes were secured confidentially by the clinical trial pharmacist and statistician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:33:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred: "Both patients and investigators were blinded to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Adequate allocation concealment can be inferred<SUP>1</SUP>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-05-11 00:34:34 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:04:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Active intervention, placebo, and active controls not distinguished by look, taste, smell, packaging, or medication regimen. Baseline and outcome assessor blinded to allocations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:04:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:05:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Described as double-blind, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:06:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Described as double-blind, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:07:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:07:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Described as double-blind. In Phytodolor<SUP>R</SUP>N and placebo groups, active intervention and placebo not distinguished by look, taste, smell or packaging (low risk)</P>
<P>Piroxicam group not blinded (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:08:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Described as double-blind. Active interventions and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:08:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:09:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Described as double-blind. Double-dummy method, placebo controls for both intervention and active controls. Active interventions and placebos not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:10:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:10:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Described as blinded, method inadequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:11:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Active intervention, placebo, and active controls not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:12:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:12:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Described as double-blind. Active interventions, active control, and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:13:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Described as double-blind. Active interventions, active control, and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:14:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:15:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:15:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Described as double-blind, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:16:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:17:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo control not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:17:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Described as double-blind, method not reported. In other studies of Phytodolor<SUP>R</SUP>N, active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:18:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Described as double-blind, method incompletely reported. Assume active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:18:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Described as double-blind. Double-dummy method, placebo controls for both intervention and active controls. Active interventions and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:19:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell or packaging or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:19:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Blinding incomplete: research assistant not blind to allocation, and medication regimens differ between active control and intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:20:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Blinding incomplete: research assistant not blind to allocation, and interventions may be distinguishable between active control and intervention. interventions distinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:20:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Described as double-blind. Double-dummy method, placebo controls for both intervention and active controls. Active interventions and placebos not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:21:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:21:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:22:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:23:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Open trial. Medication regimens differ between active control and intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:23:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Described as double-blind, method incompletely reported. Assume active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:24:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Intervention and active control not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:25:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Described as double-blind. Active interventions, active control, and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:25:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:26:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Described as double-blind. Double-dummy method, placebo controls for both intervention and active controls. Active interventions and placebos not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:27:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:27:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:28:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Described as double blind, method not reported. In other studies of Phytodolor<SUP>R</SUP>N, active intervention and placebo not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:29:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Described as double blind, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:29:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:30:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:31:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:31:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Open trial. Medication regimens differ between active control and intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:32:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Described as double-blind. Double-dummy method, placebo controls for both intervention and active controls. Active interventions and placebos not distinguished by look, taste, smell or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:32:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Described as double-blind. Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:33:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:34:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, packaging, or medication regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-11 00:34:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Active intervention and placebo not distinguished by look, taste, smell, or packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-05-11 00:34:35 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:04:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:04:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:05:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included per protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:06:35 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Withdrawals not reported. Age and gender data not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:07:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Unclear whether analysis is per protocol or intention-to-treat (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:07:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Reported no withdrawals (low risk)</P>
<P>Intention-to-treat analysis can be assumed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:08:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat and per protocol analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:08:58 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Brief report. Full report not available (high risk)</P>
<P>Reported withdrawals (low risk)</P>
<P>Unclear whether analysis is per protocol or intention-to-treat analysis (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:09:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Included per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:10:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Included per protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:10:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:11:20 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Withdrawals not reported (high risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:12:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis. Last observation carried forward to replace missing data (low risk)</P>
<P>Three participants were withdrawn by the investigators due to "efficacy failure", which may confound results (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:12:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:13:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included both intention-to-treat and per protocol analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:14:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:15:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Reported withdrawals. Reported identical per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:15:46 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Brief report. Full report not available (high risk)</P>
<P>Reported withdrawals (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:16:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Reported withdrawals. Reported intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:17:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:17:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:18:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Reported withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:18:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:19:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Reported 100% compliance, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:19:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:20:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:20:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Reported withdrawals. Included per-protocol and intention-to-treat analyses. Missing data replaced using the last observation carried forward method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:21:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Reported withdrawals. Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:21:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Reported withdrawals. Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:22:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Reported withdrawals. Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:23:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:23:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
<P>Five participants withdrew due to "efficacy failure", which may confound results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:24:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:25:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:25:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:26:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:27:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Reported 100% compliance, no withdrawals (intervention over 4 weeks) (low risk)</P>
<P>Per-protocol analysis (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:27:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Reported withdrawals</P>
<P>Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:28:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Reported 100% compliance, no withdrawals: likely in intervention over 7 days</P>
<P>Intention-to-treat analysis can be assumed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:29:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Reported 100% compliance, no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:29:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Reported withdrawals. Included per-protocol and intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:30:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:31:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:31:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:32:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:32:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Reported withdrawals (low risk)</P>
<P>Per-protocol analysis only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:33:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat and per protocol analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:34:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis (success versus failure)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-11 00:34:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Reported withdrawals. Included intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-05-11 00:34:38 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Outcome data reported as change scores, percentages, confidence intervals, and P values only, insufficient for extraction (unclear risk).</P>
<P>WOMAC subscales for pain and physical function used independently, and in different forms (VAS and 0-4).</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:05:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:06:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Described as a crossover trial, but method of crossover and data from second arm not reported. Considered as a parallel trial for this review (high risk)</P>
<P>Adverse events not reported (high risk)</P>
<P>Conclusion not supported by data: Reported efficacy and tolerability of boswellia-curcumin as superior to diclofenac, but this trial did not include diclofenac as an active control (high risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Adverse events reported generally, but not individually (unclear risk)</P>
<P>Reported WOMAC subscale scores but no standard deviations: standard deviations computed from item scores for extraction and re-analysis (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Most outcome data reported as change scores, percentages, graphs and p values only, insufficient for extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:08:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Mid-point data reported as mean scores only (no standard deviations), therefore not adequate for extraction and re-analysis (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:05 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Age and gender data not reported (high risk)</P>
<P>Reasons for withdrawal (ie: adverse events) not reported (unclear risk)</P>
<P>Outcome data reported as percentages only, insufficient for extraction (unclear risk)</P>
<P>Results showed no improvement on planned primary outcome measure (WOMAC). Alternate outcome measure and definition of improvement constructed post hoc</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:11:31 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Clinical outcome data reported as percentages and P values (non-significant) only, insufficient for extraction (unclear risk)</P>
<P>Adverse events not reported (high risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Pre-determined levels of improvement (MCID) (low risk)</P>
<P>Reported adverse events. Two participants in intervention group died, but these deaths were attributed to concomitant cardiovascular disease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Outcome data reported as change scores and percentages only, insufficient for extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:13:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Outcome data reported as means and confidence intervals only, standard deviations computed for extraction and re-analysis</P>
<P>Pain VAS 0-10 converted to 100mm scale for data extraction and re-analysis</P>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:14:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Reported no adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:28 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Reasons for withdrawals and adverse events not reported (high risk)</P>
<P>Outcome data reported as change scores, percentages, and bar charts only, insufficient for extraction (unclear risk)</P>
<P>Results show no improvement on planned primary outcome measure (WOMAC). Alternate outcome measure and definition of improvement constructed post hoc (high risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Outcome data reported as VAS 0-10, converted to 100mm scale for data extraction (low risk)</P>
<P>Reported no adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Outcome data variances reported as standard error of measurement (SEM). When converted to standard deviation (SD), data are skewed, violating an assumption of the inferential analyses (unclear risk)</P>
<P>Adverse events not reported (high risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Outcome data WOMAC-VAS converted to 100mm scale for data extraction. Error identified during data extraction (unclear risk).</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:22:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Variances reported as standard error of measurement (SEM). When converted to standard deviation (SD), data are not normally distributed, violating an assumption of the inferential analyses (unclear risk)</P>
<P>Change in JSW reported as joint loss in mm. Negative scores converted to positive for reanalysis so that higher scores mean worse (low risk).</P>
<P>Reported adverse events. Discussed intervention safety (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Clinical outcome data reported as percentages and P values only, insufficient for extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:24:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Outcome data reported as change scores, percentages, graphs, and p values only, insufficient for extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Incompletely reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:26:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Outcome measure VAS 0-10 converted to 100mm scale for data extraction (low risk)</P>
<P>Variances reported as standard error of measurement (SEM). When converted to standard deviation (SD), data are skewed, violating an assumption of the inferential analyses (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
<P>Subgroup analyses published separately (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:28:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Outcome data reported as percentages and bar charts only, insufficient for extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:30:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Reported adverse events</P>
<P>Standard errors of measure erroneously labelled as standard deviations for some outcome data (WOMAC function subscale). Errors corrected during data extraction for re-analysis (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Reported adverse events and rescue medication use</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Reported adverse events. Discussed intervention safety</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:33:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Pain data reported as percentages and graphs only, insufficient for data extraction (unclear risk)</P>
<P>Reported adverse events (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Outcome data reported as means and confidence intervals. Standard deviations calculated for data extraction (unclear risk)</P>
<P>Reported adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Reported adverse events (low risk)</P>
<P>Subgroup analyses published separately (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-05-11 00:34:40 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adegbehingbe-2008">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:04:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altman-2001">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:05:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Appelboom-2001">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:06:42 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Badria-2002">
<DESCRIPTION>
<P>Diagnosis of OA not established at baseline (high risk)</P>
<P>Unvalidated outcome measures (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2008">
<DESCRIPTION>
<P>Diagnosis and assessment based on radiographic criteria only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:07:54 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bernhardt-1991">
<DESCRIPTION>
<P>Diagnosis not based on ACR criteria. Non-homogenous sample (any degenerative arthropathy, any site) (high risk)</P>
<P>Unvalidated outcome measures (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:08:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biegert-2004">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biller-2002">
<DESCRIPTION>
<P>Diagnosis consistent with ACR criteria (low risk)</P>
<P>Post-hoc created outcome measure is unvalidated (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:09:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bliddal-2000">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blotman-1997">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:10:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2005">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:11:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheras-2010">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2004">
<DESCRIPTION>
<P>Diagnosis consistent with ACR criteria (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:12:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2011">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
<P>Synthetic ginger extract in placebo may not be inert</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:13:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chopra-2013">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
<P>Active control B, glucosamine sulphate, is not an analgesic, and may be a poor choice of control in a trial using pain as a primary outcome measure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:14:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cisar-2008">
<DESCRIPTION>
<P>Diagnosis and assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farid-2007">
<DESCRIPTION>
<P>Diagnosis / assessment based on ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:15:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferraz-1991">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (high risk)</P>
<P>Financial and in kind support not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:16:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frerick-2001">
<DESCRIPTION>
<P>Diagnosis consistent with ACR criteria (low risk)</P>
<P>Post-hoc created outcome measure not validated (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-2011">
<DESCRIPTION>
<P>Diagnosis not consistent with ACR criteria, but likely to be OA (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:17:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1991">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (unclear risk)</P>
<P>Unvalidated outcome measures (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jung-2001">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified, clinical and radiographic verification (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:18:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jung-2004">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria (low)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kimmatkar-2003">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified: "clinoradiographic verification" (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:19:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuptniratsaikul-2009">
<DESCRIPTION>
<P>Diagnosis consistent with ACR criteria (low risk)</P>
<P>Outcome assessments not validated measures (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuptniratsaikul-2011">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
<P>Reported financial and in kind support, declared no competing financial interests</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:20:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leblan-2000">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-2002">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria (ie: EULAR criteria)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:21:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-1998">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:22:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maheu-2013">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Majima-2012">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:23:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Medhi-2009">
<DESCRIPTION>
<P>Diagnosis / assessment not consistent with ACR criteria (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:24:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1996">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:25:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oben-2009">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria (low risk)</P>
<P>Possible confounder: the berberine component of the intervention may have contributed to weight loss</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:26:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2010">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piscoya-2001">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:27:55 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rein-2004a">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (high risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:28:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schadler-1988">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schmelz-1997">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified (high risk)</P>
<P>Unvalidated outcome measure (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:29:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmid-2000">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:30:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sengupta-2008">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR crtieria (low risk)</P>
<P>Non-comparable groups: Intervention low-dose group reported markedly greater pain (WOMAC subscale) than the other groups at baseline (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sengupta-2010">
<DESCRIPTION>
<P>Diagnosis/assessment consistent with ACR criteria (low risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:31:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sontakke-2007">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teekachunhatean-2004">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:32:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vishal-2011">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:33:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warholm-2003">
<DESCRIPTION>
<P>Criteria for diagnosis of OA not specified, radiographic verification only (unclear risk)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wigler-2003">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-11 00:34:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winther-2005">
<DESCRIPTION>
<P>Diagnosis / assessment consistent with ACR criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-04-04 18:25:12 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-05-21 15:15:45 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:23:43 +1000" MODIFIED_BY="[Empty name]">
<I>Boswellia serrata</I> for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Boswellia serrata</I> for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with treating osteoarthritis<BR/>
<B>Settings:</B> Community: India<BR/>
<B>Intervention:</B> <I>Boswellia serrata </I>999 mg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Boswellia serrata</I>
</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>Global pain 0-3 (higher scores mean worse)<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the control group at the end of treatment was 2.50 (0 to 3 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the intervention groups was<BR/>
<B>2.24 lower</B>
<BR/>(2.64 to 1.84 lower).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 56% (46% to 66%); Relative improvement in pain was 80% (66% to 94%)<SUP>5</SUP>; NNTB = 1 (95% CI 1 to 2).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>Loss of function 0-3 (higher scores mean worse)<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the control group at the end of treatment was 2.46 (0 to 3 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the intervention groups was<BR/>
<B>2.16 lower</B>
<BR/>(2.56 to 1.76 lower).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in function was 54% (44% to 64%); Relative improvement was 76% (62% to 90%)<SUP>5</SUP>; NNTB = 1 (95% CI 1 to 3).</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse effects<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>No (n=0) participants in the control group reported adverse events.</P>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Two (n=2) participants in the intervention group reported adverse events.</P>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 5.00 </B>
<BR/>(0.26 to 96.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 13% higher in the <I>Boswellia serrata</I> group (6% lower to 33% higher); Relative percentage change 400% worsening (74% to 9513% worsening); NNT n/a.<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>30<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Serious adverse events not reported as discrete outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Criteria for diagnosis of OA not specified.<BR/>
<SUP>2</SUP> Exploratory study design; power, effect, and sample size not determined a priori.<BR/>
<SUP>3</SUP> Ethical oversight not reported.</P>
<P>
<SUP>4 </SUP>Downgrade estimate due to single study.</P>
<P>
<SUP>5 </SUP>Control group baseline pain (SD) 2.80 (0.41), baseline disability 2.86 (0.35), from <LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>.</P>
<P>
<SUP>6 </SUP>Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). Assumed a minimal clinically important difference of 1 point of a 0 to 3 point scale (pain, function).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-03-07 14:00:50 +1100" MODIFIED_BY="Renea V Johnston" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-05-11 00:40:21 +1000" MODIFIED_BY="[Empty name]">
<I>Boswellia serrata</I> (enriched) 100 mg for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Boswellia serrata </I>(enriched) 100 mg for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with treating osteoarthritis<BR/>
<B>Settings:</B> Community: India<BR/>
<B>Intervention:</B> <I>Boswellia serrata </I>(enriched) 100 mg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Boswellia serrata</I> (enriched) 100mg</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
</P>
<P>Global pain VAS 0-100 (higher scores mean worse)<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean pain in the control groups at the end of treatment was 40.02 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The weighted mean pain in the intervention groups was<BR/>
<B>16.57 lower</B>
<BR/>(26.47 to 8.47 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>85<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 17% (8% to 26%); Relative improvement in pain was 29% (15% to 43%)<SUP>3</SUP>; NNTB 2 (95% CI 1 to 6).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>WOMAC-VAS (Function)<SUP>1</SUP> 0-100 (higher scores mean worse)<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean disability in the control groups at the end of treatment was 33.13 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The weighted mean disability in the intervention groups was<BR/>
<B>8.21 lower</B>
<BR/>(14.21 to 2.22 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>85<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement was 8% (14% to 2%); Relative improvement was 20% (5% to 34%)<SUP>3</SUP>; NNTB 4 (95% CI 2 to 18).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Adverse event episodes (n) reported<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>625 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>375 per 1000</B>
<BR/>(211 to 577)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.60 </B>
<BR/>(0.39 to 0.92)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 25% lower in the <I>Boswellia serrata</I> group (6% to 44% lower); Relative percentage change 40% improvement (61% improvement to 9% worsening); NNT = 4 (95% CI 3 to 22).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>96<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>96<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL serious adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>, <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>, <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.</P>
<P>
<SUP>2 </SUP>Confirmatory study design: statistical power 80%, alpha set at 0.05, but downgraded due to potential imprecision due to small number of participants; and lower limit of 95% CI does not preclude clincially insignificant change</P>
<P>
<SUP>3</SUP> Control group baseline measures taken from <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>, the study most heavily weighted in the meta-analyses. Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6).</P>
<P>
<SUP>4 </SUP>Downgrade estimate due to potential imprecision, eg, small number of events and participants from a single study.</P>
<P>
<SUP>5</SUP> Number needed to treat (NNT) is not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/); NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). Assumed a minimal clinically important difference of 15 points on 0 to 100 mm pain scale, and 10 points on 0 to 100 mm function scale.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-05-21 15:15:58 +1000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-05-11 00:39:31 +1000" MODIFIED_BY="[Empty name]">
<I>Boswellia serrata </I>(enriched) 250 mg for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Boswellia serrata</I> (enriched) 250mg for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with treating osteoarthritis<BR/>
<B>Settings:</B> Community: India<BR/>
<B>Intervention:</B>
<I> Boswellia serrata</I> (enriched) 250mg<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Boswellia serrata</I> (enriched) 250mg</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>Global pain VAS 0-100 (higher scores mean worse)<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the control group at the end of treatment was 41.76 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the intervention group was<BR/>
<B>27.54 lower</B>
<BR/>(34.64 to 20.44 lower).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 28% (20% to 35%); Relative improvement in pain was 48% (36% to 61%)<SUP>3 </SUP>; NNT = 1 (95% CI 1 to 2).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>WOMAC-VAS (Function)<SUP>1 </SUP>
</P>
<P>(higher scores mean worse)<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the control group at the end of treatment was 34.07 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the intervention group was<BR/>
<B>16.8 lower</B>
<BR/>(21.23 to 12.37 lower).</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in disability was 17% (12% to 21%); Relative improvement in disability was 41% (30% to 51%)<SUP>3</SUP>; NNT = 1 (95% CI 1 to 2).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Adverse event episodes (n) reported<BR/>Follow-up: mean 90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>526 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>474 per 1000</B>
<BR/>(302 to 653)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.90 </B>
<BR/>(0.62 to 1.30)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>114<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 5% lower in the <I>Boswellia serrata </I>group (24% lower to 13% higher); Relative percentage change 10% improvement (38% improvement to 30% worsening); NNT n/a.<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>114<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>114<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL serious adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.</P>
<P>
<SUP>2 </SUP>Downgrade estimate due to single study.</P>
<P>
<SUP>3</SUP> Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6), from <LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>.</P>
<P>
<SUP>4 </SUP>Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2014-05-21 15:16:08 +1000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:24:14 +1000" MODIFIED_BY="[Empty name]">
<I>Boswellia serrata</I> (enriched) plus non-volatile oil for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Boswellia serrata</I> (enriched) plus non-volatile oil for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with treating osteoarthritis<BR/>
<B>Settings:</B> Community: India<BR/>
<B>Intervention:</B> <I>Boswellia serrata </I>(enriched) 100mg plus non-volatile oil<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Boswellia serrata</I> (enriched) plus non-volatile oil</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>Global pain VAS 0-100 (higher scores mean worse)<BR/>Follow-up: 30-90 days<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean pain in the control groups at the end of treatment was 38.90 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean pain in the intervention groups was<BR/>
<B>16.09 lower</B>
<BR/>(20.37 to 11.81 lower).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>97<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 16% (12% to 20%); Relative improvement in pain was 34%(25% to 42%)<SUP>3</SUP>; NNTB 2 (1 to 4)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>WOMAC-VAS (Function)<SUP>5</SUP> normalised units</P>
<P>(higher scores mean worse)<BR/>Follow-up: 30-90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean disability in the control groups at the end of treatment was 34.90 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean disability in the intervention groups was<BR/>
<B>15.01 lower</B>
<BR/>(19.21 to 10.81 lower).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>97<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in disability was 15% (11% to 19%); Relative improvement in disability was 37% (27% to 47%)<SUP>3</SUP>; NNTB 2 (1 to 3).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse events<BR/>Follow-up: 30-90 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(6 to 241)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.14 to 6.69)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 0% lower in the <I>Boswellia serrata</I> group (8% lower to 8% higher); Relative percentage change 2% improvement (86% improvement to 569% worsening); NNT n/a.<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL serious adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>: 30 day intervention. <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>: 90 day intervention.<BR/>
<SUP>2</SUP> <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>: Exploratory study design; power, effect, and sample size not determined a priori.<BR/>
<SUP>3</SUP> Control group baseline measures taken from <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>, the study most heavily weighted in the meta-analyses. Control group baseline pain 47.6 (9.7), baseline disability 40.6 (9.5).</P>
<P>
<SUP>4 </SUP>Number needed to treat to benefit (NNTB), and harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).</P>
<P>
<SUP>5</SUP> <LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>, <LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2014-05-21 15:16:14 +1000" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:24:28 +1000" MODIFIED_BY="[Empty name]">
<I>Boswellia serrata </I>compared to valdecoxib for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Boswellia serrata </I>compared to valdecoxib for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with treating osteoarthritis<BR/>
<B>Settings:</B> Community: India<BR/>
<B>Intervention:</B> <I>Boswellia serrata</I> 999 mg<BR/>
<B>Comparison: </B>valdecoxib</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Valdecoxib</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Boswellia serrata</I>
</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>WOMAC-VAS (Pain)</P>
<P>(higher scores mean worse)<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the valdecoxib group at the end of treatment was 17.08 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the intervention groups was<BR/>
<B>0.51 lower</B>
<BR/>(7.26 lower to 6.24 higher).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 1% (7% improvement to 6% worsening); Relative improvement in pain was 1%<SUP>4</SUP>; NNT n/a.<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>WOMAC-VAS (Function)<SUP>5</SUP>
<BR/>(higher scores mean worse)</P>
<P>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the valdecoxib group at the end of treatment was 16.64 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the intervention groups was<BR/>
<B>2.49 higher</B>
<BR/>(4.07 lower to 9.05 higher).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute worsening in disability was 3% (4% improvement to 9% worsening); Relative improvement in disability was 4%<SUP>4</SUP>; NNT n/a.<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse events<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>121 per 1000</B>
<BR/>(23 to 448)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 2.0</B>
<BR/>(0.39 to 10.18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 6% higher in the <I>Boswellia serrata </I>group (8% lower to 20% higher); Relative percentage change 100% worsening (61% improvement to 918% worsening); NNT n/a.<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<B>RR 3.0 </B>
</P>
<P>(0.13 to 71.07)</P>
</TD>
<TD>
<P>66<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>Reported one (1) withdrawal possibly due to adverse events.</P>
<P>Absolute risk of withdrawal due to adverse events was 3% higher in the <I>Boswellia serrata</I> group (5% lower to 11% higher); Relative percentage change 200% worsening (87% improvement to 7007% worsening); NNT n/a.<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>66<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Reported NIL serious adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Open trial. Medication regimens differ between active control and intervention.</P>
<P>
<SUP>2 </SUP>Downgrade estimate due to single study. Treatment effect crosses midline (no effect).<BR/>
<SUP>3</SUP> Exploratory study design; power, effect, and sample size not determined a priori.</P>
<P>
<SUP>4</SUP> Baseline pain in valdecoxib group 49.2, baseline disability 51.6. Aggregate WOMAC scores converted to normalised scores for re-analysis.</P>
<P>
<SUP>5 </SUP>Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2016-04-04 18:25:12 +1000" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:26:50 +1000" MODIFIED_BY="[Empty name]">
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300 mg) for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300 mg) for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with osteoarthritis<BR/>
<B>Settings:</B> Community: France (3), Belgium (1).<BR/>
<B>Intervention:</B> <I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300 mg)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300mg)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>Global pain VAS 0-100 (higher scores mean worse)<BR/>Follow-up: 3 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean pain in the control groups at end of treatment was 40.53 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Weighted mean pain in the intervention groups was<BR/>
<B>8.47 lower</B>
<BR/>(15.90 to 1.04 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>651<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 8% (1% to 16%); Relative improvement in pain was 15% (2% to 29%)<SUP>2</SUP>; NNTB 8 (4 to 77)<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>Multiple tools<SUP>4</SUP>
<BR/>Follow-up: 3 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the control group at end of treatment was 47.10 mm, on VAS 0 to 100 mm scale (higher scores mean worse)<SUP>5</SUP>.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the intervention groups was<BR/>
<B>7 mm lower</B>
<BR/>(12 mm to 2 mm lower<SUP>6</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>642<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.42 (95% CI -0.73 to -0.11), in favour of ASU 300mg</P>
<P>Absolute improvement in disability was 7% (2% to 12%); Relative improvement in disability was 13% (4% to 23%)<SUP>7</SUP>; NNTB 5 (3 to 19)<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse events<BR/>Follow-up: 3 to 36 months</P>
</TD>
<TD>
<P>
<B>510 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>531 per 1000</B>
<BR/>(495 to 572)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.97 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1050<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events is 2% higher in the ASU group (2% lower to 7% higher); Relative percentage change 4% worsening (9% improvement to 12% worsening); NNT n/a<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>169 per 100</B>
</P>
<P>(108 to 267)</P>
</TD>
<TD>
<P>
<B>RR 1.14 </B>
</P>
<P>(0.73 to 1.80)</P>
</TD>
<TD>
<P>398</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8</SUP>
</P>
</TD>
<TD>
<P>Absolute risk of participants withdrawing due to adverse events in 2% higher in ASU group (5% lower to 9% higher); Relative percentage change 14% worsening (27% improvement to 90% worsening); NNT n/a.<SUP>3,9</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>
<B>325 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>397 per 1000</B>
</P>
<P>(306 to 517)</P>
</TD>
<TD>
<P>
<B>RR 1.22</B>
</P>
<P>(0.94 to 1.59)</P>
</TD>
<TD>
<P>398</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8</SUP>
</P>
</TD>
<TD>
<P>Absolute risk of serious adverse events is 7% higher in the ASU group (2% lower to 17% higher); Relative percentage change 22% worsening (6% improvement to 59% worsening); NNT n/a.<SUP>3,9</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
<P>Change in Joint Space Width (JSW) from baseline</P>
<P>(higher scores mean worse).</P>
<P>Follow up: 24 to 36 months.</P>
</TD>
<TD>
<P>Weighted mean JSW change from baseline in the control groups at end of treatment was 0.65.</P>
</TD>
<TD>
<P>Mean JSW change from baseline in the intervention groups was <B>0.12 lower</B> (0.43 lower to 0.19 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>453</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8</SUP>
</P>
</TD>
<TD>
<P>Absolute change</P>
<P>NNT n/a.<SUP>3,9</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgrade due to heterogeneity, inconsistency</P>
<P>
<SUP>2</SUP> Calculations based on control group baseline pain measure taken from <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>, the most heavily weighted study in the meta-analysis. Control group baseline mean (SD) pain 54.3 (11.9).</P>
<P>
<SUP>3 </SUP>Number needed to treat to benefit (NNTB), or to harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/)NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office), assuming a minimal clinically important difference of 15 mm on a 0 to 100 mm pain scale, and 10 mm on a 0 to 100 mm function scale.</P>
<P>
<SUP>4 </SUP>Multiple tools: Disability VAS reported in one study only (<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>); WOMAC change score reported in one study (<LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>); Lequesne algofunctional index reported in four studies, but to avoid over-reporting, data were extracted on this outcome from three studies only (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>, <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>, <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>)</P>
<P>
<SUP>5 </SUP>From <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>: follow-up disability score in the control group 47.10 mm (VAS 0 to 100 mm scale)</P>
<P>
<SUP>6 </SUP>Four trials pooled (<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>, <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>, <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>, <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>) using SMD, and re-expressed as MD by multiplying the SMD (95% CI) by the baseline SD in the control group of <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK> (16.78).</P>
<P>
<SUP>7 </SUP>Calculations based on data from 
<LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>: control group baseline mean (SD) disability 52.5 (16.78), 0 to 100 mm VAS scale.</P>
<P>
<SUP>8 </SUP>Downgrade estimate due to imprecision: few participants.</P>
<P>
<SUP>9 </SUP>Treatment effect crosses midline (no effect).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2014-05-21 15:15:07 +1000" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:27:17 +1000" MODIFIED_BY="[Empty name]">
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 600 mg) for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 600 mg) for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with osteoarthritis<BR/>
<B>Settings:</B> Community: Belgium<BR/>
<B>Intervention:</B> <I>Persea gratissma </I>+ <I>Glycine max </I>(ASU 600 mg)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 600mg)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>Global pain VAS 0-100</P>
<P>(higher scores mean worse)</P>
<P>Follow up: 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the control group at the end of treatment was 42.4 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the intervention group was<BR/>
<B>14.2 lower</B>
<BR/>(20.82 to 7.58 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>156<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in pain was 14% (21% to 8%); Relative improvement in pain was 26.5%<SUP>2</SUP>; NNT =</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>Lequesne algofunctional index 0-24</P>
<P>(higher scores mean worse)<BR/>Follow-up: 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the control group at the end of treatment was 7.8 (0 to 24 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean disability in the intervention group was<BR/>
<B>1.3 lower</B>
<BR/>(2.38 to 0.22 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>156<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute improvement in disability was 1% (1% to 0%); Relative improvement in disability was 13.7%<SUP>2</SUP>; NNT =</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse events<BR/>Follow-up: 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>261 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>278 per 1000</B>
<BR/>(165 to 431)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.07 </B>
<BR/>(0.66 to 1.74)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>174<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events is 2% higher in the ASU group (11% lower to 15% higher); Relative percentage change 7% worsening (34% improvement to 74% worsening); NNT n/a.<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>174<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Withdrawals due to adverse events not reported as a discrete outcome in ASU 600mg subgroup.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>174<BR/>(1 study)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Serious adverse events not reported as a discrete outcome in ASU 600mg subgroup.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Single study.</P>
<P>
<SUP>2</SUP> Control group baseline mean (SD) pain 53.5 (13.9), baseline mean (SD) disability 9.5 (2.2), from <LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>.</P>
<P>
<SUP>3 </SUP>Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2014-05-21 15:15:32 +1000" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2013-09-13 07:28:12 +1000" MODIFIED_BY="[Empty name]">
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with osteoarthritis<BR/>
<B>Settings:</B> Community: Czech Republic, Slovak Republic, Hungary, Poland, Romania<BR/>
<B>Intervention:</B> <I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300mg)<BR/>
<B>Comparison: </B>chondroitin sulphate</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Chondroitin sulphate</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>
<I>Persea gratissma</I> + <I>Glycine max</I> (ASU 300mg)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>WOMAC-VAS (Pain)</P>
<P>(higher scores mean worse)<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain in the chondroitin sulphate group at the end of treatment was 22.88 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean pain in the intervention group was<BR/>
<B>1.41 higher</B>
<BR/>(2.68 lower to 5.50 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>357<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute worsening of pain was 10% (10% improvement to 31% worsening); Relative worsening of pain was 3%<SUP>3</SUP>; NNT n/a.<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function</B>
<BR/>WOMAC-VAS (Function)</P>
<P>(higher scores mean worse)<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean function in the chondroitin sulphate group at the end of treatment was 25.14 (0 to 100 scale).</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability in the intervention group was<BR/>
<B>1.63 higher</B>
<BR/>(2.51 lower to 5.77 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>357<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute worsening of disability was 28% (43% improvement to 98% worsening); Relative worsening of disability was 3%<SUP>3</SUP>; NNT n/a.<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Participants (n) reported adverse events</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>244 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
<BR/>(139 to 304)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.59 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>357<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk of adverse events was 3% lower in the ASU group (12% lower to 5% higher); Relative percentage change 14% improvement (41% improvement to 26% worsening); NNT n/a.<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) withdrew due to adverse effects</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>357<BR/>(1 study)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Withdrawals due to adverse events not reported as a discrete outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
<P>Participants (n) reported serious adverse events</P>
</TD>
<TD>
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>17 per 1000 </B>
</P>
<P>(2 to 158)</P>
</TD>
<TD>
<P>
<B>RR 2.92</B>
</P>
<P>(0.31 to 27.78)</P>
</TD>
<TD>
<P>357<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>Absolute risk of serious adverse events was 1% higher in the ASU group (1% lower to 3% higher); Relative percentage change 192% worsening (69% improvement to 2678% worsening); NNT n/a.<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Radiographic joint changes</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Radiographic joint changes not measured.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Quality of life not measured.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> SIngle study. Treatment effect crosses midline (no effect).</P>
<P>
<SUP>2 </SUP>Chondroitin sulfate might not be active control. Non-inferiority hypothesis may be flawed.</P>
<P>
<SUP>3 </SUP>Chrondroitin sulfate group baseline pain 49.08, baseline disability 49.07. Aggregate WOMAC scores converted to normalised scores for re-analysis.</P>
<P>
<SUP>4 </SUP>Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-09-08 16:00:32 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-09-08 16:00:32 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-25 14:04:12 +1000" MODIFIED_BY="[Empty name]">Herbal medicinal products used for the treatment of OA</TITLE>
<TABLE COLS="9" ROWS="56">
<TR>
<TD COLSPAN="2">
<P>PLANT</P>
</TD>
<TD COLSPAN="3">
<P>MEDICINAL PRODUCT</P>
</TD>
<TD>
<P>DOSE</P>
</TD>
<TD COLSPAN="2">
<P>MARKER</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TH>
<P>Botanical name</P>
</TH>
<TH>
<P>Part/s</P>
</TH>
<TH>
<P>Tradename</P>
</TH>
<TH>
<P>Preparation</P>
</TH>
<TH>
<P>Drug:Extract</P>
</TH>
<TD>
<P>mg/day</P>
</TD>
<TH>
<P>Constituent marker</P>
</TH>
<TH>
<P>Quantity of marker</P>
</TH>
<TH>
<P>References</P>
</TH>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>Medicinal products from single plants</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<I>Boswellia serrata</I>
</P>
</TD>
<TD ROWSPAN="3">
<P>gum resin</P>
</TD>
<TD>
<P>CapWokvel<SUP>TM</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>extraction solvent not stated</P>
</TD>
<TD ROWSPAN="3">
<P>not stated</P>
</TD>
<TD>
<P>999</P>
</TD>
<TD>
<P>boswellic acid</P>
<P>(total organic acids 65%)</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kimmatkar-2003" TYPE="STUDY">Kimmatkar 2003</LINK>, <LINK REF="STD-Sontakke-2007" TYPE="STUDY">Sontakke 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>5-Loxin</P>
</TD>
<TD>
<P>100 or 250</P>
</TD>
<TD>
<P>AKBA</P>
</TD>
<TD>
<P>30%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sengupta-2008" TYPE="STUDY">Sengupta 2008</LINK>
</P>
<P>
<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Aflapin</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>AKBA + non-volatile oil</P>
</TD>
<TD>
<P>20%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sengupta-2010" TYPE="STUDY">Sengupta 2010</LINK>
</P>
<P>
<LINK REF="STD-Vishal-2011" TYPE="STUDY">Vishal 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Curcuma domestica</I>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>ethanolic extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>curcumoids</P>
</TD>
<TD>
<P>500mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kuptniratsaikul-2009" TYPE="STUDY">Kuptniratsaikul 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Derris scandens</I>
</P>
</TD>
<TD>
<P>stem</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>ethanolic (50%) extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>genistein derivatve</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kuptniratsaikul-2011" TYPE="STUDY">Kuptniratsaikul 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Garcinia kola</I>
</P>
</TD>
<TD>
<P>seed</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>freeze-dried aqueous extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Adegbehingbe-2008" TYPE="STUDY">Adegbehingbe 2008</LINK>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<I>Harpagophytum procumbens</I>
</P>
</TD>
<TD ROWSPAN="3">
<P>root</P>
</TD>
<TD>
<P>Arthrotabs</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>1.5-2.5:1</P>
</TD>
<TD>
<P>2400</P>
</TD>
<TD ROWSPAN="3">
<P>harpagoside<SUP>1</SUP>
</P>
</TD>
<TD>
<P>30 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Schmelz-1997" TYPE="STUDY">Schmelz 1997</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>Flexiloges</P>
</TD>
<TD>
<P>ethanolic (60%) extract</P>
</TD>
<TD>
<P>4.5-5.5:1</P>
</TD>
<TD>
<P>960</P>
</TD>
<TD>
<P>&lt;30 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Frerick-2001" TYPE="STUDY">Frerick 2001</LINK>, <LINK REF="STD-Biller-2002" TYPE="STUDY">Biller 2002</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>Harpadol</P>
</TD>
<TD>
<P>cryoground powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2610</P>
</TD>
<TD>
<P>60 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Leblan-2000" TYPE="STUDY">Leblan 2000</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Petiveria alliacea</I>
</P>
</TD>
<TD>
<P>herb</P>
</TD>
<TD>
<P>Tipi tea</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>9g / 600 ml</P>
</TD>
<TD>
<P>600 ml</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Ferraz-1991" TYPE="STUDY">Ferraz 1991</LINK>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<I>Pinus pinaster </I>(synonym <I>Pinus maritima</I>)</P>
</TD>
<TD ROWSPAN="3">
<P>bark</P>
</TD>
<TD ROWSPAN="3">
<P>Pycnogenol®</P>
</TD>
<TD ROWSPAN="3">
<P>polyphenol concentrate</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>150</P>
</TD>
<TD ROWSPAN="3">
<P>proanthocyanidins</P>
</TD>
<TD>
<P>45 (90%)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Cisar-2008" TYPE="STUDY">Cisar 2008</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Belcaro-2008" TYPE="STUDY">Belcaro 2008</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>150</P>
</TD>
<TD>
<P>70%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Farid-2007" TYPE="STUDY">Farid 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Ricinus officinalis</I>
</P>
</TD>
<TD>
<P>seed</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>oil</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>2,7 ml</P>
</TD>
<TD>
<P>ricinoleic acid</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Medhi-2009" TYPE="STUDY">Medhi 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Rosa canina lito</I>
</P>
</TD>
<TD>
<P>rose hip and seed</P>
</TD>
<TD>
<P>Hyben Vital or Litozin</P>
</TD>
<TD>
<P>powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5000</P>
</TD>
<TD>
<P>galactolipid</P>
</TD>
<TD>
<P>1.5mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Rein-2004a" TYPE="STUDY">Rein 2004a</LINK> <LINK REF="STD-Warholm-2003" TYPE="STUDY">Warholm 2003</LINK>
</P>
<P>
<LINK REF="STD-Winther-2005" TYPE="STUDY">Winther 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Salix daphnoides</I>
</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>ethanolic (70%) extract</P>
</TD>
<TD>
<P>8-14:1</P>
</TD>
<TD>
<P>1573</P>
</TD>
<TD>
<P>salicin</P>
</TD>
<TD>
<P>240 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Biegert-2004" TYPE="STUDY">Biegert 2004</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Salix pupurea x daphnoides</I>
</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>ethanolic (70%) extract<SUP>2</SUP>
</P>
</TD>
<TD>
<P>10-20:1</P>
</TD>
<TD>
<P>1360</P>
</TD>
<TD>
<P>salicin</P>
</TD>
<TD>
<P>240 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Schmid-2000" TYPE="STUDY">Schmid 2000</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Uncaria guianensis</I>
<BR/>
</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>freeze-dried aqueous extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Piscoya-2001" TYPE="STUDY">Piscoya 2001</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Vitellaria paradoxa </I>
</P>
</TD>
<TD>
<P>seed</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>patented extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>2250</P>
</TD>
<TD>
<P>triterpenes</P>
</TD>
<TD>
<P>75%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Cheras-2010" TYPE="STUDY">Cheras 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Zingiber officinale</I>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>EV.EXT 33</P>
</TD>
<TD>
<P>acetone extract<SUP>3</SUP>
</P>
</TD>
<TD>
<P>20:1</P>
</TD>
<TD>
<P>510</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Bliddal-2000" TYPE="STUDY">Bliddal 2000</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Zingiber officinale</I>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>Zintona EC</P>
</TD>
<TD>
<P>CO2 extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>1000</P>
</TD>
<TD>
<P>gingerol</P>
</TD>
<TD>
<P>40 mg</P>
</TD>
<TD>
<P>
<LINK REF="STD-Wigler-2003" TYPE="STUDY">Wigler 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>Medicinal products from two plants</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Boswellia carteri</I> + <I>Curcuma longa</I>
</P>
</TD>
<TD>
<P>gum + root</P>
</TD>
<TD>
<P>study medication</P>
</TD>
<TD>
<P>extract, solvent not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>boswellic acid</P>
</TD>
<TD>
<P>37.5%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Badria-2002" TYPE="STUDY">Badria 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Persea gratissma</I> (P) + <I>Glycine max</I> (G)</P>
</TD>
<TD>
<P>oils</P>
</TD>
<TD>
<P>Piascledine 300</P>
</TD>
<TD>
<P>unsaponifiable fraction 1/3 P;2/3 G</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>300 or 600</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Appelboom-2001" TYPE="STUDY">Appelboom 2001</LINK>, <LINK REF="STD-Blotman-1997" TYPE="STUDY">Blotman 1997</LINK>, <LINK REF="STD-Lequesne-2002" TYPE="STUDY">Lequesne 2002</LINK>, <LINK REF="STD-Maheu-1998" TYPE="STUDY">Maheu 1998</LINK>, <LINK REF="STD-Maheu-2013" TYPE="STUDY">Maheu 2013</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Phellondenron amurense</I> + <I>Citrus sinensis</I>
</P>
</TD>
<TD>
<P>bark</P>
<P/>
<P>peel</P>
</TD>
<TD>
<P>NP 06-1</P>
</TD>
<TD>
<P>extract, solvent not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>370 mixture</P>
</TD>
<TD>
<P>berberine</P>
<P>polymethoxylated flavones</P>
</TD>
<TD>
<P>50%</P>
<P>30%</P>
</TD>
<TD>
<P>
<LINK REF="STD-Oben-2009" TYPE="STUDY">Oben 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Uncaria guianensis + Lepidium meyenii</I>
</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD>
<P>Reparagen®</P>
</TD>
<TD>
<P>freeze-dried aqueous extract</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>1500</P>
<P>300</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Zingiber officinale</I> + <I>Alpinia galanga</I>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>EV.EXT 77</P>
</TD>
<TD>
<P>acetone extract<SUP>3</SUP>
</P>
</TD>
<TD>
<P>20:1</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Altman-2001" TYPE="STUDY">Altman 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>Medicinal products from three or more plants</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Clematis mandshurica</I> + <I>Prunella vulgaris</I> + <I>Trichosanthes kirilowii</I>
<BR/>
</P>
</TD>
<TD>
<P>root, flower, root; 1:1:2</P>
</TD>
<TD>
<P>SKI306X</P>
</TD>
<TD>
<P>ethanol 30% extracts, thereafter butanol extraction<BR/>
</P>
</TD>
<TD>
<P>7:1</P>
</TD>
<TD>
<P>600-1800</P>
</TD>
<TD>
<P>oleanolic acid 4%, rosmarinic acids 0.2%, ursolic acids 0.5%, hydroxybenzoic acid 0.03%,<BR/>hydroxymethoxybenzoic acid 0.03%, trans-cinnamic<BR/>acid 0.05%</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Jung-2001" TYPE="STUDY">Jung 2001</LINK>, <LINK REF="STD-Jung-2004" TYPE="STUDY">Jung 2004</LINK>.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<I>Fraxinus excelsior</I>
</P>
</TD>
<TD ROWSPAN="2">
<P>bark</P>
</TD>
<TD ROWSPAN="4">
<P>Phytodolor</P>
</TD>
<TD ROWSPAN="4">
<P>fresh plant ethanolic (45,6%) extract</P>
</TD>
<TD ROWSPAN="4">
<P>3:1:1</P>
</TD>
<TD ROWSPAN="4">
<P>5-8 ml</P>
</TD>
<TD>
<P>total flavonoids<BR/>
</P>
</TD>
<TD>
<P>0.34 - 0.56 mg</P>
</TD>
<TD ROWSPAN="4">
<P>
<LINK REF="STD-Bernhardt-1991" TYPE="STUDY">Bernhardt 1991</LINK>, <LINK REF="STD-Huber-1991" TYPE="STUDY">Huber 1991</LINK>, <LINK REF="STD-Schadler-1988" TYPE="STUDY">Schadler 1988</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>salicyl alcohol</P>
</TD>
<TD>
<P>0.48 - 0.8 mg</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Solidago virgaurea</I>
</P>
</TD>
<TD>
<P>herb</P>
</TD>
<TD>
<P>isofraxidin</P>
</TD>
<TD>
<P>0.67 - 1.1 mg</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Populus tremula</I>
</P>
</TD>
<TD>
<P>bark and leaf</P>
</TD>
<TD>
<P>salicin</P>
</TD>
<TD>
<P>4.8 - 8 mg</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Salix alba</I>
</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD ROWSPAN="5">
<P>Reumalex</P>
</TD>
<TD>
<P>powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>salicin</P>
</TD>
<TD>
<P>40-80mg</P>
</TD>
<TD ROWSPAN="5">
<P>
<LINK REF="STD-Mills-1996" TYPE="STUDY">Mills 1996</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Guaiacun officinale</I>
</P>
</TD>
<TD>
<P>resin</P>
</TD>
<TD>
<P>powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Cimicifuga racemosa</I>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Smilax</I> (species not stated)</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>extract, solvent not stated</P>
</TD>
<TD>
<P>4:1</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Populus</I> (species not stated)</P>
</TD>
<TD>
<P>bark</P>
</TD>
<TD>
<P>extract, solvent not stated</P>
</TD>
<TD>
<P>7:1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Chinese mixture<SUP>4</SUP>
</P>
</TD>
<TD>
<P>herb</P>
</TD>
<TD>
<P>Duhuo Jisheng Wan</P>
</TD>
<TD>
<P>powder</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3 x 3 g</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Teekachunhatean-2004" TYPE="STUDY">Teekachunhatean 2004</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Paeoniae alba</I>
</P>
</TD>
<TD ROWSPAN="3">
<P>root</P>
</TD>
<TD ROWSPAN="3">
<P>Chinese mixture:</P>
<P>Blood nourishing, hard softening (BNHS)</P>
</TD>
<TD ROWSPAN="3">
<P>extract, solvent not stated</P>
</TD>
<TD ROWSPAN="3">
<P>not stated</P>
</TD>
<TD ROWSPAN="3">
<P>3150</P>
</TD>
<TD>
<P>paconiflorin</P>
</TD>
<TD ROWSPAN="3">
<P>not stated</P>
</TD>
<TD ROWSPAN="3">
<P>
<LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Gentiana macrophylla</I>
</P>
</TD>
<TD>
<P>gentianine</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Glycyrrhiza </I>(species not stated)</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>Auryvedic formaulae<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>powder</P>
</TD>
<TD ROWSPAN="6">
<P>not stated</P>
</TD>
<TD ROWSPAN="2">
<P>1000</P>
</TD>
<TD ROWSPAN="2">
<P>total gingerols</P>
</TD>
<TD ROWSPAN="2">
<P>not stated</P>
</TD>
<TD ROWSPAN="6">
<P>
<LINK REF="STD-Chopra-2011" TYPE="STUDY">Chopra 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Zingiber officinale</I> </P>
</TD>
<TD>
<P>rhizome</P>
</TD>
<TD>
<P>component of formulae A, B, C, D, and E</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Tinospora cordifolia</I>
</P>
</TD>
<TD>
<P>stem</P>
</TD>
<TD>
<P>component of formulae A, B, C, D, and E</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>tinosporosides</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Withania somnifera</I>
</P>
</TD>
<TD>
<P>root</P>
</TD>
<TD>
<P>component of formulae B and E</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>600</P>
</TD>
<TD>
<P>total withanolides</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Emblica officinale</I>
</P>
</TD>
<TD>
<P>fruit</P>
</TD>
<TD>
<P>component of formulae C</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>500</P>
</TD>
<TD>
<P>tannins</P>
<P>galic acid</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Tribulus terrestris</I>
</P>
</TD>
<TD>
<P>fruit</P>
</TD>
<TD>
<P>component of formulae A and B</P>
</TD>
<TD>
<P>aqueous extract</P>
</TD>
<TD>
<P>216</P>
</TD>
<TD>
<P>total saponins</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Ayuvedic formula<SUP>6</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Antarth<SUP>3 </SUP>(for sandhigata vata)</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Gupta-2011" TYPE="STUDY">Gupta 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Ayuvedic formula</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>RA-11</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Chopra-2004" TYPE="STUDY">Chopra 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Ayuvedic formula</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>SGC</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Ayuvedic</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>SGCG</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Chopra-2013" TYPE="STUDY">Chopra 2013</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Japanese mixture<SUP>7</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Boiogito</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>7.5g</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>
<LINK REF="STD-Majima-2012" TYPE="STUDY">Majima 2012</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. Harpagoside content estimated indirectly and approximately from iridoid glycoside content in daily dose of raw material (<LINK REF="REF-Sporer-1999" TYPE="REFERENCE">Sporer 1999</LINK>).</P>
<P>2. Ethanolic extract stated in unpublished thesis but not in published paper (<LINK REF="REF-Schmid-1998b" TYPE="REFERENCE">Schmid 1998b</LINK>).</P>
<P>3. Information provided by manufacturer but not reported in paper.</P>
<P>4. Chinese herbal medicine contains 7.75% each of: radix angelicae pubescentiis, radix gentianae macrophyllae, cortex eucommiae, radix achyranthis bidentatae, radix angelicae sinensis, herba taxilli, radix rehmanniae preparata, rhizoma chuanxiong, cortex cinnamomi, radix ledebouriellae. 5% each of: radix paeoniae alba, radix codonopis, radix glycyrrhizae, poria. 2.5% herba asari.</P>
<P>5. All Ayurvedic formulae A-E contain <I>Zingiber officinale</I> (dried rhizome powder, total gingerols as marker), and <I>Tinospora cordifolia </I>(dried stem aqueous extract, marker tinosporosides). Some formulae also included <I>Emblica officinale</I>, <I>Withania somnifera</I>, or <I>Tribulus terrestris</I>. Drug:extract ratio and marker content not stated.</P>
<P>6. Ayurvedic phytomedicine Antarth contains <I>Boswellia serrata, Commiphora mukul, Curcuma longa </I>and <I>Vitex negundo, Alpinia galangal, Withania somnifera, Tribulus terrestris,</I> and <I>Tinospora cordifolia</I>.</P>
<P>7. Japanese herbal medicine Boiogito contains <I>Sinomenium acutum</I>, <I>Astragalus </I>(species not stated) root, <I>Atractylodes lancea</I> rhizome, Jujube (probably <I>Ziziphus zizyphus</I>), <I>Glycyrrhiza </I>(species not stated), and ginger (species not stated, probably <I>Zingiber officinale</I>).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-05-11 00:58:05 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-05-11 00:56:25 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>
<I>Boswellia serrata</I> 999 mg versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2013-11-27 14:27:40 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (0 to 3)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8399240269703911" CI_START="-2.6400759730296093" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="2.5" MODIFIED="2013-11-18 16:09:25 +1100" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="0.45" SD_2="0.65" SE="0.2041241452319315" STUDY_ID="STD-Kimmatkar-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-11-27 14:42:56 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.987498344799876" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function: loss of function (0 to 3)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.759188563185345" CI_START="-2.5608114368146553" EFFECT_SIZE="-2.16" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="2.46" MODIFIED="2013-09-13 07:40:24 +1000" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="0.48" SD_2="0.63" SE="0.20449938875214274" STUDY_ID="STD-Kimmatkar-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-25 15:25:30 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="138.87334978960618" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Participants (n) reported adverse effects</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="30338" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Kimmatkar-2003" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-03 11:15:27 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>
<I>Boswellia serrata</I> (enriched) 100 mg versus placebo</NAME>
<CONT_OUTCOME CHI2="2.1602564769211106" CI_END="-8.46976139185931" CI_START="-24.668160804707" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.568961098283154" ESTIMABLE="YES" I2="53.70920024157304" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-11-27 15:38:28 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14162112069823896" P_Q="1.0" P_Z="6.08211866639029E-5" Q="0.0" RANDOM="YES" SCALE="58.43" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="18.45558224160944" TOTALS="YES" TOTAL_1="43" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="4.009601959576715">
<NAME>Pain VAS 0-100 at 90 days</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-13.263480864076726" CI_START="-27.516519135923268" EFFECT_SIZE="-20.389999999999997" ESTIMABLE="YES" MEAN_1="21.37" MEAN_2="41.76" MODIFIED="2011-06-21 15:06:30 +1000" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="7.13" SD_2="15.98" SE="3.6360459641791096" STUDY_ID="STD-Sengupta-2008" TOTAL_1="24" TOTAL_2="23" WEIGHT="53.90785402030343"/>
<CONT_DATA CI_END="-3.648916829279715" CI_START="-20.551083170720283" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" MEAN_1="26.2" MEAN_2="38.3" MODIFIED="2012-05-22 00:01:29 +1000" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="16.5" SD_2="9.0" SE="4.31185635929096" STUDY_ID="STD-Sengupta-2010" TOTAL_1="19" TOTAL_2="19" WEIGHT="46.09214597969656"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.23214394764352347" CI_END="-2.219809391600722" CI_START="-14.21015165292857" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.214980522264646" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-12-03 11:15:27 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.629938682965985" P_Q="1.0" P_Z="0.007238400983102133" Q="0.0" RANDOM="YES" SCALE="25.45" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="2.685672453115391">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0935990984562007" CI_START="-18.406400901543797" EFFECT_SIZE="-9.75" ESTIMABLE="YES" MEAN_1="24.32" MEAN_2="34.07" MODIFIED="2013-11-28 18:45:36 +1100" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="20.9676" SD_2="5.2275" SE="4.416612228502353" STUDY_ID="STD-Sengupta-2008" TOTAL_1="24" TOTAL_2="23" WEIGHT="47.96544143269986"/>
<CONT_DATA CI_END="1.5110452553781855" CI_START="-15.111045255378187" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="32.0" MODIFIED="2012-05-22 00:04:26 +1000" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="15.0" SD_2="10.8" SE="4.240407130403748" STUDY_ID="STD-Sengupta-2010" TOTAL_1="19" TOTAL_2="19" WEIGHT="52.03455856730014"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-09-13 08:59:16 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event episodes (n) reported</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata </I>(e100)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9185929091046507" CI_START="0.3919037436843386" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="-0.03687691135507318" LOG_CI_START="-0.4068205878776396" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-06-21 15:07:52 +1000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.2173067468400883" STUDY_ID="STD-Sengupta-2008" TOTAL_1="48" TOTAL_2="48" VAR="0.04722222222222222" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-25 12:53:34 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>
<I>Boswellia serrata</I> (enriched) 250 mg versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2013-12-03 14:24:28 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain VAS 0-100 at 90 days</NAME>
<GROUP_LABEL_1>Favours <I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-20.442586151020198" CI_START="-34.637413848979804" EFFECT_SIZE="-27.54" ESTIMABLE="YES" MEAN_1="14.22" MEAN_2="41.76" MODIFIED="2011-06-21 15:08:20 +1000" MODIFIED_BY="[Empty name]" ORDER="258" SD_1="6.8" SD_2="15.98" SE="3.6211960551128985" STUDY_ID="STD-Sengupta-2008" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-12-03 14:31:29 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.01200499331332" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I> (e250)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-12.370075326522898" CI_START="-21.229924673477104" EFFECT_SIZE="-16.8" ESTIMABLE="YES" MEAN_1="17.27" MEAN_2="34.07" MODIFIED="2013-11-28 18:47:41 +1100" MODIFIED_BY="[Empty name]" ORDER="262" SD_1="9.7" SD_2="5.2275" SE="2.2602071815705718" STUDY_ID="STD-Sengupta-2008" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-25 12:53:34 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event episodes (n) reported</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I> (e250)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3005571932306428" CI_START="0.6228099803807348" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.11412945546177207" LOG_CI_START="-0.20564443658312226" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2011-06-21 15:09:15 +1000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.18783676709346536" STUDY_ID="STD-Sengupta-2008" TOTAL_1="57" TOTAL_2="57" VAR="0.03528265107212475" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-05-11 00:56:43 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>
<I>Boswellia serrata</I> (enriched) 100 mg plus non-volatile oil versus placebo</NAME>
<CONT_OUTCOME CHI2="0.5429203251965826" CI_END="-11.806188013563954" CI_START="-20.371006170170837" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.088597091867396" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2014-04-16 13:55:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4612250507177891" P_Q="0.4612250507177891" P_Z="1.7929043502516296E-13" Q="0.5429203251965826" RANDOM="YES" SCALE="29.24" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="7.363395295791866">
<NAME>Pain VAS 0-100</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata </I>(e+NV)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-11.246908229592016" CI_START="-24.95309177040798" DF="0" EFFECT_SIZE="-18.099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" MODIFIED="2014-04-16 13:55:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.2603075397468475E-7" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="39.048396723254484" Z="5.17654648568394">
<NAME>At 90 days</NAME>
<CONT_DATA CI_END="-11.246908229592016" CI_START="-24.95309177040798" EFFECT_SIZE="-18.099999999999998" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="38.3" MODIFIED="2012-05-22 00:16:35 +1000" MODIFIED_BY="[Empty name]" ORDER="261" SD_1="12.3" SD_2="9.0" SE="3.4965396428017534" STUDY_ID="STD-Sengupta-2010" TOTAL_1="19" TOTAL_2="19" WEIGHT="39.048396723254484"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.314760634380253" CI_START="-20.28523936561974" DF="0" EFFECT_SIZE="-14.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" MODIFIED="2014-04-16 13:55:43 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.2347367845848849E-7" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="60.951603276745516" Z="5.288277327149135">
<NAME>At 30 days</NAME>
<CONT_DATA CI_END="-9.314760634380253" CI_START="-20.28523936561974" EFFECT_SIZE="-14.799999999999997" ESTIMABLE="YES" MEAN_1="24.5" MEAN_2="39.3" MODIFIED="2013-11-18 17:55:01 +1100" MODIFIED_BY="[Empty name]" ORDER="267" SD_1="11.9" SD_2="9.5" SE="2.798642938792045" STUDY_ID="STD-Vishal-2011" TOTAL_1="30" TOTAL_2="29" WEIGHT="60.951603276745516"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.12206977162540278" CI_END="-10.8054930654469" CI_START="-19.20520133948918" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.00534720246804" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2013-12-03 14:53:01 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7268004697492516" P_Q="0.7268004697492516" P_Z="2.5123769226858533E-12" Q="0.12206977162540278" RANDOM="YES" SCALE="27.04700107405519" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="7.00260988426041">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata </I>(e+NV)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.529796516592445" CI_START="-20.07020348340755" DF="0" EFFECT_SIZE="-14.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2012-05-22 00:24:54 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.1901018536164726E-6" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="52.97685316879737" Z="4.857278440789291">
<NAME>At 30 days</NAME>
<CONT_DATA CI_END="-8.529796516592445" CI_START="-20.07020348340755" EFFECT_SIZE="-14.299999999999997" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="36.8" MODIFIED="2012-05-22 00:24:54 +1000" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="11.1" SD_2="11.5" SE="2.944035466428047" STUDY_ID="STD-Vishal-2011" TOTAL_1="30" TOTAL_2="29" WEIGHT="52.97685316879737"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.675391075843114" CI_START="-21.924608924156885" DF="0" EFFECT_SIZE="-15.8" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2012-05-22 00:20:11 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.2762572291763893E-7" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="47.02314683120264" Z="5.056229930631177">
<NAME>At 90 days</NAME>
<CONT_DATA CI_END="-9.675391075843114" CI_START="-21.924608924156885" EFFECT_SIZE="-15.8" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="32.0" MODIFIED="2012-05-22 00:20:11 +1000" MODIFIED_BY="[Empty name]" ORDER="264" SD_1="8.3" SD_2="10.8" SE="3.1248578915056706" STUDY_ID="STD-Sengupta-2010" TOTAL_1="19" TOTAL_2="19" WEIGHT="47.02314683120264"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.9450131076181674E-4" CI_END="7.286899369625088" CI_START="0.13245493334473993" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9824386852590438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.8625427720610492" LOG_CI_START="-0.8779318615683528" LOG_EFFECT_SIZE="-0.007694544753651759" METHOD="MH" MODIFIED="2013-12-03 14:58:24 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9863081428717092" P_Q="0.9863081429071813" P_Z="0.9861735195938683" Q="2.945013092357125E-4" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="0.017329790740058807">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata </I>(e+NV)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.198846065678705" CI_START="0.05754876240078989" DF="0" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="1.2094840784217942" LOG_CI_START="-1.2399640115352677" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-05-22 00:26:01 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.980542328407241" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="50.489249599109854" Z="0.024388992523881353">
<NAME>At 30 days</NAME>
<DICH_DATA CI_END="16.198846065678705" CI_START="0.05754876240078989" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2094840784217942" LOG_CI_START="-1.2399640115352677" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2012-05-22 00:26:01 +1000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="1.4388179330043724" STUDY_ID="STD-Vishal-2011" TOTAL_1="30" TOTAL_2="29" VAR="2.070197044334975" WEIGHT="50.489249599109854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.24912896114679" CI_START="0.057973941887296085" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="1.2367671691531419" LOG_CI_START="-1.2367671691531419" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-22 00:22:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="49.51075040089014" Z="0.0">
<NAME>At 90 days</NAME>
<DICH_DATA CI_END="17.24912896114679" CI_START="0.057973941887296085" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2367671691531419" LOG_CI_START="-1.2367671691531419" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-22 00:22:45 +1000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="1.4529663145135576" STUDY_ID="STD-Sengupta-2010" TOTAL_1="19" TOTAL_2="19" VAR="2.1111111111111107" WEIGHT="49.51075040089014"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-05-11 00:56:59 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>
<I>Boswellia serrata</I> 999 mg versus valdecoxib</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.2416718094860135" CI_START="-7.2616718094860095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.509999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2013-09-13 09:44:05 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8823037037365169" Q="0.0" RANDOM="YES" SCALE="21.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="31" UNITS="" WEIGHT="100.00000000000001" Z="0.14804949949004106">
<NAME>WOMAC-VAS (Pain)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Valdecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours valdecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.2416718094860135" CI_START="-7.2616718094860095" EFFECT_SIZE="-0.509999999999998" ESTIMABLE="YES" MEAN_1="16.57" MEAN_2="17.08" MODIFIED="2013-05-08 11:13:02 +1000" MODIFIED_BY="[Empty name]" ORDER="288" SD_1="12.46" SD_2="13.77" SE="3.444793813938591" STUDY_ID="STD-Sontakke-2007" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.050185228184809" CI_START="-4.070185228184813" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.4899999999999984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2013-09-08 20:19:40 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4569195938882279" Q="0.0" RANDOM="YES" SCALE="59.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="0.7439287385571433">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Valdecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours valdecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.050185228184809" CI_START="-4.070185228184813" EFFECT_SIZE="2.4899999999999984" ESTIMABLE="YES" MEAN_1="19.13" MEAN_2="16.64" MODIFIED="2013-05-08 11:13:15 +1000" MODIFIED_BY="[Empty name]" ORDER="290" SD_1="12.23" SD_2="13.25" SE="3.347094783338222" STUDY_ID="STD-Sontakke-2007" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.180767264351177" CI_START="0.39289769583539547" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="1.0077805094464374" LOG_CI_START="-0.4057205181184749" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2013-09-08 20:19:40 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4038202778531671" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.8348178575916273">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Valdecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia serrata</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours valdecoxib</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.180767264351177" CI_START="0.39289769583539547" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0077805094464374" LOG_CI_START="-0.4057205181184749" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-03-24 04:31:22 +1100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.8302975005345611" STUDY_ID="STD-Sontakke-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.6893939393939394" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.07405779123665" CI_START="0.12662848132908622" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="1.8517111110810305" LOG_CI_START="-0.8974686016417053" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-09-08 20:19:40 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4963113070323152" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.6803050896828817">
<NAME>Participants (n) withdrew due to adverse events</NAME>
<GROUP_LABEL_1>
<I>Boswellia serrata</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Valdecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Boswellia</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours valdecoxib</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.07405779123665" CI_START="0.12662848132908622" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8517111110810305" LOG_CI_START="-0.8974686016417053" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-05-08 09:59:37 +1000" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Sontakke-2007" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-09-13 07:44:05 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>
<I>Curcuma domestica</I> versus ibuprofen</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5875746613286781" CI_START="-1.387574661328678" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2013-09-13 07:43:50 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.4272830925519834" Q="0.0" RANDOM="YES" SCALE="23.32280637922562" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="45" TOTAL_2="46" UNITS="" WEIGHT="0.0" Z="0.7938494419867469">
<NAME>Pain on walking NRS 0-10</NAME>
<GROUP_LABEL_1>
<I>Curcuma domestica</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Ibuprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Curcuma</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ibuprofen</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5875746613286781" CI_START="-1.387574661328678" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.1" MODIFIED="2013-09-13 07:43:50 +1000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="2.5" SD_2="2.3" SE="0.5038738819276991" STUDY_ID="STD-Kuptniratsaikul-2009" TOTAL_1="45" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.634663125768967" CI_START="-9.23466312576896" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2013-09-13 07:44:05 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.9475291824156569" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="45" TOTAL_2="46" UNITS="" WEIGHT="0.0" Z="0.06580988976138988">
<NAME>Function: 100m walk time (seconds)</NAME>
<GROUP_LABEL_1>
<I>Curcuma domestica</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Ibuprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Curcuma</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ibuprofen</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.634663125768967" CI_START="-9.23466312576896" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="YES" MEAN_1="96.7" MEAN_2="97.0" MODIFIED="2013-09-13 07:44:05 +1000" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="17.0" SD_2="25.7" SE="4.558585359855817" STUDY_ID="STD-Kuptniratsaikul-2009" TOTAL_1="45" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8700006130635507E-31" CI_END="1.2464923944363602" CI_START="0.45563688365682703" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7536231884057971" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" I2="100.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.09568963296863504" LOG_CI_START="-0.34138112717354735" LOG_EFFECT_SIZE="-0.12284574710245615" METHOD="MH" MODIFIED="2013-09-08 20:19:44 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.2705666395615969" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="1.1017586255205194">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Curcuma domestica</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Ibuprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Curcuma</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ibuprofen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2464923944363602" CI_START="0.45563688365682703" EFFECT_SIZE="0.7536231884057971" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.09568963296863504" LOG_CI_START="-0.34138112717354735" LOG_EFFECT_SIZE="-0.12284574710245615" MODIFIED="2011-03-24 05:25:53 +1100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.2567375280426737" STUDY_ID="STD-Kuptniratsaikul-2009" TOTAL_1="48" TOTAL_2="52" VAR="0.06591415830546266" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-09-13 04:25:36 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>
<I>Derris scandens</I> versus naproxen</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.844976925139335" CI_START="-1.844976925139334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2013-05-07 20:19:50 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.15223528225215294" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="52" UNITS="" WEIGHT="99.99999999999999" Z="1.4316804906542164">
<NAME>WOMAC-VAS (Pain) change from baseline</NAME>
<GROUP_LABEL_1>
<I>Derris scandens</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Derris</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.844976925139335" CI_START="-1.844976925139334" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-17.5" MEAN_2="-22.5" MODIFIED="2011-07-16 10:39:22 +1000" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="17.0" SD_2="19.0" SE="3.4923993395448276" STUDY_ID="STD-Kuptniratsaikul-2011" TOTAL_1="55" TOTAL_2="52" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.33429284394353" CI_START="-0.1342928439435278" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2013-09-08 20:19:50 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05617462544014394" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="1.9096784645360818">
<NAME>WOMAC-VAS (Function) change from baseline</NAME>
<GROUP_LABEL_1>
<I>Derris scandens</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Derris</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.33429284394353" CI_START="-0.1342928439435278" EFFECT_SIZE="5.100000000000001" ESTIMABLE="YES" MEAN_1="-8.7" MEAN_2="-13.8" MODIFIED="2011-07-16 10:45:49 +1000" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="13.6" SD_2="14.0" SE="2.670606646464406" STUDY_ID="STD-Kuptniratsaikul-2011" TOTAL_1="55" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1466712497478706" CI_START="0.48608556275233794" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7465790914066777" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.059438923668349616" LOG_CI_START="-0.313287277732505" LOG_EFFECT_SIZE="-0.12692417703207765" METHOD="MH" MODIFIED="2013-09-08 20:19:50 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.18192539104105526" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="1.3348501651630216">
<NAME>Participants (n) reported adverse events.</NAME>
<GROUP_LABEL_1>
<I>Derris scandens</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Derris</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1466712497478706" CI_START="0.48608556275233794" EFFECT_SIZE="0.7465790914066777" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.059438923668349616" LOG_CI_START="-0.313287277732505" LOG_EFFECT_SIZE="-0.12692417703207765" MODIFIED="2011-07-16 10:19:40 +1000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.2189412157273151" STUDY_ID="STD-Kuptniratsaikul-2011" TOTAL_1="63" TOTAL_2="62" VAR="0.04793525594415472" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-09-10 20:22:42 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>
<I>Harpagophytum procumbens</I> versus diacerhein</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.6780175221729774" CI_START="-6.5219824778270254" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2013-05-07 20:20:15 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.072848846259994E-12" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="7.029493314452932">
<NAME>Pain VAS 0-100 change from baseline at 120 days</NAME>
<GROUP_LABEL_1>
<I>Harpagophytum procumbens</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerhein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Harpagophytum</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diacerhein</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.6780175221729774" CI_START="-6.5219824778270254" EFFECT_SIZE="-5.100000000000001" ESTIMABLE="YES" MEAN_1="-30.6" MEAN_2="-25.5" ORDER="30239" SD_1="3.3" SD_2="3.6" SE="0.7255145956984109" STUDY_ID="STD-Leblan-2000" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7521643544676977" CI_START="0.21271946623053026" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-0.12368725190909505" LOG_CI_START="-0.6721927654349802" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2013-09-10 20:22:42 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.004456469054328023" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.00000000000001" Z="2.8439024431718614">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Harpagophytum procumbens</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerhein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Harpagophytum</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diacerhein</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7521643544676977" CI_START="0.21271946623053026" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.12368725190909505" LOG_CI_START="-0.6721927654349802" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-05-25 23:42:03 +1000" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.3221948537911862" STUDY_ID="STD-Leblan-2000" TOTAL_1="50" TOTAL_2="42" VAR="0.10380952380952382" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-09-13 07:47:04 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>
<I>Petiveria alliacea</I> versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1089975522200675" CI_START="-1.3089975522200676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2013-09-13 07:46:48 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.871215450355376" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="99.99999999999999" Z="0.16211480171659554">
<NAME>Pain (scale unknown) with mvt change from baseline</NAME>
<GROUP_LABEL_1>
<I>Petiveria alliacea</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Petiveria</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1089975522200675" CI_START="-1.3089975522200676" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.9" MODIFIED="2011-07-19 15:31:42 +1000" MODIFIED_BY="[Empty name]" ORDER="257" SD_1="1.9" SD_2="2.0" SE="0.6168468205316454" STUDY_ID="STD-Ferraz-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.035570430792177" CI_START="0.28000501263457733" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.9050167119832477" LOG_CI_START="-0.5528341938718854" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2013-09-13 07:47:04 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6358698851622282" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4734812378348156">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Petiveria alliacea</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Petiveria</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.03557043079218" CI_START="0.28000501263457733" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.905016711983248" LOG_CI_START="-0.5528341938718854" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-07-19 15:35:02 +1000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Ferraz-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-09-10 20:23:02 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>
<I>Pinus pinaster </I>(Pycnogenol® 150 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-84.44806816481965" CI_START="-199.55193183518037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-142.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2013-05-07 20:05:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.3255035283306085E-6" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="4.835891288614561">
<NAME>WOMAC-VAS (Pain)</NAME>
<GROUP_LABEL_1>Pycnogenol 150mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pycnogenol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-84.44806816481965" CI_START="-199.55193183518037" EFFECT_SIZE="-142.0" ESTIMABLE="YES" MEAN_1="164.0" MEAN_2="306.0" MODIFIED="2012-05-24 04:36:33 +1000" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="72.0" SD_2="103.0" SE="29.36377009431941" STUDY_ID="STD-Farid-2007" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-316.4066794180802" CI_START="-741.5933205819198" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-529.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2013-09-10 20:22:52 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0770290301098217E-6" Q="0.0" RANDOM="YES" SCALE="1700.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="100.00000000000001" Z="4.877015632399254">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>Pycnogenol 150mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pycnogenol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-316.4066794180802" CI_START="-741.5933205819198" EFFECT_SIZE="-529.0" ESTIMABLE="YES" MEAN_1="485.0" MEAN_2="1014.0" MODIFIED="2012-05-24 04:38:26 +1000" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="259.0" SD_2="385.0" SE="108.46797301319245" STUDY_ID="STD-Farid-2007" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9659813518147355" CI_START="0.08138429179519381" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4000000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.29357939404425104" LOG_CI_START="-1.0894594113883262" LOG_EFFECT_SIZE="-0.39794000867203755" METHOD="MH" MODIFIED="2013-09-10 20:23:02 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.25937234174702095" Q="0.0" RANDOM="YES" SCALE="341.74" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="68" WEIGHT="99.99999999999999" Z="1.1278759235693372">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>Pycnogenol 150mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pycnogenol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9659813518147353" CI_START="0.08138429179519381" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.29357939404425104" LOG_CI_START="-1.0894594113883262" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-03-24 06:01:00 +1100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.812403840463596" STUDY_ID="STD-Cisar-2008" TOTAL_1="50" TOTAL_2="50" VAR="0.6599999999999999" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-21 11:49:37 +1000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.0" STUDY_ID="STD-Farid-2007" TOTAL_1="19" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2013-09-25 12:54:32 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>
<I>Pinus pinaster </I>(Pycnogenol® 100 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-6.56723115896284" CI_START="-8.432768841037158" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.499999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2013-05-07 20:06:07 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.934044951151703E-56" Q="0.0" RANDOM="YES" SCALE="62.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="79" UNITS="" WEIGHT="100.00000000000001" Z="15.759241987227579">
<NAME>WOMAC 0-4 (Pain)</NAME>
<GROUP_LABEL_1>Pycnogenol 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pycnogenol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.56723115896284" CI_START="-8.432768841037158" EFFECT_SIZE="-7.499999999999999" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="15.2" MODIFIED="2011-06-21 14:32:15 +1000" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="2.24" SD_2="3.57" SE="0.475911214897172" STUDY_ID="STD-Belcaro-2008" TOTAL_1="77" TOTAL_2="79" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-27.608259504264826" CI_START="-30.991740495735176" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-29.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" MODIFIED="2013-09-10 20:23:19 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="79" UNITS="" WEIGHT="100.00000000000001" Z="33.94548093622818">
<NAME>WOMAC 0-4 (Function)</NAME>
<GROUP_LABEL_1>Pycnogenol 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pycnogenol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-27.608259504264826" CI_START="-30.991740495735176" EFFECT_SIZE="-29.3" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="53.1" MODIFIED="2011-06-21 14:33:47 +1000" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="3.27" SD_2="6.92" SE="0.8631487665484714" STUDY_ID="STD-Belcaro-2008" TOTAL_1="77" TOTAL_2="79" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2013-05-07 20:16:32 +1000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>
<I>Ricinus officinale</I> versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6577375838162001" CI_START="0.0024325810769650494" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.04000000000000001" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-0.18194734138898025" LOG_CI_START="-2.6139326759550947" LOG_EFFECT_SIZE="-1.3979400086720375" METHOD="MH" MODIFIED="2013-05-07 20:16:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.024244603512913767" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.2532307498750823">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>Favours <I>Ricinus</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Ricinus</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6577375838162001" CI_START="0.0024325810769650494" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.18194734138898025" LOG_CI_START="-2.6139326759550947" LOG_EFFECT_SIZE="-1.3979400086720375" MODIFIED="2012-05-26 23:41:52 +1000" MODIFIED_BY="[Empty name]" ORDER="491" O_E="0.0" SE="1.4285602240456965" STUDY_ID="STD-Medhi-2009" TOTAL_1="50" TOTAL_2="50" VAR="2.0407843137254904" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-09-10 20:23:41 +1000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>
<I>Rosa canina</I> versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9756380714244277" CI_START="-0.11563807142442784" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.42999999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2013-05-07 20:16:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12244661781139364" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="1.5445852433868354">
<NAME>Relief of pain (0 to 4) at 3 months</NAME>
<GROUP_LABEL_1>
<I>Rosa canina</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Rosa canina</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9756380714244277" CI_START="-0.11563807142442784" EFFECT_SIZE="0.42999999999999994" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="1.02" ORDER="30247" SD_1="1.28" SD_2="1.45" SE="0.2783918866511585" STUDY_ID="STD-Rein-2004a" TOTAL_1="50" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.202709922582622" CI_START="-10.202709922582622" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" MODIFIED="2013-05-07 20:16:17 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5246929579744062" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="0.6361280653948419">
<NAME>WOMAC-VAS (Pain)</NAME>
<GROUP_LABEL_1>
<I>Rosa canina</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Rosa canina</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.202709922582621" CI_START="-10.20270992258262" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="36.3" MODIFIED="2009-06-16 22:38:19 +1000" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="17.6" SD_2="20.4" SE="3.9300262572887124" STUDY_ID="STD-Winther-2005" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.575475752930728" CI_START="-8.975475752930734" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" MODIFIED="2013-09-10 20:23:41 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7622831513011017" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="0.3024839709083488">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Rosa canina</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Rosa canina</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.575475752930728" CI_START="-8.975475752930734" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="38.2" MODIFIED="2009-06-16 22:40:56 +1000" MODIFIED_BY="[Empty name]" ORDER="182" SD_1="18.1" SD_2="20.3" SE="3.9671523631366146" STUDY_ID="STD-Winther-2005" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.371804814724131" CI_END="4.431809322441083" CI_START="0.6318519903055348" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6733940184663691" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.6465810667038842" LOG_CI_START="-0.19938464216330218" LOG_EFFECT_SIZE="0.22359821227029109" METHOD="MH" MODIFIED="2013-09-10 20:23:41 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5420224136149763" P_Q="1.0" P_Z="0.30016443164674245" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="97" WEIGHT="100.00000000000001" Z="1.0360808682048255">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Rosa canina</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Rosa canina</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.823446325509919" CI_START="0.14655350863704047" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8340037796584007" LOG_CI_START="-0.8340037796584007" LOG_EFFECT_SIZE="0.0" ORDER="30250" O_E="0.0" SE="0.9797958971132712" STUDY_ID="STD-Warholm-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.96" WEIGHT="25.722281669273197"/>
<DICH_DATA CI_END="6.191808102006847" CI_START="0.6460148528672177" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7918174881252639" LOG_CI_START="-0.18975749679730153" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-06-16 22:49:42 +1000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.5765820050180532" STUDY_ID="STD-Winther-2005" TOTAL_1="47" TOTAL_2="47" VAR="0.33244680851063835" WEIGHT="74.27771833072681"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2013-09-10 20:25:48 +1000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>
<I>Salix purpurea x daphnoides</I> versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.01" MODIFIED="2013-09-08 19:59:00 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="33" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain VAS 0-100 at 14 days</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="33.2" MEAN_2="48.2" ORDER="30262" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Schmid-2000" TOTAL_1="33" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.02" MODIFIED="2013-09-10 20:25:48 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="33" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function VAS 0-100 at 14 days</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="34.2" MEAN_2="41.3" ORDER="30263" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Schmid-2000" TOTAL_1="33" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4342907100906905" CI_START="0.5720590062821744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9058139534883721" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.1566371854966647" LOG_CI_START="-0.24255917263867122" LOG_EFFECT_SIZE="-0.04296099357100325" METHOD="MH" MODIFIED="2013-09-10 20:25:48 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6731289925841037" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="41" WEIGHT="100.0" Z="0.42185755667979785">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4342907100906905" CI_START="0.5720590062821744" EFFECT_SIZE="0.9058139534883721" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.1566371854966647" LOG_CI_START="-0.24255917263867122" LOG_EFFECT_SIZE="-0.04296099357100325" MODIFIED="2012-05-26 00:22:02 +1000" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.2344899168225385" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="41" VAR="0.054985521091441024" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2013-09-10 20:26:00 +1000" MODIFIED_BY="[Empty name]" NO="15">
<NAME>
<I>Salix purpurea x daphnoides</I> versus diclofenac</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="24.090436335553193" CI_START="5.909563664446809" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="15.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" MODIFIED="2013-05-08 11:17:15 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0012202297888935212" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="3.234108758137156">
<NAME>WOMAC-VAS (Pain)</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 14 days</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="42.0" MEAN_2="26.0" ORDER="30269" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.090436335553193" CI_START="5.909563664446809" DF="0" EFFECT_SIZE="15.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.02" NO="2" P_CHI2="1.0" P_Z="0.0012202297888935212" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="3.234108758137156">
<NAME>At 42 days</NAME>
<CONT_DATA CI_END="24.090436335553193" CI_START="5.909563664446809" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="26.0" ORDER="30270" SD_1="22.0" SD_2="21.0" SE="4.638062947716077" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="21.299327480599867" CI_START="2.7006725194001326" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" MODIFIED="2013-09-10 20:26:00 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.01143330638290831" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="2.5291686805897373">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 14 days</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="43.0" MEAN_2="28.0" ORDER="30273" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="21.299327480599867" CI_START="2.7006725194001326" DF="0" EFFECT_SIZE="12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.02" NO="2" P_CHI2="1.0" P_Z="0.01143330638290831" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.5291686805897373">
<NAME>At 42 days</NAME>
<CONT_DATA CI_END="21.299327480599867" CI_START="2.7006725194001326" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="28.0" ORDER="30274" SD_1="22.0" SD_2="22.0" SE="4.74464202095129" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9347710185733841" CI_START="0.42910092754402385" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-0.02929476083775791" LOG_CI_START="-0.3674405466959091" LOG_EFFECT_SIZE="-0.1983676537668335" METHOD="MH" MODIFIED="2013-09-10 20:26:00 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.021473094905463515" Q="0.0" RANDOM="YES" SCALE="92.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.2995611558134272">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Salix purpura</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Salix</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9347710185733841" CI_START="0.42910092754402385" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="-0.02929476083775791" LOG_CI_START="-0.3674405466959091" LOG_EFFECT_SIZE="-0.1983676537668335" MODIFIED="2012-05-26 00:26:00 +1000" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.1986285084617135" STUDY_ID="STD-Biegert-2004" TOTAL_1="43" TOTAL_2="43" VAR="0.039453284373725" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2013-09-25 12:54:32 +1000" MODIFIED_BY="[Empty name]" NO="16">
<NAME>
<I>Uncaria guianensis</I> versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.24068873159341" CI_START="-26.44068873159341" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2013-09-13 11:15:58 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.15614312299826397" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.418163200429847">
<NAME>Pain VAS 0-100 (night)</NAME>
<GROUP_LABEL_1>
<I>Uncaria</I> <I>guianensis</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Uncaria</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.24068873159341" CI_START="-26.44068873159341" EFFECT_SIZE="-11.100000000000001" ESTIMABLE="YES" MEAN_1="30.6" MEAN_2="41.7" MODIFIED="2013-09-10 20:28:11 +1000" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="20.3" SD_2="26.7" SE="7.827025829351359" STUDY_ID="STD-Piscoya-2001" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.1676154704644395" CI_START="0.5375356958454429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.7132901897260784" LOG_CI_START="-0.26959269049336554" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" MODIFIED="2013-09-10 20:28:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.376277501209928" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.8847759341707596">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Uncaria</I> <I>guianensis</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Uncaria</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.1676154704644395" CI_START="0.5375356958454429" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.7132901897260784" LOG_CI_START="-0.26959269049336554" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="30352" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Piscoya-2001" TOTAL_1="30" TOTAL_2="15" VAR="0.33333333333333337" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2013-09-13 11:02:35 +1000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>
<I>Zingiber officinale</I> (Zintona EC) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.118056823509093" CI_START="-31.118056823509093" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.01" MODIFIED="2013-09-13 10:57:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4251469159653224" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.7975237608627277">
<NAME>Pain VAS 0-100 (movement)</NAME>
<GROUP_LABEL_1>
<I>Zingiber officinale</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Zingiber</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.118056823509093" CI_START="-31.118056823509093" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="50.0" MODIFIED="2012-05-26 00:47:51 +1000" MODIFIED_BY="[Empty name]" ORDER="30322" SD_1="28.0" SD_2="27.0" SE="11.284930232378503" STUDY_ID="STD-Wigler-2003" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.248348088718426" CI_START="-27.248348088718426" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2013-09-13 11:02:35 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5799589957016573" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.5534446187599897">
<NAME>Function (handicap) VAS 0-100</NAME>
<GROUP_LABEL_1>
<I>Zingiber officinale</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Zingiber</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.248348088718426" CI_START="-27.248348088718426" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="46.0" MODIFIED="2012-05-26 00:48:49 +1000" MODIFIED_BY="[Empty name]" ORDER="30323" SD_1="26.0" SD_2="27.0" SE="10.84119313228339" STUDY_ID="STD-Wigler-2003" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="78.18735073936817" CI_START="0.15667495936567133" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="1.8931364979646812" LOG_CI_START="-0.80500040926413" LOG_EFFECT_SIZE="0.5440680443502757" METHOD="MH" MODIFIED="2013-09-13 10:58:14 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4292725427968822" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0" Z="0.7904371117779243">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Zingiber officinale</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Zingiber</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="78.18735073936817" CI_START="0.15667495936567133" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8931364979646812" LOG_CI_START="-0.80500040926413" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="30324" O_E="0.0" SE="1.584898975299297" STUDY_ID="STD-Wigler-2003" TOTAL_1="11" TOTAL_2="13" VAR="2.5119047619047614" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2013-09-13 11:22:13 +1000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>
<I>Boswellia carteri</I> + <I>Curcuma longa</I> versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-018.01" MODIFIED="2013-09-13 11:22:13 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="90" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function: pain free walking time (minutes)</NAME>
<GROUP_LABEL_1>
<I>Boswellia+Curcuma</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Boswellia+Curcuma</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-018.01.01" MODIFIED="2011-06-21 15:38:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month</NAME>
<CONT_DATA CI_END="5.065372493842217" CI_START="-0.06537249384221688" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="11.16" MEAN_2="8.66" MODIFIED="2011-06-21 15:38:57 +1000" MODIFIED_BY="[Empty name]" ORDER="30325" SD_1="5.82" SD_2="2.96" SE="1.308887568382658" STUDY_ID="STD-Badria-2002" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-018.01.02" MODIFIED="2011-06-21 15:38:59 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>At 2 months</NAME>
<CONT_DATA CI_END="6.694761602867191" CI_START="1.3052383971328099" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="12.66" MEAN_2="8.66" MODIFIED="2011-06-21 15:38:59 +1000" MODIFIED_BY="[Empty name]" ORDER="30326" SD_1="6.26" SD_2="2.96" SE="1.3749036329866904" STUDY_ID="STD-Badria-2002" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-018.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="6.346312667180789" CI_START="0.653687332819211" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="10.0" ORDER="30327" SD_1="5.89" SD_2="3.78" SE="1.4522270254107423" STUDY_ID="STD-Badria-2002" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2014-04-16 13:56:10 +1000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>
<I>Persea gratissma</I> + <I>Glycine max </I>(ASU 300 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="15.688885828606505" CI_END="-1.041051656569997" CI_START="-15.895666447640497" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.468359052105248" ESTIMABLE="YES" I2="80.87818323892755" I2_Q="65.46676360927162" ID="CMP-019.01" MODIFIED="2013-12-03 15:06:52 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001313283570948398" P_Q="0.0552570348177579" P_Z="0.02543815703893881" Q="5.791522049572418" RANDOM="YES" SCALE="39.52" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="46.19732167653146" TOTALS="YES" TOTAL_1="334" TOTAL_2="317" UNITS="" WEIGHT="100.0" Z="2.234683158563942">
<NAME>Pain VAS 0-100</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.17221042110155" CI_END="0.15463594984326612" CI_START="-23.94529580738771" DF="1" EFFECT_SIZE="-11.895329928772222" ESTIMABLE="YES" I2="87.76340857036806" ID="CMP-019.01.01" NO="1" P_CHI2="0.004253735981488149" P_Z="0.053013373430092284" STUDIES="2" TAU2="66.38863041305484" TOTAL_1="165" TOTAL_2="161" WEIGHT="51.85344308507115" Z="1.9348119720396864">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-11.652778091191372" CI_START="-24.747221908808626" EFFECT_SIZE="-18.2" ESTIMABLE="YES" MEAN_1="24.2" MEAN_2="42.4" ORDER="30209" SD_1="21.2" SD_2="21.4" SE="3.340480723346081" STUDY_ID="STD-Appelboom-2001" TOTAL_1="85" TOTAL_2="78" WEIGHT="25.037257204838113"/>
<CONT_DATA CI_END="-0.584944922997864" CI_START="-11.215055077002148" EFFECT_SIZE="-5.900000000000006" ESTIMABLE="YES" MEAN_1="37.3" MEAN_2="43.2" ORDER="30208" SD_1="17.6" SD_2="17.0" SE="2.7118126245821954" STUDY_ID="STD-Blotman-1997" TOTAL_1="80" TOTAL_2="83" WEIGHT="26.816185880233036"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.598179328821832" CI_START="-17.20182067117818" DF="0" EFFECT_SIZE="-10.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.02" NO="2" P_CHI2="1.0" P_Z="0.0027283895122129616" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="78" WEIGHT="24.65691967579165" Z="2.9967895986422466">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="-3.598179328821832" CI_START="-17.20182067117818" EFFECT_SIZE="-10.400000000000006" ESTIMABLE="YES" MEAN_1="35.3" MEAN_2="45.7" ORDER="30210" SD_1="21.07" SD_2="22.96" SE="3.4703804380233856" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" WEIGHT="24.65691967579165"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.575136059220249" CI_START="-6.575136059220249" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.03" NO="3" P_CHI2="1.0" P_Z="0.7958385766062126" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="78" WEIGHT="23.489637239137217" Z="0.25873647274684125">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="8.575136059220249" CI_START="-6.575136059220249" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="31.8" MEAN_2="30.8" ORDER="30211" SD_1="22.2" SD_2="26.7" SE="3.864936355449363" STUDY_ID="STD-Lequesne-2002" TOTAL_1="85" TOTAL_2="78" WEIGHT="23.489637239137217"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.070710359588233" CI_START="-7.390710359588233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6599999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.02" MODIFIED="2013-09-13 11:22:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8475932617892517" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="179" UNITS="" WEIGHT="100.0" Z="0.1921901494325441">
<NAME>Pain VAS 0-100 change from baseline at 36 months</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.070710359588233" CI_START="-7.390710359588233" EFFECT_SIZE="-0.6599999999999997" ESTIMABLE="YES" MEAN_1="-4.26" MEAN_2="-3.6" MODIFIED="2013-09-13 11:22:03 +1000" MODIFIED_BY="[Empty name]" ORDER="171" SD_1="32.3" SD_2="31.4" SE="3.434099000124093" STUDY_ID="STD-Maheu-2013" TOTAL_1="166" TOTAL_2="179" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9354605700248078" CI_END="-2.8834940589278393" CI_START="-15.240104793560365" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.061799426244102" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.03" MODIFIED="2013-07-29 15:32:09 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.333448165824065" P_Q="0.333448165824065" P_Z="0.004044061464243738" Q="0.9354605700248078" RANDOM="YES" SCALE="31.88" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="2.8747042197882036">
<NAME>Pain VAS 0-100 grouped by joint</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.382277867664321" CI_START="-25.217722132335673" DF="0" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-019.03.01" NO="1" P_CHI2="1.0" P_Z="0.017840818734933053" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="78" WEIGHT="29.28058845140452" Z="2.3689053449682915">
<NAME>VAS (hip OA)</NAME>
<CONT_DATA CI_END="-2.382277867664321" CI_START="-25.217722132335673" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" MEAN_1="37.5" MEAN_2="51.3" ORDER="30228" SD_1="33.91" SD_2="39.74" SE="5.825475479344116" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" WEIGHT="29.28058845140452"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24683101431614318" CI_START="-14.446831014316146" DF="0" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-019.03.02" NO="2" P_CHI2="1.0" P_Z="0.05820972070632065" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="78" WEIGHT="70.71941154859547" Z="1.8941151992087422">
<NAME>VAS (knee OA)</NAME>
<CONT_DATA CI_END="0.24683101431614318" CI_START="-14.446831014316146" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="40.1" ORDER="30229" SD_1="24.75" SD_2="22.96" SE="3.7484520492555014" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" WEIGHT="70.71941154859547"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.04" MODIFIED="2013-12-03 15:46:25 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="26.12264425643743" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="84" TOTAL_2="78" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function: disability VAS 0-100</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.396762510800533" CI_START="-20.00323748919947" EFFECT_SIZE="-13.200000000000003" ESTIMABLE="YES" MEAN_1="33.9" MEAN_2="47.1" ORDER="30216" SD_1="21.08" SD_2="22.96" SE="3.471103317643864" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.136150812897408" CI_START="-7.136150812897408" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.05" MODIFIED="2013-09-13 04:30:42 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7494136456574105" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="179" UNITS="" WEIGHT="100.0" Z="0.3194126161991422">
<NAME>WOMAC-VAS (Function) change from baseline at 36 months</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.136150812897408" CI_START="-7.136150812897408" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2013-05-07 21:58:11 +1000" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="30.0" SD_2="28.0" SE="3.1307467184594118" STUDY_ID="STD-Maheu-2013" TOTAL_1="166" TOTAL_2="179" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.0230031822718" CI_END="0.20363553336029683" CI_START="-2.5429490967574857" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1696567816985943" ESTIMABLE="YES" I2="83.36522107097962" I2_Q="88.90542543583295" ID="CMP-019.06" MODIFIED="2014-04-16 13:56:10 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0024504120177258892" P_Q="0.0026800844592722584" P_Z="0.09505097299120892" Q="9.013414567781382" RANDOM="YES" SCALE="7.038092663391631" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.2249995787437913" TOTALS="YES" TOTAL_1="241" TOTAL_2="239" UNITS="" WEIGHT="100.0" Z="1.669335174502862">
<NAME>Lequesne algofunctional index</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4782741247376374" CI_END="-0.923682970782524" CI_START="-2.6768430017535945" DF="1" EFFECT_SIZE="-1.8002629862680593" ESTIMABLE="YES" I2="32.35354774423323" ID="CMP-019.06.01" NO="1" P_CHI2="0.22404507906606308" P_Z="5.691567058563788E-5" STUDIES="2" TAU2="0.13103186836414446" TOTAL_1="156" TOTAL_2="161" WEIGHT="65.56242145806965" Z="4.025246473171674">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-1.1934767435947677" CI_START="-3.406523256405232" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.8" ORDER="30213" SD_1="3.6" SD_2="3.4" SE="0.5645630558180387" STUDY_ID="STD-Appelboom-2001" TOTAL_1="76" TOTAL_2="78" WEIGHT="31.802273314172144"/>
<CONT_DATA CI_END="-0.4616605759333937" CI_START="-2.338339424066607" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.7" ORDER="30212" SD_1="2.8" SD_2="3.3" SE="0.4787534013217122" STUDY_ID="STD-Blotman-1997" TOTAL_1="80" TOTAL_2="83" WEIGHT="33.76014814389751"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9778336996190179" CI_START="-0.7778336996190186" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-019.06.02" MODIFIED="2014-04-16 13:56:10 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8233231863452161" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="78" WEIGHT="34.43757854193035" Z="0.2232728118538484">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="0.9778336996190179" CI_START="-0.7778336996190186" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.4" ORDER="30215" SD_1="3.2" SD_2="2.5" SE="0.4478825664875775" STUDY_ID="STD-Lequesne-2002" TOTAL_1="85" TOTAL_2="78" WEIGHT="34.43757854193035"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.637401143133756" CI_END="-0.10584357875016531" CI_START="-0.7251344339189465" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.41548900633455593" ESTIMABLE="YES" I2="74.22104847034473" I2_Q="0.0" ID="CMP-019.07" MODIFIED="2013-12-04 11:10:23 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.008734368521879032" P_Q="1.0" P_Z="0.008540432601642256" Q="0.0" RANDOM="YES" SCALE="2.702466144102257" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0740875946014092" TOTALS="YES" TOTAL_1="325" TOTAL_2="317" UNITS="" WEIGHT="100.0" Z="2.62992253669279">
<NAME>Function (various tools)</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3294243877844033" CI_START="-0.978323541040759" EFFECT_SIZE="-0.6538739644125812" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.8" MODIFIED="2013-12-03 15:35:49 +1100" MODIFIED_BY="[Empty name]" ORDER="555" SD_1="3.6" SD_2="3.4" SE="0.16553854008920302" STUDY_ID="STD-Appelboom-2001" TOTAL_1="76" TOTAL_2="78" WEIGHT="24.592763219249324"/>
<CONT_DATA CI_END="-0.14353619383060284" CI_START="-0.7657806815219019" EFFECT_SIZE="-0.4546584376762524" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.7" MODIFIED="2013-12-03 15:35:59 +1100" MODIFIED_BY="[Empty name]" ORDER="556" SD_1="2.8" SD_2="3.3" SE="0.158738755558644" STUDY_ID="STD-Blotman-1997" TOTAL_1="80" TOTAL_2="83" WEIGHT="25.138939472291717"/>
<CONT_DATA CI_END="0.3418220223796499" CI_START="-0.27285663739104754" EFFECT_SIZE="0.03448269249430119" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.4" MODIFIED="2013-12-04 11:10:23 +1100" MODIFIED_BY="[Empty name]" ORDER="557" SD_1="3.2" SD_2="2.5" SE="0.15680866194971038" STUDY_ID="STD-Lequesne-2002" TOTAL_1="85" TOTAL_2="78" WEIGHT="25.294098122741797"/>
<CONT_DATA CI_END="-0.2819130582237863" CI_START="-0.9121921543373346" EFFECT_SIZE="-0.5970526062805604" ESTIMABLE="YES" MEAN_1="33.9" MEAN_2="47.1" MODIFIED="2013-12-03 15:36:43 +1100" MODIFIED_BY="[Empty name]" ORDER="558" SD_1="21.08" SD_2="22.96" SE="0.16078843822771982" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" WEIGHT="24.974199185717172"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3251643081451148" CI_END="1.1181100758430595" CI_START="0.9684603964057864" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0405985427994187" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="270" I2="0.0" I2_Q="0.0" ID="CMP-019.08" LOG_CI_END="0.0484845611335724" LOG_CI_START="-0.013918134339915131" LOG_EFFECT_SIZE="0.01728321339682867" METHOD="MH" MODIFIED="2013-12-03 15:52:48 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8570918395776814" P_Q="1.0" P_Z="0.27762349423737587" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="521" TOTAL_2="529" WEIGHT="100.0" Z="1.0856734805404773">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9824700943933682" CI_START="0.7827483985728755" EFFECT_SIZE="1.2457027300303336" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.29720664469688046" LOG_CI_START="-0.106377812234426" LOG_EFFECT_SIZE="0.09541441623122722" ORDER="30233" O_E="0.0" SE="0.2370675077767309" STUDY_ID="STD-Appelboom-2001" TOTAL_1="86" TOTAL_2="88" VAR="0.05620100324347037" WEIGHT="2.3907702035362752"/>
<DICH_DATA CI_END="2.063704733662387" CI_START="0.3823694556298164" EFFECT_SIZE="0.8883116883116883" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.31464756034171903" LOG_CI_START="-0.41751680724645035" LOG_EFFECT_SIZE="-0.051434623452365665" ORDER="30230" O_E="0.0" SE="0.4300769737933618" STUDY_ID="STD-Blotman-1997" TOTAL_1="77" TOTAL_2="76" VAR="0.184966203387256" WEIGHT="0.7264228897104132"/>
<DICH_DATA CI_END="1.264022792126474" CI_START="0.6661874531161291" EFFECT_SIZE="0.9176470588235294" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" LOG_CI_END="0.10175490496338835" LOG_CI_START="-0.17640355101101302" LOG_EFFECT_SIZE="-0.03732432302381235" ORDER="30232" O_E="0.0" SE="0.16339165394592686" STUDY_ID="STD-Lequesne-2002" TOTAL_1="85" TOTAL_2="78" VAR="0.02669683257918552" WEIGHT="5.032944772185921"/>
<DICH_DATA CI_END="1.7852742111025273" CI_START="0.6387359826627398" EFFECT_SIZE="1.0678571428571428" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.25170493149722223" LOG_CI_START="-0.19467861753280138" LOG_EFFECT_SIZE="0.02851315698221042" ORDER="30231" O_E="0.0" SE="0.2622079063344401" STUDY_ID="STD-Maheu-1998" TOTAL_1="84" TOTAL_2="78" VAR="0.0687529861442905" WEIGHT="1.954295973142871"/>
<DICH_DATA CI_END="1.1258537226207002" CI_START="0.9675324830950865" EFFECT_SIZE="1.0436953807740326" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="178" LOG_CI_END="0.051481968148183066" LOG_CI_START="-0.01433444543862551" LOG_EFFECT_SIZE="0.018573761354778777" MODIFIED="2013-05-07 11:03:26 +1000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.038660887137392984" STUDY_ID="STD-Maheu-2013" TOTAL_1="189" TOTAL_2="209" VAR="0.001494664194250238" WEIGHT="89.89556616142451"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7956916924633024" CI_START="0.7256275435119866" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1414917221368834" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-019.09" LOG_CI_END="0.25423177344722164" LOG_CI_START="-0.1392862406003354" LOG_EFFECT_SIZE="0.05747276642344316" METHOD="MH" MODIFIED="2013-12-03 15:52:44 +1100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.5669832171478703" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="209" WEIGHT="100.0" Z="0.5725001055134329">
<NAME>Participants (n) withdrew due to adverse events</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7956916924633024" CI_START="0.7256275435119866" EFFECT_SIZE="1.1414917221368834" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.25423177344722164" LOG_CI_START="-0.1392862406003354" LOG_EFFECT_SIZE="0.05747276642344316" MODIFIED="2013-05-07 19:18:22 +1000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.23115442939712064" STUDY_ID="STD-Maheu-2013" TOTAL_1="189" TOTAL_2="209" VAR="0.05343237022990843" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5860677180397702" CI_START="0.9378900736189966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.219654528478058" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-019.10" LOG_CI_END="0.2003217258209038" LOG_CI_START="-0.027848060574356546" LOG_EFFECT_SIZE="0.08623683262327363" METHOD="MH" MODIFIED="2013-12-03 15:52:41 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.13846330959482392" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="209" WEIGHT="100.0" Z="1.481537838578054">
<NAME>Particpants (n) reported serious adverse events</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5860677180397702" CI_START="0.9378900736189966" EFFECT_SIZE="1.219654528478058" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="68" LOG_CI_END="0.2003217258209038" LOG_CI_START="-0.027848060574356546" LOG_EFFECT_SIZE="0.08623683262327363" MODIFIED="2013-05-08 08:54:21 +1000" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.13402806198723424" STUDY_ID="STD-Maheu-2013" TOTAL_1="189" TOTAL_2="209" VAR="0.017963521400053906" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.195284659929474" CI_END="0.1882109961993373" CI_START="-0.43293045468971175" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12235972924518725" ESTIMABLE="YES" I2="67.71738330385665" I2_Q="67.71738330385665" ID="CMP-019.11" MODIFIED="2013-12-03 15:52:38 +1100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.04515557291223349" P_Q="0.04515557291223349" P_Z="0.4399999001962158" Q="6.195284659929474" RANDOM="YES" SCALE="2.1156595036266372" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.049580429122215865" TOTALS="YES" TOTAL_1="221" TOTAL_2="232" UNITS="" WEIGHT="100.0" Z="0.7721933937443091">
<NAME>JSW change from baseline</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.12607283964342553" CI_START="-0.7339271603565745" DF="0" EFFECT_SIZE="-0.43" ESTIMABLE="YES" I2="0.0" ID="CMP-019.11.01" MODIFIED="2013-05-08 08:38:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0055545210792161005" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="25" WEIGHT="34.102884426756496" Z="2.7729818959366734">
<NAME>&lt; median group, at 24 months</NAME>
<CONT_DATA CI_END="-0.12607283964342553" CI_START="-0.7339271603565745" EFFECT_SIZE="-0.43" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="0.86" MODIFIED="2013-05-08 08:38:44 +1000" MODIFIED_BY="[Empty name]" ORDER="335" SD_1="0.51" SD_2="0.62" SE="0.1550677271388215" STUDY_ID="STD-Lequesne-2002" TOTAL_1="30" TOTAL_2="25" WEIGHT="34.102884426756496"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6349269890158991" CI_START="-0.314926989015899" DF="0" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-019.11.02" MODIFIED="2013-11-18 15:46:47 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5090614063257508" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="28" WEIGHT="23.185162348336174" Z="0.6602998877284496">
<NAME>&gt; median group, at 24 months</NAME>
<CONT_DATA CI_END="0.6349269890158991" CI_START="-0.314926989015899" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.37" MODIFIED="2013-05-08 08:38:57 +1000" MODIFIED_BY="[Empty name]" ORDER="336" SD_1="0.89" SD_2="0.87" SE="0.24231414085261896" STUDY_ID="STD-Lequesne-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="23.185162348336174"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15805213582511973" CI_START="-0.21805213582511979" DF="0" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" I2="0.0" ID="CMP-019.11.03" MODIFIED="2013-05-08 08:39:04 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7545287309975246" STUDIES="1" TAU2="0.0" TOTAL_1="166" TOTAL_2="179" WEIGHT="42.711953224907326" Z="0.31267350024081675">
<NAME>At 36 months</NAME>
<CONT_DATA CI_END="0.15805213582511973" CI_START="-0.21805213582511979" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.64" MEAN_2="0.67" MODIFIED="2013-05-08 08:39:04 +1000" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="0.9" SD_2="0.88" SE="0.0959467303013989" STUDY_ID="STD-Maheu-2013" TOTAL_1="166" TOTAL_2="179" WEIGHT="42.711953224907326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2013-09-13 04:31:34 +1000" MODIFIED_BY="[Empty name]" NO="20">
<NAME>
<I>Persea gratissma</I> + <I>Glycine max </I>(ASU 600 mg) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-7.577192452079156" CI_START="-20.822807547920842" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.01" MODIFIED="2013-05-07 20:26:04 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.6413479527571903E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="78" UNITS="" WEIGHT="100.0" Z="4.202370124616735">
<NAME>Pain VAS 0-100</NAME>
<GROUP_LABEL_1>ASU 600mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 600mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.577192452079156" CI_START="-20.822807547920842" EFFECT_SIZE="-14.2" ESTIMABLE="YES" MEAN_1="28.2" MEAN_2="42.4" ORDER="30234" SD_1="20.8" SD_2="21.4" SE="3.379045533571384" STUDY_ID="STD-Appelboom-2001" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.21711961429116644" CI_START="-2.382880385708833" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.02" MODIFIED="2013-05-07 20:26:10 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.018625611223620334" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="78" UNITS="" WEIGHT="100.0" Z="2.352940558835801">
<NAME>Lequesne algofunctional index</NAME>
<GROUP_LABEL_1>ASU 600mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 600mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.21711961429116644" CI_START="-2.382880385708833" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="7.8" ORDER="30235" SD_1="3.5" SD_2="3.4" SE="0.5525001450284065" STUDY_ID="STD-Appelboom-2001" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7405123619139928" CI_START="0.6550254000054606" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0677451971688574" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.24067711218909046" LOG_CI_START="-0.18374185898786238" LOG_EFFECT_SIZE="0.02846762660061404" METHOD="MH" MODIFIED="2013-09-13 04:31:34 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7926071381316135" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="88" WEIGHT="100.0" Z="0.26292662039970466">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>ASU 600mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 600mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7405123619139926" CI_START="0.6550254000054607" EFFECT_SIZE="1.0677451971688574" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.2406771121890904" LOG_CI_START="-0.1837418589878623" LOG_EFFECT_SIZE="0.02846762660061404" ORDER="30238" O_E="0.0" SE="0.2493058045771324" STUDY_ID="STD-Appelboom-2001" TOTAL_1="86" TOTAL_2="88" VAR="0.06215338419585133" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2014-05-11 00:57:43 +1000" MODIFIED_BY="[Empty name]" NO="21">
<NAME>
<I>Persea gratissma</I> + <I>Glycine max </I>(ASU 300 mg) versus chondroitin sulphate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-021.01" MODIFIED="2013-12-04 11:23:45 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.554040215900006" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="176" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC-VAS (Pain)</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Chondroitin sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chondroitin</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.499573942069757" CI_START="-2.679573942069757" EFFECT_SIZE="1.4100000000000001" ESTIMABLE="YES" MEAN_1="24.29" MEAN_2="22.88" MODIFIED="2013-09-13 09:36:22 +1000" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="19.45" SD_2="19.96" SE="2.086555658332395" STUDY_ID="STD-Pavelka-2010" TOTAL_1="181" TOTAL_2="176" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-021.02" MODIFIED="2013-12-04 11:24:11 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.661492869411516" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="176" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Chondroitin sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chondroitin</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.768774181872409" CI_START="-2.508774181872411" EFFECT_SIZE="1.629999999999999" ESTIMABLE="YES" MEAN_1="26.77" MEAN_2="25.14" MODIFIED="2013-09-13 09:38:29 +1000" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="19.81" SD_2="20.08" SE="2.1116582827636288" STUDY_ID="STD-Pavelka-2010" TOTAL_1="181" TOTAL_2="176" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2614608893896724" CI_START="0.5853622048542497" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8593087498393935" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.10087379010087216" LOG_CI_START="-0.23257532213649426" LOG_EFFECT_SIZE="-0.06585076601781106" METHOD="MH" MODIFIED="2013-09-13 07:06:15 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4388587158317392" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="176" WEIGHT="100.0" Z="0.7741218975410465">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Chondroitin sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chondroitin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2614608893896724" CI_START="0.5853622048542497" EFFECT_SIZE="0.8593087498393935" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" LOG_CI_END="0.10087379010087216" LOG_CI_START="-0.23257532213649426" LOG_EFFECT_SIZE="-0.06585076601781106" MODIFIED="2012-06-09 14:13:50 +1000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.19586965912795518" STUDY_ID="STD-Pavelka-2010" TOTAL_1="181" TOTAL_2="176" VAR="0.03836492336690136" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.77787003302852" CI_START="0.3063456752820025" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9171270718232045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="1.4436989416043853" LOG_CI_START="-0.5137882462751296" LOG_EFFECT_SIZE="0.46495534766462776" METHOD="MH" MODIFIED="2013-09-13 07:07:53 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.35180841557430453" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="176" WEIGHT="100.0" Z="0.9310873056892377">
<NAME>Paricipants (n) reported serious adverse events</NAME>
<GROUP_LABEL_1>ASU 300mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Chondroitin sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASU 300</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chondroitin</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.77787003302852" CI_START="0.3063456752820025" EFFECT_SIZE="2.9171270718232045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4436989416043853" LOG_CI_START="-0.5137882462751296" LOG_EFFECT_SIZE="0.46495534766462776" MODIFIED="2013-05-08 10:44:37 +1000" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.1498376638782808" STUDY_ID="STD-Pavelka-2010" TOTAL_1="181" TOTAL_2="176" VAR="1.322126653273062" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2013-05-07 20:27:26 +1000" MODIFIED_BY="[Empty name]" NO="22">
<NAME>
<I>Phellondendron amurense</I> + <I>Citrus sinensis</I> (NP 06-1) versus placebo</NAME>
<CONT_OUTCOME CHI2="12.038863579889014" CI_END="-0.586696628218009" CI_START="-7.053516189267536" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8201064087427725" ESTIMABLE="YES" I2="91.69356813984913" I2_Q="91.69356813984913" ID="CMP-022.01" MODIFIED="2013-05-07 20:27:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.210302823051016E-4" P_Q="5.210302823051016E-4" P_Z="0.020580333670458063" Q="12.038863579889014" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.992714785214787" TOTALS="YES" TOTAL_1="21" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="2.315596069308401">
<NAME>Lequesne algofunctional index</NAME>
<GROUP_LABEL_1>
<I>Phellondendron+Citrus </I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Phellondendron+Citrus </I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0344617001534853" CI_START="-3.365538299846515" DF="0" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-022.01.01" MODIFIED="2011-03-24 06:59:13 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.1601600482711915E-4" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="11" WEIGHT="50.90586640173417" Z="3.6995101461324262">
<NAME>Normal BMI participants</NAME>
<CONT_DATA CI_END="-1.0344617001534853" CI_START="-3.365538299846515" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="9.9" MODIFIED="2011-03-24 06:59:13 +1100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="1.4" SD_2="0.9" SE="0.5946733251427742" STUDY_ID="STD-Oben-2009" TOTAL_1="7" TOTAL_2="11" WEIGHT="50.90586640173417"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.045218048227401" CI_START="-6.954781951772601" DF="0" EFFECT_SIZE="-5.500000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-022.01.02" MODIFIED="2011-03-24 07:00:16 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.2638608551568562E-13" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="49.09413359826583" Z="7.409909025772208">
<NAME>Overweight BMI participants</NAME>
<CONT_DATA CI_END="-4.045218048227401" CI_START="-6.954781951772601" EFFECT_SIZE="-5.500000000000001" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="11.8" MODIFIED="2011-03-24 07:00:16 +1100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="2.3" SD_2="1.5" SE="0.7422493286854935" STUDY_ID="STD-Oben-2009" TOTAL_1="14" TOTAL_2="13" WEIGHT="49.09413359826583"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2013-09-13 07:08:12 +1000" MODIFIED_BY="[Empty name]" NO="23">
<NAME>
<I>Uncaria guianensis + Lepidium meyenii </I>versus glucosamine sulphate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2390349552373774" CI_START="0.18113136117063486" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7659574468085106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.5104156348841478" LOG_CI_START="-0.742006349221008" LOG_EFFECT_SIZE="-0.1157953571684302" METHOD="MH" MODIFIED="2013-09-13 07:08:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7170342094217357" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="48" WEIGHT="100.0" Z="0.3624253366795255">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>
<I>Uncaria+Lepidium</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>Uncaria+Lepidium</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2390349552373774" CI_START="0.18113136117063486" EFFECT_SIZE="0.7659574468085106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5104156348841478" LOG_CI_START="-0.742006349221008" LOG_EFFECT_SIZE="-0.1157953571684302" MODIFIED="2011-03-24 07:05:04 +1100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.7356788730521755" STUDY_ID="STD-Mehta-2007" TOTAL_1="47" TOTAL_2="48" VAR="0.541223404255319" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2013-09-13 11:01:04 +1000" MODIFIED_BY="[Empty name]" NO="24">
<NAME>
<I>Zingiber officinale</I> + <I>Alpinia galanga </I>(EV.EXT77) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.3907830122076774" CI_START="-16.809216987792325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.01" MODIFIED="2013-09-13 11:01:04 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.009055698564833764" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="123" UNITS="" WEIGHT="100.0" Z="2.6099442260436714">
<NAME>Pain immediately after walking 50 feet VAS 0-100</NAME>
<GROUP_LABEL_1>EV.EXT 77</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EV.EXT 77</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fvours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.3907830122076774" CI_START="-16.809216987792325" EFFECT_SIZE="-9.600000000000001" ESTIMABLE="YES" MEAN_1="34.6" MEAN_2="44.2" MODIFIED="2013-09-13 04:34:23 +1000" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="29.5" SD_2="28.3" SE="3.678239521061462" STUDY_ID="STD-Altman-2001" TOTAL_1="124" TOTAL_2="123" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-024.02" MODIFIED="2013-09-13 08:15:20 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="124" TOTAL_2="123" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>EV.EXT 77</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EV.EXT 77</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fvours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.413266068604214" CI_START="-11.813266068604205" EFFECT_SIZE="-5.699999999999996" ESTIMABLE="YES" MEAN_1="37.7" MEAN_2="43.4" MODIFIED="2013-09-13 04:33:42 +1000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="25.3" SD_2="23.7" SE="3.119070613962742" STUDY_ID="STD-Altman-2001" TOTAL_1="124" TOTAL_2="123" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="76" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-09-13 08:15:31 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="124" TOTAL_2="123" WEIGHT="0.0" Z="0.0">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>EV.EXT 77</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EV.EXT 77</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fvours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9920031194244725" CI_START="1.1882610534343685" EFFECT_SIZE="1.5385121790651746" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="49" LOG_CI_END="0.2992900141819442" LOG_CI_START="0.07491186287693702" LOG_EFFECT_SIZE="0.1871009385294406" MODIFIED="2012-05-26 02:13:51 +1000" MODIFIED_BY="[Empty name]" ORDER="30320" O_E="0.0" SE="0.13180083676632312" STUDY_ID="STD-Altman-2001" TOTAL_1="124" TOTAL_2="123" VAR="0.017371460572302953" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2013-05-07 20:33:23 +1000" MODIFIED_BY="[Empty name]" NO="25">
<NAME>SKI306X versus placebo</NAME>
<CONT_OUTCOME CHI2="1.538682967901455" CI_END="-12.149893848283124" CI_START="-22.56862402388659" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.359258936084856" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.01" MODIFIED="2013-05-07 20:33:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46331820078472274" P_Q="0.46331820078472274" P_Z="6.5235013860336E-11" Q="1.538682967901455" RANDOM="YES" SCALE="41.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="69" UNITS="" WEIGHT="300.0" Z="6.531222469452375">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.008625382577895" CI_START="-25.191374617422106" DF="0" EFFECT_SIZE="-16.1" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.01" MODIFIED="2012-05-26 02:46:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.186814414588672E-4" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.00000000000001" Z="3.470918478117068">
<NAME>Low dose (600mg) SKI306X</NAME>
<CONT_DATA CI_END="-7.008625382577895" CI_START="-25.191374617422106" EFFECT_SIZE="-16.1" ESTIMABLE="YES" MEAN_1="-23.6" MEAN_2="-7.5" ORDER="30278" SD_1="16.3" SD_2="15.5" SE="4.638541671751986" STUDY_ID="STD-Jung-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.964049400819846" CI_START="-23.035950599180154" DF="0" EFFECT_SIZE="-14.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.02" MODIFIED="2012-05-26 02:46:52 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="8.703756405193177E-4" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="3.329386392953161">
<NAME>Medium dose (1200mg) SKI306X</NAME>
<CONT_DATA CI_END="-5.964049400819846" CI_START="-23.035950599180154" EFFECT_SIZE="-14.5" ESTIMABLE="YES" MEAN_1="-22.0" MEAN_2="-7.5" ORDER="30279" SD_1="14.0" SD_2="15.5" SE="4.355156863345777" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-12.7766863772312" CI_START="-31.8233136227688" DF="0" EFFECT_SIZE="-22.3" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.03" MODIFIED="2012-05-26 02:47:00 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="4.443204005490786E-6" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="4.5894946429933725">
<NAME>High dose (1800mg) SKI306X</NAME>
<CONT_DATA CI_END="-12.7766863772312" CI_START="-31.8233136227688" EFFECT_SIZE="-22.3" ESTIMABLE="YES" MEAN_1="-29.8" MEAN_2="-7.5" ORDER="30280" SD_1="17.4" SD_2="15.5" SE="4.858922764850519" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2581939427244807" CI_END="-1.7386237381387764" CI_START="-3.7144895498749797" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.726556644006878" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.02" MODIFIED="2013-05-07 20:32:11 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8788887401318872" P_Q="0.8788887401318872" P_Z="6.329754603112373E-8" Q="0.2581939427244807" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="69" UNITS="" WEIGHT="99.99999999999999" Z="5.409226469044596">
<NAME>Lequesne algofunctional index change from baseline</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7465677534109081" CI_START="-4.053432246589093" DF="0" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.01" MODIFIED="2012-05-26 02:47:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.004441995573510938" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="35.70114093136184" Z="2.844938806896959">
<NAME>Low dose (600mg) SKI306X</NAME>
<CONT_DATA CI_END="-0.7465677534109081" CI_START="-4.053432246589093" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-1.3" ORDER="30281" SD_1="3.4" SD_2="2.3" SE="0.8436033823229175" STUDY_ID="STD-Jung-2001" TOTAL_1="24" TOTAL_2="23" WEIGHT="35.70114093136184"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9847028925377925" CI_START="-4.615297107462207" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.02" MODIFIED="2012-05-26 02:47:20 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002501656335624444" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="29.61825520247547" Z="3.023141024217384">
<NAME>Medium dose (1200mg) SKI306X</NAME>
<CONT_DATA CI_END="-0.9847028925377925" CI_START="-4.615297107462207" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-1.3" ORDER="30282" SD_1="3.8" SD_2="2.3" SE="0.9261890125436177" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" WEIGHT="29.61825520247547"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3224165785182957" CI_START="-4.677583421481704" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.03" MODIFIED="2012-05-26 02:47:27 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="4.56646071147572E-4" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="34.68060386616268" Z="3.504977384926004">
<NAME>High dose (1800mg) SKI306X</NAME>
<CONT_DATA CI_END="-1.3224165785182957" CI_START="-4.677583421481704" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-1.3" ORDER="30283" SD_1="3.4" SD_2="2.3" SE="0.8559256367536691" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" WEIGHT="34.68060386616268"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.6670801155768042" CI_END="1.7928697731545566" CI_START="0.48507783189649983" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9325670927255485" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="0.25354874530431826" LOG_CI_START="-0.3141885722199672" LOG_EFFECT_SIZE="-0.03031991345782447" METHOD="MH" MODIFIED="2013-05-07 20:32:27 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7163832694399277" P_Q="0.717003444788247" P_Z="0.8341804264980597" Q="0.6653494545735915" RANDOM="YES" SCALE="51.64" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="69" WEIGHT="100.00000000000001" Z="0.20934307665680343">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8783417879269204" CI_START="0.3190735657697006" DF="0" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-025.03.01" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2012-05-26 02:47:39 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9395402771640293" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="35.3231473159572" Z="0.07584768632296582">
<NAME>Low dose (600mg) SKI306X</NAME>
<DICH_DATA CI_END="2.8783417879269204" CI_START="0.3190735657697006" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4591423628449439" LOG_CI_START="-0.4961091742329702" LOG_EFFECT_SIZE="-0.018483405694013126" ORDER="30284" O_E="0.0" SE="0.5611194814509367" STUDY_ID="STD-Jung-2004" TOTAL_1="24" TOTAL_2="23" VAR="0.3148550724637681" WEIGHT="35.3231473159572"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3834640952020867" CI_START="0.4255993146320035" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-025.03.02" LOG_CI_END="0.5293615721780385" LOG_CI_START="-0.3709990800827888" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2012-05-26 02:47:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7302944792120494" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="39.761418416537296" Z="0.3447338355239255">
<NAME>Medium dose (1200mg) SKI306X</NAME>
<DICH_DATA CI_END="3.3834640952020867" CI_START="0.4255993146320035" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5293615721780385" LOG_CI_START="-0.3709990800827888" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="30285" O_E="0.0" SE="0.5288763039951179" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" VAR="0.2797101449275363" WEIGHT="39.761418416537296"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2225484307270906" CI_START="0.16197622289032798" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-025.03.03" LOG_CI_END="0.34685123329505896" LOG_CI_START="-0.7905487325277718" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-05-26 02:47:51 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4445228132233239" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="24.915434267505518" Z="0.7645781120605951">
<NAME>High dose (1800mmg) SKI306X</NAME>
<DICH_DATA CI_END="2.222548430727091" CI_START="0.16197622289032795" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34685123329505907" LOG_CI_START="-0.7905487325277719" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="30286" O_E="0.0" SE="0.6681143701449648" STUDY_ID="STD-Jung-2001" TOTAL_1="23" TOTAL_2="23" VAR="0.44637681159420295" WEIGHT="24.915434267505518"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2014-05-11 00:58:05 +1000" MODIFIED_BY="[Empty name]" NO="26">
<NAME>SKI306X (600 mg) versus diclofenac</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.404187664284835" CI_START="-2.7841876642848344" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3100000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.01" MODIFIED="2013-05-07 20:33:53 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5305796448040603" Q="0.0" RANDOM="YES" SCALE="45.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="124" UNITS="" WEIGHT="100.0" Z="0.6271214292752668">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.404187664284835" CI_START="-2.7841876642848344" EFFECT_SIZE="1.3100000000000005" ESTIMABLE="YES" MEAN_1="-14.18" MEAN_2="-15.49" ORDER="30287" SD_1="17.53" SD_2="15.37" SE="2.08890964149304" STUDY_ID="STD-Jung-2004" TOTAL_1="125" TOTAL_2="124" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4396691424236825" CI_START="0.10033085757631788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7700000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.02" MODIFIED="2013-05-07 20:33:59 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.024220789649344474" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="124" UNITS="" WEIGHT="100.0" Z="2.2536087934913804">
<NAME>Lequesne algofunctional index change from baseline</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4396691424236825" CI_START="0.10033085757631788" EFFECT_SIZE="0.7700000000000002" ESTIMABLE="YES" MEAN_1="-1.95" MEAN_2="-2.72" ORDER="30288" SD_1="2.77" SD_2="2.62" SE="0.34167420815175537" STUDY_ID="STD-Jung-2004" TOTAL_1="125" TOTAL_2="124" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.968617600012012" CI_START="0.37941224969636306" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6062222222222222" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="-0.013847643983827025" LOG_CI_START="-0.42088865159797767" LOG_EFFECT_SIZE="-0.21736814779090238" METHOD="MH" MODIFIED="2013-09-13 11:38:59 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03632051078887611" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="124" WEIGHT="100.0" Z="2.093320982834249">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SKI306X</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SKI306X</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.968617600012012" CI_START="0.37941224969636306" EFFECT_SIZE="0.6062222222222222" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" LOG_CI_END="-0.013847643983827025" LOG_CI_START="-0.42088865159797767" LOG_EFFECT_SIZE="-0.21736814779090238" ORDER="30289" O_E="0.0" SE="0.23909790275803544" STUDY_ID="STD-Jung-2004" TOTAL_1="125" TOTAL_2="124" VAR="0.05716780710329097" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2013-09-13 08:20:09 +1000" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Phytodolor N versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-027.01" MODIFIED="2013-09-13 08:20:09 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Enduring pain (0 to 3)</NAME>
<GROUP_LABEL_1>Phytodolor N</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phytodolor N</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.14" MEAN_2="0.47" MODIFIED="2013-09-13 08:17:21 +1000" MODIFIED_BY="[Empty name]" ORDER="169" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Bernhardt-1991" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-027.02" MODIFIED="2013-09-13 08:20:09 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function: mobility limitations (0 to 3)</NAME>
<GROUP_LABEL_1>Phytodolor N</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phytodolor N</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.78" MEAN_2="1.17" MODIFIED="2013-09-13 08:17:41 +1000" MODIFIED_BY="[Empty name]" ORDER="170" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Bernhardt-1991" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.9199970308142" CI_START="0.014029185955349858" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="0.898725018773679" LOG_CI_START="-1.8529675282130038" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-09-13 08:20:09 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4967046763234749" Q="0.0" RANDOM="YES" SCALE="437.95" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="71" WEIGHT="99.99999999999999" Z="0.6796838378859958">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>Phytodolor N</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phytodolor N</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.9199970308142" CI_START="0.014029185955349858" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.898725018773679" LOG_CI_START="-1.8529675282130038" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-06-30 12:14:47 +1000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="1.6163578231977633" STUDY_ID="STD-Bernhardt-1991" TOTAL_1="36" TOTAL_2="36" VAR="2.612612612612612" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30302" O_E="0.0" SE="0.0" STUDY_ID="STD-Huber-1991" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-30 12:13:35 +1000" MODIFIED_BY="[Empty name]" ORDER="30303" O_E="0.0" SE="0.0" STUDY_ID="STD-Schadler-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2013-09-13 08:23:07 +1000" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Reumalex versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.05262655678363293" CI_START="-1.7273734432163672" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.89" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.01" MODIFIED="2013-05-07 20:35:51 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03723826492324812" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="2.0831421874814877">
<NAME>AIMS2 arthritis pain score change from baseline</NAME>
<GROUP_LABEL_1>Reumalex</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Reumalex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.05262655678363293" CI_START="-1.7273734432163672" EFFECT_SIZE="-0.89" ESTIMABLE="YES" MEAN_1="-0.77" MEAN_2="0.12" ORDER="30362" SD_1="1.65" SD_2="1.41" SE="0.42723919920032305" STUDY_ID="STD-Mills-1996" TOTAL_1="25" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9130679703371296" CI_START="0.40040260367320324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.4643506180976165" LOG_CI_START="-0.39750310712371706" LOG_EFFECT_SIZE="0.03342375548694973" METHOD="MH" MODIFIED="2013-09-13 08:23:07 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8791714261030459" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="27" WEIGHT="100.0" Z="0.15201966427811395">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>Reumalex</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Reumalex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9130679703371296" CI_START="0.40040260367320324" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4643506180976165" LOG_CI_START="-0.39750310712371706" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2012-05-26 03:33:08 +1000" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="0.5062571444397563" STUDY_ID="STD-Mills-1996" TOTAL_1="25" TOTAL_2="27" VAR="0.2562962962962963" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2013-09-13 11:47:34 +1000" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Chinese DJW versus diclofenac</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="33.28597254871124" CI_START="-9.665972548711228" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.81000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.01" MODIFIED="2013-05-07 20:36:35 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2811153157898377" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="1.077817295813554">
<NAME>Pain VAS 0-100 (total)</NAME>
<GROUP_LABEL_1>DJW</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DJW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.28597254871124" CI_START="-9.665972548711228" EFFECT_SIZE="11.81000000000001" ESTIMABLE="YES" MEAN_1="70.04" MEAN_2="58.23" MODIFIED="2009-06-16 17:34:36 +1000" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="83.94" SD_2="70.43" SE="10.95733019489693" STUDY_ID="STD-Teekachunhatean-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.453180480321624" CI_START="-0.8931804803216252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27999999999999936" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.02" MODIFIED="2013-09-13 08:24:39 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.639942199958891" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="0.4677796169271113">
<NAME>Lequesne algofunctional index</NAME>
<GROUP_LABEL_1>DJW</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DJW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.453180480321624" CI_START="-0.8931804803216252" EFFECT_SIZE="0.27999999999999936" ESTIMABLE="YES" MEAN_1="8.92" MEAN_2="8.64" MODIFIED="2009-06-16 22:09:46 +1000" MODIFIED_BY="[Empty name]" ORDER="178" SD_1="4.6" SD_2="3.83" SE="0.598572468461422" STUDY_ID="STD-Teekachunhatean-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.626654468277327" CI_START="0.6611396809584793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="0.21129531049224357" LOG_CI_START="-0.17970677612577982" LOG_EFFECT_SIZE="0.015794267183231885" METHOD="MH" MODIFIED="2013-09-13 11:47:34 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.874186634719968" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.1583428626127973">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>DJW</GROUP_LABEL_1>
<GROUP_LABEL_2>Diclofenac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DJW</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.626654468277327" CI_START="0.6611396809584793" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.21129531049224357" LOG_CI_START="-0.17970677612577982" LOG_EFFECT_SIZE="0.015794267183231885" MODIFIED="2012-05-26 03:41:59 +1000" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.22967656117097093" STUDY_ID="STD-Teekachunhatean-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.05275132275132275" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2013-09-10 20:51:19 +1000" MODIFIED_BY="[Empty name]" NO="30">
<NAME>Chinese BNHS versus Chinese active control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.123135852419718" CI_START="-7.123135852419718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-030.01" MODIFIED="2013-09-10 20:51:19 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6674364929078528" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.4296689244236597">
<NAME>Pain VAS 0-100 (walking)</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Chinese control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.123135852419718" CI_START="-7.123135852419718" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="13.0" MODIFIED="2012-06-19 15:21:27 +1000" MODIFIED_BY="[Empty name]" ORDER="1077" SD_1="19.0" SD_2="17.0" SE="4.654746681256314" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.566665772279305" CI_START="-7.566665772279305" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-030.02" MODIFIED="2013-09-10 20:51:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.48132144282526057" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7041787902195303">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Chinese control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.566665772279305" CI_START="-7.566665772279305" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="13.0" MODIFIED="2012-06-19 15:23:39 +1000" MODIFIED_BY="[Empty name]" ORDER="1080" SD_1="11.0" SD_2="11.0" SE="2.840187787218772" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="160.170939238357" CI_START="0.5057097147907748" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.000000000000002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.954242509439325" METHOD="MH" MODIFIED="2013-09-10 20:50:40 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.13470149407860724" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4958164473948932">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Chinese control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese control</GRAPH_LABEL_2>
<DICH_DATA CI_END="160.170939238357" CI_START="0.5057097147907748" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2012-06-19 15:24:28 +1000" MODIFIED_BY="[Empty name]" ORDER="1082" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2013-09-13 07:08:56 +1000" MODIFIED_BY="[Empty name]" NO="31">
<NAME>Chinese BNHS versus glucosamine sulphate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8142290713593203" CI_START="-6.81422907135932" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-031.01" MODIFIED="2013-09-13 07:08:29 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.41550866121899477" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8142379415222338">
<NAME>Pain VAS 0-100 (walking)</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8142290713593203" CI_START="-6.81422907135932" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="20.0" MODIFIED="2012-06-19 15:31:13 +1000" MODIFIED_BY="[Empty name]" ORDER="1083" SD_1="9.0" SD_2="10.0" SE="2.456284456925405" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5303026237633204" CI_START="-2.5303026237633204" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-031.02" MODIFIED="2013-09-13 07:08:45 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.00000000000001" Z="0.0">
<NAME>WOMAC-VAS (Function)</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5303026237633204" CI_START="-2.5303026237633204" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="12.0" MODIFIED="2012-06-19 15:33:05 +1000" MODIFIED_BY="[Empty name]" ORDER="1086" SD_1="5.0" SD_2="5.0" SE="1.2909944487358056" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="160.170939238357" CI_START="0.5057097147907748" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.000000000000002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-031.03" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.954242509439325" METHOD="MH" MODIFIED="2013-09-13 07:08:56 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.13470149407860724" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4958164473948932">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>BNHS</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BNHS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="160.170939238357" CI_START="0.5057097147907748" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2013-09-10 20:45:52 +1000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Cao-2005" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2013-09-01 16:50:02 +1000" MODIFIED_BY="[Empty name]" NO="32">
<NAME>Ayurvedic A to E versus placebo</NAME>
<DICH_OUTCOME CHI2="9.498223662361564" CI_END="1.2752462590039213" CI_START="0.7118039947829622" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9527462314231525" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="115" I2="57.88686240511764" I2_Q="57.85870515994733" ID="CMP-032.01" LOG_CI_END="0.10559405818139597" LOG_CI_START="-0.14763957897992713" LOG_EFFECT_SIZE="-0.02102276039926557" METHOD="MH" MODIFIED="2013-05-07 20:42:19 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04978379485950801" P_Q="0.049914453093478306" P_Z="0.7448619773235821" Q="9.491877302731215" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06373625523719581" TOTALS="YES" TOTAL_1="227" TOTAL_2="227" WEIGHT="100.00000000000001" Z="0.3254216438231419">
<NAME>Adverse event episodes (n) reported</NAME>
<GROUP_LABEL_1>Ayurveda</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ayurveda</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4462138792882082" CI_START="0.6326407528874084" DF="0" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" I2="0.0" ID="CMP-032.01.01" LOG_CI_END="0.16023252513407601" LOG_CI_START="-0.19884283552484927" LOG_EFFECT_SIZE="-0.01930515519538663" MODIFIED="2011-07-14 15:02:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8330830399087871" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="20.445226750197218" Z="0.21074912424779108">
<NAME>Formula A versus placebo</NAME>
<DICH_DATA CI_END="1.4462138792882082" CI_START="0.6326407528874084" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.16023252513407601" LOG_CI_START="-0.19884283552484927" LOG_EFFECT_SIZE="-0.01930515519538663" MODIFIED="2011-07-14 15:02:43 +1000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.21092264430275431" STUDY_ID="STD-Chopra-2011" TOTAL_1="45" TOTAL_2="45" VAR="0.04448836187966622" WEIGHT="20.445226750197218"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9819074579714389" CI_START="0.9166094780933554" DF="0" EFFECT_SIZE="1.3478260869565217" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" I2="0.0" ID="CMP-032.01.02" LOG_CI_END="0.2970833719299582" LOG_CI_START="-0.03781565629659861" LOG_EFFECT_SIZE="0.1296338578166798" MODIFIED="2011-07-14 15:02:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12918109498946978" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="21.6006745261525" Z="1.5173390848169128">
<NAME>Formula B versus placebo</NAME>
<DICH_DATA CI_END="1.9819074579714389" CI_START="0.9166094780933554" EFFECT_SIZE="1.3478260869565217" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.2970833719299582" LOG_CI_START="-0.03781565629659861" LOG_EFFECT_SIZE="0.1296338578166798" MODIFIED="2011-07-14 15:02:57 +1000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.19672134695720547" STUDY_ID="STD-Chopra-2011" TOTAL_1="54" TOTAL_2="54" VAR="0.03869928834865721" WEIGHT="21.6006745261525"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.214396992052759" CI_START="0.5043460865915816" DF="0" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-032.01.03" LOG_CI_END="0.0843606828461133" LOG_CI_START="-0.2972713446746868" LOG_EFFECT_SIZE="-0.10645533091428679" MODIFIED="2011-07-14 15:03:28 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.27419434596699643" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="19.411219534539324" Z="1.0934544247229019">
<NAME>Formula C versus placebo</NAME>
<DICH_DATA CI_END="1.214396992052759" CI_START="0.5043460865915816" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.0843606828461133" LOG_CI_START="-0.2972713446746868" LOG_EFFECT_SIZE="-0.10645533091428679" MODIFIED="2011-07-14 15:03:28 +1000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.22417254207472137" STUDY_ID="STD-Chopra-2011" TOTAL_1="41" TOTAL_2="41" VAR="0.050253328620242725" WEIGHT="19.411219534539324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9310491006198447" CI_START="0.3431298083207481" DF="0" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" I2="0.0" ID="CMP-032.01.04" LOG_CI_END="-0.031027415080995987" LOG_CI_START="-0.4645415523405163" LOG_EFFECT_SIZE="-0.24778448371075615" MODIFIED="2011-07-14 15:03:55 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.02505714897017875" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="17.208288812114017" Z="2.240520537904412">
<NAME>Formula D versus placebo</NAME>
<DICH_DATA CI_END="0.9310491006198447" CI_START="0.3431298083207481" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.031027415080995987" LOG_CI_START="-0.4645415523405163" LOG_EFFECT_SIZE="-0.24778448371075615" MODIFIED="2011-07-14 15:03:55 +1000" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.25464835015583076" STUDY_ID="STD-Chopra-2011" TOTAL_1="36" TOTAL_2="36" VAR="0.06484578223708659" WEIGHT="17.208288812114017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8014460299308688" CI_START="0.8226955253045107" DF="0" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="0.0" ID="CMP-032.01.05" LOG_CI_END="0.2556212554931059" LOG_CI_START="-0.08476086484385317" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2011-07-14 15:04:23 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.32519612747017335" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="21.33459037699695" Z="0.983836083180477">
<NAME>Formula E versus placebo</NAME>
<DICH_DATA CI_END="1.8014460299308688" CI_START="0.8226955253045107" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.2556212554931059" LOG_CI_START="-0.08476086484385317" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2011-07-14 15:04:23 +1000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.19994214240459945" STUDY_ID="STD-Chopra-2011" TOTAL_1="51" TOTAL_2="51" VAR="0.039976860309341125" WEIGHT="21.33459037699695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2013-09-10 20:43:22 +1000" MODIFIED_BY="[Empty name]" NO="33">
<NAME>Ayurvedic Antarth versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.785123786437875" CI_START="-9.785123786437875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-033.01" MODIFIED="2013-05-07 20:40:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8234574244623054" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.22310032643658007">
<NAME>Pain VAS 0-100</NAME>
<GROUP_LABEL_1>Antarth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antarth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.785123786437875" CI_START="-9.785123786437875" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="48.0" MODIFIED="2011-07-14 14:31:50 +1000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="20.0" SD_2="22.0" SE="4.482288376589473" STUDY_ID="STD-Gupta-2011" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" MODIFIED="2013-09-10 20:41:38 +1000" MODIFIED_BY="[Empty name]" NO="34">
<NAME>Ayurvedic RA-II versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8770613981676023" CI_START="-1.1829386018323977" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.03" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.01" MODIFIED="2013-05-07 20:46:19 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="8.793816041869468E-40" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="13.199825811723958">
<NAME>Pain VAS 0-100</NAME>
<GROUP_LABEL_1>RA-II</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RA-II</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8770613981676023" CI_START="-1.1829386018323977" EFFECT_SIZE="-1.03" ESTIMABLE="YES" MEAN_1="-2.83" MEAN_2="-1.8" MODIFIED="2012-05-25 17:17:19 +1000" MODIFIED_BY="[Empty name]" ORDER="261" SD_1="0.38" SD_2="0.36" SE="0.07803133273813083" STUDY_ID="STD-Chopra-2004" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.87506218991821" CI_START="-6.724937810081788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.799999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.02" MODIFIED="2013-09-10 20:41:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.020881628257537E-34" Q="0.0" RANDOM="YES" SCALE="68.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="12.290330210770707">
<NAME>WOMAC 0-4 (Function)</NAME>
<GROUP_LABEL_1>RA-II</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RA-II</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.87506218991821" CI_START="-6.724937810081788" EFFECT_SIZE="-5.799999999999999" ESTIMABLE="YES" MEAN_1="-12.7" MEAN_2="-6.9" MODIFIED="2012-05-25 17:26:56 +1000" MODIFIED_BY="[Empty name]" ORDER="265" SD_1="2.11" SD_2="2.36" SE="0.47191571752214867" STUDY_ID="STD-Chopra-2004" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5806759135195496" CI_START="0.6914606575980144" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-034.03" LOG_CI_END="0.19884283552484924" LOG_CI_START="-0.16023252513407604" LOG_EFFECT_SIZE="0.019305155195386624" METHOD="MH" MODIFIED="2013-09-10 20:41:38 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8330830399087872" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.210749124247791">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>RA-II</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RA-II</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5806759135195496" CI_START="0.6914606575980144" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.19884283552484924" LOG_CI_START="-0.16023252513407604" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2012-05-25 17:29:45 +1000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.21092264430275431" STUDY_ID="STD-Chopra-2004" TOTAL_1="45" TOTAL_2="45" VAR="0.04448836187966622" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" MODIFIED="2013-09-13 12:03:49 +1000" MODIFIED_BY="[Empty name]" NO="35">
<NAME>Ayurvedic SGC versus glucosamine sulphate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.282816499856207" CI_START="-3.2828164998562057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-035.01" MODIFIED="2013-09-13 12:03:31 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3493407528275977" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.9358688024319564">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.282816499856207" CI_START="-3.2828164998562057" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="-21.0" MEAN_2="-24.0" MODIFIED="2013-09-03 13:31:08 +1000" MODIFIED_BY="[Empty name]" ORDER="293" SD_1="24.8" SD_2="22.7" SE="3.205577525614889" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.716127215978386" CI_START="-0.7161272159783851" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-035.02" MODIFIED="2013-09-13 12:03:40 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.14896277393294466" Q="0.0" RANDOM="YES" SCALE="64.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="1.4432048491764398">
<NAME>WOMAC 0-4 (Function) change from baseline</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.716127215978386" CI_START="-0.7161272159783851" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-8.0" MODIFIED="2013-09-03 13:33:18 +1000" MODIFIED_BY="[Empty name]" ORDER="295" SD_1="9.5" SD_2="11.0" SE="1.3858046563114679" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8600487464779467" CI_START="0.5825201835617984" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.040920716112532" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-035.03" LOG_CI_END="0.2695243259646774" LOG_CI_START="-0.2346890223059709" LOG_EFFECT_SIZE="0.017417651829353245" METHOD="MH" MODIFIED="2013-09-13 12:03:49 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8922870735690026" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="108" WEIGHT="100.0" Z="0.13541081527443496">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8600487464779467" CI_START="0.5825201835617984" EFFECT_SIZE="1.040920716112532" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.2695243259646774" LOG_CI_START="-0.2346890223059709" LOG_EFFECT_SIZE="0.017417651829353245" MODIFIED="2013-09-01 16:36:25 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.29617741667050607" STUDY_ID="STD-Chopra-2013" TOTAL_1="102" TOTAL_2="108" VAR="0.08772106214561458" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" MODIFIED="2013-09-10 20:42:05 +1000" MODIFIED_BY="[Empty name]" NO="36">
<NAME>Ayurvedic SGC versus celecoxib</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.980065871913877" CI_START="-8.980065871913876" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-036.01" MODIFIED="2013-09-03 13:37:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3254850676784644" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.9832486931683824">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.980065871913877" CI_START="-8.980065871913876" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-21.0" MEAN_2="-18.0" MODIFIED="2013-09-03 13:37:12 +1000" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="24.9" SD_2="20.1" SE="3.051110081146324" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.604815530499864" CI_START="-1.604815530499864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-036.02" MODIFIED="2013-09-10 20:42:05 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4517872931714463" Q="0.0" RANDOM="YES" SCALE="64.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.7524386896464554">
<NAME>WOMAC 0-4 (Function) change from baseline</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.604815530499864" CI_START="-1.604815530499864" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-7.0" MODIFIED="2013-09-03 13:39:39 +1000" MODIFIED_BY="[Empty name]" ORDER="303" SD_1="9.5" SD_2="10.2" SE="1.3290119364673618" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7880107677196033" CI_START="0.5578512772458776" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9987212276214834" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-036.03" LOG_CI_END="0.2523701298665686" LOG_CI_START="-0.2534815682316639" LOG_EFFECT_SIZE="-5.557191825476612E-4" METHOD="MH" MODIFIED="2013-09-10 20:42:05 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9965640330174378" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="105" WEIGHT="99.99999999999999" Z="0.00430635930414508">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SGC</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7880107677196033" CI_START="0.5578512772458776" EFFECT_SIZE="0.9987212276214834" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.2523701298665686" LOG_CI_START="-0.2534815682316639" LOG_EFFECT_SIZE="-5.557191825476612E-4" MODIFIED="2013-09-01 16:47:12 +1000" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.29713979146919145" STUDY_ID="STD-Chopra-2013" TOTAL_1="102" TOTAL_2="105" VAR="0.08829205567435458" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" MODIFIED="2013-09-13 07:11:14 +1000" MODIFIED_BY="[Empty name]" NO="37">
<NAME>Ayurvedic SGCG versus glucosamine sulphate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.419381773030238" CI_START="-1.4193817730302376" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.01" MODIFIED="2013-09-13 07:10:53 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.14799976829053596" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="1.4466328940277953">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.419381773030238" CI_START="-1.4193817730302376" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-24.0" MODIFIED="2013-09-03 13:40:36 +1000" MODIFIED_BY="[Empty name]" ORDER="288" SD_1="21.0" SD_2="20.0" SE="2.7650415088122178" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.1581000691666326" CI_START="-1.3981000691666345" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.379999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.02" MODIFIED="2013-09-13 07:11:07 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.33025661641801085" Q="0.0" RANDOM="YES" SCALE="64.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.973597146008004">
<NAME>WOMAC 0-4 (Function) change from baseline</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.1581000691666326" CI_START="-1.3981000691666345" EFFECT_SIZE="1.379999999999999" ESTIMABLE="YES" MEAN_1="-6.74" MEAN_2="-8.12" MODIFIED="2013-09-01 16:34:46 +1000" MODIFIED_BY="[Empty name]" ORDER="291" SD_1="11.0" SD_2="10.0" SE="1.4174240399721283" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5402229464630681" CI_START="0.47233983378163846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8529411764705882" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-037.03" LOG_CI_END="0.18758358928496327" LOG_CI_START="-0.3257454275715614" LOG_EFFECT_SIZE="-0.06908091914329906" METHOD="MH" MODIFIED="2013-09-13 07:11:14 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.597831310886493" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="108" WEIGHT="100.0" Z="0.5275217612630415">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucosamine sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5402229464630681" CI_START="0.47233983378163846" EFFECT_SIZE="0.8529411764705882" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.18758358928496327" LOG_CI_START="-0.3257454275715614" LOG_EFFECT_SIZE="-0.06908091914329906" MODIFIED="2013-09-01 16:28:10 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.30153200552113707" STUDY_ID="STD-Chopra-2013" TOTAL_1="103" TOTAL_2="108" VAR="0.09092155035359903" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" MODIFIED="2013-09-10 20:42:26 +1000" MODIFIED_BY="[Empty name]" NO="38">
<NAME>Ayurvedic SGCG versus celecoxib</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.4193817730302376" CI_START="-7.419381773030238" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-038.01" MODIFIED="2013-09-03 14:00:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.46948549590686073" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.7233164470138976">
<NAME>Pain VAS 0-100 change from baseline</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.4193817730302376" CI_START="-7.419381773030238" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-18.0" MODIFIED="2013-09-03 14:00:17 +1000" MODIFIED_BY="[Empty name]" ORDER="297" SD_1="21.0" SD_2="20.0" SE="2.7650415088122178" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.968100069166633" CI_START="-2.588100069166634" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1899999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-038.02" MODIFIED="2013-09-10 20:42:26 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8933662126829575" Q="0.0" RANDOM="YES" SCALE="64.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.13404598387066696">
<NAME>WOMAC 0-4 (Function) change from baseline</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.968100069166633" CI_START="-2.588100069166634" EFFECT_SIZE="0.1899999999999995" ESTIMABLE="YES" MEAN_1="-6.74" MEAN_2="-6.93" MODIFIED="2013-09-01 16:41:40 +1000" MODIFIED_BY="[Empty name]" ORDER="299" SD_1="11.0" SD_2="10.0" SE="1.4174240399721283" STUDY_ID="STD-Chopra-2013" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1050130017851666E-31" CI_END="1.480522091940285" CI_START="0.45235201320246904" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.818362480127186" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" I2="100.0" I2_Q="0.0" ID="CMP-038.03" LOG_CI_END="0.17041489219554928" LOG_CI_START="-0.34452347250594917" LOG_EFFECT_SIZE="-0.08705429015519993" METHOD="MH" MODIFIED="2013-09-10 20:42:26 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.5075265797159025" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="105" WEIGHT="99.99999999999999" Z="0.6626939653362176">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>SGCG</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SGCG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours celecoxib</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4805220919402853" CI_START="0.45235201320246904" EFFECT_SIZE="0.818362480127186" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.17041489219554934" LOG_CI_START="-0.34452347250594917" LOG_EFFECT_SIZE="-0.08705429015519993" MODIFIED="2013-09-01 16:42:01 +1000" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.30247734441167495" STUDY_ID="STD-Chopra-2013" TOTAL_1="103" TOTAL_2="105" VAR="0.09149254388233903" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" MODIFIED="2013-09-13 07:17:12 +1000" MODIFIED_BY="[Empty name]" NO="39">
<NAME>Japanese Boiogito + loxoprofen versus loxoprofen</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.302848658872238" CI_START="-8.902848658872232" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-039.01" MODIFIED="2013-09-13 07:17:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7375259812892738" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.3351313822258846">
<NAME>Pain: Knee Society Rating System 0-100 (knee)</NAME>
<GROUP_LABEL_1>Boiogito</GROUP_LABEL_1>
<GROUP_LABEL_2>Ioxoprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Boiogito</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ioxoprofen</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.302848658872238" CI_START="-8.902848658872232" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="85.8" MEAN_2="87.1" MODIFIED="2012-06-19 15:39:01 +1000" MODIFIED_BY="[Empty name]" ORDER="1088" SD_1="11.1" SD_2="15.1" SE="3.8790756967181714" STUDY_ID="STD-Majima-2012" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.958738223805389E-32" CI_END="6.685291495312487" CI_START="0.5147085046875142" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.600000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-039.02" MODIFIED="2013-09-13 07:16:19 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.022199442537473007" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="2.2869379943724115">
<NAME>Function: Knee Society Rating System 0-50 (stairs)</NAME>
<GROUP_LABEL_1>Boiogito</GROUP_LABEL_1>
<GROUP_LABEL_2>Ioxoprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Boiogito</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ioxoprofen</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.685291495312488" CI_START="0.5147085046875146" EFFECT_SIZE="3.6000000000000014" ESTIMABLE="YES" MEAN_1="40.2" MEAN_2="36.6" MODIFIED="2012-06-19 15:43:32 +1000" MODIFIED_BY="[Empty name]" ORDER="1089" SD_1="4.4" SD_2="6.2" SE="1.5741572394436185" STUDY_ID="STD-Majima-2012" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.28973413262064" CI_START="0.12326397342650598" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-039.03" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" METHOD="MH" MODIFIED="2013-05-07 20:48:29 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.510593226807788" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6579142667226608">
<NAME>Participants (n) reported adverse events</NAME>
<GROUP_LABEL_1>Boiogito</GROUP_LABEL_1>
<GROUP_LABEL_2>Ioxoprofen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Boiogito</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ioxoprofen</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.28973413262064" CI_START="0.12326397342650598" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" MODIFIED="2012-06-19 15:53:01 +1000" MODIFIED_BY="[Empty name]" ORDER="1090" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Majima-2012" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-05-11 00:34:41 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-13 04:11:53 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3IAAAMlCAYAAAA2XMGuAAB62klEQVR42uzdDcRV6fo44EOSJIlk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-05-11 00:34:41 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAbYCAIAAACHa8PQAABamUlEQVR42u3dvY4cxfv28ZWQEMEG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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-04-04 18:08:45 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2016-04-04 18:08:45 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-03-07 13:43:30 +1100" MODIFIED_BY="Renea V Johnston">New feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="12" MONTH="11" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2016-03-07 13:45:04 +1100" MODIFIED_BY="Renea V Johnston">
<P>Date of Submission: 12-Nov-2015<BR/>Name: Bernd Kerschner<BR/>Email Address: <A HREF="mailto:bernd.kerschner@donau-uni.ac.at">bernd.kerschner@donau-uni.ac.at</A>
<BR/>Affiliation: Cochrane Austria<BR/>Role: medical journalist<BR/>
<BR/>Comment: Dear editors and authors,<BR/>
<BR/>the conclusions in the present review on oral herbal therapies for treating osteoarthritis are very confusing and in part contradictory when it comes to the efficacy of Boswellia extract.<BR/>
<BR/>While the Author's conclusions state:<BR/>
<BR/>"Several other medicinal plant products, including extracts of Boswellia serrata, show trends of benefits that warrant further investigation in light of the fact that the risk of adverse events appear low."<BR/>
<BR/>the plain language summary however says:<BR/>"There is high-quality evidence that in people with osteoarthritis Boswellia serrata slightly improved pain and function. Further research is unlikely to change the estimates."<BR/>
<BR/>When trying to interprete the results from the summary of findings tables on the different dosages of Boswellia extract (999mg, 100 mg enriched, 250 mg enriched and 100 mg enriched + volatile oils) it appears to me that there is indeed all in all HIGH evidence for the principle efficacy of Boswellia.<BR/>
<BR/>with best regards,<BR/>Bernd Kerschner, Krems, Austria<BR/>
<BR/>I agree with the conflict of interest statement below:<BR/>
<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2016-04-04 18:08:45 +1000" MODIFIED_BY="[Empty name]">
<P>Thank you for your feedback.</P>
<P>Indeed, the statements in the conclusions, Re: <I>Boswellia serrata</I>, seemingly contradict the summary of evidence in summary of findings table 2, and the plain language summary. Upon reflection, we believe the evidence for improved pain and function with <I>Boswellia </I>is moderate-quality - there is a potential for imprecision due to the small number of participants contributing to these outcomes. This is also reflected in the lower 95% confidence intervals around the effect estimates for pain and function, which include a small and possibly clinically insignificant improvement in pain and function. Thus, further research may change the estimates, and will likely improve the precision of the findings. We have altered the text in the plain language summary, abstract, text and the summary of findings tables to reflect the judgement of moderate-quality evidence for improved pain and function with treatment with <I>Boswellia serrata. </I>
</P>
<P>We will be updating the review, and splitting into separate reviews for individual herbs. Thus, we may find new studies to add to the body of evidence for assessing the benefits and possible harms of <I>Boswellia serrata </I>and other herbs</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2016-04-04 18:07:42 +1000" MODIFIED_BY="[Empty name]">
<P>Melainie Cameron, Author.</P>
<P>Renea Johnston, Managing Editor.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-05-21 18:30:56 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-05-21 18:30:56 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-21 18:30:56 +1000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-26 19:03:22 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE</B>
</P>
<P>1     exp osteoarthritis/</P>
<P>2     osteoarthr$.tw.</P>
<P>3     (degenerative adj2 arthritis).tw.</P>
<P>4     arthrosis.tw.</P>
<P>5     or/1-4</P>
<P>6     exp Medicine, Herbal/</P>
<P>7     exp Plants, Medicinal/</P>
<P>8     exp Medicine, Traditional/</P>
<P>9     exp Drugs, Chinese Herbal/</P>
<P>10     herb$.tw.</P>
<P>11     (plant or plants).tw.</P>
<P>12     phytomedicine.tw.</P>
<P>13     botanical.tw.</P>
<P>14     weed$.tw.</P>
<P>15     algae.tw.</P>
<P>16     (fungi or fungus).tw.</P>
<P>17     ((traditional or chinese or herbal) adj medicine).tw.</P>
<P>18     ((oriental or chinese) adj tradition$).tw.</P>
<P>19     or/6-18</P>
<P>20     5 and 19</P>
<P> </P>
<P>
<B>EMBASE </B>
</P>
<P>1     exp osteoarthritis/</P>
<P>2     osteoarthr$.tw.</P>
<P>3     (degenerative adj2 arthritis).tw.</P>
<P>4     arthrosis.tw.</P>
<P>5     or/1-4</P>
<P>6     exp Herbal Medicine/</P>
<P>7     exp Medicinal Plant/</P>
<P>8     exp Traditional Medicine/</P>
<P>9     exp Chinese Medicine/</P>
<P>10     herb$.tw.</P>
<P>11     (plant or plants).tw.</P>
<P>12     phytomedicine.tw.</P>
<P>13     botanical.tw.</P>
<P>14     weed$.tw.</P>
<P>15     algae.tw.</P>
<P>16     (fungi or fungus).tw.</P>
<P>17     ((traditional or chinese or herbal) adj medicine).tw.</P>
<P>18     ((oriental or chinese) adj tradition$).tw.</P>
<P>19     or/6-18</P>
<P>20     5 and 19</P>
<P> </P>
<P>
<B>CINAHL</B>
</P>
<P>1     exp OSTEOARTHRITIS/</P>
<P>2     osteoarthr$.tw.</P>
<P>3     (degenerative adj2 arthritis).tw.</P>
<P>4     arthrosis.tw.</P>
<P>5     or/1-4</P>
<P>6     exp Medicine, Herbal/</P>
<P>7     exp Plants, Medicinal/</P>
<P>8     Medicine, Traditional/</P>
<P>9     exp Plant Extracts/</P>
<P>10     herb$.tw.</P>
<P>11     (plant or plants).tw.</P>
<P>12     phytomedicine.tw.</P>
<P>13     botanical.tw.</P>
<P>14     weed$.tw.</P>
<P>15     algae.tw.</P>
<P>16     (fungi or fungus).tw.</P>
<P>17     ((traditional or chinese or herbal) adj medicine).tw.</P>
<P>18     ((oriental or chinese) adj tradition$).tw.</P>
<P>19     or/6-18</P>
<P>20     5 and 19</P>
<P> </P>
<P>
<B>Revised Strategy (EBSOhost)</B>
</P>
<P>S24 S5 and S22<BR/>S23 S5 and S22</P>
<P>S22 S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21</P>
<P>S21 ti chinese tradition* or ab chinese tradition*</P>
<P>S20 ti oriental tradition* or ab oriental tradition*</P>
<P>S19 ti herbal medicine or ab herbal medicine<BR/>S18 ti chinese medicine or ab chinese medicine<BR/>S17 ti traditional medicine or ab traditional medicine</P>
<P>S16 ti fungi or ti fungus or ab fungi or ab fungus</P>
<P>S15 ti algae or ab algae</P>
<P>S14 ti weed* or ab weed*</P>
<P>S13 ti botanical or ab botanical</P>
<P>S12 ti phytomedicine or ab phytomedicine</P>
<P>S11 ti plant or ti plants or ab plant or ab plants</P>
<P>S10 ti herb* or ab herb*</P>
<P>S9 (MH "Plant Extracts+")</P>
<P>S8 (MH "Medicine, Traditional+")<BR/>S7 (MH "Plants, Medicinal+")</P>
<P>S6 (MH "Medicine, Herbal+")</P>
<P>S5 S1 or S2 or S3 or S4</P>
<P>S4 ti arthrosis or ab arthrosis</P>
<P>S3 ti degenerative N2 arthritis or ab degenerative N2 arthritis<BR/>S2 ti osteoarthr* or ab osteoarthr*</P>
<P>S1 (MH "Osteoarthritis+")</P>
<P> </P>
<P>
<B>AMED </B>
</P>
<P>1     exp Osteoarthritis/</P>
<P>2     osteoarthr$.tw.</P>
<P>3     (degenerative adj2 arthritis).tw.</P>
<P>4     arthrosis.tw.</P>
<P>5     or/1-4</P>
<P>6     exp herbal drugs/</P>
<P>7     exp traditional medicine/</P>
<P>8     exp plant extracts/</P>
<P>9     exp plants medicinal/</P>
<P>10     herb$.tw.</P>
<P>11     (plant or plants).tw.</P>
<P>12     phytomedicine.tw.</P>
<P>13     botanical.tw.</P>
<P>14     weed$.tw.</P>
<P>15     algae.tw.</P>
<P>16     (fungi or fungus).tw.</P>
<P>17     ((traditional or chinese or herbal) adj medicine).tw.</P>
<P>18     ((oriental or chinese) adj tradition$).tw.</P>
<P>19     or/6-18</P>
<P>20     5 and 19</P>
<P> </P>
<P>
<B>The Cochrane Library 2008, Issue 4</B>
</P>
<P>#1           MeSH descriptor Osteoarthritis explode all trees</P>
<P>#2           osteoarthr*:ti,ab</P>
<P>#3           (degenerative near/2 arthritis):ti,ab</P>
<P>#4           arthrosis:ti,ab</P>
<P>#5           (#1 OR #2 OR #3 OR #4)</P>
<P>#6           MeSH descriptor Medicine, Herbal explode all trees</P>
<P>#7           MeSH descriptor Plants, Medicinal explode all trees</P>
<P>#8           MeSH descriptor Medicine, Traditional explode all trees</P>
<P>#9           MeSH descriptor Drugs, Chinese Herbal explode all trees</P>
<P>#10         herb*:ti,ab</P>
<P>#11         (plant or plants):ti,ab</P>
<P>#12         phytomedicine:ti,ab</P>
<P>#13         botanical:ti,ab</P>
<P>#14         weed*:ti,ab</P>
<P>#15         algae:ti,ab</P>
<P>#16         (fungi or fungus):ti,ab</P>
<P>#17         ((traditional or chinese or herbal) next medicine):ti,ab</P>
<P>#18         ((oriental or chinese) next tradition*):ti,ab</P>
<P>#19         (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)</P>
<P>#20         (#5 AND #19)</P>
<P> </P>
<P>
<B>ISI Web of Science</B>
</P>
<P>#7 #4 AND #1</P>
<P>Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005 OR 2003 OR 2000 OR 2008 OR 2006 OR 2002 ) AND Document Type=( PROCEEDINGS PAPER OR MEETING ABSTRACT )</P>
<P>#6 #4 AND #1</P>
<P>Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005</P>
<P>#5 #4 AND #1</P>
<P>#4 #3 OR #2</P>
<P>#3 Topic=(((oriental or chinese or traditional) and (medicine or therap*)))</P>
<P>#2 Topic=(herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus)</P>
<P>#1 Topic=(arthrit* or arthrosis or osteoarthrit* or osteoarthrosis)</P>
<P> </P>
<P>
<B>Dissertation Abstracts</B>
</P>
<P>arthrit* or arthrosis or osteoarthrit* or osteoarthrosis AND</P>
<P>herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or ((oriental or chinese or traditional) and (medicin* or therap*))</P>
<P> </P>
<P>
<B>World Health Organization International Clinical Trials Registry Platform</B>
</P>
<P>Osteoarthritis in Condition AND</P>
<P>herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or oriental or chinese or traditional in Intervention</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;ASU: 5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;i&gt;Boswellia serrata&lt;/i&gt;: 2 studies included in quantitative synthesis.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;49 studies included in qualitative synthesis.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;89 full-text articles assessed for eligibility.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;309 records screened.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;309 records after duplicates removed.&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;Approximately 2500 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;5 additional records identified through other sources. &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;210 records excluded.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 abstracts excluded. Duplicate publications. Full text already included. &lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies not available in full text, awaiting classification.&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;40 full-text articles excluded, with reasons.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>